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Abstract 
Background: Obesity is currently a worldwide epidemic that increases the risk of developing 
metabolic disorders like diabetes, hypertension and cardiovascular diseases (CVDs) which 
causes great public health concern. A series of studies involving animal models and 
epidemiological investigations have demonstrated a relationship between the importance of 
vitamin B12 (B12) and various components of metabolic syndrome. High prevalence of B12 
deficiency has been shown in Europeans (27%) and South Indians (32%) with type 2 diabetes 
mellitus (T2DM) as well as several T2DM patients on prolonged metformin treatment. 
Similarly, studies in human adipose tissues showed evidence of dysregulation in lipids by low 
B12, accounting for higher adiposity and adipocyte dysfunction. However, the liver is the 
principal storage organ for B12, and hepatic contribution to the lipogenesis of the entire body 
is also significantly higher compared to adipose tissue. Several clinical studies have shown that 
metformin, the first drug of choice for T2DM treatment and proposed to reduce lipid levels in 
patients, had no effect on intrahepatic triglyceride levels. Metformin treatment has also shown 
an association with low B12 levels. Some studies in the liver have also reported no expression 
of adiponectin in the liver, unlike its receptors (adipoR1 and adipoR2). Adiponectin is an 
adipose tissue-derived hormone that regulates glucose and lipid metabolism and is known to 
upregulate glycolysis and fatty acid oxidation (FAO) as well as reduces gluconeogenesis in 
liver. Therefore, we hypothesized that low B12 may dysregulate hepatic metabolism of lipids 
and reduce the lipid lowering effect of metformin in the liver that might be improved by 
adiponectin treatment. Methods: Hep G2 cell line was cultured using custom-made B12 
deficient Eagle’s Minimal Essential Medium (EMEM) and seeded in different concentrations 
of B12 media including 500nM (control) and 25pM (low) B12. Oil Red O (ORO) staining, RT-
qPCR, total intracellular triglyceride (TG), radioactive flux assay, fatty acid profiling using gas 
chromatography and extracellular seahorse XF24 flux assay were employed to examine the 
effect of B12 on lipid metabolism. Results: The intrahepatic uptake of B12 was increased in 
lower circulating B12 concentrations by increased expression of B12 receptors (CD320) and 
transporters (TCN2), whereas decreased expressions of CD320 and TCN2 accounted for 
reduced B12 uptake in higher circulating B12 levels. Low B12 increased de novo lipogenesis 
and levels of fatty acid (FA) groups associated with higher CVD risk. There was further 
decrease in FAO and mitochondrial functional efficiency, accounting for high hepatic lipid 
accumulation in low B12. Similarly, the lipid lowering effect of metformin was decreased by 
low B12, but improved via adiponectin, in the metformin-treated hepatocyte cell line. 
xvi 
 
Conclusion: Our data, therefore, provides novel evidence that B12 deficiency dysregulates 
lipid metabolism leading to hepatic lipid accumulation. 
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1.1 METABOLIC SYNDROME 
1.1.1 Background: 
Metabolic syndrome (MetS), also known as syndrome X or insulin resistant syndrome, is a 
medical term describing a network of biochemical, metabolic, clinical and physiological factors 
that upregulate the risk of developing type 2 diabetes mellitus (T2DM), cardiovascular disease 
(CVD) and all-cause mortality [1, 2]. As a result of elevation in cases of obesity, excess 
consumption of energy, sedentary lifestyle and advancement in urbanization, MetS currently 
presents a major global clinical and public health problem [2]. As predicted by an earlier study 
[3], the risks of developing T2DM and CVD may be increased to about 5-fold and 2-fold, 
respectively, as a result of MetS. Similarly, the risks of incidences of myocardial infarction 
(MI), stroke and death are about 2-4-fold, 2-5-fold and 2-fold higher respectively in MetS 
patients [4].  
 
1.1.2 Epidemiology  
Depending on the particular diagnostic conditions, criteria, sociodemographic and geographic 
factors, the prevalence of MetS differs across the globe [5]. Evidence shows that the global 
prevalence of MetS may vary from less than 10% to about 84% depending on the population 
demographics and syndrome definition applied [6]. The International Diabetes Federation 
(IDF) estimates that a quarter of the global adult population have MetS [7]. The highest 
prevalence of MetS has been reported in Mexican-American women [8]. About 35% of adults 
and 50% of elderly beyond 60 years old in the US were diagnosed with MetS based on the 
criteria developed by National Cholesterol Education Program Adult Treatment Panel III [9]. 
In Europe, about 38% of women and 41% of men have been reported based on diagnostic 
criteria developed by the IDF [10]. In Chinese adults at 60 years and beyond, 58.1% MetS 
prevalence has been recorded [11]. Finally, MetS prevalence in the Middle East was reported  
32.1-42.7% in women and 20.7-37.2% in  men based on the criteria of Adult Treatment Panel 
III [12]. The risk factors aggravating the risk of MetS include obesity [13], decreased physical 
activity [14], western dietary forms [15], smoking [16], existing family history [17], 
postmenopausal phase [13], low socioeconomic status [13] and excessive alcohol consumption 
[18]. 
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1.1.3 Pathophysiology of metabolic syndrome 
The precise cause of MetS is not entirely understood. However, some probable 
pathophysiological mechanisms underlying MetS include insulin resistance and 
hyperinsulinaemia, with a flux of fatty acids [19-21] (Fig 1). A complex interaction between 
environmental and genetic factors may also contribute to MetS, manifesting as a chronic, low-
grade, inflammatory condition. The syndrome constitutes several of the following components: 
endothelial dysfunction, atherogenic dyslipidaemia, increased blood pressure, prolonged stress, 
visceral adiposity, insulin resistance and a hypercoagulable condition [2, 22].  
 
 
 
Figure 1: Pathophysiology of metabolic syndrome: Development of resistance to insulin together with 
endothelial dysfunction are propagated by conditions of dyslipidaemia and or dysregulated partitioning of lipids 
as observed in cases of central obesity. The resultant effect is the manifestation of metabolic syndrome (MetS) 
with the subsequent risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).  
 
1.1.3.1 Insulin resistance (IR) 
MetS is also known as IR syndrome [22]. It is, therefore, hypothesized that IR is the most 
acceptable factor for defining the pathophysiology of MetS [22]. Clinically, IR is defined as the 
4 
 
failure of insulin to achieve the desired uptake and usage of glucose in tissues of an individual 
compared with the normal population [23]. This results from a damage in the action of insulin 
in metabolically active tissues such as the liver, skeletal muscle and adipose tissue [24]. 
Systemic resistance to insulin could be a measure of decline in the rate of disposal of glucose 
in response to distinct insulin concentrations [25]. In adipose tissue (AT), IR interferes with the 
inhibition of lipolysis by insulin which may further elevate the free fatty acid  (FFA) pool in 
circulation [26]. In muscles, insulin-facilitated uptake of glucose is compromised as a result of 
reduced sensitivity to insulin caused by FFA. Hyperinsulinemia, therefore, develops due to high 
levels of glucose in circulation promoting pancreatic insulin secretion. Consequently, elevation 
in the synthesis of triglycerides (TG), glucose and very low-density lipoproteins (VLDL) in the 
liver due to the high FFA pool is observed. In effect, an ultimate decline in glycogen production 
from glucose and upregulated accumulation of lipids in the form of TG are evident [22].  
1.1.3.2 Obesity and increased waist circumference 
The build-up of body fat to levels exceeding the suitable range required for normal functioning 
of the body is termed obesity [27]. Body fat can be broadly categorized into either essential or 
storage fat. Fat stored in organs such as heart, lungs, bone marrow, liver, muscle and spleen are 
essential and may facilitate the normal functioning of the body. Total body fat in healthy young 
adult women and men constitutes 20 to 25% and 15 to 20% of the entire body weight, 
respectively [27]. Central obesity is basically marked by deposition of fat in the upper torso and 
abdomen especially is males. However, regional obesity is common in females and may be 
characterized by deposition of fat in the hips and thighs. Evidence shows that central obesity 
presents with higher risks of developing T2DM, hypertension, CVD and mortality, compared 
with total obesity [27]. Waist circumference (WC) measurement, similar to the waist to hip 
ratio (WHR) for central obesity assessment, provides vital information about body fat 
distribution and accumulation [28]. Visceral fat has been shown to demonstrate much resistance 
to metabolic actions initiated by insulin, as compared with subcutaneous fat [29]. The former, 
likewise, shows much responsiveness to effects of glucocorticoids, lipolytic hormones and 
catecholamine [29]. Therefore, increased FFAs from lipolysis results in the elevation of hepatic 
biosynthesis of TGs and VLDL [30].  
In spite of the complexity in the pathogenesis of MetS and its concomitant components, central 
(abdominal) obesity remains a crucial contributory factor, as included in definitions, both by 
the World Health Organisation (WHO) and ATP III [22, 31]. Central obesity is also indicated 
as a necessary requirement in the IDF definition of MetS [22, 31]. Excessive build-up of body 
fat is undoubtedly the commonest contributing factor to the increase in cases of MetS [32].  In 
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recent times, the global epidemic of obesity is considerably the most significant motivating 
factor leading to the much higher recognition of MetS [19]. Several definitions of MetS, 
however, involve utilization of waist circumference [33, 34]. Obesity is known to contribute 
significantly to conditions of hypertension and hyperglycaemia as well as demonstrating an 
association with elevation in the risk of developing CVD [35]. Obesity also shows a strong 
association with several cardiovascular risk factors according to data from epidemiological and 
clinical studies [35]. Lastly, obesity is associated with metabolic changes in individuals leading 
to alterations in their metabolism of lipids such as elevation in total cholesterol and triglyceride 
levels [35]. These obesity-induced metabolic modifications heighten the propensity of 
developing atherosclerosis in patients [35]. Despite these evidence, the precise mechanisms that 
account for the association between MetS and abdominal obesity (visceral obesity) are complex 
and not clearly understood.  
1.1.3.3 Dyslipidaemia  
Atherogenic dyslipidaemia has been shown to be common in patients presenting with MetS 
[36]. Dyslipidaemia refers to a defect in the metabolism of lipoproteins, which could either be 
due to insufficiency or overproduction [37]. The development of ischaemic diseases in humans 
is known to be predominantly caused by dyslipidaemia which, in turn, demonstrates a close 
association with atherosclerosis [37]. Cerebrovascular and ischaemic cardiovascular events are, 
however, shown to be the principal causes of mortality and morbidity [37]. Dyslipidaemia 
presents with three primary components which demonstrate direct linkage with MetS. These 
include upregulation in fasting and postprandial triglyceride-rich lipoproteins (TRLs), 
increased small dense LDL-C and reduced HDL-C. Similarly, high levels of triglyceride stores, 
in the form of very low-density lipoprotein (VLDL) particles, may result from compensatory 
hyperinsulinaemia status achieved in conditions of IR [38]. Reduction in the production of 
HDL-C units, together with a decline in the rate of fasting and postprandial TRLs clearance, 
may be due to a deficiency of the insulin-sensitive enzyme, lipoprotein lipase. Therefore, the 
principal anomaly of MetS is centred on increased fasting and postprandial TRLs, whereas 
reduction in HDL with increased LDL-cholesterol may represent consequential events.  
Individuals resistant to insulin may, therefore, be predisposed to a higher risk of developing 
CVD due to the defects associated with these lipoproteins [38].   
1.1.3.4 Hypertension 
Hypertension represents a chronic rise in blood pressure that might result in an end-stage organ 
injury after a prolonged period which, consequently, results in high mortality and morbidity. 
The blood pressure is a result of the product of both resistance in the systemic vascular system 
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and cardiac output. It implies, therefore, that patients presenting with arterial hypertension 
demonstrate resistance in their systemic vascular system, elevated cardiac output or both [39]. 
Studies have shown that hypertension usually demonstrates an association with diverse 
metabolic disorders predominated by glucose intolerance, obesity and dyslipidaemia [40]. It is, 
therefore, hypothesized that both hyperinsulinaemia and hyperglycaemia may facilitate 
hypertension development in insulin resistant patients [41]. This may result from activation of 
the renin angiotensin system via upregulating the receptors of angiotensin I and II (AT1 and II) 
and angiotensinogen [41]. Hypertension, resulting from effects of IR and hyperinsulinemia, 
may subsequently increase renal reabsorption of sodium, cardiac output and vasoconstriction 
of arteries via sympathetic nervous system (SNS) activation [40]. Insulin expresses a potent 
effect on the endothelium due to its vasodilation property, explained by regulation of complex 
pathways leading to endothelial stimulation to produce the vasodilator called nitric oxide [42]. 
Therefore, insulin resistant patients commonly demonstrate a diminished response to 
vasodilation. Other reasons could be due to enhancement of the reabsorption of sodium by 
insulin or an increased circulatory pool of fatty acids leading to an indirect vasodilation 
impairment [42].  
 
1.1.4 Consequences of metabolic syndrome 
T2DM and CVD are the principal conditions likely to be developed in MetS patients. Studies 
show that MetS patients present with five- and three-times risks of developing T2DM and CVD 
respectively [43]. Likewise, disorders of the cardiovascular system such as myocardial 
infarction (MI), coronary heart disease (CHD) and stroke may subsequently develop as a result 
of MetS in patients [35]. However, the establishment of a precise algorithm aiding the 
determination of an individualized relative risk for T2DM or CVD remains to be achieved [44]. 
Evidence of the possible development of breast [45], pancreas [46], colon and rectal cancers  
[47], as a result of MetS and its associated abdominal obesity and IR, has also been shown [47].  
Furthermore, MetS has been shown to induce the likelihood of sleep disturbance in patients 
[48]. The health and quality of life of individuals may be grossly affected by MetS due to 
induction physical incapacity in subjects, hence affecting daily performance of regular activities 
[49]. Chronic kidney disease, glomerulomegaly, renal microalbuminuria and hypo- and/ or 
hyper-filtration are all possible renal manifestations in MetS patients [50]. Lastly, liver 
manifestation of disorders such as cirrhosis, fibrosis, non-alcoholic steatohepatitis (NASH) and 
non-alcoholic fatty liver disease (NAFLD) have been reported in MetS conditions [29].  
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1.2 DIABETES MELLITUS (DM) 
1.2.1 Background 
Diabetes mellitus (DM) is a long-lasting and complex group of metabolic disorders marked by 
high plasma glucose due to insufficient or defective production of insulin from the β-cells of 
pancreas and/or elevated resistance of the cells to insulin action [51]. However, ‘diabetes’ and 
‘mellitus’ were originally derived from the Greek language, signifying ‘a passer through’ and 
‘sweet’ respectively. The terms were descriptive of an observation in patients who produced 
large volume of urine that baited bees and flies [52]. It was reported that diabetes alone has 
accounted for a minimum of 1.5 million mortalities in the past decade [53]. According to the 
WHO, DM is currently the 7th principal cause of mortality in the US with about 422 million 
adults cases, a figure that is four-times greater than cases in 1980 [53]. Economically, diabetes 
care has attracted much attention globally due to the rising epidemic of the disease, imposing 
pressure in several healthcare sectors to achieve more within limited resources [54]. In the last 
decade, an assessment of the entire annual budget for diabetes care in the Caribbean and Latin 
America was US$65.216 billion [55]. Likewise in the UK, the cost of diabetes in the last decade 
was £23.7 billion, and is further estimated to increase to about £39.8 billion by 2035/36 [56]. 
 
1.2.2 Types of Diabetes  
Diabetes may generally be classified into the following categories [57]: 
1.2.2.1 Type 1 diabetes mellitus (T1DM): This type basically results from autoimmune-
facilitated deterioration of the beta cells of the pancreas. The consequence is a complete 
deficiency in insulin; therefore, survival or good health may be dependent on the administration 
with insulin. Prevalence of T1DM is relatively low, especially in India, although the incidence 
of the disease is on the rise [58].  
1.2.2.2 Type 2 diabetes mellitus (T2DM): T2DM is marked by increase in the resistance of 
cells to insulin alongside progressive loss of insulin secretion from the pancreatic beta cells, 
with either of these being predominant. T2DM constitutes more than 90-95% cases of DM and 
accounts for the emergence of the global epidemic of DM [57]. T2DM is basically a progressive 
disorder demonstrating an association with metabolic conditions such as dyslipidaemia, central 
obesity and hypertension [57]. T2DM is predominant in middle- to late-aged individuals 
presenting with obesity or overweight conditions. However, evidence of increasing emergence 
has also been noted in younger-aged individuals as well as those presenting with lower body 
mass index (BMI) [57].  
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1.2.2.3 Gestational diabetes mellitus (GDM): This refers to diabetes that is first diagnosed in 
pregnancy, especially within the second or third trimester [59]. However, the development of 
diabetes, especially in the first trimester is generally classified as T2DM, although it could be 
GDM or T1DM [59]. According to the latest IDF data, about 14% of global pregnancies, nearly 
18 million annual births, are affected by GDM [60]. Conditions such as obesity and being 
overweight, micronutrient deficiencies, family history of IR or DM and westernized diet are 
risk factors for the development of GDM [60]. Whereas GDM may induce lasting consequences 
as well as risk of developing CVD and T2DM in mothers,  their offspring are also exposed to 
risk of developing T2DM, CVD, obesity and GDM later in life [60].  
1.2.2.4 Specific type: DM may also be categorized based on any other causes. For instance, 
monogenic diabetes syndromes may include maturity-onset diabetes of the young (MODY) as 
well as neonatal diabetes. Chemical or drug-induced diabetes may include those resulting from 
administration of glucocorticoid following organ transplant or for HIV/AIDS therapy [60].  
 
1.2.3 Epidemiology of DM 
As early as 1985, the global prevalence of diabetes was about 30 million [61]. In both the US 
and globally, a significant rise in the prevalence of DM has been recorded in the last four 
decades. An estimate of about 366 million people globally were diabetic in the past decade, 
with a further prediction of about 552 million cases by the year 2030 [62]. T2DM accounting 
for >90% of cases of DM, is expected to increase rampantly as compared to T1DM which is 
predicted to stay stable. Currently, DM is categorized as the ninth leading cause of death 
globally and cases of DM have increased fourfold in the last three decades [63].  It is evident 
that one out of eleven adults, globally, has DM and nearly 90% of these cases are T2DM [63]. 
India and China are the two topmost countries with high evidence of diabetes incidence. This 
puts Asia at the global front of the rapid emergence of the T2DM epidemic [63]. Emergence of 
the current worldwide epidemic of DM is primarily as a result of a more sedentary way of life 
and unhealthy dietary behaviours, although susceptibility to DM could partly be explained by 
genetic predisposition in some individuals.  Additionally, vulnerability to T2DM later in life 
could also be due to developmental factors or intrauterine exposure [63]. Adults over 65 years 
are likely to dominate the prevalence of DM in the industrialized nations [61]. However, 
persons between 45 to 65 years may predominate DM prevalence in developing countries [61], 
posing a negative threat on reproduction, fertility and economic productivity [61]. An 
appreciable fraction of the entire population of the US still presents with undiagnosed DM. 
About 5.4 million (2.7%)  people present with fasting glucose ≥125mg /dL and 13.4 million 
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(6.9%) individuals also have compromised fasting glucose (110 – 125 mg /dL) [64]. To 
minimize the risk of individuals being at high risk, screening of individuals is highly 
recommended [65]. Research shows that the onset of CVD complications of diabetes might 
precede the clinical diagnosis of T2DM by several years, therefore, early diagnosis is highly 
essential to minimize this risk [66]. Surprisingly, 7.4% of DM cases in patients between 30 to 
74 years in the US were T1DM [67]. Likewise, T2DM cases in adolescents and children are 
likely to overtake T1DM cases in the next 20 years [68]. Among the Native American, Mexican 
American and African American ethnic backgrounds, T2DM is disproportionately diagnosed 
in minority children as well as adolescents [69-71].  
 
1.2.4 Pathophysiology of DM  
1.2.4.1 Type 2 Diabetes Mellitus (T2DM)  
Factors such as IR (in the liver and muscles) and impaired secretion of insulin play key roles in 
the development of the pathophysiological condition of T2DM [72] (Fig 2). Evidence of an 
association between T2DM and abdominal obesity has been reported, with about 80% of T2DM 
patients presenting with obesity [72]. Abdominal fat demonstrates more resistance to the action 
of insulin from achieving an anti-lipolytic effect than subcutaneous fat. In effect, the release of 
FFAs from abdominal fat is upregulated compared with subcutaneous fat. Elevation in FFAs is 
the primary reason for development of resistance to insulin by the cells of the liver and muscles. 
This accounts for the elevation in circulatory glucose due to inhibition of glucose uptake in 
muscles, mediated by insulin [73]. Similarly, upregulation in hepatic gluconeogenesis occurs 
leading to hyperglycaemia. Adipocytes, upon expanding, may be unable to store additional fat, 
resulting in deposition of fat in the liver, muscle and pancreas. The resultant effect is the 
worsening of cellular resistance to insulin. Development of resistance to insulin and 
hyperglycaemia induce higher pancreatic release of insulin leading to hyperinsulinemia. 
Subsequently, maintenance of high insulin concentrations may be compromised affecting the 
physiology of pancreatic beta cells with gradual degeneration of insulin output. The effect is 
the dominance of hyperglycaemia underlying the obvious symptoms of T2DM in patients. Loss 
of about 50% functionality of pancreatic beta cells is usually evident at the time of diagnosis in 
T2DM patients [73].  
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Figure 2: Pathophysiology of T2DM: A history of genetic predisposition in some families could account for 
defective beta cell functionality leading to the development of T2DM. Development of resistance to insulin 
accounts for hyperglycaemic conditions that propagate elevated secretion of insulin by the beta pancreatic cells as 
well as the dysfunction of beta cells. Obesity also presents with excessive accumulation of abdominal fat, with 
adipose tissues showing elevated resistance to insulin’s anti-lipolytic effect, leading to elevation in the circulatory 
levels of free fatty acids (FFAs) encouraging further resistance to insulin in the liver and skeletal muscles. Hepatic 
output of glucose is increased boosting hyperglycaemia, whereas CNS detection and response to high circulatory 
glucose is also reduced.   
 
1.2.4.2 Gestational Diabetes Mellitus (GDM)  
During pregnancy, the co-existence of chronic resistance to insulin by tissues and deteriorated 
or dysfunctional beta cells of the pancreas collectively constitute key components involved in 
the pathophysiology of GDM. Generally, these critical components may be developed earlier 
before conception and might be progressive, maximizing the risk of T2DM development even 
after delivery [74]. Beta cells become dysfunctional by their failure to sense effectively precise 
levels glucose leading to secretion of abnormal insulin levels. However, the precise underlying 
mechanism accounting for dysfunctional pancreatic beta cells may be complex [75, 76].  
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Meanwhile, it is believed that a dysfunctional state could be the consequence of dysregulation 
in the beta cells, leading to prolonged over-secretion of insulin in response to availability of 
long-lasting excessive fuel [77]. The stages involving pre-biosynthesis of insulin, modulations 
at post-translational level, storage of granules and circulatory glucose level detection could all 
be defective. It is evident that the detection of minor deficiencies in the machinery of the beta 
cells may probably be obvious in the event of pregnancy wherein metabolic stress is inevitable 
[78]. Development of resistance to insulin by tissues aggravates dysfunction of the beta cells. 
In the event of hyperglycaemia, the influence of glucose on impaired beta cell functioning is 
termed glucotoxicity [79]. In effect, GDM resulting from these underlying factors may affect 
other systems and organs such as adipose tissue, muscle, brain and placenta [78].  
 
1.2.4.3 Type 1 Diabetes Mellitus (T1DM)  
The underlying mediators include macrophages as well as CD4+ and CD8+ T-lymphocytes that 
actively penetrate the islets of the pancreas causing autoimmune destruction [80]. Evidence of 
antibodies to islet cells in the circulation has been detected in about 85% of patients [80]. In 
addition, the bulk of patients also present with anti-insulin antibodies that are detectable prior 
to administration of insulin treatment [81]. The majority of anti-islet cell antibodies demonstrate 
an affinity to glutamic acid decarboxylase (GAD) present in the beta cells of the pancreas [81]. 
T1DM-associated metabolic disorders are, therefore, a result of the decline in levels of secreted 
insulin because of the autoimmune-mediated damage of the beta cells of the pancreas. Another 
observation in patients with T1DM is superfluous levels of glucagon secretion, aside from the 
deficiency in insulin production, resulting from abnormal or dysregulated function of the alpha 
cells of the pancreas [81]. Generally, a reduction in the production and release of glucagon are 
induced by hyperglycaemia. However, the hyperglycaemia-suppressing effect of glucagon is 
not achieved in patients with T1DM [82]. Insulin deficiency-induced defects of metabolism in 
T1DM are incongruously increased by circulatory concentrations of glucagon. The resulting 
effect is the suppression of the metabolism of glucose in other peripheral organs and tissues 
like the muscles due to dysregulated lipolysis with increased FFA levels [82]. Evidence shows 
that the insufficiency of insulin and impairment in the utilization of glucose further hamper the 
expression of key genes that play major roles in the transport of glucose in adipocytes (GLUT4) 
and hepatocytes (glucokinase) [82]. Generally, various pathways such as lipid, protein and 
glucose metabolism may be dysregulated as a result of T1DM-associated deficiency of insulin 
[82].  
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1.2.5 Consequences of Diabetes Mellitus (DM) 
Complications associated with DM may be categorized as acute or chronic.  
Acute complications associated with T1DM usually involve diabetic ketoacidosis (DKA), 
whereas T2DM results in the development of non-ketotic, hyper-osmolar state (NKHS). 
Evidence of total or relatively insufficient insulin, distorted mental condition and volume 
reduction are commonly observed in both types of DM [82]. The facilitation of metabolic events 
such as glycogenolysis, gluconeogenesis and development of ketone bodies within hepatocytes 
with a concomitant elevation in the muscle and adipose tissue release of FFA and amino acids 
to the liver are promoted by a decline in the insulin : glucagon ratio [83]. Aggravation in FFA 
discharge from adipocytes due to an elevation in lipolysis results in ketosis. In the event of 
severe DKA, coma may develop from CNS depression and lethargy. In children, development 
of serious complications such as cerebral coma is common. Features, usually common in adults 
with T2DM as a result of NKHS development, may include orthostatic hypotension, polyuria, 
lethargy and seizures as well as likelihood of coma. The insufficient intake of fluids alongside 
insufficiency of insulin together account for the condition of NKHS. Osmotic diuresis, 
principally resulting from hyperglycaemia caused by deficiency in insulin, progresses into 
exhaustion of the intravascular volume [83].  
Chronic complications associated with DM normally account for cases of mortality and 
morbidity due to several organ systems being affected. Both nonvascular and vascular disorders 
are the main components of the chronic complications of DM. Similarly, macrovascular 
abnormalities may comprise cerebrovascular disease, coronary artery disease and retinopathy. 
On the other hand, microvascular disorders may involve neuropathy, retinopathy and 
nephropathy. Elevated intracellular glucose concentration, especially at the initial stages of 
DM, facilitates blood flow complications as well as elevating the permeability of the vessels. 
This, therefore, highlights the impairment effect on the normal functioning of vasodilators like 
nitric oxide while facilitating the vasoconstriction effects of endothelin I and angiotensin II.  
Another vascular defect may involve amplification of vascular endothelial growth factor 
(VEGF), a potent vascular permeability factor. In the arteries of DM patient, the effects of 
hyperglycaemia and resistance to insulin, targeted at the pathway of phosphatidylinositol-3-OH 
kinase, account for dysfunction of the endothelium. 
Development of nonvascular abnormalities such as sexual dysfunction, gastroporesis and 
alterations in the normal skin are also marked in DM. Blindness, usually as a result of 
retinopathy or cataract in adults, renal disease, amputation, pregnancy complications, cerebral 
and cardiac abnormalities as well as various devastating neuropathies are collectively the result 
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of chronic complications that are largely caused by DM [83]. Emergence of severe 
complications resulting from DM are mostly associated with evolving renal disease [84]. 
Evidence or signs of diabetic renal involvement are normally seen after a period of 18 years in 
almost 35% T1DM patients [85]. There is, lastly, evidence indicating that nearly 35% of new 
renal disease patients, at the time of commencement of dialysis treatment, would have type 2 
diabetes [86]. 
 
1.3 CARDIOVASCULAR DISEASE (CVD) 
CVDs indicate a broad range of abnormalities affecting the vascular system (which constitutes 
the heart and blood vessels), as well as cardiac muscle disorders [87]. CVD involves disorders 
like stroke, coronary heart disease (CHD), cardiomyopathy and rheumatic heart disease and, 
collectively, are the principal cause of death globally [88].  CVDs may be primarily caused by 
underlying conditions of atherosclerosis and/or infectious diseases. Conditions such as physical 
immobility, diabetes, hypertension, increased levels of LDL- cholesterol, smoking of tobacco 
and several interconnected metabolic risk factors, collectively, present as probable risk factors 
to the development of CVD [89].  
 
1.3.1 Epidemiology of CVD 
An estimate of less than 10% of global mortalities were as a result of CVD at the beginning of 
the 20th century [90]. However, this estimate increased to about 30% by the year 2001 [90]. 
Evidence shows that CVD was the second major cause of mortality in the UK in the year 2014 
[90]. However, recent data from the Global Burden of Disease (GBD) indicate that the 
challenge imposed by CVD is decreasing in the UK [91]. For instance, between the years 1990 
and 2013, mortalities resulting from CVD in England reduced significantly by 52%, strokes by 
46% and CHD by 60% [91]. Evidence from the Quality and Outcomes Framework (QOF) 
demonstrates that, over a decade in England, the prevalence of CHD was held stable at about 
3%, whereas Wales, Scotland and Northern Ireland recorded a prevalence of 4% particularly 
between the years 2004/2005 and 2014/2015 [90]. However, there is evidence of only a slight 
elevation in cases of stroke in Scotland, England and Northern Ireland with a prevalence 
estimated to be about 2%. Evidence demonstrates that men resident in England generally 
present with a slight elevation in the prevalence of stroke in comparison with women [90]. 
Similarly, the prevalence of CVD in the year 2008, as estimated by the Scottish Health Survey, 
declined significantly for women but not men [90]. However, in middle and low-income nations 
across the world, about 80% of mortalities are a result of CVD [92]. It is, therefore, estimated 
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that CVD will be the principal cause of disability and mortality, particularly in middle and low-
income nations across the globe by the year 2020 [92]. Approximately 9% of global deaths per 
annum could be attributed to CVD [93].  
In India, CVDs are known to be the principal cause of death since the last century [94]. Indians 
more or less develop CVDs in the course of their midlife ages where productivity is high [95]. 
When compared with other ethnic origins such as the Europeans, Indians may acquire CVDs at 
least ten years earlier [95]. Among individuals below the age of seventy, CVDs account for 
52% mortalities among Indians compared with about 23% in Europeans [96]. It is predicted 
that the global rate of CVD may be increased as long as countries, formerly known to be at low-
risk, show evidence of a rising prevalence of risk factors for CVD [96]. Evidence recently 
showed that CVD accounts for about 80% mortality in developing countries [96]. It is further 
predicted that CVD would become the principal cause of death, exceeding infectious disorders, 
in several developing countries by the year 2020 [97]. The major cause of worldwide loss of 
disability-altered years of life, aside being the principal cause of global deaths, is CVD [98].  
 
1.3.2 Pathophysiology of CVD 
Obesity, marked by excessive accumulation of fat around the waist, is a major risk factor for 
T2DM development, it strongly aggravates the risk of developing coronary heart disease 
(CHD). Excessive weight build-up elevates cardiac strain, increases the blood pressure as well 
as lipids such as TG and cholesterol whilst decreasing levels of HDL cholesterol. As a result, 
the risk of developing conditions such as atherosclerosis and thrombolytic embolism are 
increased [99].  
Similarly, diabetes (T1DM and T2DM) also independently presents as a major risk factor for 
various forms of  CVDs [86, 99]. Evidence shows that the innate protection against 
development of CVD in women may be lost due to diabetes [100]. Diabetes can affect muscles 
of the heart which might result in both diastolic and systolic failure of the heart. 
Hyperglycaemia is evident in cases of DM and plays a key role in damaging the myocardium 
following ischaemic events. However, under conditions of normal glucose, other disorders like 
MetS and pre-diabetic conditions could aggravate the risk of development of major CVDs [101-
103]. Efforts to ensure a reduction in the risk of CVD development in patients diagnosed with 
diabetes by healthcare providers are achieved via provision of treatment for conditions such as 
hypertension and dyslipidaemia, alongside targeting the improvement of glycaemic control 
[104]. Following the development of CVD in diabetic patients, prognosis for survival is 
normally worse as compared with non-diabetic patients [105].  
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In CVD-mediated defects of the macro-vasculature in patients, atherosclerosis is the principal 
underlying cause independent of diabetes mellitus. Clinical evidence demonstrates a high 
association between atherosclerosis and dyslipidaemia with about 97% of diabetic patients 
additionally presenting with dyslipidaemia [106]. Not only this but also dysfunction of the 
endothelium, presents as an underlying mechanism through which atherosclerosis could be 
promoted by DM. Other conditions such as deficiency and resistance to insulin also enhance 
the development of dyslipidaemia together with other processes such as glycosylation, 
decreased oxidation as well as augmentation of TGs within lipoproteins. All these factors 
adding up to endothelial dysfunction, therefore contribute towards the development of 
atherogenicity as is evident in patients with DM and CVD. Likewise, DM demonstrates an 
effect on smaller blood vessels in the whole body such as those found in the heart, brain and 
the vasculature in the circulation. The condition of myocardial damage, devoid of 
macrovascular defects such as coronary artery disease (CAD), demonstrates a greater 
probability of resulting from microvascular dysfunction. Conditions such as fibrosis, 
myocardial injury and hypertrophy, as observed in cases of cardiomyopathy in diabetic patients, 
could be as a result of microvascular damage in DM patients [107].  
The amount of fat in the liver has similarly been shown to be prognostic of the risk of 
developing MetS and CVD [108]. Non-alcoholic fatty liver disease (NAFLD), comprising 
simple steatosis (SS), non-alcoholic steatohepatitis (NASH) and liver cirrhosis, is a well-known 
chronic liver disease which is commonly associated with IR and MetS. Substantial evidence 
has been shown in the past years suggesting that NAFLD may be significantly associated with 
CVDs including subclinical carotid atherosclerosis and CAD [108]. Likewise, elevations in 
pulse wave velocity, development of endothelial dysfunction as well as increased thickness of 
the carotid intima-media are associated with NAFLD and have been similarly shown to be 
potential markers for CVD [109]. CVD and NAFLD have also been proposed to be bi-
directionally associated, such that one condition could potentially potentiate the other, although 
the causal relationship between them has not been completely proven [110]. Moreover, studies 
have reported higher rate of CVD incidence in NAFLD patients and the former may furthermore 
be accountable for increased mortality in NAFLD patients [110]. To buttress this, a previous 
meta-analysis reported that the risk of fatal and/or non-fatal CVD development in NAFLD 
patients was about 64% greater compared with patients without NAFLD [111].  
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1.3.3 Consequences of CVD 
Coronary atherosclerosis in diabetic patients usually develops into myocardial ischaemia even 
without any manifestation of prior symptoms [112]. This subsequently results in the emergence 
of multi-vessel atherosclerosis earlier, before the manifestation of ischaemic symptoms or 
commencement of treatment. In effect, a worsening prognosis for survival may be observed as 
a result of delayed recognition of the diverse groups of coronary heart disease (CHD) in diabetic 
patients [112].  Similarly, diabetic patients with a diagnosis of ischaemic heart disease tend to 
demonstrate a poor prognosis as a result of the advanced state of myocardial dysfunction with 
higher chances of developing cardiac failure [113-115]. There is about three-fold higher 
likelihood of death resulting from stroke in diabetic patients [116]. Lastly, the development of 
carotid emboli leading to irreversible damage to the brain is most likely to be observed in 
diabetic patients diagnosed with CVD. 
 
 
1.4 ENVIRONMENTAL FACTORS AND METABOLIC RISK 
Humans, in the course of evolution, have adapted geographically to different ecosystems for 
the principal purpose of survival. Humans, therefore, do inhabit complex microenvironments 
that were self-generated as well as socially networked and moulded by culture and history. 
Unlike humans, other animals dwell strictly within only their natural environment. It is, 
therefore, essential for critical evaluation of the human environment (constituting natural, 
personal and social domains) in order to appreciate the entire settings governing humans. These 
domains of the environment may, therefore, play a crucial role in balancing both the pathogenic 
and salutogenic impacts on humans as exposed by the natural environment. However, unlike 
the other environmental domains, the personal environment, which is characteristically flexible 
and proximal to humans, is a major contributing factor to human health.  
The personal environment, as in the perspective of the social environment, is usually fashioned 
by both the preferences of an individual and adoption of a personal lifestyle. Some key factors 
that constitute the personal environment may include nutrition or dietary behaviour, physical 
activity, alcohol consumption and smoking.  
It is obvious that a person’s life does not necessarily commence at the time of birth but from 
the onset of conception, wherein all the information required for growth into a new individual 
is contained within the genome of the conceptus [117]. The flow of the information originates 
from DNA, through RNA and ends up in proteins as explained by the central dogma of 
molecular biology. This flow may, however, be subjected to regulation by external factors, 
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hence influencing the growth and differentiation of the systems, organs, tissues and cells that 
make up the phenotype of the person. The exact environmental processes connecting the 
components of the genotype to that of the phenotype at birth are termed epigenetics [118]. In 
the event of unfavourable conditions or adversity in utero, efforts are made by the foetus to 
adapt to this unconducive environment. The foetus is, therefore, subjected to go through 
predictive, adaptive programming by way of lessening the influence of the incompatible 
environment in utero. However, the in utero adaptations in the foetus normally persist even 
after birth and could probably be helpful if the environmental conditions in utero do not alter 
even after birth. Meanwhile, environmental orientation in postnatal life is normally different 
and, therefore, adaptation to the new postnatal environment by the individual becomes 
unrealistic. Some factors that may adversely affect the foetal environment may include 
smoking, alcohol intake, maternal undernutrition, DM, uterine artery blockage, as well as drugs 
and pharmaceutical products [118].  
Evidence from numerous studies showed that the risk of developing CVD during the late stages 
of life may be determined by the uterine environment [118] (Fig 3). Similarly, it was evident 
that stimulation of atherosclerotic lesions during the developmental stages of the foetus could 
be as a result of poor uterine environment [118]. This is further confirmed by the identification 
of fatty streaks, build-up of oxidized lipids as well as signs of inflammation within the aorta of 
foetuses of premature humans, with further thickening of the intima of their coronary arteries  
[119]. Again, an underprivileged environment in utero normally accounts for low birth weight 
and has been shown to demonstrate a strong negative association with ischaemic cardiac disease 
[119]. Upon further adjustment for duration of gestation, the negative relationship continues, 
therefore, highlighting that restrictions to foetal growth, though not premature delivery, was 
accountable for the elevated risk of CVD [120]. Exposure of parents to small volumes of smoke 
derived from tobacco within the environment, in a study involving mouse models, accounted 
for an effect on the weight gain of the offspring [121]. This also induced lipid profiles capable 
of altering the risk of CVD in the offspring later in life [121]. Similarly, mothers who normally 
smoked in the course of pregnancy had infants who presented with elevated risk of developing 
obesity [122]. In the UK population, the maternal level of vitamin B12 was shown to 
demonstrate an association with increased BMI and the risk of developing GDM and it is also 
an autonomous determinant of macrosomia [123]. The authors further recommended B12 
assessment in early pregnancy by longitudinal studies to explore this association, due to the 
rising burden of GDM and maternal obesity [123]. Similar studies have also shown a 
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relationship between low maternal plasma B12 and increased IR and obesity in a White British, 
non-diabetic population [124].  
In conclusion, parental exposure to pollutants and other hostile conditions of the environment 
can elevate the risk of CVD development in the mother and could also trigger reprogramming 
of the foetus that may cause an alteration in the risk of future CVD.  
 
 
 
Figure 3: Developmental origins of health and disease (DOHaD) and the periconceptional period [125]: The 
periconceptional phase of a mouse originating from fertilization, following initial maturation of the oocyte, with 
subsequent formation of the blastocyst after cleavage as well as isolation of lineages of embryonic / 
extraembryonic cells leading to foetal development until late gestation. In vivo, maternal health, metabolism and 
dietary conformation can collectively, or separately, result in periconceptional programming. Similarly, probable 
conditions in vitro including cryopreservation, culture of embryo, fertilization (IVF) as well as other treatments 
supporting conception may also induce related effects [125] (p. 36).  
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1.5 VITAMIN B12: ROLE IN METABOLIC DISEASES 
1.5.1 Vitamin B12 deficiency 
1.5.1.1 Background  
Description of deficiency in vitamin B12 (B12) was first reported in 1849 as a result of its 
deadly consequences observed in patients [126]. However, in 1926, the remedy for slowing the 
fatal effects of B12 deficiency was recognized via ingestion of B12-rich liver diet [126]. So far, 
two key aspects of nutrition involving B12 prevail as a great challenge for human nutrition in 
the past century.  First, the incidence of pernicious anaemia (PA), an exclusive autoimmune 
disorder of humans and second, the challenge of the sources of B12 entirely restricted to animal-
rich protein diets [126]. It was formerly assumed that developing B12 deficiency was a gradual 
process requiring several years for its manifestation and that the vulnerable groups of 
individuals were only strict vegetarians and patients with pernicious anaemia. However, it is 
currently evident that dietary insufficiency and malabsorption of B12 may result in a condition 
of sub-clinical deficiency which could additionally account for some disease consequences in 
patients [126]. PA is normally a result of an autoimmune impairment of intrinsic factor (IF) 
secretion that consequently leads to inception of a severe deficiency of B12. Patients with B12 
deficiency resulting from PA clinically present with macrocytic anaemia and an impairment of 
the bone marrow efficacy affecting all cell lines. It was initially challenging to distinguish B12 
deficiency-induced megaloblastic anaemia from that of folate deficiency because the anaemia 
tends to respond to pharmacologic therapy with folic acid [127]. About 30% of individuals 
diagnosed with PA present with the signs and symptoms associated with demyelination of the 
cerebral part of the brain, the spinal cord and peripheral or cranial nerves. This impairment of 
the central nervous system (CNS) is inversely associated with the severity of the megaloblastic 
anaemia and usually presents with the challenge of adequately finding a deficiency of B12 when 
elucidation of the deficiency is based on the megaloblastic anaemia [128]. Defects associated 
with movement are usually evident in younger children and infants with B12 deficiency. 
Irritability, difficulties in feeding, unusual reflexes, likelihood of coma following obtundation 
and the possibility of long-lasting disabilities resulting from poor brain development are all 
symptoms noticeable in infants [129]. Adequate B12 replacement in cases of PA facilitates 
improvement of disorders of the central nervous system (CNS) as well as reversing the 
condition of megaloblastic anaemia. Therefore, it suggests that identification and treatment of 
PA is essential. Likewise, milder forms of B12 deficiency also require early detection and 
treatment. This may help alleviate the associated hyper-homocysteinaemia presenting as a key 
risk factor for development of cognitive impairment as well as disorders of the vascular system. 
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Evidence of high rates of B12 sub-clinical deficiency have been shown in aged individuals, 
population of vegetarians and inhabitants of several developing countries [126]. Although the 
detailed long-term outcomes associated with B12 deficiency remain quite unclear, the proposed 
implications may involve possible effects on ageing and on the aftermath of pregnancy [126].  
 
1.5.1.2 Epidemiology  
Studies from the Global Hunger Index reported that around 2 billion humans are affected by 
micronutrient deficiency. The WHO is specifically concerned about the levels of vitamin B12 
(B12) and folate due to the increasing prevalence of deficiency across populations [130]. 
Epidemiological studies have clearly shown an association of these nutritional metabolites and 
manifestations of metabolic risk [131-134]. 
Global epidemiological assessment of the prevalence of total B12 deficiency is currently 
missing [135], however, evidence suggests a probable higher prevalence among vegetarians 
and the high prevalence in the vegan population found in Southern part of Asia [136]. 
Manifestation of B12 deficiency could be evident in various groups of individuals, such as 
actively growing children, in pregnancy and adolescence, where high B12 demand is observed. 
Similarly, a significant reduction in B12 intake leading to deficiency may be observed in other 
groups of individuals including the elderly, strict vegetarians as well as those on poor nutrition. 
Among people younger than 60 years in the UK and US, the prevalence of B12 deficiency is 
about 6% [137]. However, almost 20% prevalence has been reported in the elderly over 60 
years of age [137]. Almost 40% of children as well as adults living across Latin America present 
with subclinical and clinical deficiencies of B12 [137].  Countries of both Asian and African 
origin have recorded higher prevalence of B12 deficiency. For instance, 80% prevalence of B12 
deficiency was reported among preschool children in India, 70% in school children of Kenya 
and also 70% prevalence in adults resident in India [138]. The rates of prevalence may, 
however, differ among vegan and vegetarian populations. In the UK, for instance, prevalence 
of B12 deficiency among vegans was 11%, whereas about 62% of pregnant vegetarian women 
were B12 deficient in Ethiopia. [139].  
 
1.5.1.3 Diagnostic markers and risk factors 
Investigation of B12 deficiency is ideal for patients presenting with suspected clinical indicators 
and screening may now be recommended for patients presenting with the known risk factors 
[137, 140, 141]. However, performance of routine screening among individuals presenting with 
an average risk of deficiency of B12 is generally not recommended [142]. Laboratory tests such 
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as complete blood count (CBC) and serum B12 are recommended for patients who may be 
suspected of deficiency in B12 [143]. Deficiency of B12 may be non-dependent on an 
established ‘cut-off’ value internationally but serum B12 levels lower than 150 pmol/l are 
termed deficient (Lower limit: 120-200 pmol/l, normal range: 150-850 pmol/l)  [140, 144]. 
There is evidence that other parameters such as levels of B12-bound-transcobalamin II complex 
(holotranscobalamin, holoTC), serum methyl malonyl CoA (MMA) and homocysteine give a 
more reliable basis for the diagnosis of B12 deficiency [131]. Currently, there are limited data 
on the global prevalence of B12 deficiency based on MMA and homocysteine levels [145]. The 
risk of developing B12 deficiency is higher in vegetarian populations such as in India [146]. 
However it is not uncommon (10-30% prevalence) in other populations, and is higher in 
pregnant populations [144]. Some causes of B12 deficiency are shown in Table 1. 
 
Table 1: Causes of B12 deficiency [137].  
a). Reduced B12 intake 
i. Malnutrition 
ii. Decreased ingestion of animal-rich products 
iii. Strict vegan diet 
 
b). An impairment of B12 bioavailability via gastric wall damage.  
i. Due to total and or partial gastrectomy 
ii. Zollinger-Ellison syndrome 
iii. Pernicious anaemia 
 
c). Impairment of absorption via the intestines 
i. Blind loop syndrome 
ii. Infections including overgrowth of bacteria and giardiasis  
iii. Ileal resection 
iv. Luminal disturbances 
 
d). Inherited (Congenital) conditions of B12 deficiency 
i. Defect of the intrinsic factor receptor such as in ImerslundGräsback syndrome  
ii. Juvenile pernicious anaemia – A congenital intrinsic factor (IF) deficiency 
iii. Cobalamin mutation (C-G-1 gene) 
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iv. Deficiency in Transcobalamin (TC) 
 
e). Increased B12 requirements 
i. Haemolytic anaemic conditions 
ii. HIV infection 
 
f). Drugs 
i. Nitrous oxide 
ii. Alcohol intake 
iii. Inhibitors of proton pump  
iv. Blockers of H2 receptor  
v. Metformin 
 
 
1.5.2 B12: Biochemical structure and synthesis 
B12 (cobalamin) classified as an essential vitamin, is entirely obtained from the diet. Although 
the vitamin is synthesized naturally by the large intestine-resident bacteria in humans, the 
human B12 uptake system is located in the small intestine so this source is generally less 
bioavailable to humans [127, 147]. B12 was first isolated in 1948 [148] following the discovery 
of liver extract as a source of therapy for pernicious anaemia [149]. Using X-ray 
crystallography, B12 was structurally described as a massive organometallic compound with 
size ranging between 1300 to 1500Da [150]. The vitamin is uniquely composed of a central 
cobalt atom linked to six ligands, four of which are structurally reduced to form a corrin ring 
that encircles and is linked to the cobalt atom through direct nitrogen linkages (Fig. 4). Directly 
below the central cobalt atom is an α-axial 5,6-dimethylbenzimidazole (DMB) ligand which, 
through phosphoribosyl moiety, links to the corrin ring and confers a high specificity on the 
vitamin for intrinsic factor (IF) binding in the lower gastrointestinal tract [151]. The β-axial 
ligand (R-ligand) positioned above the corrin ring may vary from a methyl-, 5’-deoxyadenosyl, 
hydroxo-, acquo- or cyano- group. These are named as methylcobalamin, deoxyadenosyl 
cobalamin, hydroxycobalamin, acquocobalamin and cyanocobalamin, respectively.  
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Figure 4: Structure of vitamin B12 [150]: The central point of the vitamin is a cobalt atom to which a corrin ring 
is formed from four of the six ligands directly linked to the cobalt, encircling through nitrogen atom linkages. The 
R-group at the β-axial (upper) position may be a methyl-, 5’-deoxyadenosyl-, hydroxo- or a cyano- group whereas 
the α-axial (lower) ligand is a 5,6-dimethylbenzimidazole (DMB) linked through phosphoribosyl moiety to the 
central cobalt atom.  
 
1.5.3 Sources, bioavailability, transport and hepatic uptake of B12 
B12 is absent in plants but natural sources predominate in animals and their products such as 
eggs and milk. In addition, the gastrointestinal (GIT)-resident microorganisms possess the 
enzymes needed for B12 biosynthesis [152, 153]. The absorptive capability of the GIT of an 
individual undergoes adverse alteration with age which determines the bioavailability of B12 
in humans [154]. However, the absorption of B12 is aided by availability of calcium and takes 
place at the terminal ileum where precise receptors, such as cubam, are expressed on microvilli 
on the intestinal endothelium. The receptors bind to the intrinsic factor (IF) part of the IF-B12 
complex and then delivers the B12 into the peripheral blood [154, 155]. While in circulation, 
plasma protein such as transcobalamin (TC) II plays a major role in transporting B12 to various 
tissues but predominantly in the liver (Fig 5). Therefore, significant amounts of the water 
soluble B12 are stored in the liver of healthy humans. An in-depth study using samples obtained 
from liver biopsies showed an average healthy liver B12 content of 1.94µg (range: 1.41 to 
2.58µg) per gram of wet liver tissue [156]. However, B12 content of the liver may be lower in 
cases of cirrhosis, viral hepatitis, fatty liver and obstructive jaundice [157]. The human body is 
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known to eliminate a total of about 2 to 5µg of vitamin B12 daily, primarily via faeces with 
minimal amounts in urine [158]. 
 
 
 
Figure 5: Hepatic uptake and metabolism of B12: Hepatocytes internalize B12-bound transcobolamin (holo-
TC) with the aid of transcobalamin receptors (TCR) TCbIR / CD320 via endocytosis and it is fused into lysosomes. 
Within this organelle, B12 is liberated from the TC with the free TC (Apo-TC) subjected to degradation while the 
former (B12) is transported to the cytosol and further processed to its catalytic forms: 5’-adenosyl cobalamin 
(AdoCbl) and methyl-cobalamin (MeCbl). These serve either in the mitochondria or cytosol as co-enzymes in the 
Methyl malonyl CoA mutase (MCM) and methionine synthase (MS) pathways, respectively. The transcobalamin 
receptors (TCbIR) are, however, recycled back to the surface of the hepatocyte. 
 
1.5.3.1 Hepatic metabolism of lipids  
Apart from being the principal storage organ for B12, the liver is also paramount in the 
regulation of lipid metabolism in humans. During the stabilization of blood sugar levels, the 
liver, as a result of responding to the energy requirements of the body, induces modifications 
in the hepatic metabolism of lipids and carbohydrates [159]. Following the hepatic uptake of 
glucose and complete restocking of the liver stores of glycogen, facilitated by the insulin-
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dependent liver enzyme glycogen synthase, a further mechanism to facilitate a prolonged 
storage of energy is adopted by the liver via de novo lipogenesis which makes use of the excess 
glucose available [160].  Lipids such as triglycerides (TG) are synthesized from fatty acids and 
glycerol and undergo further packaging into very low density lipoprotein (VLDL) which are 
suitable for delivery via the circulation to the adipose tissue for storage [161, 162]. Hepatic lipid 
metabolism normally undergoes modulations by key hepatic nuclear transcription factors 
including the carbohydrate responsive element binding protein (ChREBP) [163, 164], sterol 
regulatory element binding protein 1c (SREBP 1c), peroxisome proliferator-activated receptor 
gamma (PPAR-γ), liver X receptor alpha (LXR-α) as well as the x-box binding protein 1 
(XBP1) [165, 166]. Regulation of hepatic metabolism of lipids by these transcription factors is 
achieved via their interaction with diverse transporters and lipogenic enzymes present in the 
liver (Fig 6). However, abnormal lipid accumulation in the liver may result from dysregulation 
of the hepatic metabolism of lipids. The lipid accumulation usually begins with simple steatosis 
(SS) and further progresses into steatohepatitis. Possible further progression may end up in 
deadly conditions such as fibrosis of the liver, cirrhosis and even hepatocellular carcinoma 
(HCC). All these conditions, collectively referred to as non-alcoholic fatty liver disease 
(NAFLD) [160], have shown a significant association with hyperlipidaemia, obesity, IR and 
T2DM [167].  
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Figure 6: Hepatic lipid metabolism: Lipogenesis constitutes fatty acid, triglyceride and cholesterol biosynthesis. 
De novo fatty acid synthesis (II) begins with the utilization of citrate, a product from the tricarboxylic acid (TCA) 
cycle in the mitochondria using pyruvate from glycolysis (I), which is further converted to acetyl co-enzyme A in 
the cytosol using the enzyme ATP citrate lyase (ACLY). Palmitate is first synthesized followed by elongation (III) 
into stearate, with both subjected to desaturation (IV) to produce palmitoleate and oleate, respectively, by 
collectively utilizing the enzymes ACC, FASN, ELOVL6 and SCD1. 
Esterification of fatty acids onto a glycerol-3-phosphate (G3P) substrate using enzymes such as GPAT, AGPAT, 
LIPIN1 and DGAT2 leading to triglyceride biosynthesis (V). TGs are further packaged into very low-density 
lipoprotein (VLDL) for storage in adipose tissues. Acetyl CoA derivation from the TCA or Krebs cycle in the 
mitochondria is utilized for cholesterol synthesis (VI) using rate limiting enzymes such as 3-hydroxy-3-
methylglutaryl-CoA synthase (HMGCS). In the fatty acid oxidation (FAO) pathway, long chain fatty acyl CoA 
derived from long chain fatty acids is delivered into the mitochondria with the aid of carnitine palmitoyl transferase 
I alpha (CPT1α) (VII) for subsequent breakdown into small units of acetyl CoA.  
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1.5.4 Vitamin B12 deficiency is associated with obesity 
i. Evidence from pre-clinical studies 
Given the vastness of observational and epidemiological evidences on the effects of B12 on 
metabolic risk, it is expected that animal studies based on these hypotheses provide cues on the 
underlying mechanisms. Studies in adult Wistar rats with restricted B12 levels in Wistar rats’ 
maternal or postnatal period, predicted higher visceral adiposity and resulted in alterations in 
the metabolism of lipids in the offspring [168]. Severe, not moderate, deficiency of B12 also 
induced higher adiposity in C57BL/6 mice [169]. Separate and/or combined exposure to B12 
and folate deficiency for a period of three months in pre-pregnant Wistar rats resulted in an 
increase in body weight in both B12-deficient and folate deficient cases rather than in controls. 
Observation of higher total body fat was evident in B12-deficient animals whereas folate-
deficient rats presented with elevations in visceral fat mass [168, 170]. 
ii. Evidence from clinical studies: 
Among adults in the US, an inverse association was recently shown between serum B12 levels 
and obesity [171]. In a cross-sectional and primary care-based study that assessed the probable 
correlation of B12 with obesity, IR and MetS, low level of B12 was associated with overweight 
and obesity, but not with gender [172]. The study further concluded that B12 had a stronger 
negative association with BMI than IR and MetS [172].  Low concentration of B12 was reported 
to be associated with higher risk of obesity in adolescents and children [173]. In another study, 
mean B12 concentrations were observed to be significantly less in obese children compared 
with healthy volunteers [174] and B12 was also negatively associated with the severity of 
obesity [175]. The inverse relationship between maternal BMI at early stage pregnancy and 
plasma B12 and folate, according to a recent observational study, was observed in obese women 
compared with normal BMI women [176]. In a recent systematic review of clinical data [177], 
lower concentration of B12 was observed among individuals with higher BMI, according to the 
evidence from direct pairwise subnetworks such as; overweight versus control, obesity versus 
overweight and obesity versus control [177]. Sukumar et al. reported that pregnant women 
presenting with insufficiency of B12, at the first trimester, had increased BMI compared with 
those with normal B12 levels [178]. In India, low maternal circulatory levels of B12 were 
suggestive of contributing to an increased likelihood of developing higher adiposity as well as 
the risk of T2DM in pregnancy [179].  
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1.5.5 Vitamin B12 is associated with metabolic disorders 
1.5.5.1 Vitamin B12 and insulin resistance 
i. Evidence from pre-clinical studies: 
Increased resistance and elevated blood pressure in models such as lambs (sheep offspring) due 
to restriction of maternal B12/folate/methionine at conception was explained by induction of 
epigenetic modulations [180]. In addition, the adult male offspring were observed to have 
higher adiposity and altered functioning of their immunity. This evidence was explained by 
observation of male-specific demethylation of the affected loci, therefore, providing concrete 
reasons for the observation of these differences in the phenotypes of the various sexes of the 
offspring [180]. Further, this result of decreased methylation of DNA could be explained by 
lower availability of the methyl donor SAM, affecting the epigenetic mechanisms that account 
for the increased resistance to insulin [180, 181]. 
ii. Evidence from clinical studies:  
Among obese children presenting with IR, the levels of B12 were observed to be significantly 
decreased [182]. Likewise, in other population groups such as non-pregnant adults, polycystic 
ovarian syndrome women and obese adolescents, the evidence of higher insulin resistance has 
been shown to be a result of insufficiency of B12 levels in these subjects [172, 183-185]. In 
obese adolescents with low or borderline levels of B12, there was a  demonstrable association 
between low B12 status and insulin resistance as well as obesity [186]. In an observational 
study based in Pune, India, cases of either B12 deficiency in mothers, particularly at the 
eighteenth week of gestation, or high folate in red blood cells at the twenty-eighth week of 
gestation, independently predicted an increased risk of resistance to insulin in their children 
between the ages of 6 to 7 years [179]. The highest resistance to insulin was observed in children 
born to mothers with both deficiency in B12 and elevated folate in pregnancy [179]. Low levels 
of B12 in the plasma of mothers at early, not late, pregnancy was linked with a significant 
increase in the resistance to insulin, expressed by homeostasis models of insulin resistance 
(HOMA-IR), in their children [187]. However, there was no association established between 
folate status in the mothers and insulin resistance in their children [187]. In White Caucasian 
pregnant women without GDM, evidence of an inverse relationship existing between B12 and 
resistance to insulin has been reported [183]. Children, after six years of age, born to mothers 
with low circulatory B12 levels had higher adiposity as well as high insulin resistance, 
according to the Pune maternal nutrition study [179]. Similarly, within school children of Nepal, 
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high insulin resistance was tangible as a result of low maternal levels of B12 [188]. Though 
these clinical studies provide clear evidence of association between B12 and IR, a study from 
our group further demonstrated that altered, circulating, micro-RNAs derived from adipose 
tissues could possibly mediate adiponegic and insulin resistant phenotypes as a precursor to 
obesity in low B12 pregnant women [189]. 
1.5.5.2 Vitamin B12 and dyslipidaemia  
i. Evidence from pre-clinical studies: 
Mother Wistar rats, deficient in B12, produced offspring which had an increased level of 
adiposity, triglycerides and total cholesterol, as well as decreased leptin and adiponectin 
compared with control offspring, showing dysregulated metabolism of lipids [168]. Similarly, 
offspring of mice presenting with a severe deficiency in B12 during pregnancy, portrayed with 
altered lipid profiles as well as elevation in body fat percentage [190]. Additionally, rats of B12-
deficient, folate-deficient and combined B12-folate-deficient groups had increased plasma TG, 
cholesterol and pro-inflammatory markers including interleukin-6, tumor necrosis factor-alpha 
(TNFα), IL-1b as well as lower adiponectin concentrations [170]. B12 deficiency inhibited 
hepatic beta oxidation as well as lipolysis in rat offspring born to B12 deficient mothers whereas 
supplementation during parturition resulted in restoration as in controls [191]. Similarly, 21-
day old offspring of methyl donor deficient rats with NAFLD displayed dysregulation of genes 
involved in the beta-oxidation of fatty acids [192]. An adipocyte model study from our group 
targeting the elucidation of the cellular mechanism induced by low B12 in human adipocyte 
cell line (Chub-S7), exhibited elevated levels of cholesterol as well as hyper-homocysteinaemia 
in low B12 cells compared with controls.  This was explained by a reduction in the methylation 
potential (MP), SAM: SAH ratio [193]. Validation of the above findings was further endorsed 
in primary human adipocyte models demonstrating that B12-deficient, primary human 
adipocytes had significantly elevated levels of total cholesterol, homocysteine and mRNA 
expression of genes involved in the biosynthesis and regulation of cholesterol compared with 
controls [193]. 
ii. Evidence from clinical studies: 
A deficiency of B12 was observed to be significantly associated with both low HDL and 
hyperhomocysteinemia, whereas following control for co-founders homocysteine was found to 
be negatively correlated with all lipid indices with the exemption of HDL [194]. A negative 
correlation was established between serum B12 levels and the prevalence of metabolic 
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syndrome, marked by any three of the following biomarkers: high BMI, fasting blood glucose, 
high triglyceride levels, low HDL and high blood pressure in erythroid participants [195].  Our 
clinical studies involving three independent cohorts of women (i) in early pregnancy (ii) at 
child-bearing age (iii) at delivery, revealed that insufficient levels of vitamin B12 were 
associated with elevated levels of LDL-cholesterol, total-cholesterol and cholesterol-to-HDL 
ratio [196]. The study also showed that the women who were due childbirth had high prevalence 
of serum B12 deficiency (39.6%), increased BMI, triglycerides, homocysteine, total cholesterol 
and LDL cholesterol compared with mothers with normal serum B12 levels [196]. To further 
validate this evidence, maternal subcutaneous adipose tissues (ScAT) obtained from mothers 
with low B12, showed that the expression of genes involved in regulation and biosynthesis of 
cholesterol like HMGCR, SREBF2, LDLR and SREBF1 was significantly upregulated 
compared with controls [193]. Further evidence have shown that babies born to B12 deficient 
mothers are ‘thin-fat’, a term describing phenotypically lean individuals with increased fat 
accumulation in their bodies as well as decreased lean mass [179, 197]. This may consequently 
lead to elevated resistance to insulin as well as increased risk of developing CVD in adulthood 
[179, 197]. Thus, these studies implicate low B12 status at child-bearing age, in mothers at early 
pregnancy and pregnant mothers at delivery, with a link to increased LDL cholesterol, total 
cholesterol, cholesterol-to-HDL ratio and subsequent insulin resistance. Studies in patients with 
NAFLD and NASH showed that deficiency in B12 significantly increased the levels of 
triglycerides, cholesterol and blood glucose levels in these patients [198]. A similar study by 
Setola et al [199] demonstrated that folate and B12 treatment in patients with MetS improved 
IR and endothelial dysfunction as well as decreased homocysteine levels, suggesting the 
beneficial effects of these vitamins on CVD risk factors. 
 
1.5.5.3 Vitamin B12 and cardiovascular diseases 
i. Evidence from pre-clinical studies: 
B12 deficiency resulting from prolonged stress, a condition associated with disruption in the 
intrinsic factor release from gastric parietal cells of the stomach, in adult male Sprague-Dawley 
rat models, was shown to be significantly interconnected with peripheral cortisol and androgen 
testosterone levels as well as demonstrated an association with vascular dysfunction [200]. A 
study delivered simultaneous therapy with 10mg/kg folate and 500 µg/kg B12 for exactly four 
weeks aiming to assess the effect of B12 and folate supplementation on isoprenaline (ISO)-
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induced myocardial infarction (MI) in hyperhomocysteinemic (Hhcy) rats. It demonstrated 
significant reductions in the elevated heart rate and blood pressure as well as attenuation of 
severe cardiac histopathological alterations [201]. It is, therefore, recommended that 
aggravation of MI results from hyperhomocysteinemia (Hhcy).  Therefore, B12 and/or folate 
administration reduces MI risk and Hcy levels accounting for reduced harmful consequences 
associated with Hhcy [201].   
ii. Evidence from clinical studies: 
B12 is involved in the remethylation of homocysteine leading to generation of methionine 
[202]. Therefore, deficiency of B12 is associated with an elevation of circulatory homocysteine 
which is known to be an independent risk factor for cardiovascular diseases (CVD) [203]. In 
Chinese subjects, a recent study showed a correlation between the highest circulating levels of 
B12 and the lowest Hcy levels in patients presenting with CVD only [204]. However, in 
Japanese subjects, evidence of an inverse association was observed between dietary intake of 
folate and B6 and the incidence of heart failure mortality in men as well as mortality resulting 
from stroke, CAD and total CVD in women, though no association was evident between B12 
ingestion and risk of mortality [205]. This was similar to the evidence in an American 
population study in which a follow-up on subjects after 7.3 years therapy with B12, B6 and 
folate combination pill resulted in no significant reduction in a joint end stage of total CV events 
among women at high risk, although evidence of a significant decrease in homocysteine was 
observed [206]. Other studies suggested that supplementation with 250µg B12 and 5mg folate 
resulted in 32% reduction of fasting plasma total homocysteine (tHcy) level following 12 weeks 
of therapy in patients with coronary artery disease (CAD) [207]. Recent evidence has shown 
that elevated tHcy and decreased circulatory B12 levels in women, demonstrated a strong 
association with higher risk of all-cause and CVD deaths in the aged [208]. Meta-analysis of 
several prospective studies showed reliable evidence of a correlation existing between plasma 
total homocysteine (tHcy) and elevated CVD risk [209]. For instance, twelve (12) RCTs 
targeting an established renal disease or CVD with B12 supplementation (3 studies) using a 
dosage range 0.4 to 1.0 mg B12 per day, accounted for a significant reduction in the risk of 
developing stroke [209]. Hyperhomocystenemia and the incidence of cardiovascular risk and 
CV events are associated with chronic kidney disease (CKD), end-stage renal disease (ESRD) 
and dialysis [210-212]. Although CKD patients demonstrate an impairment in tissue uptake of 
B12 resulting in functional deficiency [213], the current evidence remains unclear to consider 
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altered B12, folate and elevated homocysteine  levels as markers for CVD and CV mortality 
risk in ESRD and CKD individuals [214].  
 
1.5.6 Molecular mechanisms regulating B12 deficiency and lipogenesis 
Environmental factors such as nutrition may affect lipid metabolism by targeting at the 
transcriptional level and, thereby, regulating the expression of genes as well as the phenotype 
without altering the sequence of nucleotides by the process of epigenetics [215]. B12 plays a 
crucial role in humans by acting as a cofactor in the reaction pathways essential for maturation 
and preservation of cells [216, 217]. In the cytosol, B12 is a cofactor for methionine synthase 
(MS), which is actively involved in the reaction resulting in generation of methionine from 
homocysteine and further used for synthesis of s-adenosyl methionine (SAM) that acts as a 
methyl donor for methylation of several biochemical processes. Currently, the well-known 
markers of epigenetic mechanisms involved in the regulation of lipid metabolism and insulin 
resistance are DNA methylation, microRNAs, chromatin remodelling as well as modification 
of histones [218, 219]. B12, acting as a co-enzyme for a source of methyl groups (SAM), 
regulates these epigenetic mechanisms and several transcriptional as well as post-translational 
factors involved in the process of de novo lipogenesis. In the mitochondrial-based propionate 
metabolism pathway, B12  serves as a cofactor in the conversion of methyl malonyl-CoA to 
succinyl-CoA by methyl malonyl-CoA mutase (MCM) [220]. Succinyl-CoA is utilized as 
substrate in the Krebs cycle for ATP synthesis essential for the sustenance of cellular 
metabolisms (reviewed by [221]) and utilized for haemoglobin synthesis in red blood cell 
production. Deficiency of B12, therefore, results in a reversible increase in methyl malonyl-
CoA leading to methyl malonic acidaemia (MMA). MMA, in turn, acts as a potent inhibitor of 
the rate limiting enzyme CPT1, critical for the breakdown of long chain fatty acids in the beta 
oxidation pathway. This results in dyslipidaemia due to the build-up of FAs and triglycerides  
(reviewed by [222]), accounting for higher lipogenesis and IR [223] (Fig 7).  
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Figure 7: The Cellular role of B12 in lipogenesis. B12 deficiency in the cytosol results in the decline of 
methionine synthesis leading to reduced production of methyl donor SAM-e, accounting for 
hyperhomocysteinaemia with reciprocal elevation in s-adenosyl homocysteine (SAH) level, which is a potent 
inhibitor of DNA methyl transferases (DNMTs). The inhibition of DNMTs, together with low levels of SAMe, 
results in hypomethylation of DNA and altered gene expressions. Again, beta oxidation of fatty acids is grossly 
impaired resulting from the inhibition of the rate limiting enzyme CPT1 by build-up of MMA from MM-CoA 
inside the mitochondria due to insufficiency of the B12 cofactor required in the propionate metabolism pathway 
for conversion of methyl malonyl CoA to succinyl-CoA.  
 
1.5.7 Epigenetic mechanisms underlying B12 deficiency in lipid metabolism:  
There is, currently, emerging evidence suggesting that abnormalities, associated with one-
carbon metabolites due to B12 deficiency, might possibly exert their modulations through 
epigenetic mechanisms. Some preliminary findings have indicated that induction of alterations 
in normal methylation of DNA is due to changes in levels of one-carbon metabolites. However, 
it was suggested that, in order to elucidate the molecular mechanism underlying these effects, 
there is a need for future studies to target combinations of gene expression assays with 
epigenetic studies [221]. Studies in animals might be initially informative since there is a 
likelihood of confrontations in the elucidation of molecular mechanisms in humans due to 
tissue-specificity orientation of epigenetic phenomena [221]. 
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1.5.7.1 Regulation of DNA methylation and lipid metabolism through B12 deficiency 
Methylation generally involves the process of transferring a methyl group to substrates such as 
enzymes, proteins, amino acids and DNA of various cells and tissues in the body [224].  In the 
process, guanine is normally bound with 5-methylcytosine following its development from 
cytosine [225]. Usually, hypermethylation of global DNA and CpG islets, located within the 
promoters of genes involved in lipid synthesis, accounts for the stability of the genome and 
silencing of the lipogenic genes, respectively [226]. This is greatly dependent on the availability 
and sufficiency of SAM synthesized with the aid of methyl donors such as B12 and folate [218]. 
B12 deficiency independently impairs the methionine synthase action [227] affecting 
SAM/SAH ratio which is a key determinant of the methylation potential of cellular DNA, 
thereby inducing dysregulation of gene expressions [228, 229]. Demethylation, associated with 
DNA of the genome, persists as one of the earliest evidence of epigenetic modifications induced 
by methyl donor-deficient diets contributing to hepatocarcinogenesis in animals [230]. 
Study of zebrafish showed that parental micronutrient deficiency affects liver DNA methylation 
and gene expression of lipogenesis leading to lipid accumulation in the F1 offspring [229]. High 
global methylation of DNA and promoter region methylation of lipid genes are critical to the 
maintenance of normal physiology of metabolism [192, 231] by ensuring stability of the 
genome and silencing of abnormal lipogenic genes [226]. The adipocyte model showed that 
hypomethylation in promoter regions led to higher expressions of LDLR and SREBF1 genes 
and cholesterol biosynthesis under low B12 conditions [193]. Increased genome incorporation 
with uracil subsequent to hypomethylation, due to low B12, was observed in rats  [232], 
whereas fatty acid supplementation in low B12 conditions could not restore global methylation 
[233]. Evidence of hypomethylation, as observed in low B12, was observed in the CpG sites of 
some liver-derived genes involved in the pathogenesis of T2DM due to folate deficiency [234]. 
Methyl donor supplementation in rat obesogenic models ameliorated hypomethylation near the 
promoter of genes such as AGPAT3, SREBF2 and ESR1 (estrogen receptor-1) resulting in the 
reversion of higher fatty acid, triglyceride and cholesterol accumulation in the liver [235]. These 
studies, thus, implicate that methyl donor deficiency compromises methylation capacity 
expressing a direct consequence in the dysregulation of lipid metabolism [229, 236, 237] and 
this can be reversed by supplementation of methyl donors. 
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1.5.7.2 Regulation of microRNAs (miRNAs) and lipid metabolism through B12 deficiency 
MicroRNAs (miRNAs), formerly termed as small temporal RNAs (stRNAs), are the class of 
small RNAs comprising 21-25 nucleotides of single-stranded RNA which are highly conserved 
and engaged in regulating the expression of genes at the transcriptional and post-translational 
levels [238]. MiRNAs physiologically express diversified patterns and are involved in the 
regulation of genes in lipid metabolism and inflammation [239, 240]. MiRNAs are proposed to 
be involved in modulation of adipocyte differentiation accounting for the development of 
T2DM, insulin resistance and dyslipidaemia [189, 241, 242]. Genes involved in the hepatic 
metabolism of fatty acids as well as insulin signalling may be repressed by some miRNAs 
regulating the levels of HDL, TG and insulin [243]. About 100 different miRNAs are expressed 
differentially in cases of NASH in humans [244] and alterations in miRNA-29c, miRNA-34a, 
miRNA-200b and miRNA-155 are due to methyl-donor deficiencies [245]. In humans, miRNA-
122 is largely expressed in hepatocytes but under-expressed in NASH [245] and, therefore, it 
is proposed to be the potential target for treatment of dyslipidaemia [246] and high cholesterol 
[247]. Using adipocyte models, our group reported that twelve different adipocyte-derived 
miRNAs targeting PPARγ (miRNA-31, miRNA-130b and miRNA-23a), adipocyte 
differentiation (miRNA-143, miRNA-145, miRNA-146a, miRNA-125b, miRNA-222 and 
miRNA-221), CEBPα (miRNA-31) and pathways of insulin resistance (miRNA-107 and 
miRNA-103a) were identified to be significantly altered as a result of low B12, thereby 
modulating adipocyte differentiation and physiology [189]. Assessing the relationship between 
obesity, serum B12 and miRNAs, maternal BMI was inversely correlated with B12, with the 
latter further showing  a significant positive correlation with seven different circulating 
miRNAs (miRNA-27b, miRNA-130, miRNA-103a, miRNA-107, miRNA-125b, miRNA-23a, 
miRNA-221 and miRNA-222) [189]. Finally, following the adjustment for confounding 
variables like age, insulin, glucose, smoking, parity and usage of supplement, four different 
miRNAs within the circulation (miRNA-107, miRNA-27b, miRNA-23a and miRNA103a) in 
addition to circulating B12 levels were found to be independently associated with BMI [189]. 
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1.5.7.3 Regulation of hepatic lipogenesis through modifications of histone by B12 
The mechanistic role of B12 in the regulation of hepatic lipid metabolism via modulation of 
histones is primitive. However, mechanisms including methylation, acetylation, 
phosphorylation as well as ubiquitylation are proposed to be involved in ubiquiltylation 
modification of histones that contribute to regulation of lipid metabolism in the liver [248]. The 
most intensively understood mechanism directly involved in dysregulation of hepatic lipid 
metabolism is the acetylation of histones which is normally catalysed by histone 
acetyltransferases (HATS) and histone deacetylases (HDACs). In female C57BL/6 mice, 
chronic vitamin B12 deficiency showed altered expression of histone-modifying enzymes in 
the brain and abnormal behavioural anomalies [249]. Recent evidence from pilot data indicated 
that folate deficiency in the liver had an association with modulations presenting with higher 
levels of methylation in H3K4 [250]. Reduced methylation of histone has also been shown in 
liver X receptor-alpha (LXRα) in rats, following consumption of a high-fat diet after the third 
generation in rats [251]. Histones such as H3 lysine 4 (H3K4) and H3 lysine 9 (H2K9) are 
known to be subjected to regulation by methylation of the histones in association with DNA 
methylation [252]. Evidence of  deficiency in the methyl donor, choline, in C57BL/6 mice at 
the 12th -17th  days of gestation resulted in alterations in the methylation of histone H3, whereas 
choline, after undergoing conversion to betaine, enhanced re-methylation to homocysteine 
[253]. Profound evidence showing the link between NAFLD [254], resistance to insulin and 
obesity, and modification of histone such as demethylation of H3 at lys9, has been shown [255]. 
Conditions of hyperlipidaemia and obesity were observed in mouse models following the 
functional loss of Jhdm2a, the H3K9-specific demethylase, which implies that the status of 
methylation of H3K9 is very essential and tends to regulate the expression of metabolic genes 
[256]. The need for further studies is, however, recommended for elucidating the role of B12 
on the metabolism of lipids via modulation of histones. 
 
1.5.8 Impact of one carbon micronutrient supplementation on hepatic lipid metabolism 
In recent times, although agents that potentially resolve insulin resistance appear promising, the 
general therapy for correcting dysregulation of lipogenesis has not been established.  However, 
current treatment may be reliant on alterations in lifestyle such as diet, weight reduction and/or 
exercise [257]. It is generally suggested that interventions involving fortification of foods, 
supplementation with B12 during preconception period and provision of adequate education 
37 
 
could, collectively, be the most effective ways to enhance improvement in the levels of  B12 in 
infants as well as mothers [258]. Supplementing with diet rich in methyl donors such as vitamin 
B6, B9 and B12, is the principal way to significantly influence methylation of DNA because of 
their contribution to the synthesis of SAM [259]. A similar micronutrient, bataine, obtained 
from food, functions as a methyl donor and has been identified as a potent alleviator of fatty 
livers.  Bataine was shown to facilitate the export of triglycerides from the liver as a way of 
attenuating steatosis of the liver, especially in cases of NAFLD [260]. Post-supplementation 
with only B12 was associated with significant alteration in the methylation of DNA in which 
589 CpGs demonstrated differential methylation in addition to 2892 regions. Supplementation 
with both B12 and folate resulted in differential methylation of 169 CpGs and 3241 regions, 
thereby influencing the expression of genes associated with type 2 diabetes [261]. Evidence of 
higher percentage of transmethylation to methionine and reduced transsulfuration to cysteine 
were observed as a result of supplementation with both B12 and milk protein compared with 
only milk supplementation in women. Therefore, among Indian women presenting with low 
B12 in early pregnancy, supplementation with B12 and energy-protein balance plays a crucial 
role in enhancing the optimum function of the methionine cycle especially at the third trimester 
of pregnancy [262]. Similarly, B12, folate, choline and betaine-rich methyl donor supplements 
were used to regress the accumulation of fats in the liver induced by high-fat-sucrose (HFS) 
probably by changing the levels of methylation of CpG areas in the promotor regions of 
SREBF2, oestrogen receptor 1 (ESR1) and/or acylglycerol-3-Oacyltransferase-3 (AGPAT3) 
[237]. Hypermethylation of DNA in FAS gene expression was estimated after supplementation 
with methyl donors that apparently boosted the retrogression of NAFLD induced by high fat 
diet (HFD) [235]. Normalization of histochemical indices in hepatic lobules was achieved in an 
animal-model study where the accumulation of lipids towards the centre of hepatic lobules was 
brought under control subsequent to treatment with methionine in combination with vitamin 
B12 rather than B15 [263]. Depreciation of circulatory levels of homocysteine and methyl 
malonic acid was attained following the upregulation of plasma B12 levels in infants whose 
mothers were supplemented orally with B12 during pregnancy [264].  
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1.6 Conclusion and prospects 
In summary, the global incidence of metabolic disorders is increasing with advancement in 
urbanization alongside several environmental and genetic factors. The pathogenesis of MetS, 
T2DM and CVD have been associated with deficiencies in micronutrients such as B12 and 
folate. The role of B12 deficiency in the pathogenesis of several metabolic disorders especially 
T2DM, CVD, IR as well as obesity, has been studied at the pre-clinical and clinical levels. 
Clinically, B12 deficient subjects such as children, adolescents and pregnant mothers presented 
with increased adiposity and higher lipids, as well as increased risk of T2DM, CVD and IR later 
in life. Babies born to B12 deficient mothers via maternal programming have a high 
accumulation of fats at birth with higher risk of developing CVDs later in life. However, there 
is no evidence, so far, whether dyslipidaemia and increased adiposity due to B12 deficiency are 
directly linked with regulation in the hepatic metabolism of lipids. Therefore, exploring the 
effect of B12 deficiency on the hepatic lipid metabolism in humans, as well as elucidating the 
mechanisms underlying the modulations, will help develop novel biomarkers for the diagnosis 
of MetS and will further enhance the development of possible therapeutic targets. 
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1.7 Hypothesis and Aims  
 
The liver is foremost in the storage and metabolism of about 50% of the entire body’s B12. 
Following uptake and processing into its co-enzyme forms, B12 plays a crucial role as a 
cofactor to rate limiting steps and/or enzymes in two key metabolic pathways such as the MS 
and the MCM pathways in the hepatocellular cytoplasm and mitochondria, respectively. 
Evidence has shown that B12 deficiency is associated with attenuation of these pathways 
leading to accumulation of metabolites such as homocysteine and MMA which are known to 
be associated with metabolic risk including CVD. Similarly, the liver is again paramount in the 
regulation of lipid metabolism including de novo fatty acids (FA), TG and cholesterol 
biosynthesis, as well as fatty acid oxidation (FAO). Dysregulation in the hepatic metabolism of 
lipids is normally associated with the accumulation of lipids in the liver in the form of simple 
steatosis (SS), steatohepatitis (SH), non-alcoholic steatohepatitis (NASH) and non-alcoholic 
fatty liver disease (NAFLD). These disorders are also known to be associated with other 
metabolic disorders including dyslipidaemia, obesity, MetS, T2DM and CVD. There is 
evidence that low B12 accounts for dysregulation of normal adipocyte integrity and function in 
the storage of lipids, thereby leading to the accumulation of higher levels of TG and cholesterol. 
We, therefore, hypothesize that B12 deficiency may affect hepatic metabolism of lipids 
accounting for dysregulation in the lipogenesis (FA, TG and cholesterol biosynthesis) and FAO 
pathways.  
 
In order to investigate this, we aimed: 
1. To assess the liver regulation of B12 uptake and storage in various circulatory B12    
concentrations ranging from deficient to high levels; 
2. To assess whether B12 deficiency affects hepatic de novo lipogenesis; 
3. To assess whether deficiency in B12 affects the hepatic FAO pathway; 
4. To assess the effect of B12 deficiency on the lipid lowering influence of metformin in 
human hepatocyte cell line; 
5. To elucidate the underlying mechanisms regulating the lipid metabolism in B12 
deficient state in human hepatocyte cell line. 
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Chapter Two – Materials and Methods 
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2.1 List of Materials and Reagents 
2.1.1 Reagents / materials for culture of Hep G2 cell line (ATCC, Manassas, Virginia, USA) 
Eagle’s minimal essential media (EMEM) (Custom-made, School of Life Sciences, University 
of Warwick, UK) 
Eagle’s minimal essential medium powder (Fisher Scientific, Loughborough, UK) 
Vitamin B12 (5g- powder) (Sigma Aldrich, UK) 
Penicillin / Streptomycin (100X) (Fisher Scientific, Loughborough, UK) 
Foetal Bovine Serum, heat inactivated (South American origin) (Fisher Scientific, 
Loughborough, UK) 
L-Glutamine (100X) (Invitrogen, Fisher Scientific, Loughborough, UK) 
Seahorse XF Base Media (Agilent Technologies, Stockport, UK) 
Bovine Serum Albumin (Sigma-Aldrich, Gillingham, Dorset, UK) 
0.05% Trypsin-EDTA (Invitrogen, Fisher Scientific, Loughborough, UK) 
1, 1-Dimethylbiguanide hydrochloride (Metformin) (Sigma-Aldrich, Gillingham, Dorset, UK) 
Krebs-Henseleit Buffer (Sigma-Aldrich, Gillingham, Dorset, UK) 
Adiponectin human, recombinant (Sigma-Aldrich, Gillingham, Dorset, UK) 
AICAR (Sigma-Aldrich, Haverhill, UK) 
 
2.1.2 Reagents for protein characterization studies 
Primary antibodies 
Anti-CD320 Antibody-C-Terminal (ab171634) (ABCAM PLC, Cambridge, UK) 
Anti-TCN2 antibody (ab189871) (ABCAM PLC, Cambridge, UK) 
AMPK Alpha (D63G4) Rabbit mAb (Cell Signalling Technology, London, UK) 
Acetyl-CoA Carboxylase (C83B10) Rabbit mAb (Cell Signalling Technology, London, UK) 
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Phospho-AMPK Alpha (Thr172) (D795E) Rabbit mAb (Cell Signalling Technology, London 
UK) 
Phospho-Acetyl-CoA Carboxylase (Ser79) (D7D11) Rabbit mAb (Cell Signalling Technology, 
London, UK) 
Beta-actin antibody (49675) (Cell Signalling Technology, London, UK) 
 
Secondary antibodies 
Anti-rabbit IgG HRP-linked Antibody (Cell Signalling Technology, London, UK) 
 
Reagents for gel preparation 
10% Resolving Gel (two plates): Resolving buffer (5.2ml), Acrylamide (6.6ml), distilled water 
(7.8ml), 10% APS (150µl) and Temed (15µl)  
10% Stacking Gel (two plates): Stacking buffer (2.5ml), Acrylamide (1.3ml), distilled water 
(6.1ml), 10% APS (50µl) and Temed (10 µl) 
 
General western blot reagents 
Protein Assay Dye Reagent Concentrate; Bradford reagent (Bio-Rad Laboratories LTD, Hemel 
Hempstead, UK) 
Protein Ladder; Page ruler plus prestained; Nine proteins spanning 10 to 250kDa (Thermo 
Scientific Pierce, Fisher Scientific, Loughborough, UK) 
Ponceau S stain (Sigma-Aldrich, Gillingham, Dorset, UK) 
Whatman filter paper (Sigma-Aldrich, Gillingham, Dorset, UK) 
PVDF membrane (Sigma-Aldrich, Gillingham, Dorset, UK) 
Enhanced chemiluminescence (ECL) (BIO-RAD Laboratories LTD, Hemel Hempstead, UK) 
I-Block(tm) Protein-Based Blocking Reagent (Invitrogen, Fisher Scientific, Loughborough, 
UK) 
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Temed (Sigma-Aldrich, Gillingham, Dorset, UK) 
10% Ammonium per sulphate (APS) (Sigma-Aldrich, Gillingham, Dorset, UK) 
Acrylamide (Sigma-Aldrich, Gillingham, Dorset, UK) 
Running Buffer (Sigma-Aldrich, Gillingham, Dorset, UK) 
Stacking Buffer (Sigma-Aldrich, Gillingham, Dorset, UK) 
Methanol (Sigma-Aldrich, Gillingham, Dorset, UK) 
 
2.1.3 Reagents and materials for RNA, cDNA and gene expression studies 
Qiazol (Thermo scientific, UK) 
Chloroform (Sigma-Aldrich, Gillingham, Dorset, UK) 
Isopropanol (Fisher Scientific, Loughborough, UK) 
RNASe-free water (Invitrogen, Fisher Scientific, Loughborough, UK) 
Enzyme mix (Thermo scientific, Loughborough, UK) 
5X Reaction buffer (Thermo scientific, Loughborough, UK) 
10mM nucleotides dNTP Mix (Applied Biosystems, Warrington, UK) 
Eukaryotic 18S rRNA Endogenous Control (Applied Biosystems, Warrington, UK) 
TaqMan Universal PCR Master Mix (Applied Biosystems, Warrington, UK) 
Reverse transcriptase RevertAid H Minus MMLV (Applied Biosystems, Warrington, UK) 
Random hexamer primer (Applied Biosystems, Warrington, UK) 
RiboLock RNase Inhibitor; Recombinant (Applied Biosystems, Warrington, UK) 
Frosted and semi-skirted, thin wall 96 x 0.2ml high profile plate (Geneflow Ltd, Elmhurst, UK) 
Amplification grade DNase 1 Kit (Sigma-Aldrich, Gillingham, Dorset, UK) 
100x ROX reference dye (Sigma-Aldrich, Gillingham, Dorset, UK) 
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2.1.4 Genes for RT- qPCR 
2.1.4.1 Genes for Human  
SREBF1 - Hs01088691_m1 (Applied Biosystems, Warrington, UK) 
ACACA - Hs01046047_m1 (Applied Biosystems, Warrington, UK) 
ATP citrate lyase (ACLY) - Hs00982738_m1 (Applied Biosystems, Warrington, UK) 
FASN - Hs01005622_m1 (Applied Biosystems, Warrington, UK) 
SCD – Hs01682761_m1 (Applied Biosystems, Warrington, UK) 
DGAT2 - Hs01045913_m1 (Applied Biosystems, Warrington, UK) 
Adipo R2 - Hs00226105_m1 (Applied Biosystems, Warrington, UK) 
Adipo R1 - Hs00360422_m1 (Applied Biosystems, Warrington, UK) 
CPT-1α Hs00912671_m1 (Applied Biosystems, Warrington, UK) 
ACADM - Hs00936575_m1 (Applied Biosystems, Warrington, UK) 
LDLR - Hs01092524_m1 (Applied Biosystems, Warrington, UK) 
IDI1 - Hs00743568_s1 (Applied Biosystems, Warrington, UK) 
CaMMKK2 - Hs00198032_m1 (Applied Biosystems, Warrington, UK) 
DGAT1 - Hs01020362_g1 (Applied Biosystems, Warrington, UK) 
LKB1/ STK11 - Hs00975988_m1 (Applied Biosystems, Warrington, UK) 
HMGCR - Hs00168352_m1 (Applied Biosystems, Warrington, UK) 
ChREBP or MLXIPL - Hs00975714_m1 (Applied Biosystems, Warrington, UK) 
ATP citrate lyase (ACLY) - Hs00982738_m1 (Applied Biosystems, Warrington, UK) 
ELOVL6 - Hs00907564_m1 (Applied Biosystems, Warrington, UK) 
GPAT1 (GPAM) - Hs00326039_m1 (Applied Biosystems, Warrington, UK) 
AGPAT2 - Hs00944961_m1 (Applied Biosystems, Warrington, UK) 
Lipin1 - Hs00299515_m1 (Applied Biosystems, Warrington, UK) 
45 
 
ACSL1 Hs00960561_m1 (Applied Biosystems, Warrington, UK) 
CACT or SLC25A20 Hs00386383_m1 (Applied Biosystems, Warrington, UK) 
ACADL Hs00155630_m1 (Applied Biosystems, Warrington, UK) 
ACADS Hs00163506_m1 (Applied Biosystems, Warrington, UK) 
HADHA Hs00426191_m1 (Applied Biosystems, Warrington, UK) 
HADHB Hs01027271_m1 (Applied Biosystems, Warrington, UK) 
2.1.4.2 Primers for mouse genes 
L19:  GGAAAAAGAAGGTCTGGTTGGA–Forward, TGATCTGCTGACGGGAGTTG-
Reverse (Sigma-Aldrich, UK) 
CD320: GGTCCAAGTCTCCGGCTCTA-Forward, AGCACATGACTCAATCCTACAGT-
Reverse (Sigma-Aldrich, UK) 
TCN2: CTTTGCTGGATCTTCCTTGG-Forward, TCCTGGGGTTTGTAGTCAGC-Reverse 
(Sigma-Aldrich, UK) 
 
2.1.5 Reagents and materials for Radioactive flux assay 
Glass TLC Plate (Thermo scientific, Loughborough, UK) 
14C 50µCi (1.85MBq) Oleic Acid (Perkin Elmer Las LTD, Seer Green, UK)  
Oxygen-free nitrogen gas (BOC LTD, Middlesbrough, UK) 
100mM L-Carnitine inner salt (Sigma-Aldrich, Gillingham, Dorset, UK) 
43mg Glyceryl tri-palmitate (Sigma-Aldrich, Gillingham, Dorset, UK) in chloroform (500µl) 
70mM Sodium oleate (Sigma-Aldrich, Gillingham, Dorset, UK) 
Iodine, ACS reagent (Sigma-Aldrich, Gillingham, Dorset, UK) 
Rectangular TLC developing tanks (Sigma-Aldrich, Gillingham, Dorset, UK) 
Flat Head Borosilicate Glass (Sigma-Aldrich, Gillingham, Dorset, UK) 
0.88 % (w/v) Potassium Chloride (Sigma-Aldrich, Gillingham, Dorset, UK) 
Hexane (Sigma-Aldrich, Gillingham, Dorset, UK) 
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Glyecerol (Sigma-Aldrich, Gillingham, Dorset, UK) 
Diethyl ether (Sigma-Aldrich, Gillingham, Dorset, UK) 
Formic acid (Sigma-Aldrich, Gillingham, Dorset, UK) 
Chloroform (Sigma-Aldrich, Gillingham, Dorset, UK) 
Methanol (Sigma-Aldrich, Gillingham, Dorset, UK) 
 
2.1.6 Reagents and materials for seahorse flux assay 
Seahorse XF24 FluxPak (Agilent Technologies, Stockport, UK) 
Oligomycin D (Sigma-Aldrich, Gillingham, Dorset, UK) 
Rotenone (Sigma-Aldrich, Gillingham, Dorset, UK) 
Antimycin A (Sigma-Aldrich, Gillingham, Dorset, UK) 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (Sigma-Aldrich, Gillingham, 
Dorset, UK) 
Palmitate (Sigma-Aldrich, Gillingham, Dorset, UK) 
Bovine Serum Albumin (Sigma-Aldrich, Gillingham, Dorset, UK) 
Sodium Pyruvate (Sigma-Aldrich, Gillingham, Dorset, UK) 
L-Glutamine (Sigma-Aldrich, Gillingham, Dorset, UK) 
Sodium Chloride (Sigma-Aldrich, Gillingham, Dorset, UK) 
Glucose (Sigma-Aldrich, Gillingham, Dorset, UK) 
 
2.1.7a Media formulations 
Media for seahorse assay (oxygen consumption rate - OCR) 
- 1x Krebs-Henseleit Buffer (KHB) (Sigma-Aldrich, UK), 10mM Hepes, 0.1% BSA, 
2mM Glutamine, Sodium Pyruvate, 2.5mM Glucose, pH 7.4, Filter sterilize  
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Eagle’s minimal essential media (EMEM) for cell culture 
- Custom-made B12-deprived-EMEM media supplemented with compounds such as 1% 
v/v Penicillin/ Streptomycin, 1% v/v L-Glutamine, 10% v/v FBS and various 
concentrations of B12.  
2.1.7b Buffers 
5X Krebs-Henseleit Buffer (KHB) (Sigma-Aldrich, UK) (1 Litre) 
- 32.53g Sodium Chloride (NaCl), 1.752g Potassium Chloride (KCl), 1.204g Magnesium 
Sulphate (MgSO4) and 0.852g Disodium Hydrogen Phosphate (Na2HPO4) dissolved 
in 1 litre of distilled water, filter sterilized and stored at 4oC. 
Stop solution for DNase step (Sigma-Aldrich, Gillingham, Dorset, UK) 
- Constitutes 50mM Ethylenediamine tetraacetic acid (EDTA) 
 
Reaction buffer of 10x DNase I (Sigma-Aldrich, Gillingham, Dorset, UK) 
- Made of 200mM Tris-HCl and 20mM Magnesium Chloride (MgCl2) at pH 8.3 
Phosphate Buffered Saline (PBS) 
- 2.5mM Potassium Chloride (KCl), 10mM Disodium hydrogen Phosphate (Na2HPO4), 
140mM Sodium Chloride (NaCl) and 1.5mM Potassium Dihydrogen Phosphate 
(KH2PO4) at pH 7.2 
 
RIPA lysis buffer (Merck Millipore, UK) (with cocktail of protease and phosphatase inhibitors)  
- 1x RIPA lysis buffer, 2 tablets of Roche Complete-Mini protease inhibitor cocktail 
(Sigma-Aldrich, Gillingham, Dorset, UK), 20mg sodium vanadate (Sigma-Aldrich, 
Gillingham, Dorset, UK) and 8mg Sodium Fluoride (Sigma, UK)  
 
Buffers for western blot 
Running Buffer: 100ml 10x Tris-Glycine (SDS) (Bio-Rad Laboratories Ltd, Hemel, 
Hempstead, UK) in 900ml distilled water  
Transfer Buffer: 100ml 10x Tris-Glycine (Bio-Rad Laboratories Ltd, Hemel, Hempstead, UK), 
200ml Methanol (Sigma-Aldrich, Gillingham, Dorset, UK) and 700ml distilled water  
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PBS-Tween: 1ml Tween (Sigma-Aldrich, Gillingham, Dorset, UK), 100ml 10x PBS and 900ml 
distilled water 
I-Block buffer: 0.2% (w/v) I-Block (Invitrogen, Fisher Scientific, Loughborough, UK) in PBS-
Tween, slightly warmed and stirred overnight in a cold room.  
2.1.8 Solutions 
Stock solution of Oil Red O (Sigma-Aldrich, Gillingham, Dorset, UK): 0.5g of ORO powder 
dissolved in 100ml of isopropanol (absolute, >99.7%), stir overnight for complete dissolution 
at room temperature  
Oil Red O working solution: Prepared by dissolving ORO stock with distilled water at 3:2 ratio 
(Stock: water), Leave at room temperature for 10 minutes followed by filtering through a 
0.45µm filter unit (or Whatman No 1 filter paper) 
4% Paraformaldehyde in 1x Phosphate buffered saline (PBS) (Affymetrix, Buckinghamshire, 
UK) 
Calibrant solution for seahorse (Agilent Technologies, Stockport, UK) 
75% Ethanol (Sigma-Aldrich, Gillingham, Dorset, UK) 
 
2.1.9 Miscellaneous materials and reagents 
Triglyceride Quantification Kit (ab65336) (ABCAM PLC, Cambridge, UK) 
Sterile six-well cell culture plates (Thermo scientific, Loughborough, UK) 
Seahorse XF24 microplates for cell culture, with cartridges (Agilent Technologies, Stockport, 
UK) 
0.22µm filters for Syringes  
Sarstedt Scintillation Vial 58mm x 27mm Screw Cap (Sarstedt Ltd, Leicester, UK) 
Sterile filter unit, Vacuum Stericup; Filter diameter of 73mm with 500mL funnel and 500mL 
receiver; Membrane: PVDF; Pore Size: 0.22µm (Thermo Scientific, Loughborough, UK) 
RNase-free Eppendorf tubes (Sigma-Aldrich, Gillingham, Dorset, UK) 
Plain adhesive seals (Appleton Woods)  
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Pipette tips (Sigma-Aldrich, Gillingham, Dorset, UK) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Gillingham, Dorset, UK) 
Disposable Plastic BioSafe Pipette – 10ml, 25ml (Sigma-Aldrich, Gillingham, Dorset, UK) 
50ml Falcon tubes (Sigma-Aldrich, Gillingham, Dorset, UK) 
10ml Falcon tubes (Sigma-Aldrich, Gillingham, Dorset, UK) 
Disposable latex gloves (Sigma-Aldrich, Gillingham, Dorset, UK) 
 
2.2 Methods 
In this section, the general descriptions of principal methods performed in the study are 
outlined, however, brief descriptions with specific modifications in each method are stated 
accordingly in the respective chapters.  
2.2.1 Cell culture 
 2.2.1.1 Hep G2 cell line:  
Hep G2 cell line (ATCC, Manassas, Virginia, USA) is mainly an epithelial, continuous cell line 
which is characteristically adherent to cell culture plates. The cells were originally developed 
subsequent to isolation from liver biopsy of a 15-year-old male Caucasian American who was 
diagnosed with a well-differentiated hepatocellular carcinoma [265, 266]. Under suitable 
conditions of culture environment, the Hep G2 model is highly suitable for in vitro experiments 
targeting the examination of metabolism of lipids in the liver of humans as a result of its 
capacity to grow on a large scale and furthermore demonstrating a high level of differentiation 
both physiologically and morphologically in vitro.  All cell cultures in this study were therefore 
done using the Hep G2 cell line. 
 2.2.1.2 Thawing of Hep G2 cells: 
Hep G2 cells, formerly cryopreserved within cryovials and stored in the liquid nitrogen, were 
thawed at 37oC using the water bath. The resultant suspension of cells was steadily added to an 
initially warmed (37oC) 10ml EMEM media in a clean and sterile 50ml falcon tube, followed 
by centrifugation at 250g for 5 minutes. The supernatant was then discarded whereas the pellet 
of cells was carefully suspended in 20ml of fresh pre-warmed (37oC) custom-made B12-
deficient-EMEM medium supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/ 
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streptomycin in a 50ml falcon tube. The entire suspension of cells was then transferred into a 
sterile T75 (75cm2) cell/tissue culture flask (Sigma, UK) and incubated at 37oC at 5% CO2 
saturation, with routine changing of media every 48-hours until reaching confluence on the10th 
day.  
2.2.1.3 Passaging of Hep G2 cells: 
After reaching confluence in the 75cm2 culture flask on the 10th day, the Hep G2 cells were 
washed two-fold to ensure removal of all traces of medium, following initial aspiration of the 
last EMEM medium in the flask, using pre-warmed (37oC) sterile 1x phosphate buffered saline 
(PBS).  The cells were subsequently tripsinized, to ensure detachment from the T-75 flask, by 
carefully adding 2ml of trypsin-EDTA solution (0.02% EDTA and 0.25% porcine trypsin) to 
the cells, followed by incubation in an incubator at 37oC and 5% CO2 saturation for 5 minutes. 
Then, 20ml of fresh EMEM medium was then pipetted into the flask to re-suspend cells. The 
cell suspension was transferred into 50ml-falcon tubes followed by centrifugation at 250g for 
5 minutes. The supernatant was subsequently aspirated, followed by resuspension of the pellet 
of cells with 5ml EMEM medium in the falcon tubes. 1ml of the cell suspension was then 
transferred into 20ml pre-warmed sterile EMEM medium supplemented with 10% FBS, 1% L-
glutamine and 1% penicillin/ streptomycin in T-75 flasks and kept in an incubator at 37oC and 
5% CO2 saturation. The maximum number of passages of Hep G2 cells maintained in cell bank 
and used for the experiment was passage 25 to 30, which were securely kept in cryovials and 
stored in liquid nitrogen until required.  
2.2.1.4 Freezing of Hep G2 cells 
Following the trypsinization and harvest of confluent Hep G2 cells from T-75 flasks as 
previously described, the resultant suspension of cells (in 5ml EMEM media) was transferred 
into freezing media [EMEM (70%), DMSO (10%) and FBS (20%)] with 1ml of the subsequent 
suspension added to cryogenic vials (Sigma, UK). The cryovials were first kept frozen at -20oC 
and subsequently transferred to -80oC for 24 hours, followed by permanent storage in the liquid 
nitrogen.  
 2.2.1.5 Seeding of Hep G2 cells for B12-lipid metabolism experiments 
Following the initial thawing of cells from the liquid nitrogen and subsequent culturing in T-75 
flask until 90-100% confluence on the 10th day, Hep G2 cells were trypsinized and re-suspended 
in 20ml EMEM medium in 50ml falcon tubes. This was followed by centrifuging the falcon 
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tubes at 250xg for 5min, decanting the supernatant and re-suspending cell pellets in 5ml fresh 
sterile EMEM medium, to obtain seeding cells for the experiment. 10µl of 1 in 5 dilution of the 
cell suspension was loaded in the haemocytometer and counted under x40 objective of the light 
microscope. To determine the total number of cells in the cell suspension stock (5ml), the 
number of cells in each quadrant was counted. The average number of cells in the four quadrants 
was multiplied by the dilution factor (x5) and the volume of suspension medium (5ml) to 
determine the total number of cells in the suspension. The equivalent volume of suspension 
medium containing 75 000 (in six-well plates) or 50 000 cells (within 24-well seahorse plates) 
was diluted in fresh EMEM medium of different concentrations of B12 such as (500nM, 
1000pM, 100pM and 25pM). This was further supplemented with 10% FBS, 1% L-glutamine 
and 1% penicillin / streptomycin and seeded either at a volume of 2ml into wells of sterile six-
well plates (Thermo scientific, Loughborough, UK) or 100µl into XF24-seahorse microplates 
(Agilent Technologies, Stockport, UK) respectively for the assigned assays.  
 2.2.1.6 Harvest of Hep G2 cells for B12-lipid metabolism experiments: 
Adherent Hep G2 cells in 2ml EMEM-B12 medium suspension within six-well plates, 
incubated at 37oC and 5% CO2 saturation, were routinely replenished with fresh EMEM-B12 
medium at 48-hour intervals until 100% confluence was reached on the 10th day. After the last 
medium change, 1ml of the conditioned medium was transferred into 1.5 ml Eppendorf tubes 
and stored at -80oC. The Hep G2 cells were washed twice with 1x PBS to remove traces of the 
medium from the cells. The hepatocyte cell line was then harvested using the following; Qiazol 
(Trizol) (Thermo Scientific, UK), 1x Phosphate Buffered Saline (PBS) (Sigma, UK) and RIPA 
lysis buffer (Applied Biosystems, UK) depending on the specific assay to be performed with 
the cells. In the process, 500µl of lysis solution was carefully added to the cells and placed on 
shaker for five minutes, followed by scraping of detached cells into 1.5ml Eppendorf tubes. The 
lysed cell suspensions were stored at -80oC until utilized. 
2.2.2 Gene expression assay 
2.2.2.1 Total RNA isolation 
Total RNA was successfully isolated from Hep G2 cells in six-well plates by washing the cells 
twice with ice-cold 1x PBS, followed by harvesting using 500µl Qiazol (Thermoscientific, UK). 
The lysates in the plates, following initial shaking on a shaker for five minutes, were scraped 
and transferred into 1.5 ml Eppendorf tubes and stored at -80oC until required. Using the Trizol 
method of extraction [267], total RNA was obtained by adding 200 µl chloroform to Qiazol 
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suspension of cells in 1.5 ml Eppendorf tubes. The tubes were subsequently incubated for 2-3 
minutes at room temperature, following initial shaking for about 15 seconds. The Eppendorf 
tubes were centrifuged at 12,000xg speed at 4 oC temperature for 10 minutes, resulting in phase 
separation of the suspension into a lower red organic phase, an interphase and a colourless upper 
aqueous phase (Fig 8).  The upper aqueous phase was cautiously transferred into another 
RNAse-free tube. The RNA present in the aqueous phase was then precipitated by adding 300 
µl of 99% isopropyl alcohol (Sigma, UK) and centrifuging at 12,000xg speed, at a temperature 
of 4oC for 20 minutes. The precipitate (RNA) was subsequently washed by adding 800 µl of 
75% ethanol and centrifuging at 12,000xg speed, at 4oC temperature for 20 minutes. The 
ethanol was carefully aspirated off the pellets and allowed to completely dry. The RNA was re-
dissolved in 25 µl nuclease-free water and later utilized for the DNASe step using the DNASe 
I amplification grade (Sigma, UK). 
 
 
Figure 8: Isolation of RNA using the Trizol method: Separation of sample into phases following the lysis and 
harvest of cells in 500 µl Qiazol (Thermo scientific, UK), was achieved by adding 200 µl chloroform (Sigma, UK) 
and centrifuging at 12000xg speed for 10 minutes at 4oC. This was done after the initial incubation of samples for 
2-3 minutes at room temperature. The lower red organic phase contained proteins and lipids whereas the white 
interphase contained DNA, however, the upper clear aqueous phase contained the RNA.  
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2.2.2.2 DNASe treatment of RNA 
The aim of the DNASe treatment step was to ensure removal of residual contamination of DNA 
from RNA samples. In the process, 3 µl of 10x reaction buffer (Sigma, UK) and 3 µl of DNASe 
I amplification grade (Sigma, UK) were added to 25 µl of RNA suspension in nuclease-free 
water (Sigma, UK) and incubated at room temperature for 15 minutes, preceded by an initial 
gentle mixing for 5 seconds. After incubation, 3 µl of the STOP solution (containing 50mM 
EDTA) (Sigma, UK) was added to ensure inactivation of the DNASe 1 enzyme, calcium (Ca2+) 
and magnesium (Mg2+).  The tubes were incubated at 70oC for 10 minutes, followed by chilling 
of samples on ice. The DNASe-free RNA was then quantified spectrophometrically 
(NANOdrop, Labtech, UK) and 300ng was used for cDNA synthesis. 
 
2.2.2.3 Reverse transcription (cDNA synthesis) 
Principle: Reverse transcribing a single stranded RNA by using the enzyme RNA-dependent 
DNA polymerase (reverse transcriptase) in the presence of a primer and nucleotides (dNTPs), 
describes the process involved in the synthesis of cDNA.  
In the current study, cDNA was synthesized by using 300ng of DNASe-free RNA in RNASe-
free PCR tubes to which 1µl random hexamer primer (Thermo scientific, UK) and DNASe-free 
water (Sigma, UK) were added and subsequently incubated at 65 oC for 5 minutes. This was 
followed by preparing a cocktail consisting of 5x Buffer (Thermo scientific, UK), nucleotides 
(dNTPs) (Thermo scientific, UK), Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase (Thermo scientific, UK) and Ribolock RNAse Inhibitor (Thermo scientific, UK). 
7.5 μl of the cocktail was then added to the DNASe-free RNA in the PCR tubes, followed by 
mixing and subsequently placing the tubes in the iCycler (Bio-Rad, UK). Following the 
manufacturer’s protocol for programming the equipment, the assay was conducted by 
incubating samples at successive temperatures of 25 oC for about 10 minutes, 42 oC for 60 
minutes and 70 oC for 10 minutes in the iCycler. Cooling of the synthesized cDNA samples 
was carried out on ice and further stored at -20 oC. 
2.2.2.4 Real-time quantitative polymerase chain reaction (RT-qPCR)  
Principle: The principle involves amplification and subsequent quantification of DNA 
principally at the exponential phase of the reaction, leading to precise estimation of amplicons 
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which is proportionally equivalent to the original amount of cDNA that is shown by the quantity 
of fluorescent emission generated.  
 
a. Taqman qPCR: In this study, the mRNA expressions in Hep G2 cell line were all 
analysed using Taqman qPCR. The probe obtained from Taqman operates on the principle of 
5’-3’ exonuclease activity of the enzyme Taq polymerase, which is involved in slashing of the 
reporter-quencher-labelled probe, and subsequently hybridized complementarily to its target 
leading to detection resulting from generation of fluorescence. To run the assay, 24 μl cocktail 
comprising eukaryotic 18S rRNA endogenous control (Applied Biosystems, UK), universal 
PCR master mix (Applied Biosystems, UK), and RNASe-free water, was transferred unto 1 μl 
cDNA in a 96-well PCR plate (Gene Flow, UK). 
 b. SYBR Green I qPCR: mRNA analysis involving mice liver tissues has been well 
optimized in our laboratory using SYBR Green I PCR and therefore utilized in the current study. 
Primers for gene expressions were manufactured by Sigma Aldrich, UK. Stock concentration 
(100µM) of primers were prepared following dissolution of the nucleic acids (dry) in nuclease-
free water and kept at -20oC storage. The primers were designed using Ensemble Genome 
Browser Primers tool (http://genome.uscs.edu/cgi-bin/hgPcr). To run the assay, 2µl of cDNA 
was carefully mixed with 18µl master mix solution in a 96-well plate. Preparation of the master 
mix was done by cautiously adding 0.1x ROX reference dye, 300nM reverse and forward 
primers, 1x Jumpstart SYBR Green I mix and nuclease free water to obtain final volume of 
20µl.  
After carefully mixing the content in 96-well plates by mechanical vortexing, followed by 
centrifuging at 10,000 rpm for 15 seconds, the PCR assay was performed in about 90 minutes 
according to the manufacturer’s protocol, using a standard RT qPCR analyser (Applied 
Biosystems, UK). Specificity of the amplification was confirmed with the melting curve 
analysis. The data was subsequently analysed by using the method of quantitative comparative 
threshold cycle (qCCT). Also, the expressions of the target mRNA were normalized to the 
housekeeping gene 18s rRNA / L19. The results were achieved in the form of cycle threshold 
(CT) (Fig 9) estimates and utilized for determining the Δ CT values (Δ CT = CT of gene of 
interest-CT of r18s/L19). For each sample, measurements were done on a minimum of three 
occasions. Exclusion of probable bias resulting from averaging was done by transforming the 
data via the power equation 2-ΔΔCT.  
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Figure 9: Real time quantitative PCR [268]. ΔRn describes the rise in fluorescent signal detected at individual 
time point and the values are normally plotted against the number of cycles. The baseline describes cycles of PCR 
by which accumulation of signals from a reporter fluorescence remains under the detection limits of the equipment. 
The threshold represents a random fluorescence level usually chosen based on the variability of the baseline. For 
any sample, detection of a real signal usually higher than the threshold is useful for the definition of the threshold 
cycle (Ct). Adjustments in the threshold for individual assays could be done to ensure that across all plots, it 
appears in the exponential amplification region. The threshold cycle (Ct) describes the fractional PCR cycle 
number whereby the threshold is lower than the reporter fluorescence, and it essentially facilitates the generation 
of precise and accurate data.  
2.2.3 Estimation of total intracellular TG levels in Hep G2 cells  
Principle: The principle governing the assay includes generation of glycerol and free fatty acids 
via catabolism of TGs by the enzyme lipase. Additional oxidation of the resulting glycerol leads 
to the development of a product that is made to react with a probe to form a colour and its 
absorbance measured at 570nm wavelength.  
TG was estimated by using a kit from Abcam plc, UK. The frozen stock of 1mM TG standard 
was thawed in water bath at 80oC – 100oC for 1 minute, gently vortexed for 30 seconds and 
then diluted to 0.2 mM. The probe was also warmed in water bath at 37oC for 5 minutes to 
enable thawing of the DMSO solution. TG enzyme mix and lipase were prepared by 
reconstituting each in 220μl of assay buffer and kept on ice throughout the test. Then the TG 
standard was diluted with the assay buffer to a total volume of 50μl per well to generate standard 
concentrations of 0, 2, 4, 6, 8 and 10 nmol/well. 2 μl of lipase was added to each well and 
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incubated for 20 minutes. A cocktail of reaction mix (50 μl) comprising TG assay buffer, probe 
and enzyme mix (46:2:2) was added to each well, gently mixed and the absorbance was 
measured at 570nm wavelength. The data was used to derive a standard curve. Then, the 
samples were prepared by homogenising cells in PBS and subsequently making up cell 
suspensions to 50 μl of TG assay buffer per well. Then, 2 μl of lipase was added and incubated 
for 20 minutes at room temperature. Afterwards, 50 μl of the reaction mix was also added and 
the final content was gently mixed. The absorbance of the mixture was then measured at 570nm 
and the concentration of TG was calculated from the standard curve. 
 
2.2.4 Radioactive flux assessment of TG synthesized via utilization of radiolabelled-fatty 
acid (14C-oleate) by Hep G2 cells  
Principle: The amount of TG synthesized by cells in an interval of time can be quantified by 
initially exposing cells to radiolabelled fatty acid (14C-oleate) in the presence of L-carnitine.  
Preparation of cocktail of BSA and oleate: A cocktail consisting of 497 μl each of 70 mM oleate 
and 0.25% BSA was prepared in a glass tube. 32μl of the radioactive compound 14C-labelled-
0.75mM oleate at 2000 dpm/nmol stored at -20 oC was transferred in a glass tube and 
evaporated under nitrogen gas to obtain a dry residue. The radioactive residue in the glass tube 
was then placed on a shaker at 37oC and the cocktail was gently transferred by drops into the 
glass tube and left on the shaker for 1hour. Finally, the radiolabelled media was prepared by 
adding 1mM L-carnitine, 0.75 mM cold glycerol and 0.75 mM 14C-Oleate to the fresh EMEM 
medium.  
Experimental procedure: At 100% confluence, the condition medium in each well of Hep G2 
cells was removed and replaced with 1ml of the radiolabelled medium and kept at 37oC 
incubation for 2 hours (or 5 minutes for background correction control cells). After the 
incubation, the radiolabelled medium was removed, and the cells were then harvested in 2ml of 
methanol. The extraction of total lipids from the Hep G2 cells was done using a mixture of 
chloroform and methanol (2:1 v/v) [269]. The resulting layer of chloroform containing the TG 
fraction was then transferred into a glass tube and completely made dry under nitrogen gas. The 
dried content in the glass tube was then reconstituted in 500 μl of chloroform and finally 
transferred gradually, 15 μl at a time, onto a plate of silica gel 60-coated-TLC. The resultant 
radiolabelled TG was separated by use of a mobile phase made of formic acid/diethyl 
ether/hexane (1:30:70, v/v/v). To accurately locate the band of the separated TG from the total 
lipids, 10 nmol of glyceryltripalmitate (tripalmitin), a TG standard, was run alongside the test 
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and also included in each sample. Visualisation of the TG bands was aided by use of iodine 
vapour. The bands were then scraped into scintillation vials and the radioactivity of TG fraction 
was quantified by the scintillation counter. Finally, the TG concentration was calculated by 
normalizing with the protein concentration in the chloroform extract by Bradford method as 
described in section 2.2.6.2 
2.2.5 Estimation of lipid content in Hep G2 cells - Oil Red O (ORO) staining  
Preparation of ORO stain: To obtain a stock of ORO (0.5%) stain, 0.5g of ORO powder (Sigma, 
UK) was dissolved in 100ml of absolute isopropanol (Sigma, UK). The solution was carefully 
stirred and placed in water bath at 56oC for 1hour to enhance complete dissolution. After 
cooling, a working solution of 60% ORO was prepared from the stock, thoroughly stirred and 
allowed to stand for 10 minutes. The stain was finally filtered through Whatman Number 42 
filter paper (Sigma, UK) and kept away from direct exposure to light.  
Experimental procedure: At 100% confluence, the culture medium was removed and Hep G2 
cells in six-well plates were gently washed twice with PBS. After this, the cells were fixed with 
10% formalin at room temperature for an hour, washed with PBS and allowed to dry 
completely. The cells were then stained for two hours with ORO and washed 3-times until the 
water contained no noticeable colouration of the dye. The plates were observed under x40 
objective of the microscope, followed by capturing of images. After completely drying the 
wells, an elution assay was then performed by adding 300μl of 99.9% isopropanol to each well 
and placed on a shaker for about 20 minutes to elute the dye. At this stage, 200μl of isopropanol 
from the six-wells were transferred into 96 micro-well plate and the absorbance read at 520nm. 
The absorbance was normalized to the concentration of proteins, estimated by the Bradford 
method, in the cells of the respective wells. 
 
2.2.6 Protein characterization study (Western blot analysis) 
2.2.6.1 Hep G2 cells harvest for western blot analysis  
Hep G2 cells at 100% confluence were lysed using 500 µl of lysis buffer per well of culture 
plate. To prepare the lysis buffer, a cocktail of protease and phosphatase inhibitors was first 
prepared by dissolving protease inhibitor, comprising 2 tablets of Roche Complete-Mini 
protease inhibitor cocktail (Sigma, UK), and phosphatase inhibitors made up of 8mg Sodium 
Fluoride (Sigma, UK) and 20mg sodium vanadate (Sigma, UK), in 1ml of milli-Q water and 
stored at -20oC in aliquots. Then, 1x of the RIPA buffer was then prepared from 10x RIPA 
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stock (Merck Millipore, UK) and mixed with the cocktail of protease / phosphatase inhibitors 
at 50:1. The cells were subsequently harvested in 500µl of the lysis buffer and transferred into 
1.5 ml Eppendorf tubes which were stored at -20oC. 
2.2.6.2 Protein quantification using Bradford reagent   
To quantify proteins, 1:4 dilution of the Bradford reagent (Bio-Rad, UK) and standard BSA of 
1mg/ml were first prepared. Then, the standard concentration of BSA (1-7μg/μl) were prepared. 
To 200 μl of diluted Bradford reagent, standard BSA/ samples (μl) were added to 96-well 
microplates. The absorbance was obtained spectrophotometrically (Magellan, UK) at 595 nm. 
The concentration of the protein was then calculated from the standard curve using the 
absorbance of samples obtained. 
2.2.6.3 Western blot analysis 
Principle: The western blot (BioRad) technique initially separates proteins according to their 
molecular weights using SDS-poly acrylamide gel electrophoresis (SDS-PAGE) and 
subsequently electro-transfers the separated proteins unto a nitrocellulose membrane for 
detection with a primary antibody of a high specificity, followed by secondary antibody labelled 
with enzyme which is detected on a substrate (Fig 10). 
 
 
Figure 10: Principle of western blot [270]: The principle of western blot is reliant on the principle of 
immunochromatography involving the separation of proteins on the basis of their molecular weight into a 
polyacrylamide gel followed by the electro-transfer unto a nitrocellulose membrane for their detection aided by a 
substrate together with specific primary and secondary antibodies.  
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Procedure: For protein expression studies, 10% resolving and 5% stacking gels were prepared 
and casted, with comb carefully inserted, in the assembled glass plates (BioRad) and allowed 
to solidify. The samples were prepared by adding 20 μg of protein to 5x dye and milli-Q water 
to a total of 30ul, followed by vortexing and centrifuging at 10,000 for 15 seconds. Samples 
were incubated at 95oC for 10 minutes, cooled on ice for 5 minutes and loaded together with 8 
μl protein ladder (Sigma, UK) into wells of stacking gel and finally run at 100V for two hours. 
The gel was carefully removed and assembled in a blotting cassette, together with Whatman 
filter paper (Sigma, UK), PVDF membrane (Sigma, UK), and sponge, and placed in a tank of 
transfer buffer as per manufacturer instructions and ran at 100V for 1hour on a magnetic stirrer 
at room temperature. The membrane was then stained with ponceau S stain (Sigma, UK) and 
carefully cut at specific regions containing desired protein, followed by blocking and probing 
with 1:1000 mab conc/µg of primary antibody [(p-AMPKa, New England BioLabs, UK), p-
ACC (New England BioLabs, UK), CD320 (Abcam Plc, UK) and TCN2 (Abcam Plc, UK) for 
2 hours. The membrane was washed in PBS-T and probed with 1:1000 mab conc/µg of anti-
rabbit secondary antibody (Cell signal, UK) for 1 hour, followed by another wash with PBS-T 
and detection with enhanced chemiluminescence (ECL). Proteins of primary antibodies CD320 
and TCN2 were normalized to the housekeeping protein beta-actin. Similarly, pACC and 
pAMPK were also normalised to total ACC and total-AMPK proteins respectively.  
 
2.2.7 Analysis of fatty acids in total lipids of hepatic cell pellets  
Fatty acid levels, (µg) normalized per milligram protein of hepatocytes cell line, were obtained 
after preparing pellets of hepatocyte cell line from cell culture. Hep G2 cells were seeded at 
75,000 cells / well in six-well plates under different conditions of B12 [500nM (control), 
1000pM, 100pM and 25pM] until 100% confluence was achieved on the 10th day. Confluent 
cells were harvested, following initial washes 2x in PBS, by adding 300µl of trypsin to cells in 
each well of six-well plates and incubating at 37 oC for five minutes. 1000µl of EMEM media 
was then added to each well to inactivate the trypsin, with the subsequent cell suspension 
transferred into Eppendorf tubes and centrifuged 2000rpm for 10 minutes at 4 oC. The 
supernatant was carefully discarded whereas the pellets were frozen at -80 oC. Total lipid 
extraction into chloroform/ methanol (2:1) was carried out after adding 100µl pentadecanoic 
acid (internal standard) to cell pellets [269, 271]. Drying of the lipid extract was achieved using 
a flow of nitrogen, followed by synthesis of fatty acid methyl esters (FAME) using 3mol/l 
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methanolic hydrochloric acid (HCl) (Supelco, Bellafonte, PA) for 45 minutes at a temperature 
of 85oC [271]. The FAME was then extracted into hexane and subsequently stored at -20oC. 
Finally, analysis of the FAs, as previously described [272], was done using gas chromatography 
on a HewlettePackard 6890 from Agilent Technologies, Inc. Palo Alto, CA, together with FID 
system for detection and SP-2560 capillary column (60m x 0.25mm id x 0.15mm) supplied by 
Supelco, Sigma Aldrich, St Louis, MO.   
 
2.2.8 Mitochondrial dysfunction assessment using seahorse extracellular flux assay 
2.2.8.1 Cell culture for seahorse assay 
Hep G2 cells were first cultured by seeding 75 000 cells in T-25 flasks under four different B12 
concentrations [500nM (Control), 1000pM, 100pM and 25pM] of EMEM media supplemented 
with 10% FBS, 1% L-Glutamine and 1% streptomycin and/ penicillin. The plates were 
subsequently kept at 37oC incubation with 5% CO2 saturation. The respective B12-media were 
changed every 48-hours until 90-100% confluence was achieved on the 10th day in the flasks. 
On the last day, following the last media change, the cells were washed twice in 1x-PBS, 
tripsinized, counted and seeded at 50 000 cells /well into the XF-24 seahorse plates.  
2.2.8.2 Cell density optimization and seeding for XF24 seahorse assay 
For the optimum number of Hep G2 cells in 24-well (XF-24) seahorse plates for the experiment, 
we first optimized using different cells densities such as 10,000, 20,000, 30,000 and 50,000 
cells / well. The optimum cell density of 50,000 cells/well showing highest oxygen 
consumption rate (OCR) was then chosen for the experiment. The cells were first dispensed in 
100 µl EMEM-B12 media (supplemented with 10% FBS, 1% L-glutamine, 1% Penicillin and 
/ streptomycin) into seahorse plates and securely incubated at 37oC and 5%-CO2 saturation for 
one (1) hour to allow settling of cells on the plate. After this, 150 µl of B12-EMEM medium 
was further added to each well of seahorse plates, incubated at 37 oC and 5%-CO2 saturation 
overnight (24 hours) and used for the seahorse assay.  
2.2.8.3 Seahorse inhibitors  
Following the optimisation for the optimum concentrations of inhibitors such as oligomycin, 
carbonyl cyanide-p-tri-fluoro-methoxy-phenylhydrazone (FCCP) and rotenone / antimycin-A 
to be used for the seahorse assay (Fig 11), we chose optimum 10x concentrations such as 4.0 
µM, 7.5 µM and 4.0 µM for oligomycin, FCCP and rotenone/antimycin-A respectively.  
The 10x concentration (stock) of the inhibitors were therefore prepared in KHB buffer to obtain 
final concentrations (1x), of oligomycin (0.4µM), FCCP (0.75µM) and rotenone/ antimycin 
(0.4µM), after injecting into seahorse XF-24 plates. The inhibitors were loaded into the 
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allocated ports of the seahorse cartridge which was initially hydrated with 1ml calibrant for 24 
hours at 37oC without CO2 saturation.  
 
 
Figure 11: Seahorse assay [273]: This involves measuring of oxygen consumption rate (OCR) in cells undergoing 
respiration prior to and/ or after addition of inhibitors for the derivation of diverse markers of respiration in the 
mitochondria. OCR measurement is taken repeatedly at 8 mins intervals. An average is obtained from about 3-4 
readings to ensure reliability of measurements. First, measurement of a baseline cellular OCR is obtained, and this 
derives the basal respiration following the subtraction of respiration of non- mitochondrial source. Then, the 
addition of an inhibitor of complex V or ATP synthase, Oligomycin, is done to produce an OCR which is useful 
to derive the ATP-linked respiration (Baseline OCR – Oligomycin rate) or respiration of proton leak (Oligomycin 
rate – non mitochondrial respiration). Next, the addition of FCCP is done to enhance electron transport chain 
(ETC) to function to its maximal rate following FCCP-induced shutting off the inner membrane gradient. This 
results in the derivation of the maximal respiratory capacity (FCCP rate – non mitochondrial respiration). Finally, 
addition of complex III inhibitor, antimycin A, and complex I inhibitor, rotenone, is done to shut down the action 
of the ETC resulting in the measurement of non-mitochondrial respiration. To calculate the reverse capacity of the 
mitochondria, basal respiration is subtracted from maximal respiratory capacity.  
 
2.2.8.4 Seahorse media optimization  
Following the optimisation for the more effective seahorse media for this experiment, [between 
XF medium and Krebs-Henseleit Buffer (KHB)], we observed a higher spare respiratory 
capacity in hepatocyte cell line incubated in Krebs-Henseleit Buffer (KHB), therefore, KHB 
was selected for the experiment. KHB was prepared by using the same protocol described in 
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section 2.1.7b of chapter 2. The buffer was filter-sterilized, maintained at pH 7.4 and stored at 
4 oC until required.   
2.2.8.5 Sample preparation and seahorse assay. 
After 24-hour incubation at 37oC and 5% CO2 saturation, the cells were washed in KHB buffer 
by removing 200 µl EMEM media off the cells in seahorse plates, and subsequently adding 1ml 
fresh KHB. Then, 950 µl of the KHB in 24-well seahorse plates was removed, and 675 µl of 
fresh KHB was finally added to the wells of the plate. The plates were then incubated at 37 oC 
for one hour without CO2 saturation. To run the seahorse assay, the cartridge was initially 
loaded into the seahorse analyser for a calibration and equilibration runs, performed according 
to the manufacturers’ protocol, after which the utility plate of the cartridge was replaced with 
the seahorse XF24 plate of the hepatocyte cell line. The oxygen consumption rates (OCRs) in 
the cells were subsequently measured as similarly described in another study  [273]. 
 
2.2.9 Animal model 
Studies involving metabolic diseases frequently engage C57BL/6 models due to their capability 
of developing obesity, intolerance to glucose as well as resistance to insulin following long-
term exposure to obesogenic diet, thereby highlighting the essentials of human-related 
metabolic disorders including MetS and obesity [274]. 
The study was done in agreement with the UK Animals (Scientific Procedures) Act of 1986 
and subject to the UK Home Office License. Appropriate approvals were also obtained from 
the local ethics review committee at the University of Southampton, the genetic modification 
and biosafety committee and the animal welfare and ethical review body (AWERB) of the 
University of Warwick.  The C57BL/6 mouse models were all nurtured at the Southampton 
General Hospital, Division of Biomedical Research, Southampton. In the process, female 
C57/BL6J mice were sustained under a 12h light/dark cycle (lights on at 07.00h), and at a 
constant temperature of 22±2°C with food and water available ad libitum.  
The mice (n=6 per group) were fed either a control diet containing 7.49µg/kg vitamin B12 
(RM1 diet, Special Diet Services, UK) or a high vitamin B12 diet containing 30.82µg/kg 
vitamin B12 (824053 Diet, Special Diet Services, UK) for 8-10 weeks. Following appropriate 
killing and validation of death by cervical dislocation as similarly described elsewhere [275], 
the liver, among several other tissues, was taken and the weights assessed, followed by instant 
freezing in the liquid nitrogen.  Blood was obtained via cardiac puncture and the plasma was 
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subsequently acquired by specimen separation in heparinised tubes. B12 concentrations in the 
plasma of the mice were measured by electrochemiluminescent immunoassay using a Roche 
Cobas immunoassay analyzer (Roche Diagnostics UK, Burgess Hill, UK). 
On this basis, the mice were categorized into two groups: High plasma B12 group, HB (have 
6.5-fold higher levels of plasma B12 compared with LB group, n=6) and low plasma B12 group, 
LB (have low serum levels of B12 compared with HB group, n=6). When required, the liver 
tissues were homogenised in cryovials with 500µl phosphate buffered saline (PBS), RIPA 
buffer and Qiazol for intrahepatic B12 measurement, protein isolation for western blots and 
RNA isolation for RT-qPCR assays respectively. Homogenized samples were stored at -80°C 
until later use.  
 
2.2.10 Statistical analysis  
Analysis of all data was performed using the software of Prism 8 (GraphPad, San Diego, USA). All 
quantitative measurements, where applicable, were obtained in triplicates for standards, 
controls as well as cases in order to ensure precision of data. Data obtained from the oil red O 
staining, total intracellular triglycerides, scintillation count of the radioactive flux assay and 
fatty acid profiling using gas chromatography were normalized with the total protein 
concentration (mg) in each sample (n) of Hep G2 cells to alleviate possible variations that might 
misrepresent the data. The final data were then expressed as mean + standard error of mean 
(SEM). Data for all samples obtained were tested for normality prior to analysis using 
Kolmogorov-Smirnov and Shapiro-Wilk normality tests to assess if they were distributed 
normally. For samples that passed the normality assessment, comparisons between cases and 
their corresponding controls were done using a two-tailed unpaired t-test. Likewise, where test 
for normality was not passed, comparisons between two sample groups were done using the 2-
tailed Mann-Whitney U test. Statistically significant differences were assigned to p-values < 0.05. 
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3.0  Uptake and storage of vitamin B12 is modulated by CD320 receptor 
and TCN2 transporter in hepatocytes in various extracellular B12 
concentrations 
 
3.1 Introduction 
Vitamin B12 (B12) or cobalamin (Cbl) is synthesized naturally by cobalamin-producing 
bacteria in the gastrointestinal tract (GIT) of animals [147]. Intestinal absorption of the bulk of 
B12 is aided by intrinsic factor (IF) binding Cbl, however, only 1% of free B12 is known to be 
passively absorbed from the GIT [276]. B12 deficiency is associated with various metabolic 
and neurodevelopment diseases, but its levels are dependent on the B12 receptors and 
transporters. Specific membrane B12 receptors (CD320) and transport proteins such as 
haptocorrins (HC) and transcobalamin II (TCN2) facilitate the uptake and delivery of B12 into 
the tissues [277]. Dietary uptake of B12 occurs following sequential binding of B12 onto HC 
and IF in the ileal epithelium. Then, IF degrades in the bloodstream allowing B12 to form a 
B12-TCN2 complex (Fig 12) which is actively available for tissue uptake via the 
transcobalamin receptor (CD320). 
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Figure 12: Intestinal absorption and transport of B12 in the circulation:  
(I) Following ingestion, B12 is usually complexed with food protein prior to entering the stomach.  
(II) Protein undergoes breakdown releasing free B12 in the acidic medium of the stomach following the 
action of pepsin secreted by the gastric parietal cells.  
(III) Free B12 is then bound to R-binders (haptocorrins) following their secretion and release into the 
stomach by the salivary glands.  
(IV) B12 is again liberated into the duodenum by pancreatic proteases which cause degradation of the R-
binders.  
(V) The gastric parietal cells generate and release intrinsic factor (IF) into the duodenum that binds free 
B12 forming the B12-IF complex. Specific IF receptors known as cubam take up the B12-IF 
complex and release B12 into circulation.   
(VI) B12 is then bound to transcobalamin II (holo-TC) in the circulation and transported to all tissues of 
the body expressing specific transcobalamin receptors (CD320), with the liver taking about 50% of 
the total circulating B12.  
 
TCN2 is an essential protein for the delivery of B12 from blood to various tissues. Its 
potential role in the transport of B12 from maternal to foetus was shown in pregnant 
adolescents, where higher placental TCN2 abundance was associated with higher cord blood 
B12 concentrations [278]. CD320 is required for the uptake of TCN2 bound B12. Studies have 
shown that CD320 knockout mice have associated B12 deficiency and demonstrate behavioural 
deficits, macrocytic anaemia, infertility and hypomethylation of DNA in brain [279]. However, 
the current knowledge on the absorption and tissue distribution of B12 have been reported only 
in few animal studies   [280-285]. Tissue-specific concentrations of B12 according to a study 
in Wistar rats were: lungs (10 pmol/g tissue), spleen (25 pmol/g tissue), brain (33 pmol/g tissue), 
heart (72 pmol/g tissue), liver (74 pmol/g tissue) and kidney (1350 pmol/g tissue) [286]. A study 
in B12 deficient rats has shown that the liver uptake of hydroxyl Cbl was more than twice that 
of cyano Cbl, while the opposite was observed in other tissues such as kidney, brain and spleen 
[281]. Similarly, animals fed with imbalanced methyl containing nutrients (low B12, high 
folate, and high methionine) during pregnancy showed a redistribution of B12 in the maternal 
tissue from the kidneys to the liver and in foetal compartment (uterus, placenta, foetuses) [287]. 
Although it is known that the liver is the primary source of TCN2 and storage organ for 
B12 [288], the mechanism of B12 transporter and receptor modulation as well as hepatic levels 
of B12 in relation to circulatory B12 levels are unexplored. No data exists on the role of B12 
transporter (TCN2) and receptor (CD320) and their association with intracellular levels of B12 
in hepatocytes. Therefore, the present study was designed to; (a) assess and understand the 
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relationship between different circulating B12 levels, their corresponding intracellular hepatic 
concentrations and the levels of CD320 and TCN using Hep G2 cell line and C57BL/6 mice 
models. (b) Identify the appropriate concentrations of B12 required in the circulation for 
optimum hepatic uptake.  (c) Studies show that B12 transport into the placenta is increased 
during pregnancy regardless of reduced circulating levels, therefore, we aimed to understand 
the discrepancy of B12 transport in diverse circulating levels. 
 
3.2 Methods 
3.2.1 Cell culture: 
The cell culture was performed with slight modifications, as described in another study [289] 
and previously described in sections 2.2.1.5 - 2.2.1.6. In this experiment, Hep G2 cells were 
seeded in ten (10) different concentrations of B12 medium: 500nM (Control), 400nM, 200nM, 
100nM, 50nM, 20nM, 10nM, 1nM, 100pM and 25pM B12 in six-well plates. At 100% 
confluence the cells were harvested for intracellular B12, RNA and protein assessments, 
whereas the conditioned medium (1ml) was taken into Eppendorf tubes and stored at -20oC for 
extracellular B12 quantification.  
3.2.2 Animal model 
The liver tissues and plasma from HB (n=6) and LB (n=6) mice used in this study were obtained 
using the same method described in section 2.2.9.  
 
3.2.3 RNA isolation, cDNA synthesis and quantitative real time-PCR (qRT-PCR) 
Total RNA and cDNA synthesis for gene expression assays in Hep G2 cells and liver tissues 
(mice) were done following the protocol as previously described in sections 2.2.2.1-2.2.2.4 and 
similarly performed in another study [290]. In the qRT-PCR assays, as described in section 
2.2.2.4, the housekeeping genes 18s rRNA (Applied Biosystems, Paisley, UK) and L19 (Sigma, 
UK) were used to normalize RNA expressions in Hep G2 and liver tissues respectively.  
 
3.2.4 Western blot analysis 
Hep G2 cells in plates were harvested using the lysis buffer, radioimmunoprecipitation assay 
(RIPA), with dissolved phosphatase and protease inhibitors and stored at −80°C until required 
[290]. Similarly, liver tissues of the mice were also suspended in RIPA buffer, homogenised 
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and stored at -80°C. Protein samples of both Hep G2 and liver tissues were subsequently 
quantified using the Bradford assay. 30µg of the protein was used for the western blot analysis 
as described in section 2.2.6.3.  Primary antibodies targeting CD320 (molecular weight: 29 
kDa) and TCN2 (molecular weight: 48 kDa) were normalized to beta-actin (molecular weight: 
42 kDa). 
 
3.2.5 Measurement of intracellular B12 levels 
Intracellular concentrations of B12 in Hep G2 cell lysates and liver tissues, prepared by 
homogenising cells / tissues in PBS, were determined by electrochemiluminescent 
immunoassay using a Roche Cobas immunoassay analyzer (Roche Diagnostics UK, Burgess 
Hill, UK). 
 
3.2.6 Measurement of B12 concentrations in EMEM media and plasma 
Before the Hep G2 cell culture, stock concentration of B12 (10mM) was carefully prepared  
from B12 powder (Sigma Aldrich, UK), filter-sterilized and supplemented in the EMEM media 
to obtain various final B12 concentrations such as 500nM, 400nM, 200nM, 100nM, 50nM, 
20nM, 10nM, 1nM, 100pM and 25pM. Moreover, to confirm whether the exact concentrations 
of B12 supplemented in the media were similar to the concentrations present in the media, 
1000µl of the different B12 fresh media were taken into Eppendorf tubes and stored at -20oC 
until required. Similarly, 1000µl of the Foetal Bovine Serum (FBS) (Labtech international LTD, 
UK), used in the cell culture, was transferred into Eppendorf tubes and stored at -20oC. The 
fresh medium was initially custom-made (without B12 supplementation) and was subsequently 
supplemented with 10% FBS in addition to 1% penicillin/streptomycin and 1% L-glutamine. 
Therefore, for B12 concentrations within Hep G2 cells, their corresponding levels in the media 
were measured using electrochemiluminescent immunoassay with Roche Cobas immunoassay 
analyzer (Roche Diagnostics UK, Burgess Hill, UK). Likewise, B12 levels in the plasma of 
mice were also measured the same way.  
The B12 concentration present in the FBS stock was found to be 234pM, therefore, 
supplementation of the fresh medium with 10% FBS contributed low levels of B12 (23.4pM) 
to the medium. Other probable sources of B12 in the medium are unknown, however, sources 
of proteins and/or amino acids used in the medium (powder) preparation, by the manufacturer, 
might be accountable for additional low levels of B12. In the fresh medium containing 10% 
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FBS, without B12 supplementation (0pM), B12 concentration of about 48pM was detected. 
Likewise, in the media supplemented with low B12 concentrations such as 25pM, about 69pM 
B12 concentration was measured, whereas 100pM supplementation accounted for about 136pM 
B12 measurement (Fig 13). This data showed that the clinical definition of B12 deficiency 
(<150pM) or low B12 (150-230pM) was applicable to the low B12 conditions used in the 
current study.  
 
 
 
Figure 13: B12 concentrations in fresh and conditioned media: B12 levels supplemented in the EMEM 
medium, containing 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine, were measured in the EMEM 
media using the electrochemiluminescent immunoassay with Roche Cobas immunoassay analyzer (Roche 
Diagnostics UK, Burgess Hill, UK). 
 
 
3.3 Results  
3.3.1 Hepatic uptake of B12 
3.3.1.1 B12 uptake in Hep G2 cell line:   
The lower B12 concentrations (25-100pM) in the extracellular medium resulted in 2.84 - 2.11-
fold increase in the intracellular levels of B12 in the hepatocyte cell line. However, an increase 
in the extracellular concentration to 1nM B12 resulted in only 0.43-fold storage in the 
hepatocyte cell line. Likewise, further increased circulating concentrations: 10nM, 20nM, 
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50nM, 100nM, 200nM, 400nM and 500nM B12 resulted in progressive decreases (0.05, 0.04, 
0.03, 0.02, 0.02, 0.01 and 0.02-fold) in Hep G2 cell line uptake of B12, respectively (Fig 14). 
 
 
Figure 14: Intracellular fold uptake of B12 in hepatocyte cell line: Hep G2 cell line was cultured in ten (10) 
different concentrations of B12 [500nM (high B12), 400nM, 200nM, 100nM, 50nM, 20nM, 10nM, 1nM, 100pM 
and 25pM] in EMEM media supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin. 
These were incubated at 37oC with 5% CO2 saturation until reaching 100% confluence on the 10th day after seeding 
the cells in six-well plates with 48hours-interval medium change. One ml of conditioned medium was taken and 
the hepatocytes, following 2x washing in PBS, were lysed in 250 µl 1x PBS with the B12 of both medium and cell 
lysate determined by electrochemiluminescent immunoassay using a Roche Cobas immunoassay analyzer (Roche 
Diagnostics UK, Burgess Hill, UK). All the data are graphed as mean ± SEM (n=6). * indicates significance 
compared with 500nM (high B12-control); * p< 0.05, ** p< 0.01, *** p< 0.001 
 
3.3.1.2 B12 uptake in mice liver:  
To evaluate the tissue-specific effect of uptake of B12, we assessed the intracellular levels of 
B12 in liver tissues from mice in relation to B12 levels in plasma. The average B12 
concentration in the group of mice with low levels of B12 in plasma (LB (n=6)) was 0.82nM 
and in the group with high levels of B12 in plasma (HB (n=6)) was 5.36nM. The average B12 
concentration in the HB group was therefore 6.5-fold higher than the concentration in the LB 
group of mice. Like the in-vitro model, we observed that the intrahepatic B12 uptake in the low 
B12 group (LB) was significantly higher compared with the high B12 group (HB) (Fig 15).   
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Figure 15: Intrahepatic B12 fold uptake in mice liver: The mice (n=6 per group) were fed either a control diet 
containing 7.49µg/kg vitamin B12 (RM1 diet, Special Diet Services, UK) or a high vitamin B12 diet containing 
30.82µg/kg vitamin B12 (824053 Diet, Special Diet Services, UK) for 8-10 weeks. Following the measurement of 
B12 in the plasma, the mice were categorized into two groups: High plasma B12 group, HB (have 6.5-fold higher 
levels of plasma B12 compared with LB group, n=6) and low plasma B12 group, LB (have low serum levels of 
B12 compared with HB group, n=6). Liver tissues of both HB (5.36nM) and LB (0.82nM) mice were homogenized 
in 500µl of PBS and the B12 of lysates were measured. All the data are graphed as mean ± SEM (n=6). * indicates 
significance compared with HB mice (control); * p< 0.05, ** p< 0.01, *** p< 0.001 
 
3.3.2 Transcobalamin receptor CD320  
3.3.2.1 Hep G2 cell line 
We assessed the protein and mRNA expression of CD320 in hepatocyte cell line under ten 
different B12 medium concentrations. Low extracellular B12 concentrations of 1nM, 100pM 
and 25pM resulted in significantly increased expression of the CD320 receptors in hepatocytes 
compared with control (500nM). Increasing B12 medium concentrations: 10nM, 20nM, 50nM, 
100nM, 200nM and 400nM resulted in decreased transcobalamin receptor (CD320) gene 
expression and were not significantly different from control (500nM) (Fig 16).   
Similarly, we also observed upregulation in protein levels of CD320 in decreasing B12 
concentrations of the medium: 20nM, 10nM, 1nM, 1nM and 25pM compared with control 
(500nM). The highest CD320 protein expression was observed in hepatocyte cell line cultured 
in the lowest B12 medium concentration of 25pM. However, hepatocyte cell line in the 
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increasing B12 medium concentrations: 50nM, 100nM, 200nM and 400nM, showed no 
significant change compared with control (Fig 17). 
 
Figure 16: Transcobalamin receptors (CD320) expression in Hep G2: The mRNA expressions of 
transcobalamin receptors (CD320) in hepatocyte cell line of ten (10) different B12 conditions [500nM (control), 
400nM, 200nM, 100nM, 50nM, 20nM, 10nM, 1nM, 100pM and 25pM] normalized to 18S rRNA endogenous 
control (Applied Biosystems, UK) were analysed using RT-qPCR. All the data are graphed as mean ± SEM (n=6). 
* indicates significance compared with 500nM (high B12-control); * p< 0.05, ** p< 0.01, *** p< 0.001 
 
 
Figure 17: Level of transcobalamin receptor (CD320) proteins in Hep G2: CD320 proteins in hepatocyte cell 
line of different B12 concentrations [500nM (control), 400nM, 200nM, 100nM, 50nM, 20nM, 10nM, 1nM, 100pM 
and 25pM] were extracted and analysed using western blotting. All the data are graphed as mean ± SEM (n=6). * 
indicates significance compared with 500nM (high B12-control); * p< 0.05, ** p< 0.01, *** p< 0.001 
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3.3.2.2 Mice liver  
Then, we assessed the mRNA expression and protein levels of CD320 in the liver tissue of mice 
with high (HB) and low (LB) levels of B12. There was no significant difference in the mRNA 
expression of CD320 between the LB and HB mice (Fig 18A).  However, we observed that 
liver tissues from the LB mice had significantly increased level of CD320 protein compared 
with HB group of mice (Fig 18B).  
 
Figure 18: Transcobalamin receptors (CD320) in mice liver:  (A) The CD320 mRNA expression in liver tissues 
of HB and LB mice normalized to L19 endogenous control and (B) CD320 protein levels in liver tissues of HB 
and LB mice following homogenisation and extraction of RNA and protein from liver tissues and analysed with 
RT-qPCR (Applied Biosystems, UK) and western blotting respectively. All the data are graphed as mean ± SEM 
(n=6). * indicates significance compared with HB mice (control); * p< 0.05, ** p< 0.01, *** p< 0.001 
 
3.3.3 B12 transporter transcobalamin II (TCN2)  
3.3.3.1 Hep G2 cells 
To further evaluate the transporter involved in B12 uptake, we assessed the protein and gene 
expressions of B12 transporter transcobalamin II (TCN2) in hepatocytes cultured in ten 
different B12 medium concentrations. In B12 deficient conditions 100pM and 25pM, the 
mRNA expression of hepatic TCN2 was significantly higher. However, we observed that 
mRNA expression of TCN2 was decreased in hepatocyte cell line cultured in increasing 
medium concentrations of B12: 1nM, 10nM, 20nM, 50nM, 100nM, 200nM and 400nM, 
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showing no significant difference compared with control (500nM). The highest TCN2 mRNA 
expression was observed in hepatocyte cell line cultured in the least concentration of B12 
medium (25pM) compared with control (500nM) (Fig 19).  
Similarly, Hep G2 cells cultured in low medium concentrations of B12 resulted in high 
expression of protein levels of TCN2 (50nM, 20nM, 10nM, 1nM, 100pM and 25pM) compared 
with control (500nM). However, high B12 media concentrations such as 100nM, 200nM and 
400nM showed low levels of TCN2 protein and were not significantly different from control 
(500nM) (Fig 20).  
 
Figure 19: Gene expression of transcobalamin II (TCN2) in Hep G2: mRNA expressions of transcobalamin II 
(TCN2) in hepatocyte cell line of ten (10) different B12 medium concentrations such as [500nM (control), 400nM, 
200nM, 100nM, 50nM, 20nM, 10nM, 1nM, 100pM and 25pM] were analysed using RT-qPCR (Applied 
Biosystems, UK) and normalized to 18S rRNA endogenous control (Applied Biosystems, UK). All the data are 
graphed as mean ± SEM (n=6). * indicates significance compared with 500nM (high B12-control); * p< 0.05, ** 
p< 0.01, *** p< 0.001 
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Figure 20: Protein levels of B12 transporter transcobalamin II (TCN2) in Hep G2: B12 transporter 
transcobalamin II (TCN2) protein levels in hepatocyte cell line of ten (10) different B12 medium concentrations 
such as 500nM (control), 400nM, 200nM, 100nM, 50nM, 20nM, 10nM, 1nM, 100pM and 25pM were analysed 
using western blotting. All the data are graphed as mean ± SEM (n=6). * indicates significance compared with 
500nM (high B12-control); * p< 0.05, ** p< 0.01, *** p< 0.001 
3.3.3.2 Mice liver 
Like Hep G2 cells, we observed that both mRNA expression and protein levels of TCN2 were 
significantly higher in the liver tissue with low levels of B12 (LB) compared to HB group. We 
found that liver tissue expressed about 75% increase in the mRNA levels (Fig 21A) and 50% 
increase in the protein levels (Fig 21B) of TCN2 in LB mice compared with HB mice. 
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Figure 21: B12 transporter TCN2 in mice liver:  (A) The TCN2 mRNA expression in liver tissues of HB and 
LB mice normalized to L19 endogenous control and (B) levels of B12 transporter transcobalamin II (TCN2) 
protein in HB and LB groups of mice following homogenisation, extraction and analysis of RNA and proteins 
using RT-qPCR (Applied Biosystems, UK) and western blotting respectively from liver tissues. All the data are 
graphed as mean ± SEM (n=6). * indicates significance compared with HB mice (control); * p< 0.05, ** p< 0.01, 
*** p< 0.001 
 
3.4 Discussion  
In this study, Hep G2 cells in increasing extracellular B12 medium concentrations 
resulted in progressive decreased intracellular B12 uptake. Both protein and gene expressions 
of B12 receptor CD320 and transporter TCN2 decreased progressively in increasing 
extracellular B12 medium concentrations. Similarly, liver tissues of the HB mice demonstrated 
decreased B12 uptake and lower expressions of CD320 and TCN2 compared with LB mice.  
In clinical practice, both higher and lower concentrations of circulating B12 are 
common. For instance, B12 deficiency may be due to vegetarianism, prolonged metformin 
treatment in T2DM patients and during pregnancy [291, 292].  However, high plasma levels 
may result from either supplementation with a traditional B12 supplement or lack of affinity of 
B12 receptor and transporter for B12 [282]. The transcellular movement of B12 across 
membranes of cells involves mechanisms such as transcytosis of holo-TC (B12-TC) via CD320 
receptors and exocytosis of free B12 (Cbl) according to a recent in-vitro study in bovine aortic 
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endothelial cells [293]. In the current study, we assessed the uptake of B12 in Hep G2 cells 
cultured in increasing concentrations of ten different B12 media. When the circulatory level in 
low B12 medium was 25pM, the intracellular level was 178pM (2.8-fold) but when circulatory 
level in High B12 medium was 500nM (20,000-fold higher than 25pM), the intracellular level 
was only 8nM (0.02-fold). Similarly, in the animal model, we observed that when the 
circulatory level in LB was 0.82nM, the intracellular level was 27nM (i.e. 33.8 fold higher) but 
when the circulatory level in HB was 5.36nM (6.5 fold higher than 0.82nM), the intracellular 
level was only 46nM (8.6 fold). This was also supported by a recent study in rats that a single 
dose supplementation with 4-fold higher B12 concentration in plasma was unable to deliver 
any further B12 to the tissues [282]. Our findings are confirmed by a recent study in rat models 
which showed that low circulating B12 resulted in elevated endogenous B12 concentration in 
different tissues such as spleen, brain, heart and liver (higher tissue/plasma B12 ratio) [284]. In 
the cobalamin-deficient rats, Scott et al found that the proportion of the administered [57Co] 
Cbl present in the liver was twice than in normal rats [294]. Similarly, in an earlier study in 
folate (B9) deficient rats, low folate resulted in the elevation in the uptake of folate in the brush 
border membrane vesicles [295]. Our data hence suggests that in low circulating B12, 
intracellular uptake as observed in this study could indicate a probable active transport of B12 
[296] from the circulation leading to intracellular accumulation within the hepatocyte cell line, 
a possible mechanism to compensate physiologically for depleted intracellular hepatic stores. 
In high B12 environment, the intracellular level of B12 observed in both our in-vitro (8nM) and 
in-vivo model (46nM) demonstrated that these levels are sufficient for the cells to perform their 
action, therefore, the high amount of B12 supplemented to cells or the levels prevailing high in 
circulation are not required for further cellular uptake. Since the liver tissue plays a paramount 
role in the maintenance of B12 homeostasis among other tissues such as gut and kidney [297], 
this may account for the adjustment in hepatic B12 uptake amidst variant extracellular 
conditions.  
 
Furthermore, in the current study, we observed increased protein and gene expressions 
of B12 receptor (CD320) in Hep G2 particularly in low circulating B12 concentrations. 
However, low B12 medium concentrations resulted in higher expression of CD320 in the 
hepatocyte cell line. In liver of HB mice, decreased protein level of CD320) was observed 
compared with the LB group. Our findings supports an earlier study in hepatocytes which 
showed that modulations in the cellular uptake of B12 was the result of alterations in the number 
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of cellular receptors but not affinity [298]. Clinically, B12 deficiency may be observed during 
pregnancy due to increased demand of B12 for foetus [299] but a recent study showed 
progressive increase in serum levels of soluble CD320 receptors up to 35 weeks of gestation 
[300]. High serum sCD320 receptors in pregnancy might be derived from the placenta where 
higher expression of the receptor has been shown [301]. Similarly, a recent study has shown 
that serum levels of the B12 co-receptor [amnionless (AMN)], which plays a key role in 
anchoring the transport complex of B12 to epithelial cell membranes [297], were increased in 
aged humans presenting with B12 deficiency [297]. In the same study, a negative association 
was observed between serum AMN and B12 levels in rats [297]. The authors also observed 
increased expression of AMN in the kidneys of the B12-deficient-aged subjects, suggesting that 
the high serum AMN levels originated from kidney accounting for high renal uptake [297]. 
Although high B12 uptake and accumulation are common in the liver and kidneys [296, 302, 
303], there might be a threshold beyond which cells might limit further uptake in excessive 
supply.  Probable modulation of receptors or the availability of an efflux system which actively 
expels excessive B12 from cells, has been proposed to account for regulation of intracellular 
concentration of B12 [304, 305].  
The B12 transporter - TCN2 is principally produced by hepatocytes and less commonly 
intestines, endothelia and monocytes [306-308]. The de novo biosynthesis of TCN2 has been 
demonstrated in liver perfusates as well as cultured liver parenchymal cells using models 
involving rats [309, 310], supporting our observation of TCN2 expression in Hep G2 cells and 
liver tissues from mice. Although TCN2 accounts for about 22-37% binding and transport of 
plasma B12 [311], it is the key transporter of up to 99% of active B12 (holo-TC) into tissues 
[312]. Therefore, modulations in both gene and protein expressions of TCN2 in the liver reflects 
its crucial role involved in the regulation of B12 uptake and metabolism in different circulating 
B12 conditions. In the current study, we also observed higher TCN2 levels in hepatocytes under 
decreasing concentrations of extracellular B12 media. However, decreased levels of TCN2 
were observed in the hepatocyte cell line under higher medium concentrations of B12. 
Similarly, the liver tissues of HB mice showed significantly decreased TCN2 levels compared 
with LB mice. In pregnancy,  the TCN2 levels required for B12 transport are produced by the 
liver and placenta of the mother [300]. In spite of the reduction in serum B12 levels observed 
in pregnancy, the placenta was shown to have an increased expression and release of TCN2 
into the circulation, accounting for increased cord blood [278] and foetal concentrations of B12 
[300]. Similarly, following B12 supplementation in a clinical study, the level of total serum 
79 
 
transcobalamin (TC) was observed to be higher in low B12 patients [313]. In support to these 
evidences, our data indicates that the receptor and transporter levels only uptake the B12 levels 
to a certain level showing a threshold at cellular membrane entry and suggests the cellular 
uptake is limited even though high levels of B12 are in circulation.  
 
3.5 Conclusion 
In summary, our study highlights that when extracellular B12 levels were low, the intracellular 
B12 levels were 2-3fold higher whereas the opposite was observed in higher extracellular B12 
levels. This was supported by the increased gene and protein expression of receptor/ transporter 
in both hepatocyte cell line and liver tissues in lower extracellular B12 levels. This shows that 
at low B12 concentration, the active transport of B12 in these tissues is higher and might be 
due to the higher expression of B12 receptors/transporters in the membrane of hepatocytes. 
However, at high B12 concentrations, neither intracellular B12 levels nor the receptor and 
transporter expression increase according to the corresponding rise in B12 in circulation. 
Moreover, some recent studies indicate that elevated circulatory B12 levels are associated with 
cancer, liver diseases, blood disorders and solid neoplasms where cell proliferation is evident. 
Hence, we suggest the optimal physiological levels of B12 are required rather than overloading 
with supplements. This provides us with the impetus to study further whether the tissue-specific 
effect of low B12 in liver dysregulates the hepatic metabolism.  
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4.0 Vitamin B12 deficiency alters lipid synthesis triggering accumulation in 
hepatocyte cell line 
4.1 Introduction  
The impact of higher adiposity on metabolic health is vastly explored in recent times 
due to rapid increase in the global incidence of obesity [314, 315]. Individuals above 18 years 
of age were reported to be 39% overweight, 13% obese and 48% NAFLD [316-318]. Obesity, 
characterized by excessive storage of fat in both adipose and hepatic tissues, is been associated 
with dyslipidaemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD) [319]. 
Hepatic de novo lipogenesis (DNL) is a major pathway of lipid biosynthesis that is actively 
influential on fat balance in the body. Similarly, hepatic fatty acid oxidation (FAO) is crucial 
in suppressing lipolysis of adipose fats as well as improving liver physiology [320, 321]. 
However, increased free fatty acids (FFA) from these hypertrophic tissues have been associated 
with insulin resistance (IR), inflammation and GDM [322, 323].  
Environmental factors including nutrition (macro and micronutrients) [324] may affect 
metabolism of lipids (DNL and FAO) and regulate the expression of lipogenic and FAO genes 
[254]. Deficiency in methyl donors such as vitamin B12 (B12) and folate is associated with 
obesity [325], liver steatosis [326] and increased risk of metabolic syndrome  [327]. Low B12 
in pregnancy was associated with elevated BMI, IR and GDM in mothers [328-330]. This was 
subsequently associated with higher risk of offspring adiposity, IR and NAFLD incidence in 
later life [331, 332]. Clinical studies showed that maternal low B12 was associated with higher 
levels of lipids in both maternal and cord blood [333].  Human adipocyte models showed that 
the nuclear transcription factor and master regulator of lipogenesis, sterol regulatory element 
binding protein (SREBP1c) and regulator of cholesterologenesis, low density lipoprotein 
receptor (LDLR), were dysregulated leading to dyslipidaemia by low B12 [193]. The same 
study has also elucidated the epigenetic mechanisms of B12 deficiency via regulation of DNA 
methylation [193] and microRNAs leading to higher adiposity and dyslipidaemia [334]. B12 
restricted rat models have demonstrated in offspring, higher maternal adiposity [335], 
dyslipidaemia [335], upregulation of enzymes in lipogenesis [336] and lipid oxidation [337, 
338]. Though dysregulation of lipid metabolism in human adipose tissue has also been 
extensively explored in relation to B12 deficiency [193, 334], the contribution of adipose tissue 
to lipid metabolism to the entire body is considerably lower compared to the liver [339-341]. 
Therefore, if parallel effects of B12 are evident within hepatocytes, this may enlighten the 
observation of low B12 induced dyslipidaemia in humans.  
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DNL is the key lipid synthesis pathway within hepatocytes that account for generation 
of lipids for hepatic storage and secretion into circulation [342]. Hepatic DNL utilizes substrates 
from metabolism of glucose or glycolysis, suggesting that increased carbohydrate-rich diet 
could account for higher hepatic DNL rate due to substrate overload [343]. The products of 
DNL, principally FAs, which may be utilized for TG and cholesterol biosynthesis (Fig 22-25) 
may end up accumulating within hepatocytes resulting in harmful effects.  Low B12 has been 
shown to be associated with elevation in key enzymes and or genes involved in regulating key 
DNL pathways in human adipocytes [193]. Therefore, moderation of the level of lipids in 
human is crucial, achieved through careful modulation in the DNL and FAO pathways (Fig 6). 
Excessive circulating levels of free fatty acids (FFAs) is a key contributor to 
dyslipidaemia as well as adverse effects associated with obesity. Increased level of FFAs is 
shown to be associated with the development of IR in the liver as well as muscles [344]. In 
animal models, apart from the increased TG and cholesterol levels [345], deficiency of B12 
demonstrated unfavourable alterations in the levels of long chain polyunsaturated FAs (LC-
PUFAs) in the plasma and liver of subjects across three generations [345]. Recent evidences 
suggest that FAs in circulation may be implicated in metabolic dysregulation. Abnormal 
circulating FA profile was demonstrated in GDM [322], postmenopausal obese and overweight 
women [346], MetS [347], T2DM and CVD [348]. Despite the varied origins and diverse roles 
of these FAs, studies are lacking on these individual FAs with respect to micronutrient 
deficiency in particular cell type. Therefore, actual measurement of these individual FAs will 
provide the understanding of their distinct pathophysiologic roles in relation to B12 deficiency. 
Therefore, we hypothesised that low B12 levels in hepatocytes might dysregulate lipid 
metabolism. We therefore aimed to investigate (1) the effects of B12 deficiency on lipogenesis 
in human hepatocyte cell line (Hep G2) and (2) the effects of B12 deficiency on the FA profile 
in Hep G2. 
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Figure 22: Hepatic de novo FA synthesis pathway 
Hepatic lipogenesis constitutes FA, TG and cholesterol biosynthesis. De novo FA synthesis begins with the 
utilization of citrate, a product from the tricarboxylic acid (TCA) cycle in the mitochondria using pyruvate from 
glycolysis, which is further converted to acetyl co-enzyme A in the cytosol using the enzyme ATP citrate lyase 
(ACLY). Acetyl CoA is then carboxylated to malonyl CoA, a potent inhibitor of fatty acid oxidation by limiting 
carnitine palmitoyl transferase 1-alpha (CPT1α), by acetyl CoA carboxylase (ACC) and further converted by fatty 
acid synthase (FASN) into palmitate. Palmitate (16:0) is, finally, elongated by the enzyme elongation of a very 
long chain fatty acid 6 (ELOVL6) into stearate (18:0). 
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Figure 23: TG biosynthesis pathway. In the TG synthesis pathway, the saturated FA: palmitate and stearate, are 
desaturated by stearoyl CoA desaturase (SCD) into palmitoleate (16:1) and oleate (18:1) respectively, with either 
of these fatty acids incorporated into glycolysis-derived glycerol-3-phosphate (G3P) substrate, using the enzymes 
glycerol-3-phosphate acyl transferase (GPAT), acyl glycerol-3-phosphate acyl transferase (AGPAT), phosphatidic 
acid phospatase 1 (Lipin1), diacylglycerol acyl transferase 1 and 2 (DGAT 1&2), to derive lysophosphatidic acid 
(LPA), phosphatidic acid (PA), diacylglycerol (DAG) and triacylglycerol (TG) respectively. 
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Figure 24: De novo biosynthesis of diverse FAs. De novo synthesis of FA begins with the generation of short to 
medium, long and very long chains. FAs may be saturated, thus presenting with no double bonds in the carbon 
chains, e.g.: palmitate (16:0), stearate (16:0), arachidic acid (C20:0), behenic acid (C22:0) and lignoceric acid 
(C24:0). Unsaturated FAs may either be monounsaturated, presenting with a single double bond in carbon chains, 
e.g.: oleate (18:1 n-9),  gondoic acid (C20:1 n-9),  erucic acid (C22:1 n-9) and nervonic acid (C24:1 n-9), or 
polyunsaturated with more than a one double bond and are commonly referred to as essential FAs. A pool of acyl-
CoAs from these fatty acids are utilized for esterification into a glycerol-3-phosphate substrate for triglyceride 
biosynthesis.  
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Figure 25: The Cholesterol synthesis pathway: The cholesterol biosynthesis pathway begins with acetyl CoA 
which is a product of the beta oxidation of a fatty acid and or pyruvate incorporation in the TCA cycle in the 
mitochondria regulated by rate limiting enzymes CPT1α and pyruvate dehydrogenase (PDH), respectively. 
Acetoacetyl CoA formation from acetyl CoA substrates under the influence of the thiolase enzyme, facilitates their 
metabolism into mevalonic acid through the 3-hydroxy-3-methylglucatyl-CoA intermediate, which is synthesized 
by the 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS) and, subsequently, reduced by 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR). Mevalonate is further dehydrogenated to isopentenyl pyrophosphate by 
the enzyme mevalonic acid dehydrogenase (MVD) and, subsequently, subjected to series of modulations to derive 
lanosterol and cholesterol. Cholesterol may also be derived from triglyceride stores within very low-density 
lipoprotein (VLDL) by enzymatically modifying them into intermediate-density lipoproteins (IDS) and cholesterol 
by nuclear transcription factor low density lipoprotein receptor (LDLR) 
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4.2 Methods 
4.2.1 Cell culture 
Hep G2 cell culture was the same as previously described (sections 2.2.1.5 – 2.2.1.6), however, 
it was performed under four (4) different concentrations of B12: 500nM (Control), 1000pM, 
100pM and 25pM. The cells were either harvested for isolation of RNA, total intracellular TG 
estimation and FA profiling, or maintained within plates for oil red o (ORO) staining and 
radioactive flux assays.  
 
4.2.2 Oil Red O staining and elution assay 
The oil red o (ORO) staining followed by elution assay of lipids within the Hep G2 cells, at 
100% confluence, was the same as previously described in section 2.2.5. 
 
4.2.3 RNA isolation, cDNA synthesis and gene expression  
Total RNA isolation, cDNA synthesis and gene expression assays were the same as previously 
described in sections 2.2.2.1- 2.2.2.4, for the four conditions of B12 (500nM, 1000pM, 100pM 
and 25pM). The qRT-PCR involved the use of 18s rRNA (Applied Biosystems, Paisley, UK, 
4319413E) for normalizing expressions of RNA.  
 
4.2.4 Total intracellular TG estimation  
An estimation of total intracellular TG in hepatocytes under four (4) conditions of B12 (500nM, 
1000pM, 100pM and 25pM) was performed using the commercial TG quantification kit 
(ab65336) from Abcam plc, Cambridge, UK following the same protocol as described in section 
2.2.3. 
 
4.2.5 Radioactive flux assay for TG biosynthesis  
Hep G2 cells at 100% confluence, after the last medium change for four different B12 
conditions: 500nM, 1000pM, 100pM and 25pM within six-well plates, were incubated in 
EMEM medium containing radiolabelled oleates (14C-Oleate) at 37oC for two hours. The cells 
were harvested and the radiolabelled TG within the hepatocytes were extracted and assessed 
following the same protocol as previously described in section 2.2.4.  
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4.2.6 Analysis of FA in total lipids of hepatic cell pellets  
The profile of fatty acids (FA) in the lipids of Hep G2 cells in different conditions of B12 
[500nM (control), 1000pM, 100pM and 25pM] was analysed as previously described in section 
2.2.7.  
 
 
4.3 Results 
4.3.1 Lipogenesis 
4.3.1.1 Effect of B12 on lipid droplets formation in hepatocytes  
To obtain the fundamental evidence of a B12 effect on hepatic lipid synthesis (lipogenesis), we 
observed lipid droplets in hepatocyte cell line using x40 objective of a light microscope, under 
different conditions of B12 [500nM (control), 1000pM, 100pM and 25pM] following the initial 
fixation and staining of cells with ORO. First, we observed more densely stained lipids in the 
cell-culture plates of hepatocytes under low B12 compared with the control which had Hep G2 
cells that were only faintly coloured (Fig 26B). Observing images captured under the x40 
objective, hepatocyte cell line had a high number of intensely stained lipid droplets under low 
B12 compared with the control B12 which had only few lightly stained lipids (Fig 26A). The 
above data were confirmed by our quantitative assessment, using the elution assay standardized 
by milligram protein concentration of hepatocyte cell line in respective wells of various B12 
conditions, which indicated that significantly higher amounts of lipids were eluted from cells 
of low B12 compared with control (Fig 26C). These data gave preliminary evidence that low 
B12 significantly increased lipid levels in hepatocyte cell line compared with control, hence 
motivating the need for further investigations into the diverse pathways of lipid metabolism 
trying to account for this effect.  
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Figure 26: Oil Red O staining of lipid droplets in hepatocytes of different B12 conditions 
Hep G2 cells were cultured in a custom-made eagle’s minimal essential medium (EMEM) using EMEM powder 
(catalogue number 41500) from Thermo-Scientific, which contained 1000 mg/dL concentration of D-glucose. 
Lipids de novo synthesized in Hep G2 cells from metabolism (glycolysis) of the excessive glucose were visualized 
and quantified. Unaided visualization of cell culture plates of Hep G2 cells, following fixation and staining with 
formalin and ORO respectively, indicating more deeply stained lipids in the low B12 hepatocyte cell line compared 
with control (B). Images of Hep G2 captured under x40 objective showing an increasing intensity of ORO 
colouration of lipid droplets with decreasing concentrations of B12 [500nM (Control), 1000pM, 100pM and 25pM] 
(A). Spectrophotometric estimation of lipids eluted from hepatocyte cell line of different B12 [500nM (Control), 
1000pM, 100pM and 25pM] conditions standardized per milligram protein showed higher amount of lipids in low 
B12 (25pM) compared with control (500nM) (C). The data are representative of mean ± SEM (n=6). * indicates 
significance compared with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
 
4.3.1.2 Effect of B12 on total intracellular TG levels in hepatocyte cell line  
To obtain more specific evidence on the effect of low B12 on hepatic lipogenesis, we assessed 
the total intracellular TG levels synthesized by hepatocyte cell line under various conditions of 
B12 normalized per milligram protein of cells. Low B12 hepatocyte cell line had significantly 
higher levels of total intracellular TG compared with control (Fig 27), thus confirming the 
earlier evidence obtained in ORO staining and elution assays. 
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Figure 27: Effect of B12 deficiency on hepatic total intracellular triglyceride levels 
Total intracellular levels of triglycerides were quantified in hepatocyte cell line under different B12 (500nM, 
1000pM, 100pM and 25pM) conditions using the TG kit (ab65336) from Abcam Plc and normalized per milligram 
protein of Hep G2 under each B12 condition. The data are representative of mean ± SEM (n=6). * indicates 
significance compared with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
 
4.3.1.3 Effect of B12 on genes regulating FA synthesis 
Next, we assessed effect of B12 on gene expression of sterol regulatory element-binding protein 
(SREBF), which is a transcription factor and master regulator of the biosynthesis pathways of 
FAs, TG and cholesterol. Then we also assessed B12 effect on downstream genes regulating 
hepatic de novo FA synthesis (Fig 22 and Fig 24). Hepatic DNL uses substrates from diet or 
adipocyte lipolysis. Through a series of coordinated enzymatic reactions, the substrates are 
metabolized to pyruvate, which enters mitochondria to be used for energy production. When 
energy stores are adequate, citrate is transported out to cytoplasm and is converted to acetyl-
CoA by ATP citrate lyase (ACLY). Acetyl-CoA carboxylase (ACC) converts acetyl-CoA to 
malonyl-CoA. Fatty acid synthase (FASN), the key rate-limiting enzyme in de novo FA 
synthesis, converts malonyl-CoA into palmitate, which is further elongated to stearate or longer 
FAs by the action of elongation of very long-chain fatty acids (ELOVL6). We observed that 
gene expression of SREBF1 and the genes in de novo FA synthesis such as ATP citrate lyase 
(ACLY), Acetyl-CoA carboxylase (ACC), Fatty acid synthase (FASN) and elongation of very 
long-chain fatty acids (ELOVL6) were increased in low B12 hepatocyte cell line compared 
with control, suggesting that hepatocyte cell line in low B12 could synthesize higher levels of 
de novo FAs (Fig 28).  
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Figure 28: Low B12 increases mRNA expression of enzymes regulating hepatic de novo FA synthesis  
The mRNA expression of enzymes regulating de novo FA synthesis [SREBF1 (A) ACLY (B) ACC (C) FASN 
(D)] as well as elongation [ELOVL6 (E)] normalized to 18S rRNA endogenous control (Applied Biosystems, 
UK). The data are representative of mean ± SEM (n=6). * indicates significance compared with 500nM (control): 
* p< 0.05, ** p< 0.01, *** p< 0.001 
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4.3.1.4 Effect of B12 on genes regulating TG biosynthesis  
TG biosynthesis occurs by sequential esterification of FAs into glycerol-3-phosphate (G3P) and 
conversion of saturated FAs to monounsaturated FAs by Stearoyl-CoA desaturase 1 (SCD1). 
Glycerol-3-phosphate acyltransferase (GPAT) adds acyl-CoA to glycerol-3-phosphate (G3P) 
to form lysophosphatidicacid (LPA). Then 1-acylglycerol-3-phosphateacyltransferase 
(AGPAT) adds a second acyl-CoA to produce phosphatidic acid (PA), which is then 
dephosphorylated by Phosphatidate phosphatase (LPIN1) to form 1, 2-diacylglycerol (DAG). 
Finally, Diacylglycerol acyltransferase (DGAT) converts diacylglycerols into triglycerides 
(TG), which may be stored in the liver or assembled into VLDL and exported to circulate in the 
blood (Fig 23).  
Since we initially observed higher total intracellular TGs in low B12 hepatocyte cell line, we 
further investigated the expression of genes involved in the TG biosynthesis pathway. The 
expression of genes such as Stearoyl-CoA desaturase 1 (SCD1), Glycerol-3-phosphate 
acyltransferase (GPAM), 1-acylglycerol-3-phosphateacyltransferase (AGPAT), phosphatidate 
phosphatase (LPIN1) and Diacylglycerol acyltransferase 2 (DGAT2) crucial in de novo TG 
biosynthesis including desaturation, monoacyl, diacyl and triacylglycerol synthesis, were 
increased in low B12 hepatocyte cell line compared with control. Similarly, gene expression of 
DGAT1 involved in TG recycling was increased in hepatocytes under low B12 compared with 
control. Therefore, these findings demonstrate that both de novo synthesis and regeneration of 
TGs were increased in hepatocyte cell line under low B12 compared with control (Fig 29).  
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Figure 29: Low B12 increases mRNA expression of genes regulating TG biosynthesis 
The mRNA expression of enzymes involved in the regulation of de novo TG biosynthesis such as [SCD (A), 
GPAM (B), AGPAT (C), LIPIN (D) and DGAT1 (F)] and or TG regeneration from residues of hydrolysed lipids 
by the enzyme DGAT1 in hepatocyte cell line normalized to 18S rRNA endogenous control (Applied Biosystems, 
UK). The data are representative of mean ± SEM (n=6). * indicates significance compared with 500nM (control): 
* p< 0.05, ** p< 0.01, *** p< 0.001 
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4.3.1.5 Effect of B12 on TG synthesis utilizing radiolabelled FA  
To further confirm our observation of high total intracellular TGs and dysregulated genes 
involved in de novo TG synthesis and regeneration in hepatocytes under low B12 condition, we 
performed a real-time flux assay [349]. We incubated the hepatocytes with radiolabelled FA 
(14C-Oleate) and FA transporter (L-carnitine) and assessed dysregulation of enzymes involved 
in TG synthesis pathway by investigating the amount of FA incorporation in the TG 
biosynthesis for a stipulated period. Interestingly, we observed high measure of radioactivity 
(disintegration per minute, DPM) by scintillation count in low B12 hepatocyte cell line 
following initial extraction and isolation of radiolabelled-TGs using glyceryl tripalmitate as 
standard. This provided a direct indication that increased number of FAs were incorporated and 
synthesised in hepatocytes treated with low B12 compared with control (Fig 30). 
 
 
Figure 30: Low B12 increased biosynthesis of radiolabelled-TG in hepatocytes exposed to 14C-oleate and L-
carnitine: Flux assay was performed after seeding 75,000 Hep G2 cells in six-well plates under different 
conditions of B12 [500nM (control), 1000pM, 100pM and 25pM] until reaching confluence at the 10th day of the 
cell culture. After the last medium change, the cells were incubated with 14C-Oleate (0.75mM concentration at 
2000 dpm/nmol) and L-carnitine (1mM) to facilitate incorporation of 14C-Oleate into hepatocytes for two (2) hours 
in EMEM, against five minutes incubation for background normalizing control at 37oC and 5% CO2 saturation. 
Hep G2 cells were harvested in 2ml methanol and the synthesized radiolabelled-TG was extracted, following an 
initial total lipid isolation with the liquid-liquid (chloroform-methanol, 2:1 v/v) extraction method, using a mobile 
phase such as hexane/diethyl ether/formic acid (v/v/v, 70/30/1) on a thin layer chromatography (TLC) plate with 
10 nmol glyceryltripalmitate (tripalmitin) as a standard. TG bands on TLC plates were transferred into vials of 
5ml scintillation fluid for scintillation counter assessment of radioactivity (for 5 minutes) of the synthesized TG 
fraction, normalized per milligram (mg) protein concentration by the Bradford method. The data are representative 
of mean ± SEM (n=6). * indicates significance compared with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 
0.001 
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4.3.1.6 Effect of B12 on genes regulating cholesterol synthesis 
Dysregulation in FA and TG metabolism could affect cholesterol biosynthesis as the latter 
utilizes acetyl-CoA and VLDL which are derivatives of FA’s (endogenous or exogenous) and 
TGs in the mitochondria and cytosol, respectively (Fig 24). Therefore, assessment of gene 
expression in the hepatic cholesterol biosynthesis pathway was performed to examine possible 
dysregulation resulting from B12 conditions. We observed an increased gene expression of the 
nuclear transcription factor LDLR (master regulator of cholesterol synthesis) in low B12 
compared with control.  Likewise, the expressions of key cholesterol genes such as 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR), 3-hydroxy-3-methylglutaryl-CoA synthase 
(HMGCS1) and Isopentenyl-Diphosphate delta Isomerase 1 (IDI1) were also increased in low 
B12 compared with control (Fig 31). This evidence therefore suggests that hepatocyte cell line 
in low B12 had higher levels of cholesterol compared with control. 
 
 
Figure 31: Low B12 upregulates genes in the cholesterol synthesis pathway 
The mRNA expression of enzymes involved in the regulation of cholesterol biosynthesis such as LDLR (A) 
HMGCS1 (B), HMGCR (C) and IDI1 (D) in hepatocyte cell line normalized to 18S rRNA endogenous control 
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(Applied Biosystems, UK). The data are representative of mean ± SEM (n=6). * indicates significance compared 
with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
 
4.3.2 Fatty acid (FA) profiling in hepatocytes 
4.3.2.1 Total FA   
We showed evidence of low B12-induced upregulation of genes involved in pathways leading 
to de novo synthesis, elongation and desaturation of certain FA. We further performed FA 
profiling in hepatocyte cell line under different conditions of B12 to assess how levels of 
different FA were affected in the hepatocyte cell line. We observed that the highest group of 
FAs synthesized in the hepatocyte cell line was saturated FA (SFA - 43%), then 
monounsaturated FA (MUFA - 32%), polyunsaturated n-6 FA (PUFA n-6 - 12%), 
polyunsaturated FA–n-3 (PUFA n-3 - 10%), long chain polyunsaturated n-9 FA (LC-PUFA n-
9 - 0.9%), and trans FA (0.5%) [(Fig 32 (control)]. Interestingly, our data showed that the level 
of total FAs synthesized in hepatocytes in low B12 was 38% higher compared with control (Fig 
33A). 
 
 
Figure 32: Profile of total FA groups in hepatocytes: The composition (%) of various FA groups in hepatic 
total FA levels: Even chain FA, Odd chain FA, MUFA, Trans FA, PUFAn-3, PUFAn-6 and PUFA n-9 in 
hepatocyte cell line under low B12 compared with control.  
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4.3.2.2 Grouped fatty acids 
Saturated FAs (SFA) 
Next, we assessed the level of diverse groups of FAs in hepatocyte cell line under different B12 
conditions. We observed that the predominant FA group, the SFA, was significantly higher in 
low B12 compared with control (Fig 33.B).  
 
Monounsaturated FAs (MUFAs) 
We observed that MUFA levels in low B12 hepatocyte cell line were significantly higher 
compared with control (Fig 33. C). Since the FA profile was predominated by SFAs and 
MUFAs, higher levels of both groups observed in low B12 accounted for the overall increase 
in the total fatty acids (TFAs) under low B12 hepatocyte cell line compared with control. 
 
Polyunsaturated fatty acids (PUFAs) 
In PUFAs-total, there was no significant difference observed between low B12 and control 
however, sub-groups of PUFA such as PUFA n-6, LC-PUFA n-6, PUFA n-6/n-3 and Trans-FA 
were significantly higher in low B12 hepatocyte cell line than control (Fig 33. E, H, J). 
Moreover, in groups such as PUFA n-3 and LC-PUFA n-3, no significant difference was 
observed between low B12 and control (Fig 33, F, G). 
 
4.3.2.3 Individual FA profile in hepatocytes 
Even chain FAs 
We observed that all even chain FA’s such as lauric acid (C12), myristic acid (C14), palmitic 
acid (C16) and stearic acid (C18) comprising 43% of the total FA in the control were 
significantly increased to 63% in low B12 hepatocyte cell line (Fig 32). 
 
Odd chain FAs 
Similarly, odd chain FAs such as margaric acid (C17), heneicosylic acid (C21) and tricosylic 
acid (C23) comprising 1.5% of the total FA in the control were significantly increased to 2.7% 
in low B12 hepatocyte cell line (Fig 32). 
 
MUFAs 
Among the MUFAs, oleic acid (C18:1n-9) and cis-vaccenic acid (C18:1n-7) were present 
predominantly than other MUFAs such as hexadecanoic acid (C16:1n-9), palmitoleic acid 
(C16:1n-7) and gondoic acid (C20:1n-9). These MUFA’s comprising 31.9% of the total FA in 
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the control were significantly increased to 40.6% in low B12 hepatocyte cell line (Fig 32). 
However, the only very long chain MUFA, gondoic acid was significantly decreased in low 
B12 hepatocyte cell line compared with control (Table 2).  
 
Trans FAs 
Among the trans FAs accounting for only 0.5% of total FAs in control, higher levels of 
palmitelaidic acid (C16:1t) and elaidic acid (C18:1t) were observed in low B12 hepatocyte cell 
line (which accounted for 0.9%). There was no significant difference in linoelaidic acid (all 
trans-9, 12) (C18:2tt) and linoelaidic acid (trans-12) C18:2ct (Table 2) 
 
PUFAs 
PUFA n-3 comprising 10% of the total FA in the control were significantly increased to 12.6% 
in low B12 hepatocyte cell ine, PUFA n-6 from 12% to 17% and PUFA n-9 from 0.9% to 1.1 
(Fig 32).  PUFAs n-3 (such as eicosapentaenoic acid (EPA) (C20:5 n-3), docosapentaenoic acid 
(DPA)(C22:5 n-3) and docosahexaenoic acid (DHA) (C22:6 n-3)),  PUFAs n-6 (such as linoleic 
acid (C18:2 n-6), dihomo-γ-linolenic acid (C20:3n-6), arachidonic acid (AA) (C20:4 n-6) and 
docosapentaenoic acid (C22:5 n-6)) and PUFA n-9 such as mead acid (C20:3 n-9) were 
significantly higher in hepatocyte cell line with low B12. However, no significant difference 
was observed in some PUFAs n-3 (such as α-linolenic acid (C18:3n-3) and eicosatrienoic acid 
(C20:3n-3)) and PUFAs n-6 (such as adrenic acid (C22:4n-6)) (Table 2). 
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Figure 33: Profile of various groups of fatty acids in hepatocytes under different conditions of B12 
The fatty acid profile of Hep G2 cells under different B12 conditions [500nM (Control), 1000pM, 100pM and 
25pM] obtained in total lipids extracted from cell pellets of the hepatocyte cell line and analysed using gas 
chromatography in connection with SP-2560 capillary column (60m x 0.25mm id x 0.15mm) supplied by Supelco, 
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Sigma Aldrich, St Louis, MO and FID system for detection. Fatty acid levels (µg) normalized per milligram protein 
showing various fatty acid groups such as total fatty acid (A), saturated fatty acids (SFA) (B), monounsaturated 
fatty acids (MUFA) (C), total polyunsaturated fatty acids (PUFA-total) (D), polyunsaturated n-6 fatty acids 
(PUFAn-6) (E), polyunsaturated n-3 fatty acids (PUFAn-3) (F), long chain polyunsaturated n-3 fatty acids (G),  
long chain polyunsaturated n-6 fatty acids (LC-PUFAn-6) (H), Trans fatty acids (I) and polyunsaturated fatty acids 
n-6/n-3 ratio (J). The data are representative of mean ± SEM (n=6). * indicates significance compared with 500nM 
(control): * p< 0.05, ** p< 0.01, *** p< 0.001 
 
 
100 
 
 
Table 2: Profile of individual fatty acids in hepatocytes under different B12 conditions 
Fatty acid levels (µg) normalized per milligram protein of hepatocyte cell line under different B12 conditions 
[500nM (control), 1000pM, 100pM and 25pM]. The data are representative of mean ± SEM (n=6). * indicates 
significance compared with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
Fatty acids   Vitamin B12     
µg FA/mg 
protein 
500nM (Control) 
(n=6) 1000pM (n=6) 100pM (n=6) 25pM (n=6) 
       
Even chain      
C12 0.00     ± 0.0 0.00    ± 0.0 0.93     ±  0.3*** 0.61     ±  0.1*** 
C14 3.73     ± 0.7 3.86    ± 0.3 4.82     ±  0.4** 5.71      ± 1.1** 
C16 75.47  ±12.3 77.65  ± 7.8 102.85 ±  11.3** 111.72 ± 15.8** 
C18 34.76  ± 5.9 35.07  ± 3.7  47.53  ±  5.0** 47.74   ± 9.0* 
       
Odd Chain      
C17 1.97   ± 0.4 2.01   ±  0.2 3.05    ± 0.5** 3.43     ± 1.2* 
C21 0.66   ± 0.1 0.70   ± 0.2 0.81    ± 0.2 1.45     ± 0.4** 
C23 1.20   ± 0.2 1.29   ± 0.1 2.38    ± 0.3*** 2.34     ± 0.7** 
       
MFA      
C16:1 n-9 3.47    ± 0.6 3.70    ± 0.5 3.9      ± 0.5 5.00    ± 1.0** 
C16:1 n-7 7.95    ± 0.7 8.36    ± 1.2 8.39    ± 0.8 10.27  ± 1.7* 
C18:1 n-9 47.66  ± 2.3 47.21  ± 5.3 47.20  ± 5.0 61.04  ± 10.6* 
C18:1 n-7 23.01  ± 1.3 23.66  ± 2.9 23.54  ± 2.2 29.94  ± 5.2* 
C20:1 n-9 1.80    ± 0.4 2.20    ± 1.0 0.55    ± 0.6** 0.53    ± 0.1*** 
       
Trans FA      
C16:1t 0.33   ± 0.1 0.47   ± 0.1 0.6    ± 0.0*** 0.99   ± 0.4** 
C18:1t 0.32   ± 0.0 0.38   ± 0.1 0.00  ± 0.0*** 0.54   ± 0.1** 
C18:2tt 0.00   ± 0.0 0.00   ± 0.0 0.00  ± 0.0 0.17   ± 0.3 
C18:2ct 0.66   ± 0.1 0.53   ± 0.1 0.49  ± 0.01 0.63   ± 0.1 
       
PUFA n-6      
C18:2 n-6 10.31  ± 1.1 10.47   ± 0.9 12.75  ± 1.5** 14.4   ± 2.4** 
C20:3n-6 3.03    ± 0.5 3.17     ± 0.4 3.24    ± 0.4 4.27   ± 1.1* 
C20:4 n-6 17.72  ± 2.6 18.07   ± 2.0 21.17  ± 2.7* 25.09 ± 5.1** 
C22:4 n-6 0.00    ± 0.0 0.00     ± 0.0 0.00    ± 0.0 0.25   ± 0.3 
C22:5 n-6 0.29    ± 0.0 0.29     ± 0.0 0.49    ± 0.04** 0.58   ± 0.2* 
       
PUFA n-9      
C20:3 n-9 2.32   ± 0.3 2.41   ± 0.3 2.88   ± 0.4* 2.86   ± 0.4* 
       
PUFA n-3      
C18:3 n-3 2.32   ± 0.1 2.16   ± 0.1 1.90   ± 0.2 2.93   ± 0.5 
C20:3 n-3 0.43   ± 0.1 0.46   ± 0.0 0.43   ± 0.0 0.67   ± 0.4 
C20:5 n-3 3.66   ± 0.6 3.98   ± 0.5 3.92   ± 0.5 5.04   ± 1.1* 
C22:5 n-3 2.5     ± 0.5 2.97   ± 0.9 2.97   ± 0.5 3.45   ± 0.7* 
C22:6 n-3 17.41 ± 1.3 17.83 ± 1.8 17.87 ± 1.7 21.00 ± 2.9* 
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4.4     Discussion  
           Here we show that B12 deficiency in hepatocyte cell line influences increased gene 
expression of lipogenesis and decreased lipid oxidation, resulting in increased intracellular TG 
and accumulation of more lipid droplets. In addition, we also observed subclasses of FAs such 
as SFAs, MUFAs, PUFA n-6, LC-PUFA n-6 and trans-FAs were also significantly higher in 
low B12 hepatocyte cell ine. Hence our findings indicate that increased fatty acid synthesis in 
low B12 condition and subsequent impairment of fatty acid oxidation in catabolising FAs in 
hepatocyte cell ine might likely lead FAs to accumulate in hepatocytes in low B12 resulting in 
dyslipidaemia.    
 
Hepatocytes demonstrate an elevated turnover of FAs, which is immediately converted 
to TG and are stored in lipid droplets [350]. In the current study, Hep G2 cells were supplied 
with excess glucose concentration (1000 mg/dL), beyond the normal circulating levels (63.0-
99.0 mg/dL) [351], in the media. This was to facilitate the utilization of the excess products 
from glycolysis (pyruvate) for de novo lipid synthesis. The lipids synthesized were stored in the 
hepatocyte cell line as lipid droplets. We observed that lipid droplets were higher in Hep G2 
cells in low B12 and subsequent increase in total intracellular TGs, radiolabelled-FA uptake for 
TG synthesis in low B12 compared with control. This evidence was similar to the observation 
of elevated accumulation of lipid droplets, increased  levels of TG [334] and cholesterol in 
adipocytes differentiated in deficient B12 condition [334]. Early studies have hypothesized that 
lipid droplets (LDs) are much sensitive to conditions such as nutritional stress capable of 
inducing unique alterations in the lipidome of LDs present in mice hepatocytes [350]. Lipid 
droplets resident in hepatocytes may demonstrate variations in numbers and sizes which are 
reflective of the precise state of the pathological and or physiological condition of an individual 
[350]. Accumulation of LDs underlies and defines steatosis of the liver [352], therefore 
implying that our observation of low B12-induced hepatic accumulation of LDs may be 
associated with the pathogenesis of hepatic steatosis. We also observed that total intracellular 
TGs and radiolabelled-FA uptake for TG synthesis in hepatocyte cell line were increased in low 
B12. Clinical evidences have showed that serum B12 negatively correlates with triglyceride 
[196, 333, 353] and VLDL levels in Indian subjects [354, 355]. In an animal study, severe B12 
deficiency was associated with higher triglyceride levels compared with control which resulted 
in adverse pregnancy outcome [356]. These findings therefore confirm that in hepatocytes B12 
deficiency causes increased accumulation of LDs.  
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Furthermore, we observed that gene expression of the master regulator of lipogenesis 
(SREBF1) and cholesterol (LDLR), and downstream genes regulating synthesis of FAs (ACLY, 
ACC, FASN, ELOVL6), TGs (SCD, GPAM, AGPAT, LPIN1, DGAT1 and DGAT2) and 
cholesterol (HMGCR, HMGCS1 and IDI1) was increased in low B12 hepatocyte cell line. In a 
previous study, hepatic transcription factors: SREBP1c, liver X receptor (LXRα) and retinoid 
X receptor (RXRα) in Wistar rat offspring, were differentially regulated by B12 restriction 
[357]. SREBP1c was high but not significant in B12 deficient rats compared with control [357]. 
However, significantly higher expression of SREBF1 and LDLR were observed in human 
adipocytes with low B12 levels [193] and increased level of SREBP-1c in the fatty livers of ob 
/ob mice, [358, 359]. Similar studies have also shown increased expression of genes involved 
in biosynthesis of FA, TG and cholesterol in animals [336] and human adipocytes [189]. Three 
separate clinical studies involving women at (a) child-bearing period but non-pregnant (b) early 
pregnancy and (c) at the time of delivery showed associations between low B12 and higher 
LDL cholesterol, total cholesterol and ratio of cholesterol-to-HDL [193]. It was further revealed 
in these studies that, low B12-induced elevation in cholesterolgenesis and lipogenesis may 
result from epigenetic modulations via hypomethylation of SREBF and LDLR [360] and micro 
RNAs targeting PPARg and IR [189], respectively. Generally, DNL in humans is reported to 
be responsible for about 26% of total TG levels in the liver and contributes to the incidence of 
hepatic steatosis and NAFLD [361]. Therefore, our findings may suggest that increase in 
hepatic DNL resulting from low B12 may be associated with the risk of developing NAFLD.  
 
A particularly interesting finding in the present study was that FA profile was altered in 
hepatocyte cell line with low B12. Total FA, subclasses of FAs (SFAs, MUFAs, PUFA n-6, 
LC-PUFA n-6 and trans-FAs) and individual FAs (saturated even chains (C12, C14, C16 and 
C18), odd chains (C17, C21 and C23) and MUFA (C18:1n-9, n-7and C16:1n-9, n-7) were 
higher in hepatocyte cell line in low B12 compared with control. A prospective and longitudinal 
study showed that circulating even chain SFA’s in early pregnancy (10week gestation) was 
associated with glucose metabolism, cardio-metabolic markers and subsequent GDM risk 
[362]. Another study in pregnant women at delivery showed that grouped FAs (SFA, MUFA 
and PUFA) were elevated in GDM women and showed a graded trend between the severity of 
maternal hyperglycaemia and serum FA composition [363]. Similarly, Chen et al, have showed 
that SFA - myristic acid was inversely associated with IR and inflammation [364]. Several 
studies have also shown evidence of association of SFAs [365], MUFAs [366] and trans-FAs 
[367, 368] with subclinical inflammation, increased risk of T2DM and  CVD. Adolescent 
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females presenting with slightly lower levels of active B12 (holo-TC) than males, had 
significantly higher plasma levels of SFA, MUFA and trans-fatty acids and showed association 
with B12 [367]. The same study found a positive correlation between serum B12 and n-3 
PUFAs, and a negative association with n-6 PUFAs and PUFA n-6/n-3 ratio [367].  Similar 
relationship in liver tissues of rat offspring was shown between B12 and PUFAs n-3 (omega-
3) and PUFA n-6 (Omega-6) [345]. Likewise, we observed higher levels of individual n-3 and 
n-6 fatty acids, total PUFA n-6 (PUFAn-6 and LC-PUFAn-6) and PUFA n-6/n-3 ratio in low 
B12 hepatocyte cell line. Higher n-6 /n-3 ratio is associated with dysregulation in hepatic 
metabolism of lipids [369] and the risk of developing NAFLD [370]. Finally, higher levels of 
individual FAs such as myristic acid (C14:0), palmitate (C16:0), palmitoleate (C16:1), stearate 
(C18:0), oleate (C18:1), as shown in this study, were supported by an animal study involving 
liver tissues of B12-deficient rat [371]. In support to this, placental tissues and plasma from 
GDM women and NAFLD patients [372, 373] showed similar observation. Our data in 
agreement with these evidences indicate that B12 deficiency may alter the FA composition and 
may lead to dyslipidaemia and increased IR. Furthermore, a recent study in adolescents showed 
that an anti-obesity program comprising calorie restricted diet, increased physical activity, 
psychological therapy and nutritional education on adolescents modified plasma FA, reduced 
adiposity and improved cardiometabolic markers [374]. This indicates that similar programs 
with relevance to B12 supplementation should be encouraged in young women and women 
planning for pregnancy where B12 deficiency is common to reduce the burden of metabolic 
disorders including obesity, GDM, T2DM and CVD.  
 
4.5 Conclusion:  
In summary, our study provided novel evidence that B12 deficiency in hepatocyte cell line 
accumulated more lipids, intracellular TG and increased uptake of FA under the influence of 
increased FA synthesis. The nuclear transcription factors, SREBF1 and LDLR, that regulate the 
genes involved in the biosynthesis of FA, TG and cholesterol pathways were also significantly 
increased in hepatocyte cell line due to B12 deficiency. Interestingly, we found that there was 
alteration in the FA profile especially the abundant subclasses of SFA and MUFA. Our evidence 
may therefore suggest that low B12 dysregulates lipid synthesis in hepatocytes and may 
predispose to NAFLD and dyslipidaemia. Future studies elucidating possible epigenetic 
mechanisms and clinical studies endorsing its relevance to B12 deficiency are warranted. 
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5.0  Vitamin B12 deficiency reduces oxidation of fatty acids and 
compromises mitochondrial functional integrity 
 
5.1  Introduction 
Obesity increases the risk of developing metabolic disorders including IR, CVD and 
T2DM, therefore, compromising the health of adults and children globally [320]. Failure of 
excessive fat storage in the adipose tissues accounts for inappropriate build-up in other tissues 
including the liver [375]. Within hepatocytes, the entry of medium and short-chain FAs 
(MCFAs and SCFAs) into the mitochondria for oxidation may occur freely without activation 
[376]. However, enzymes including the carnitine palmitoyltransferase (CPT) system which 
comprises CPT1, CPT2 and carnitine acylcarnitine translocase (CACT) may be required to 
facilitate the entry of long-chain FAs (LCFAs) into the mitochondria [377, 378] for beta 
oxidation (Fig 34). Moreover, CPT1 (the rate limiting enzyme) may be inhibited due to changes 
in levels of methyl malonyl-CoA [378] regulated by vitamin B12 (B12) [379].  
It is hypothesized that promotion of fatty acid oxidation (FAO) is a probable mechanism 
to alleviate the risk of developing resistance to insulin [375, 380]. Also, growing evidence 
supports the hypothesis that white adipose tissue (WAT) oxidation of fats contributes 
significantly towards the maintenance of metabolic homeostasis [381-383]. FAO is further 
shown to be inversely associated with de novo lipogenesis [376]. However, the rate of FAO in 
adipocytes is relatively minimal compared with other tissues such as liver and muscles [384, 
385]. Some clinical studies have shown evidence of association between low B12 and higher 
obesity/adiposity in pregnancy among the British [314] and Indian [386] populations. Similar 
evidence was also shown in pre-clinical studies involving animal [336] and cell line [360] 
models. Moreover, the potential role of B12 in limiting tissue accumulation of  long chain FAs 
in humans through CPT1 regulation in the FAO pathway has been reported [371, 387]. In a 
study involving rat model, impairment in the oxidation of FAs resulting from deficiency in 
methyl donors (B12 and folate) was demonstrated in liver tissues [327]. Clinically, systemic 
deficiency of carnitine during pregnancy was shown to be associated with CVDs [388]. Also, 
increasing evidence suggests that dysfunction in the mitochondria of the liver is associated with 
lipid accumulation underlying the incidence of non-alcoholic fatty liver disease (NAFLD) 
[389].  
We initially showed evidence of increased lipogenesis resulting from B12 deficiency in 
human adipose tissues [360] and currently in hepatocytes, including increased levels of total, 
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saturated and monounsaturated FAs (TFA, SFA and MUFA). Higher levels of long FAs 
including palmitate (C16:0), stearate (C18:0) and oleate (18:1) were also observed in 
hepatocytes as a result of low B12.   
Since mitochondrial oxidation of FAs is crucial in limiting the accumulation of lipids in the 
liver, we therefore assessed the effect of B12 deficiency on the FAO pathway as well as 
mitochondrial functional potency in the utilization of long chain FA for ATP metabolism under 
various conditions of B12.  
 
 
 
Figure 34: Fatty acid oxidation pathway: Long chain FAs derived from lipolysis of TGs and de novo FA 
synthesis may be utilized in the beta oxidation of FA pathway in the mitochondria to maintain levels of energy 
(ATP) for cellular metabolism. In the process, long chain fatty acyl CoA is synthesized from FA by the enzyme 
fatty acyl CoA synthase (ACSL1) and transported from the cytosol across the outer and inner mitochondrial 
membranes with the help of carnitine palmitoyl transferase 1α (CPT1α) and CPT II respectively through acyl 
carnitine intermediate modulated by acyl carnitine acyl translocase (CACT). Long chain fatty acyl CoA is 
sequentially shortened by cleavage of two-carbon units until generation of only two-carbon compounds, acetyl 
CoAs, by various enzymes long chain Acyl–CoA dehydrogenase (LCAD), medium chain Acyl–CoA 
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dehydrogenase (MCAD), short chain Acyl–CoA dehydrogenase (SCAD) and long-chain 3-hydroxyacyl-CoA 
dehydrogenase alpha (HADHA). Acetyl CoA is finally utilized in the Krebs or TCA cycle for ATP generation 
 
 
5.2 Methods 
5.2.1 Beta-oxidation of fatty acid assessment:  
5.2.1.1 Cell culture for gene expression assay: The culture of Hep G2 cells in four different 
concentrations of B12: 500nM (Control), 1000pM, 100pM and 25pM, was done as described 
in sections 2.2.1.5 – 2.2.1.6.  
 
5.2.1.2 Gene expression assay: 
Total RNA isolation, cDNA synthesis and gene expression assays were same as previously 
described in sections 2.2.2.1-2.2.2.4, for the four conditions of B12 (500nM, 1000pM, 100pM 
and 25pM).  
 
5.2.2 Mitochondrial dysfunction assessment using seahorse XF24 extracellular flux assay 
Hep G2 cell culture for seahorse assay was done as described in section 2.2.8. 
However, optimization for the desired final (1x) concentrations of the respiratory inhibitors 
oligomycin, FCCP and rotenone / antimycin was done by testing a range of different inhibitor 
concentrations: Oligomycin (0.2µM, 0.4µM, 0.6µM, 0.8µM and 1.0µM), FCCP (0.1µM, 
0.3µM, 0.5µM, 1.0µM, 3.0µM and 5.0µM) and rotenone /antimycin (0.1µM, 0.2µM, 0.4µM, 
0.6µM, 0.8µM and 1.0µM) (Fig 35). 
Likewise, optimization for the cell density was done by seeding Hep G2 cells at different 
densities comprising 10 000 (10K), 20 000 (20K), 30 000 (30K) and 50 000 cells (50K) / well 
of seahorse XF24 plate. In the presence of respiratory inhibitors (oligomycin, FCCP and 
rotenone/antimycin), the highest maximal respiratory capacity, estimated by the oxygen 
consumption rate (OCR) in hepatocyte cell line, was observed in the 50K cell density with the 
lowest seen in the 10K cells (Fig 36).  
We also optimized for the more efficient substrate medium, between Krebs-Henseleit Buffer 
(KHB) and seahorse XF buffer, accounting for higher spare respiratory capacity (SRC) in 
hepatocytes (Fig 37).  Therefore, following optimization of assays, 50 000 cell density per well 
of seahorse XF24 plate, KHB medium and inhibitor final (1x) concentrations of 0.40 µM 
oligomycin, 0.75 µM FCCP and 0.40 µM rotenone/antimycin were used for the experiment. 
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Assessment of mitochondrial functional competence in condition of B12 was done using same 
protocol as described in section 2.2.8 of chapter 2.  
 
 
 
 
 
Figure 35: Optimisation for concentrations of inhibitors for seahorse assay: Oxygen consumption rate (OCR) 
of hepatocyte cell line (50K cells/well) obtained following injection of different concentrations of inhibitors such 
as oligomycin (A), FCCP (B) and rotenone / antimycin D (C) after basal respiration measurements.  
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Figure 36: Optimisation of Hep G2 cell density for seahorse flux assay: Oxygen consumption rate (OCR) for 
different densities of Hep G2 (10K, 20K, 30K and 50K cells) following the sequential injection of different 
inhibitors Oligomycin, FCCP and rotenone/ antimycin after an initial basal respiration measurement.  
 
 
 
Figure 37: Optimisation for the desired seahorse media: Spare respiratory capacity (%) of hepatocyte cell line 
incubated in two different seahorse buffers such as KHB and XF-buffer. The data is representative of mean ± SEM 
(n=6), and * indicates significance compared with control; * p< 0.05, ** p< 0.01, *** p< 0.001 
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5.3 RESULTS 
5.3.1 Effect of B12 on the expression of genes regulating the FAO pathway 
Free long chain-FAs are activated and transported across the mitochondrial membranes by the 
enzymes: acyl-CoA synthetase (ACSL), carnitine palmitoyl transferase 1 (CPT1), carnitine acyl 
carnitine translocase (CACT) and carnitine palmitoyl transferase 2 (CPT2). Subsequently, 
consecutive processes involving dehydrogenation, hydration, oxidation and thiolytic cleavage 
to finally generate acetyl-CoA (two-carbon units), are crucial in the beta-oxidation (FAO) 
pathway under the regulation of the enzymes such as acyl-CoA dehydrogenase long chain 
(ACADL), acyl-CoA dehydrogenase medium chain (ACADM), acyl-CoA dehydrogenase short 
chain (ACADS) and hydroxyacyl-CoA dehydrogenase trifunctional multi enzyme complex 
subunits beta and alpha (HADHB and HADHA).  
B12 deficiency is associated with elevation in the levels of methyl malonic acid (MMA) 
resulting from the inefficient conversion of methyl malonyl-CoA to succinyl CoA during 
propionate metabolism by the enzyme methyl malonic CoA mutase (MCM) in the 
mitochondria. MMA is however known to be a potent inhibitor of CPT1 [390], the rate limiting 
enzyme in the FAO pathway. Since the lipid metabolism is co-ordinated by an intricate balance 
of FA synthesis and fatty acid oxidation (FAO), we assessed the effect of B12 deficiency on 
CPT1α and the downstream genes involved in FAO in the mitochondria. 
 
We observed that, the genes regulating oxidation of FAs: carnitine palmitoyl transferase 1α 
(CPT1α), carnitine acyl carnitine translocase (CACT), acyl-CoA synthase (ACSL1), acyl-CoA 
dehydrogenase long chain (ACADL), acyl-CoA dehydrogenase medium chain (ACADM), 
acyl-CoA dehydrogenase short chain (ACADS) and hydroxyacyl-CoA dehydrogenase 
trifunctional multi enzyme complex subunits beta and alpha (HADHB and HADHA), were 
significantly decreased in low B12 hepatocyte cell line compared with control. This suggests 
that FAO may be significantly impaired in hepatocyte cell line in low B12 compared with 
control (Fig 38).  
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Figure 38: Low B12 downregulates gene expression of enzymes involved in fatty acid oxidation (FAO) in 
hepatocytes : The mRNA expression of enzymes involved in the regulation of FAO such as CPT1a (A), CACT 
(B), ACSL1 (C), ACADL (D), ACADM (E), ACADS (F), HADHB (G) and HADHA (H) in hepatocyte cell line 
normalized to 18S rRNA endogenous control (Applied Biosystems, UK). The data are representative of mean ± 
SEM (n=6). * indicates significance compared with 500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
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5.3.2 Effect of B12 on mitochondria functional integrity  
5.3.2.1 Efficiency of mitochondria in utilizing a rich-substrate supply 
The electron transport chain (ETC) is partly dependent on the beta-oxidation of FA in the 
mitochondria for supply of electrons required for the synthesis of ATP [391]. We initially 
observed a decrease in the genes facilitating FAO in the mitochondria, that may account for a 
compromised beta-oxidation in low B12 hepatocyte cell line. We, therefore, further assessed 
the effect of B12 on mitochondrial respiration by measuring the OCR in hepatocyte cell line as 
an assessment of mitochondrial functional integrity in various conditions of B12.  
 
In the presence of respiratory inhibitors such as oligomycin (inhibits ATP synthase or complex 
V), FCCP (protonophore uncoupler which shuts the inner membrane gradient) and rotenone 
(inhibits complex I) / antimycin A (inhibits complex III of the ETC), we measured the maximal 
respiratory capacity by the OCR in hepatocyte cell line (in a rich-substrate medium) and found 
that the OCR was decreased in low B12 compared with control (Fig 39B). Then, we estimated 
the spare respiratory capacity (SRC), a measure of the capacity of electron transport chain and 
substrate supply to respond to elevation in energy demand. We observed that the SRC was also 
decreased significantly in low B12 hepatocyte cell line compared with control (Fig 39A). This 
suggests that the efficiency of the mitochondria in utilising a rich-substrate for energy 
metabolism was compromised in low B12.  
 
 
 
Figure 39: Low B12 compromises mitochondrial fumctional integrity of hepatocyte cell line in a rich-
substrate medium: The spare respiratory capacity (A) and oxygen consumption rate (OCR) (B) of hepatocytes in 
a rich-substrate KHB medium containing glucose (2.5mM), pyruvate (1mM), amino acid (L-Glutamine) (2mM) 
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and BSA (0.1%) at pH 7.4 and 37oC temperature, in various conditions of B12 [500nM (control), 1nM (1000pM), 
100pM and 25pM]. The data are representative of mean ± SEM (n=6). * indicates significance compared with 
500nM (control): * p< 0.05, ** p< 0.01, *** p< 0.001 
 
5.3.2.2 Efficiency of mitochondria in utilizing limited-substrate (palmitate) supply 
Then, to examine how the low B12 hepatocyte cell line function with the endogenous supply 
of high extracellular levels of palmitate and other limited substrate, we incubated hepatocyte 
cell line in a limited-substrate KHB medium, which is poorly enriched with other supplements, 
except palmitate, compared with the rich-substrate KHB medium, containing only 0.5mM L-
carnitine and 1.25mM glucose for one hour. After the basal respiration (OCR) was measured 
in the hepatocyte cell line, the cells were then exposed to 200µM palmitate or 33.3µM BSA 
(basal control) in the substrate medium to assess how Hep G2 cells efficiently uptake palmitate 
for ATP metabolism. We observed that in low B12 condition, the spare respiratory capacity 
(SRC) of the hepatocyte cell line upon exposure to (a) palmitate (Fig 40A) and (b) palmitate 
and respiratory inhibitors (Fig 40B), was significantly lower compared with control. This 
observation further suggests that the capacity of the mitochondria to catabolise long chain fatty 
acid (palmitate) for energy metabolism was impaired in low B12, therefore, implying that FAs 
were likely to accumulate in the hepatocyte cell line treated with low B12, leading to 
dyslipidaemia.  
.  
 
Figure 40: Low B12 impaired FA (palmitate) uptake leading to decline in spare respiratory capacity in 
hepatocyte cell line:  The spare respiratory capacity of hepatacytes in response to; (A) uptake of palmitate 
compared with BSA (basal control) and (B) uptake of palmitae in the presence of inhibitors such as oligomycin 
A, FCCP and rotenone / antimycin A in a substrate-limited KHB medium containing only 0.5mM L-carnitine and 
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1.25mM glucose for one hour at pH 7.4 and 37oC temperature without CO2 saturation. The data is representative 
of mean ± SEM (n=6), * indicates significance compared with 500nM-palmitate control; and $ indicates 
significance compared with 500nM-BSA control; * p< 0.05, ** p< 0.01, *** p< 0.001; $ p <0.05, $$ p < 0.01, $$$ 
p < 0.001 
 
5.4 Discussion 
In the current study, we observed that gene expression of the rate limiting enzyme 
(CPT1α) as well as key enzymes (CACT, ASCL1, ACADL, ACADM, ACADS, HADHA and 
HADHB) involved in the FAO pathway was significantly decreased in low B12 hepatocytes 
cell line compared with control. Likewise, the mitochondrial functional potency in low B12 
hepatocyte cell line was compromised, resulting in the impairment of long chain FA (palmitate) 
utilization for ATP metabolism.  
Low B12 impaired the beta-oxidation of FAs by decreasing expression of the rate 
limiting enzyme carnitine palmitoyl transferase 1-alpha (CPT1α) and downstream enzymes 
crucial in the FAO pathway. Similarly, an animal model study showed evidence of decrease in 
the hepatic FAO due to methyl donor (B12 and folate) deficiency [327]. The authors observed 
a deficit of carnitine in the liver of subjects compared with control [327]. However, FAO 
improvement via CPT1α upregulation following supplementation with methyl donors (B12) in 
mice was shown in another study [392]. Reduction in the expression of CPT1β and CPT2 due 
to low B12 was also observed in a similar study involving human adipocytes  [393]. 
Catabolism of FAs to prevent their accumulation in hepatocytes is achieved via beta oxidation 
in the mitochondria [394]. Normally, the transport of acyl-CoA across the mitochondrial 
membrane represents the rate limiting step. FAs presenting with an overall number of carbon 
atoms from one to six are generally short-chain fatty acids (SCFAs), whereas those with seven 
to twelve carbon atoms are medium-chain fatty acids (MCFAs) [395]. SCFAs and MCFAs are 
basically independent of carnitine-facilitated uptake and do not require prior activation into 
acyl-CoAs before transported across the mitochondria membranes for catabolism [395]. 
However, long chain fatty acids (LCFAs) such as palmitate (C16) and stearate (C18)  [396], the 
most abundant of total FAs in animal tissues [397], require the role of carnitine to enhance their 
oxidation. Therefore, reduction in the levels of CPT1α in low B12 hepatocyte cell line might 
affect the efficient transport of LCFAs across mitochondrial membrane for beta-oxidation.  
Similarly, we observed that other key enzymes (ACLS1, CACT, ACADL, ACADM, 
ACADS, HADHB and HADHB) crucial in the FAO pathway were also decreased in low B12 
compared with control. Similar evidence has been shown in human adipocyte model where low 
114 
 
B12 triggered adipocyte dysfunction by promoting TG biosynthesis as well as inhibiting FAO 
[393]. In that study, the expressions of key FAO genes including ACSL1, Acyl-CoA-
dehydrogenase group (ACDL, ACADS and ACADM) and HADHB were all shown to be 
decreased in adipocytes as a result of low B12 [393]. Similar evidence of impaired FAO was 
also shown in myocardial cells resulting from low B12 and folate [398]. 
Generally, an inverse relationship between de novo synthesis of LCFAs and the rate of beta 
oxidation in the mitochondria has been reported [376]. It therefore confirms our earlier 
observation of higher levels of LCFAs synthesized in hepatocyte cell line under low B12. Since 
LCFAs are also associated with the development of hepatic steatosis [370], it suggests that 
compromised beta-oxidation due to low B12 and may account for long chain-FA accumulation 
in hepatocytes leading to the development of NASH or NAFLD [399]. However, the precise 
mechanism of low B12 downregulation of the mitochondrial FAO downstream enzymes 
requires further investigation, nevertheless, epigenetic modulation may be the most probable 
mechanism [400, 401].  
Finally, we observed that the mitochondrial functional integrity, assessed by OCR and 
SRC, was impaired in low B12 compared with control. This observation was evident in the 
hepatocyte cell line in both rich and limited (palmitate)-substrate supply in low B12. Similarly, 
a recent study has shown that functional deficiency of B12 is associated with dysfunctional 
lysosomal metabolism (Gaucher disease) [402], which in turn is accompanied by mitochondrial 
dysfunction [402, 403]. Moreover, acute fatty liver of pregnancy (AFLP) is shown to be 
triggered by impaired hepatic mitochondrial function [404] which is further suggested to 
underlie several pathological disorders in pregnancy [405]. 
Beta-oxidation of FAs (FAO) and oxidative phosphorylation involving the electron transport 
chain (ETC) complexes in the mitochondria are not entirely independent pathways of cellular 
energetics [406]. Deficiencies identified in the FAO in patients are associated with detection of 
biochemical and/or clinical evidence suggestive of a subsequent abnormality in the oxidative 
phosphorylation pathway, or vice versa [406]. Also, a potential reduction of key FAO enzymes 
due to B12 deficiency may affect the supply of end-products (acetyl-CoA) of beta- oxidation 
to TCA (Krebs) cycle. Altogether, dysregulation in both beta-oxidation and TCA cycle may 
collectively affect the overall electrons (NADH and FADH2) supply to the electron transport 
chain (ETC) of the mitochondria for efficient ATP metabolism [406]. This may explain our 
observation of compromised mitochondrial respiration in hepatocyte cell line in low B12, 
therefore, suggesting that LCFAs are likely to accumulate in hepatocytes. In conclusion, our 
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evidence in low B12 supports the hypothesis that impairment of FAO and mitochondrial 
respiration increases the incidence of NAFLD [405].  
 
5.5 Conclusion 
In conclusion, this study provides novel evidence of the role of B12 deficiency in hepatic FAO 
as well as mitochondrial respiration (oxidative phosphorylation) by utilization of LCFA for 
energy metabolism. The study shows that B12 deficiency may limit the entry of LCFAs into 
the mitochondria due to decreased CPT1α expression. Low B12 further decreased beta-
oxidation by decreasing expression of the key downstream enzymes involved in the FAO 
pathway. Likewise, low B12 compromised the mitochondrial functional integrity by decreasing 
the maximal respiratory capacity, assessed by OCR, and the SRC in hepatocyte cell line 
compared with control. This may therefore explain the observation of lipid accumulation in 
hepatocyte cell line in low B12 accounting for elevation in the risk of NAFLD and incidence 
of T2DM. 
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6.0 The desired lipid lowering effect of metformin in human hepatocytes 
may be decreased in B12 deficient state 
6.1 Introduction 
The emergence of non-alcoholic fatty liver disease (NAFLD) is increasingly reported 
with the concomitant rise in cases of obesity. The prevalence of NAFLD is 25% in the general 
population of Asia [407] and Western countries [408]. Whereas prevalence rate in T2DM [409, 
410] and obese population [409, 411] is much higher at 70% in the West, in lean or non-obese 
Asians [407], it is lower at 8-19%. NAFLD is known to be an independent risk factor associated 
with the development of T2DM and cardiovascular disease (CVD) [412]. Evolving evidence 
show that micronutrients may demonstrate a crucial role in the progression of NAFLD [331] 
and the association of NAFLD with certain vitamins has further been suggested by different 
studies [331]. In NAFLD patients presenting with higher levels of circulating alanine 
aminotransferase (ALT), serum B12 concentrations were shown to be significantly lower [332]. 
Supplementation with diverse vitamins, according to different studies, present as a hopeful 
alternative in NAFLD management [331]. Likewise, metformin offers some lipid lowering 
effect along with other potential drugs such as glucagon-like peptide 1 (GLP-1) [413], although 
their efficacy are still being tested.  
In the management of T2DM, and in reduction [414] of fat accumulation in the liver 
[415-419] in other co-morbidities, metformin is used as the first line therapy. It is also 
increasingly accepted as an alternative therapy to insulin in GDM. Recently, the MiG 
(Metformin in Gestational Diabetes) trial reported similar pregnancy outcomes for metformin 
versus insulin treatment, however, supplemental insulin was required in 46% of women on 
metformin [420]. Studies in animals [421] and humans [422] have shown that metformin 
treatment had no effect on intra-hepatic TG content [415]. This suggests failure of metformin 
therapy in a subgroup of these patients, however, the exact underlying mechanism accounting 
for this remains unclear. Several clinical studies have shown that prolonged treatment with 
metformin is linked to deficiency of B12 [423-428]. Though metformin has a lipid lowering 
effect, some studies show metformin reduces B12 levels, and B12 deficiency induces lipid 
dysregulation. These observations thus provide us a clue that B12 might interfere with the 
action of metformin (Fig 41). Therefore, we hypothesize that B12 deficiency might impair the 
lipid lowering effect of metformin. Hence, we aimed to investigate the relation between 
deficiency of B12, metformin and adverse lipids and the underlying mechanisms. In the present 
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study, therefore, we performed to determine the effect of metformin on lipid synthesis, 
oxidation and mitochondrial function in hepatocytes treated with low B12. 
 
Figure 41: Mechanism underlying metformin and B12 actions resulting in lipid lowering effect: Metformin 
plays a key role in the activation of the adenosine monophosphate activated protein kinase (AMPK) by 
encouraging higher AMP/ATP ratios achieved via suppression of ATP production resulting from inhibition of 
complex 1 of the electron transport chain (ETC) as well as blocking of AMP deaminase (AMPD) which is capable 
of degrading AMPs present. Higher levels of AMPs achieved via metformin treatment subsequently results in the 
activation of AMPK by binding to its gamma subunit. Activated AMPK inhibits lipogenesis by directly 
phosphorylating and inactivating rate limiting enzymes such as acetyl CoA carboxylase (ACC) and sterol 
regulatory element binding protein (SREBF) involved in lipid biosynthesis. AMPK again ensures upregulation of 
CPT1, enhancing beta-oxidation of FAs to prevent their accumulation. Concurrently, B12 (adenosyl cobalamin) 
acting as a cofactor to methylmalonyl-CoA mutase (MCM) engaged in the propionate metabolism in the 
mitochondria plays a key role in alleviating the build-up of methyl malonic acid (MMA) by facilitating the 
generation of succinyl-CoA from methyl malonyl-CoA, thereby providing succinyl-CoA substrates to the Kreb’s 
cycle leading to generation of AMP, ADP and ATP molecules required for AMPK activation. Similarly, B12 via 
inhibition of MMA build-up facilitates activation of CPT1 which decreases accumulation of FAs by enhancing 
their breakdown via the beta-oxidation. 
 
 
 
 
118 
 
6.2 Methods 
6.2.1 Cell culture 
Hep G2 cell culture was done as described in sections 2.2.1.5-2.2.1.6, in control B12 (500nM) 
and low B12 (25pM) conditions. After the last media change at the 10th day of incubation, the 
cells (cases) were treated with 1mM metformin (Sigma, UK) in a serum-free EMEM media for 
24-hours or maintained in serum-free media without metformin. The cells were harvested for 
isolation of RNA, proteins and total intracellular TG estimation. Some cells were also 
maintained in six-plates for radioactive flux assays.  
 
6.2.2 RNA isolation, cDNA synthesis and gene expression  
Total RNA isolation, cDNA synthesis and gene expression assays were same as previously 
described in sections 2.2.2.1-2.2.2.4 for cases (1mM metformin treated hepatocytes) and 
controls (without metformin treatment) under conditions of low B12 (25pM) and control B12 
(500nM).  
 
6.2.3 Western blot analysis 
Protein characterization studies were done as previously described in section 2.2.6. Primary 
antibodies (cell signalling) targeting pAMPKα (molecular weight: 62 kDa) and pACC 
(molecular weight: 280 kDa) were normalised to total AMPK (molecular weight: 62 kDa) and 
total ACC (molecular weight 280kDa) proteins respectively.  
  
6.2.4 Total intracellular TG estimation 
Total intracellular TG in hepatocytes was quantified as previously described in section 2.2.3 of 
chapter 2. In cases involving Hep G2 cells treated with 1mM metformin as well as control 
(without metformin treatment) in low (25pM) and control (500nM) B12 conditions, TGs were 
quantified using the commercial TG quantification kit (ab65336) from Abcam Plc, Cambridge, 
UK, following the manufacturer’s protocol.  
 
6.2.5 Radioactive flux assay for TG biosynthesis  
Upon reaching 100% confluence in six-well plates following the last media change for different 
conditions of B12: 500nM (control) and 25pM, Hep G2 cells were treated with 1mM metformin 
in serum-free media for 24-hours in cases, whereas controls were maintained in serum-free 
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EMEM medium at 37oC and 5% CO2 saturation. The radioactive flux assay was then performed 
as previously described in section 2.2.4 of chapter 2.  
 
6.2.6 Mitochondrial dysfunction assessment using seahorse assay 
Hep G2 cell culture was done as described in section 2.2.8. Additionally, the cells in control 
B12 (500nM) and low B12 (25pM) conditions were trypsinized and seeded at 50 000 per well 
of the seahorse XF 24 plate and allowed to settle overnight at 37 oC and 5% CO2 saturation. 
This was followed by replacement of the B12-EMEM medium with a serum-free medium for 
24-hours incubation, followed by subsequent treatment with 1mM metformin in a serum-free 
medium for 24-hours. The samples, seahorse substrate medium and respiratory inhibitors 
(oligomycin, FCCP and rotenone /antimycin) were then prepared and used for the seahorse 
assay as previously described in section 2.2.8.  
Following the estimation of OCR in a rich-KHB substrate medium, we further incubated the 
Hep G2 cells in a limited-KHB substrate medium containing only 0.5mM L-carnitine and 
1.25mM glucose for one hour. After measuring the basal respiration (OCR) in hepatocytes, the 
cells were then exposed to 200µM palmitate or 33.3µM BSA (basal control) in the substrate 
medium to assess how the hepatocyte cell line efficiently uptake palmitate for ATP synthesis. 
 
 
6.3 Results 
6.3.1 Effect of metformin on total intracellular TG level in hepatocyte cell line  
Metformin is shown to significantly reduce plasma levels of TG and cholesterol [429]. We 
therefore quantified the total intracellular TG in metformin treated hepatocyte cell line to assess 
whether metformin would achieve a significant lowering effect in different B12 conditions. In 
low B12 hepatocyte cell line (without metformin), the total intracellular TG level was 
significantly higher compared with control. As predicted, metformin treatment in control cells 
showed significant reduction (20.7%) of TG levels but treatment with metformin in low B12 
cells did not achieve significant reduction (6.2%). This finding suggests that there is higher TG 
level in low B12 hepatocyte cell line following metformin treatment and thereby confirms our 
hypothesis that B12 deficiency in metformin treatment might lessen its lipid lowering effect 
(Fig 42).  
 
120 
 
  
Figure 42: Effect of metformin on total intracellular TG levels in hepatocytes 
Total intracellular levels of TGs were quantified in metformin (Met) and non-metformin treated (No met) / basal 
hepatocyte cell line in different B12 conditions: 25pM (low B12) and 500nM (control), using the TG kit (ab65336, 
Abcam plc, UK) and normalized per milligram protein of hepatocytes under each B12 condition. The data is 
representative of mean ± SEM (n=6). * represents significance compared with 500nM-No-met control; and $ 
represents significance compared with 25pM-No-met control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 
0.01, $$$< 0.001.  
6.3.2 Effect of metformin on FA (radiolabelled) uptake for TG synthesis  
Following the observation that metformin treatment in low B12 did not reduce total intracellular 
TG levels, we further assessed to see how this affects the uptake of FA in hepatocyte cell line 
for TG synthesis. We therefore performed the radioactive flux assay to assess the amount of 
radiolabelled-FA utilized in the hepatocytes cell line for TG synthesis after a period, following 
the extraction and isolation of TG in metformin treated hepatocyte cell line.  
We observed that, the level of TG synthesized following the uptake of radiolabelled-FA was 
significantly higher in hepatocyte cell line in low B12 (without metformin) compared with 
control. However, in metformin treated hepatocyte cell line, the level of TG synthesized was 
significantly reduced in control hepatocyte cell line (58%) but not in low B12 hepatocyte cell 
line (13%) (Fig 43). This evidence may also suggest that the esterification of FA for TG 
synthesis in low B12 hepatocyte cell line might not be significantly reduced by metformin 
treatment.  
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Figure 43: TG synthesized, following radio-labelled-FA uptake in metformin treated hepatocyte cell line, in 
different B12 conditions:   Radioactive flux assay was performed after seeding 75,000 Hep G2 cells in six-well 
plates under different conditions of B12 [500nM (control) and 25pM (low B12)] until reaching about 100% 
confluence at 10th day of the cell culture. The cells were then treated with 1mM metformin in a serum-free media 
for 24-hours after which hepatocytes were incubated with 14C-Oleate (0.75mM concentration at 2000 dpm/nmol) 
and L-carnitine (1mM) to facilitate incorporation of 14C-Oleate into hepatocytes for 2-hours in EMEM, against 5-
minutes incubation for background normalizing control, at 37oC and 5% CO2 saturation. Hep G2 cells were 
harvested in 2ml methanol and the synthesized radiolabelled TG was extracted, following an initial total lipid 
isolation with the liquid-liquid (chloroform-methanol, 2:1 v/v) extraction method, using a mobile phase such as 
hexane/diethtyl ether/formic acid (v/v/v, 70/30/1) on thin layer chromatography (TLC) plate with 10 nmol 
glyceryltripalmitate (tripalmitin) as a standard. TG bands on TLC plates were transferred into vials of 5ml 
scintillation fluid for scintillation counter assessment of radioactivity (for 5 minutes) of the synthesized TG 
fraction, normalized per milligram (mg) protein concentration by Bradford method. The data is representative of 
mean ± SEM (n=6), whereby * represents significance compared with 500nM-No met control; and $ represents 
significance compared with 25pM-No-met control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 
0.001.  
 
6.3.3 Effect of metformin on the lipid synthesis pathways in hepatocyte cell line 
6.3.3.1 De novo fatty acid (FA) synthesis 
De novo lipogenesis in the liver involves the synthesis of lipids by converting excess products 
of glycolysis, pyruvate, into FA, which also undergoes esterification into TG for storage. We 
have initially shown that de novo lipogenesis was increased in low B12 hepatocyte cell line. 
However, following our observation of inefficient lowering of total intracellular TG levels and 
FA uptake by metformin in low B12 hepatocyte cell line, we further assessed the probable effect 
of metformin on gene expression of de novo lipid synthesis in different B12 conditions.   
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In the FA synthesis pathway, we observed significantly higher expression of the genes 
regulating FA synthesis in low B12 hepatocyte cell line (without metformin) compared with 
control (Fig 34). In control cells with metformin treatment, there was greater reduction of 
expression of genes - SREBF1 (49.6%), ACLY (21.0%), ACC (23.8%), FASN (36.0%) and 
ELOVL6 (35.8%) (Fig 44). Similarly, in low B12 hepatocyte cell line with metformin 
treatment, the nuclear transcription factor and master regulator of lipogenesis, SREBF1, was 
significantly decreased (34%) in low B12. We also observed a significantly decreased 
expression of FA synthesis genes such as ACLY (17.6%), FASN (27.4%) and ELOVL6 
(29.9%). However, the expression of the rate limiting enzyme, ACC, was not significantly 
reduced in metformin treated hepatocyte cell line in low B12 (8.9%) compared with control. 
Although metformin showed significant reduction in FA genes (except ACC) in low B12, these 
data may suggest that, the lowering effect of metformin in the FA synthesis genes in control 
may be greater than in low B12 hepatocyte cell line.  
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Figure 44: Effect of metformin on gene expression of enzymes regulating de novo FA synthesis: The mRNA 
expression of nuclear transcription factor SREBF1 (A) and genes regulating de novo FA synthesis: ACLY (B), 
ACC (C) and FASN (D) and EVOVL6 (E) in different B12 conditions [25pM (low B12) and 500nM (control)] in 
both metformin (Met) and non-metformin treated (No met) / basal hepatocyte cell line, normalized to 18S rRNA 
endogenous control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby * 
represents significance compared with 500nM-No-met control; and $ represents significance compared with 
25pM-No-met control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001.  
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6.3.3.2 TG biosynthesis  
We subsequently assessed the TG biosynthesis pathway to ascertain whether metformin was 
effective in the downregulation of TG synthesis due to the observation of impaired lowering of 
total intracellular TG levels in metformin treated hepatocyte cell line in low B12. TG 
biosynthesis involves sequential esterification of FA, following synthesis and desaturation, into 
glycerol-3-phosphate substrate by utilizing enzymes such as SCD1, GPAT (GPAM), AGPAT, 
DGAT1 and DGAT2.  
We observed that the expression of TG biosynthesis genes including SCD1, GPAM, AGPAT, 
DGAT1 and DGAT2 was significantly higher in low B12 hepatocyte cell line (without 
metformin) (Fig 45). However, following metformin treatment in control cells, the expression 
of the TG biosynthesis genes: SCD1 (36.3%), GPAM (26.1%), AGPAT (40.5%), DGAT1 
(48.2%) and DGAT2 (29.0%), and in low B12 cells, SCD1 (22.3%), GPAM (21.1%), AGPAT 
(39.5%), DGAT1 (37.1%) and DGAT2 (23.8%) was lower significantly. Here the finding again 
suggests that, metformin may decrease gene expression of TG synthesis significantly in both 
control and low B12 cells, but more efficiently in control cells than the low B12 hepatocyte cell 
line.  
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Figure 45: Effect of metformin on gene expression of enzymes regulating TG synthesis: The mRNA 
expression of enzymes regulating TG biosynthesis: SCD1 (A), GPAM (B), AGPAT (C) DGAT2 (D) and DGAT1 
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(E) in hepatocyte cell line of different B12 conditions [25pM (lowB12) and 500nM (control)] in metformin (Met) 
and non-metformin treated (No met) /basal hepatocyte cell line, normalized to 18S rRNA endogenous control 
(Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby * represents significance 
compared with 500nM-No-met control; and $ represents significance compared with 25pM-No-met control; * p< 
0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001.  
 
6.3.2.3 Cholesterol biosynthesis  
We next assessed the lowering effect of metformin on cholesterologenesis in hepatocyte cell 
line in different B12 conditions. Cholesterol biosynthesis is chiefly regulated by the nuclear 
transcription factor LDLR and the rate limiting enzymes HMGCR and HMGCS [430].  
The expression of the cholesterol biosynthesis genes HMGCR, HMGCS1 and LDLR was 
significantly higher in low B12 hepatocyte cell line (without metformin) (Fig 46). However, in 
control cells with metformin treatment, we observed significantly decreased expression of 
HMGCR (32.9 %), HMGCS1 (32.6 %) and LDLR (34.2 %), with similar observation in low 
B12 hepatocyte cell line which had decreased expression of HMGCR (24.4%), HMGCS1 
(27.1%) and LDLR (27.6%). The finding again suggests that, metformin may decrease gene 
expression of cholesterol synthesis significantly in both control and low B12 cells, but more 
efficiently in control cells than low B12 hepatocyte cell line.  
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Figure 46: Effect of metformin on gene expression of enzymes regulating cholesterol biosynthesis: The 
mRNA expression of enzymes regulating cholesterol biosynthesis such as HMGCR (A), HMGCS1 (B) and LDLR 
(C) in different B12 [25pM (low B12) and 500nM (control)] conditions)] in metformin (Met) and non-metformin 
treated (No met) / basal hepatocyte cell line, normalized to 18S rRNA endogenous control (Applied Biosystems, 
UK). The data is representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM-
No-met control; and $ represents significance compared with 25pM-No-met control; * p< 0.05, ** p< 0.01, *** 
p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001.  
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6.3.4 Effect of metformin on fatty acid oxidation (FAO)  
Fatty acid oxidation (FAO), involving the catabolism or breakdown of FA, is crucial in 
preventing the accumulation of FA in hepatocytes leading to dyslipidaemia and development 
of NASH and NAFLD.  FAO of long chain-FA requires initial activation into fatty acyl-CoA, 
followed by facilitated transport via the mitochondrial membranes utilizing the carnitine system 
which includes CPT1a, CACT and CPT2. The long chain FAs are then subjected to consecutive 
processes in the mitochondria involving dehydrogenation, hydration, oxidation and thiolytic 
cleavage to generate acetyl-CoA (two-carbon units) utilizing enzymes such as ACADL, 
ACADM, ACADS and HADHA. 
Metformin was effective in reducing the expression of various FA synthesis genes in low B12. 
However, the rate limiting enzyme, ACC, was not significantly decreased in metformin treated 
hepatocyte cell line in low B12. ACC is also critically involved in the regulation of FAO via 
inhibition of CPT1, resulting from ACC-catalysed generation of methyl malonyl-CoA (MMA) 
from acetyl-CoA [431]. We therefore assessed whether metformin was effective in upregulating 
FAO in hepatocyte cell line in low B12 condition. We observed that the expression of CPT1a, 
CACT, HADHA, ACADS, ACADM and ACADL was significantly decreased in hepatocyte 
cell line (without metformin) in low B12 compared with control. However, in control cells with 
metformin treatment, there was a significant increase in the expression of CPT1a (35.5%), 
CACT (37.8%), HADHA (52.0%), ACADS (79.3%), ACADM (74.3%) and ACADL (27.9%) 
(Fig 38). Contrarily, there was no significant– increase in CPT1α (2.5%), CACT (14.7%), 
HADHA (14.1%), ACADS (29.6%), ACADM (23.6%) and ACADL (2.0%) in metformin 
treated hepatocyte cell line in low B12 (Fig 47). This evidence suggested that in low B12 
condition, the expressions of FAO genes were lower and their levels following metformin 
treatment, were not significantly increased accounting for decreased FAO in low B12 Hep G2 
cells treated with metformin.  
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Figure 47: Effect of metformin on gene expression of enzymes regulating fatty acid oxidation (FAO): The 
mRNA expression of enzymes involved in the regulation of FAO: CPT1a (A), CACT (B), HADHA (C), ACADS 
(D), ACADM (E) and ACADL (F) normalized to 18S rRNA endogenous control (Applied Biosystems, UK) in 
metformin (Met) and non-metformin (No met) treated / basal hepatocyte cell line under different conditions of 
B12: 500nM (control) and 25pM (low B12). The data is representative of mean ± SEM (n=6), whereby * represents 
significance compared with 500nM-No met control; and $ represents significance compared with 25pM-No-met 
control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001 
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6.3.5 Effect of metformin on the mitochondria functional integrity  
FAO is functionally interconnected with the mitochondrial respiration involving the electron 
transport chain (ETC) [432]. Since FAO was impaired in metformin treated hepatocyte cell line 
in low B12, we further assessed this effect on the mitochondrial functional efficiency with 
regards to the utilization of substrate supply for mitochondrial respiration in low B12 condition, 
following metformin treatment.  
First, we assessed whether B12 independently affects mitochondria functional integrity in the 
utilization of substrate supply for energy metabolism, using the seahorse XF24 flux mito-stress 
assay. We observed that the spare respiratory capacity (SRC) of the mitochondria in hepatocyte 
cell line in low B12 was significantly lower compared with control (Fig 48).  This suggested 
that low B12 independently decreased the mitochondrial functional potency in hepatocyte cell 
line by reducing the spare respiratory capacity.  
 
Figure 48: Effect of B12 on the spare respiratory capacity in hepatocytes: The spare respiratory capacity of 
mitochondria in hepatocyte cell line in different conditions of B12: 500nM (control) and 25pM (low B12). The 
data is representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM control; * 
p< 0.05, ** p< 0.01, *** p< 0.001 
 
Afterwards, we assessed whether metformin might improve mitochondrial functional efficiency 
in low B12 hepatocyte cell line. We observed a significant increase (43.6%) in the SRC of 
metformin treated Hep G2 cells in control, whereas upregulation of the SRC was not significant 
in low B12 accounting for only 8.6% increase (Fig 49). Therefore, suggesting that restoration 
of the mitochondrial functional efficiency by metformin treatment was decreased in Hep G2 
cells in low B12 compared with control.  
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Figure 49: Effect of metformin on the spare respiratory capacity in hepatocytes: The spare respiratory 
capacity of mitochondria in metformin treated hepatocyte cell line in different conditions of B12: 500nM (control) 
and 25pM (low B12). The data is representative of mean ± SEM (n=6), whereby * represents significance 
compared with 500nM-No-met control; * p< 0.05, ** p< 0.01, *** p< 0.001;  
 
Subsequently, we assessed whether metformin might efficiently improve mitochondrial 
respiration by utilizing long chain FA, palmitate, in low B12. The upregulation of SRC in 
metformin treated hepatocyte cell line in palmitate-rich substrate was significantly decreased 
in low B12 (17.0%) compared with control B12 (60.0%) (Fig 50). Therefore, suggesting that 
the mitochondrial functional efficiency in metformin treated hepatocyte cell line was 
compromised in low B12 resulting in the inefficient utilization of palmitate for respiration. This 
may hence account for the accumulation of long chain FA (palmitate) in metformin treated 
hepatocyte cell line in low B12 leading to dyslipidaemia.   
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Figure 50: Effect of metformin on the spare respiratory capacity in hepatocyte cell line exposed to palmitate: 
The spare respiratory capacity of mitochondria in metformin treated hepatocyte cell line supplemented with 
palmitate in different conditions of B12: 500nM (control) and 25pM (low B12). The data is representative of mean 
± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and $ represents 
significance compared with 500nM-Met+Pal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, 
$$$< 0.001.  
 
 
6.3.6 Effect of B12 on the lipid lowering effect of metformin via activation of AMPK  
Reduction in hepatic lipid levels is shown to be achieved via the activation of AMPK  and 
subsequent upregulation of FAO [433]. Metformin is known to achieve a lowering effect on 
lipids via the activation of AMPK.[434]. AMPK activation involves phosphorylation of the 
alpha subunit (pAMPKα) which further results in the phosphorylation (inactivation) of its 
downstream target, acetyl-CoA carboxylase (pACC).  
Therefore, in order investigate the underlying mechanism in lipid regulation through AMPK, 
we assessed the independent effect of B12 on pAMPKα and pACC levels in hepatocyte cell 
line to ascertain whether B12 affects the activation of AMPK with subsequent inactivation of 
ACC. We observed that pAMPKα level in the hepatocyte cell line was significantly decreased 
in low B12 compared with control (Fig 51A). Similarly, the level of pACC was significantly 
decreased in low B12 hepatocyte cell line compared with control (Fig 51B), concurrent to the 
gene expression. Our observation suggests that, the phosphorylation (activation) of AMPK and 
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subsequent phosphorylation (inactivation) of ACC were decreased in hepatocyte cell line in 
low B12 compared with control.  
 
Figure 51: B12 effect on pAMPKα and pACC levels: The level of pAMPKα (A) and pACC (B) proteins in 
hepatocyte cell line in different conditions of B12: 500nM (control) and 25pM (low B12). The data is 
representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM control; * p< 0.05, 
** p< 0.01, *** p< 0.001. 
 
Since the levels of pAMPKα and pACC were significantly reduced in low B12 hepatocyte cell 
line, we further assessed whether the activation of AMPK and subsequent inactivation of ACC 
would be restored in low B12 hepatocyte cell line following metformin treatment. We observed 
that the levels of pAMPKα (Fig 52A) and pACC (Fig 52B) increased significantly (93.1% and 
115.6% respectively) in control hepatocyte cell line treated with metformin but not significantly 
(22.4% and 37.7% respectively) in metformin treated hepatocyte cell line in low B12. This 
evidence suggests that, metformin did not efficiently restore the levels of pAMPKα and pACC 
in low B12 therefore confirming that impaired FAO may be mediated through AMPK in low 
B12 hepatocyte cell line in metformin treated condition. 
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Figure 52: Effect of metformin on pAMPKα and pACC levels: The level of pAMPKα (A) and pACC (B) 
proteins in metformin treated hepatocyte cell line under different conditions of B12: 500nM (control) and 25pM 
(low B12). The data is representative of mean ± SEM (n=6), whereby * represents significance compared with 
500nM-No-met control; * p< 0.05, ** p< 0.01, *** p< 0.001. 
 
 
6.4 Discussion  
Metformin treatment in low B12 hepatocyte cell line improved the expression of genes 
involved in hepatic FAs, TG and cholesterol biosynthesis, but total intracellular TG levels and 
biosynthesis of TGs remained significantly higher. Likewise, gene expression of FAO and the 
mitochondrial functional integrity in metformin treated hepatocytes was compromised in low 
B12 state. Importantly, the ability of metformin to reduce lipids through AMPK was impaired 
in B12 deficient state. 
Our group initially showed that B12 deficiency increased lipogenesis in adipocytes 
resulting from upregulation of genes regulating fatty acid (FAS and ACACA) [189] and 
cholesterol (SREBF1, SREBF2, HMGCS1 and HMGCR) biosynthesis [196]. We have also 
shown clinical evidence that B12 deficiency is associated with high TG levels in diabetes 
patients of both Indian and European ethnic groups [435]. Similar to this, we have shown in 
hepatocyte cell line in the previous chapter, that lipid metabolism is dysregulated. The nuclear 
transcription factor SREBF1 and downstream genes regulating fatty acids (ACLY, ACC, FASN 
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and ELOVL6), triglycerides (SCD, GPAM, AGPAT, DGAT1 and DGAT2) and cholesterol 
(HMGCS1 and HMGCR) biosynthesis were upregulated in low B12 hepatocyte cell line. We 
also observed that upregulation of the rate limiting enzyme of the FAO pathway, CPT1α, and 
downstream genes (CACT, HADHA, ACADM, ACADS and ACADL) were impaired in low 
B12 hepatocyte cell line. In this study, we found that metformin treatment in low B12 state 
resulted in significant reduction in hepatic expression of SREBF1 and downstream genes 
regulating fatty acids (ACLY, ACC, FASN and ELOVL6), triglycerides (SCD, GPAM, 
AGPAT, DGAT1 and DGAT2) and cholesterol (HMGCS1 and HMGCR) biosynthesis. 
However, the total intracellular TG and radio-labelled TG synthesized in metformin-treated low 
B12 hepatocyte cell line did not reduce significantly. Likewise, the mitochondrial functional 
potency assessed by its spare respiratory capacity was compromised in low B12 hepatocyte cell 
line exposed to palmitate-rich substrate. Similarly, metformin treatment could not improve the 
mitochondrial dysfunction in low B12 hepatocyte cell line. Our study therefore suggests that 
both FAO enzymes and mitochondrial functional efficiency in hepatocytes treated with 
metformin may be hampered under low B12 condition. Therefore, implying that B12 deficiency 
may decrease the desired lipid lowering effect of metformin in human hepatocyte cell line 
through downregulation of FAO.  
It is known that metformin action activates AMPK, resulting in the inactivation and 
phosphorylation of ACC leading to reduction in lipogenesis, thus alleviates hepatic 
accumulation of lipids [436]. Several studies involving animal models and cell lines have 
reported the lipid lowering effect of metformin via reduction of SREBP1 [416, 419, 437, 438], 
ACC [417, 437, 439], FAS [419, 438, 440], ELOVL6 [438], SCD1 [419, 440], HMGCS1 [438] 
and HMGCR [438] leading to reduction of intrahepatic triacylglycerol (IHTAG) content [415]. 
Studies also show that metformin reverses hepatic steatosis by blocking acetyl-CoA 
carboxylase (ACC) via AMPK activation which subsequently minimizes build-up of malonyl-
CoA (inhibitor of carnitine palmitoyl transferase 1, CPT1), therefore upregulating hepatic 
oxidation of fatty acids (FAO) [418, 434, 441]. Currently, clinical studies targeting the hepatic 
lipid lowering effect of metformin have also shown that intrahepatic TG level in humans 
remains unaffected following metformin treatment [415]. Some studies involving humans 
[442], animals [443] and cell lines [444] have also shown that metformin failed to increase FAO 
in subjects. A study in diabetes cohort similarly showed that compromised hepatic and whole 
body oxidation of fatty acids was not improved after metformin treatment [442]. As metformin 
administration has been associated with circulating low B12 levels  [428, 445], it may be 
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conceivable that metformin treatment in humans might result in probable reduction of B12 in 
hepatic stores. This may explain its ineffective lipid lowering impact on intrahepatic TG levels 
in a subgroup of patients, due to hepatic B12 deficiency. Activation (phosphorylation) of 
AMPKα was shown to minimize lipid levels in the liver [433]. We observed decreased levels 
of pAMPKα in low B12 hepatocyte cell line, an indication that B12 independently might play 
an epigenetic role in the in-activation of AMPK in the liver. B12 is a well-known methyl donor 
[446], and similar studies have shown that methyl donor supplementation in mice resulted in 
the activation (phosphorylation) of AMPK leading to reduction of hepatic lipid accumulation 
[447]. The probable epigenetic mechanism underlying B12 activation of AMPK requires 
further investigation. However,  derivatives of the axial ligand of cobalamin (B12), 5,6-
dimethyl benzimidazole [448] have been reported to prevent dephosphorylation as well as 
engage in allosteric activation of AMPK [449-451]. Similarly, we observed that 
phosphorylated-acetyl-CoA carboxylase (pACC) was decreased in low B12 hepatocyte cell 
line. It has been reported that the inhibitory effect of AMPK on lipogenesis may be achieved 
via phosphorylation (inactivation) of acetyl-CoA carboxylase (ACC) [452]. This may confirm 
our observation that decreased pAMPKα in low B12 accounted for reduced pACC in the 
hepatocyte cell line. In addition, we observed that protein expression of pAMKα and pACC in 
low B12 hepatocyte cell line, following metformin treatment, was impaired. Metformin 
treatment resulted in the decline of circulating B12 level and altered B12 distribution in rat 
tissues [453] and humans [454]. However, metformin has been shown to elevate 
phosphorylation or activation of AMPK in tissues including duodenum [414], skeletal muscles 
[455] and the liver [456]. Activation of AMPK by metformin in the liver is known to be 
achieved via elevation of AMP: ATP and ADP: ATP ratios [457]. However, an earlier study 
also showed that ethanol ingestion together with diet deficient in methyl donor (B9) accounted 
for downregulation of pAMPK resulting in increased lipogenesis [458]. Our findings may also 
be supported by the observation of another study in which mice fed with methyl donor deficient 
diet had decreased levels of AMP, ADP and ATP [459]. In support to these evidences, our 
findings may suggest that metformin action through AMPK is impaired in B12 deficient 
condition and hepatic accretion of fat may be partly mediated by AMPK. 
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6.5 Conclusion 
B12 deficiency may be associated with dysregulated metabolism of lipids resulting from 
increased lipogenesis and impaired oxidation of fatty acids in the liver. Risk of developing B12 
deficiency is associated with metformin treatment in type 2 diabetes patients. In this study, 
metformin treatment in low B12 hepatocyte cell line improved hepatic fatty acid biosynthesis 
but showed higher total TG levels and impaired FAO. Metformin, playing a crucial role in the 
activation of AMPK, failed to restore pAMPK levels in low B12 hepatocyte cell line. The 
ultimate effect was a decreased downregulation of lipogenesis and reduced upregulation of 
mitochondrial oxidation of fatty acids by metformin in low B12 hepatocyte cell line. Therefore, 
indicating that the desired lipid-lowering effect of metformin in the hepatocyte cell line was 
compromised by low B12 condition. 
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7.0 Adiponectin restores the lipid lowering effect of metformin in B12 
deficient human hepatocyte cell line  
 
7.1 Introduction 
NAFLD generally comprises a range of abnormal liver disorders, extending from non-
alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which demonstrate 
variable levels of severity and may result in adverse hepatic conditions including hepatic failure, 
hepatocellular carcinoma and cirrhosis [460, 461]. NASH may also be associated with elevated 
risk of developing CVD and malignancy [462]. De novo lipogenesis (DNL) is reported to be 
one of the principal sources of FAs in NAFLD accounting for hepatic lipid accumulation [361]. 
Clinical studies recently showed that significant elevation in the circulating levels of total 
cholesterol, VLDL, LDL and TG was observed in 45.7%, 67.1%, 25.7% and 34.3% of NAFLD 
patients respectively, whereas in 62.9% of patients, decreased concentration of HDL was 
observed [463]. This may therefore suggest that increasing hepatic lipid accumulation, 
accounting for higher grades of NAFLD, is associated with significantly higher circulating 
levels of VLDL, LDL and total-cholesterol as well as decreased HDL levels [463]. 
Several factors that may account for improvement in hepatic lipid levels include 
lifestyle interventions such as general weight loss [464], prolonged adherence to calorie-
restricted nutrition [465] and increased physical activity [466]. Likewise, insulin sensitizers 
have been proposed to improve the hepatic lipid levels in conditions of NAFLD or NASH. 
However, some studies showed that metformin treatment does not result in the significant 
improvement of liver histology in NAFLD and NASH patients [467]. Adiponectin is known to 
enhance several valuable effects in the liver. Some studies have shown clinical evidence that 
adiponectin demonstrates an inverse relationship with NAFLD, obesity and IR [468, 469]. In 
addition to regression of hepatic generation of glucose due its insulin sensitizing property, 
adiponectin further reduces inflammation, lowers hepatic fibrosis, increases survival of cells 
and augments the oxidation of FAs in the liver [468].  
Adiponectin has been shown to exert its effects via adiponectin receptor subtypes adipoR1 and 
R2 through stimulation of AMPK (Fig 53). It is proposed that adiponectin has a potential of 
regulating hepatic metabolism of lipids via the activation of AMPK signalling pathway [470, 
471]. Thus, investigating the functional role of adiponectin via AMPK in B12 deficiency in the 
presence of metformin will elucidate whether adiponectin can influence the activation status of 
AMPK and its effect on lipogenesis and lipid oxidation in hepatocytes. In the present study, we 
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performed to determine (1) whether adiponectin-mediated AMPK regulates the hepatocellular 
lipid accumulation in B12 deficient state and then, whether (2) treatment of adiponectin and 
metformin ameliorates lipid synthesis, oxidation and mitochondrial function in hepatocytes 
treated with low B12.  
 
 
 
Figure 53: Mechanism of adiponectin impairment of hepatic lipid accumulation: Adiponectin activates 
adiponectin receptors (AdipoR1 and AdipoR2) (a) in hepatocytes leading to the activation of AMPK (b). Activated 
AMPK directly phosphorylates acetyl CoA carboxylase (ACC) (c) which results in the inhibition of malonyl CoA 
synthesis (d). Decreased malonyl CoA levels facilitates the upregulation of carnitine palmitoyl transferase 1 
(CPT1) (e) and subsequently upregulates oxidation of fatty acids (FAO) (f) in the mitochondria. Similarly, 
activation of AMPK results in the inactivation or inhibition of the key nuclear transcription factor, sterol regulatory 
element binding protein 1 (SREBP1) (g), that subsequently decreases de novo lipid synthesis in hepatocytes (h).  
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7.2 Methods 
7.2.1 Optimisation for the concentration and duration of adiponectin treatment 
To optimize for the concentration and duration of adiponectin treatment, Hep G2 cells were 
cultured as previously described in 2.2.1. After the last medium change on the 10th day, at 100% 
confluence, Hep G2 cells were incubated with a serum-free medium for 24-hr. This was 
followed by treatment with two different concentrations of adiponectin (25ng and 50ng) in a 
serum-free medium at different durations: 4-hr, 8-hr, 12-hr, 24-hr and 48-hr, and AICAR 
(positive control) for 24-hr. The cells were then harvested for both RNA and protein extractions 
and stored at -20oC until utilized. Following the extraction of RNA and cDNA synthesis 
(described in sections 2.2.2.1-2.2.2.3), the effect of different concentrations and durations of 
adiponectin treatment on the expression of adipoR1 and R2 receptors (Fig 54), lipogenesis [FA, 
TG and cholesterol biosynthesis] (Fig 56) and FAO (Fig 57) was assessed using RT-qPCR. 
Likewise, the effect of different adiponectin concentrations and treatment durations on the 
levels of pAMPKα and pACC (Fig 55) was also assessed using western blot analysis. Therefore, 
following the optimization for two different concentrations (25ng and 50ng) of adiponectin at 
different durations (hours) of treatment: 0hr, 4hr, 8hr, 24hr and 48hr, we used the 25ng 
concentration and 24hr duration for this study.  
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Figure 54: Dose and time-dependent activation of adiponectin receptors by adiponectin: Different 
concentrations of adiponectin (25ng and 50ng) activates adiponectin receptors AdipoR1 (A) and AdipoR2 (B). 
The mRNA expressions in hepatocytes were normalized to 18S rRNA endogenous control (Applied Biosystems, 
UK). The data is representative of mean ± SEM (n=6), and * indicates significance compared with 0hr (control); 
* p< 0.05, ** p< 0.01, *** p< 0.001.  
 
 
Figure 55: Dose and time-dependent activation of AMPK by adiponectin: Different concentrations of 
adiponectin (25ng and 50ng) upregulates pAMPKα levels in Hep G2. The data is representative of mean ± SEM 
(n=6), and * indicates significance compared with 0hr (control); * p< 0.05, ** p< 0.01, *** p< 0.001.  
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Figure 56: Dose and time-dependent effect of adiponectin on lipogenesis Different concentrations of 
adiponectin (25ng and 50ng) decreases enzymes involved in fatty acid [FASN (A) and ACC (B)], triglycerides 
[SCD (C)] and cholesterol [LDLR (D)] biosynthesis. The mRNA expressions in hepatocytes were normalized to 
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18S rRNA endogenous control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), and 
* indicates significance compared with 0hr (control); * p< 0.05, ** p< 0.01, *** p< 0.001.  
 
Figure 57: Dose and time-dependent effect of adiponectin on fatty acid oxidation (FAO): Different 
concentrations of adiponectin (25ng and 50ng) upregulated enzymes CPT1a (A) and ACADM (B) involved in 
fatty acid oxidation. The mRNA expressions in hepatocytes were normalized to 18S rRNA endogenous control 
(Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), and * indicates significance compared 
with 0hr (control); * p< 0.05, ** p< 0.01, *** p< 0.001.  
 
7.2.2 Cell culture 
Hep G2 cell culture was done as previously described in section 2.2.1. On the 10th day of cell 
culture, the B12 (500nM and 25pM) EMEM medium was replaced with a serum-free media 
(0.1% BSA, 1% L-Glutamine) overnight. The hepatocyte cell line was then maintained in the 
serum-free media or treated with (a) 25ng adiponectin, (b) combined 25ng adiponectin and 
1mM metformin and (c) 1mM AICAR (positive control) for 24-hours, following initial 
optimization of concentrations and duration (hours) of adiponectin and AICAR. The cells were 
subsequently harvested and stored at -20oC until utilized for RNA and protein assays. The same 
treatments were done in the hepatocyte cell line for extracellular seahorse XF24 flux assay 
using 24-well seahorse plates.  
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7.2.3 RNA isolation, cDNA synthesis and gene expression  
Total RNA isolation, cDNA synthesis and gene expression assays were same as previously 
described in sections 2.2.2.1-2.2.2.4 of chapter 2.  
 
7.2.4 Western blot analysis 
Protein characterization studies using western blot (pAMPKα and pACC proteins normalized 
to total AMPK and total ACC respectively), were same as previously described in section 
2.2.6.3 of chapter 2.  
 
7.2.5 Total intracellular TG estimation 
Total intracellular TG in hepatocyte cell line was quantified as previously described in section 
2.2.3 of chapter 2. In each condition, the TGs were quantified using the commercial TG 
quantification kit (ab65336) from Abcam plc, Cambridge, UK, following the manufacturer’s 
protocol.  
 
7.2.6 Radioactive flux assay for TG biosynthesis  
Upon reaching about 100% confluence in six well plates following the last media change for 
different B12 conditions such as 500nM and 25pM, Hep G2 cells were treated as previously 
described (section 7.2.2) for 24 hours and exposed to radiolabelled fatty acid (14C-oleate) for 2 
hours. The cells were then harvested and the radiolabelled TGs synthesized within the 
hepatocyte cell line were extracted and assessed as previously described in section 2.2.4 of 
chapter 2.  
 
7.2.7 Mitochondrial dysfunction assessment using seahorse assay 
Following the same protocol in section 2.2.8.1, Hep G2 cells of different B12 conditions were 
afterwards trypsinized and seeded at 50 000 cells per well of the seahorse XF 24 plate and 
allowed to settle overnight at 37 oC and CO2, followed by replacement of the B12-EMEM 
medium with a serum-free medium for 24-hours incubation, and subsequent treatment with (a) 
25ng adiponectin, (b) combined 25ng adiponectin and 1mM metformin and (c) 1mM AICAR 
(positive control) for 24-hours in a serum-free medium for 24-hours. The samples, seahorse 
substrate medium and respiratory inhibitors (oligomycin, FCCP and rotenone /antimycin) were 
then prepared and used for the seahorse assay as previously described in section 2.2.8.  
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Following the estimation of OCR in a rich-KHB substrate medium, we further incubated the 
hepatocyte cell line in a limited-KHB substrate medium containing only 0.5mM L-carnitine 
and 1.25mM glucose for one hour. After the basal respiration (OCR) was measured in the 
hepatocyte cell line, the cells were then exposed to 200µM palmitate or 33.3µM BSA (basal 
control) in the substrate medium to assess how hepatocytes efficiently uptake palmitate for ATP 
synthesis. 
 
 
7.3 Results 
7.3.1 Effect of B12 on the expression of adiponectin receptors (AdipoR1 and R2) 
In this study, we observed that adiponectin was not expressed in Hep G2 cells, however, the 
expression of adiponectin receptors (adipoR1 and adipoR2) was detected in the hepatocyte cell 
line. Therefore, we assessed the expression of these receptors in low B12. The gene expression 
of both adipoR1 and R2 receptors was significantly decreased in low B12 hepatocyte cell line 
compared with control (Fig 58). This evidence suggested that low B12 impaired and or 
downregulated the levels of adipoR1 and R2 receptors in the hepatocyte cell line accounting 
for decreased expression.  
 
Figure 58: AdipoR1 and R2 receptors were decreased by low B12. Regulation of AdipoR1 (A) and R2 (B) in 
different conditions of B12: 500nM (control) and 25pM. The mRNA expressions in hepatocyte cell line were 
normalized to 18S rRNA endogenous control (Applied Biosystems, UK). The data is representative of mean ± 
SEM (n=6), and * indicates significance compared with 500nM control; * p< 0.05, ** p< 0.01, *** p< 0.001.  
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7.3.2 Effect of adiponectin treatment on Adipo-R1 and R2 expression  
Adiponectin has been shown to induce the activation of signalling pathways leading to 
regulation of lipid metabolism by binding to adipoR1 and R2 receptors in the liver [472]. We 
next assessed whether treatment with adiponectin would affect the receptors in the hepatocyte 
cell line. Following adiponectin treatment in control cells, there was significant increased 
expression of adipoR1 (43.5%) and R2 (45.0%), as well as similarly increased adipoR1 (67.7%) 
and R2 (81.0%) receptors in low B12 (Fig 59). This implies that the adiponectin treatment 
upregulates adipoR1 and R2 receptors significantly in low B12 condition.  
 
 
Figure 59: Adiponectin treatment independently increases AdipoR1 and R2 receptors in hepatocytes cell 
line Decreased expression of AdipoR1 (A) and R2 (B) in low B12 hepatocyte cell line was increased after 
adiponectin treatment. The mRNA expression, in different B12 conditions: 500nM (control) and low B12 (25pM) 
in both basal and adiponectin (Adipo) treated hepatocyte cell line, was normalized to 18S rRNA endogenous 
control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby * represents 
significance compared with 500nM-basal control; and $ represents significance compared with 25pM-basal 
control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
 
7.3.3 Effect of adiponectin on pAMPKα and pACC levels in hepatocytes 
We further assessed whether adiponectin treatment and subsequent upregulation of adipoR1/R2 
affect the activation of AMPK in B12 conditions. We observed that the levels of pAMPKα and 
pACC were significantly lower in low B12 compared with control. However, pAMPKα and 
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pACC levels as observed in control cells (199.6% and 83.3%-increase), were significantly 
increased in low B12 (426% and 211%) respectively following adiponectin (positive control-
AICAR) treatment (Fig 60). Therefore, this suggests that there was significant activation 
(phosphorylation) of AMPKα and subsequent inactivation (phosphorylation) of ACC in low 
B12 hepatocyte cell line following adiponectin treatment.  
 
Figure 60: Adiponectin increases pAMPKα and pACC levels in hepatocyte cell line: Level of pAMPKα (A) 
and pACC (B) proteins in hepatocyte cell line, in different conditions of B12 [500nM (control) and 25pM (low 
B12)], treated with 25ng adiponectin (Adipo) or 1mM AICAR (positive control). The data is representative of 
mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and $ represents 
significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 
0.001. 
 
7.3.4 Effect of adiponectin on hepatic lipid metabolism 
7.3.4.1 De novo FA synthesis 
Observing the significant elevation in the levels of pAMPKα and pACC in low B12 hepatocyte 
cell line following adiponectin treatment, we therefore assessed this effect on several genes 
regulating lipogenesis and FAO in hepatocyte cell line. In basal condition (without 
adiponectin), we observed that the gene expression of the key nuclear transcription factor 
SREBF1 and downstream genes regulating FA synthesis (ACC, FASN and ELOVL6) was 
upregulated in low B12 hepatocyte cell line. However, treatment with adiponectin (positive 
control -AICAR) in control cells resulted in significantly decreased expression of SREBF1 
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(22.1%), ACC (41.1%), FASN (36.8%) and ELOVL6 (22.2%) (Fig 61). Likewise, in low B12 
hepatocyte cell line, significantly decreased expression of SREBF1 (41.5%), ACC (49.3%), 
FASN (46.7%) and ELOVL6 (44.6%) was observed.  This therefore suggests that adiponectin 
was effective in reducing FA synthesis in low B12 hepatocyte cell line.  
 
Figure 61: Adiponectin decreases FA synthesis in low B12 hepatocyte cell line. The expression of SREBF1 
(A) and fatty acid synthesis genes such was ACC (B), FASN (C) and ELOVL6 (D) in hepatocytes was decreased 
after adiponectin (positive control-AICAR) treatment. The mRNA expressions in hepatocytes were normalized to 
18S rRNA endogenous control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), 
whereby * represents significance compared with 500nM-basal control; and $ represents significance compared 
with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
 
7.3.4.2 TG and cholesterol biosynthesis 
We observed that the gene expression of enzymes regulating TG synthesis (SCD1, DGAT1 and 
DGAT2) and the master regulator of cholesterol (LDLR) biosynthesis in basal condition was 
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increased in low B12 compared with control. However, treatment with adiponectin (positive 
control AICAR) in resulted in significant reduction of expression of genes - SCD1 (27.2%), 
DGAT1 (26.3%), DGAT2 (23.1%) and LDLR (24.1%) in control cells. Similarly, in low B12 
hepatocyte cell line, significantly decreased expression of genes - SCD1 (39.8%), DGAT1 
(39.1%), DGAT2 (41.4%) and LDLR (36.4%) was observed following adiponectin treatment 
(Fig 62).  
 
Figure 62: Adiponectin decreases TG and cholesterol synthesis in low B12 hepatocyte cell line. Expression 
of genes involved in TG [SCD (A), DGAT2 (B) and DGAT1 (C)] and cholesterol [LDLR (D)] biosynthesis was 
decreased after adiponectin (or AICAR) treatment. The mRNA expressions in hepatocytes were normalized to 18S 
rRNA endogenous control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby 
* represents significance compared with 500nM-basal control; and $ represents significance compared with 25pM-
basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
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7.3.4.3 TG synthesis using radiolabelled FA (14C-oleate) 
To confirm adiponectin effect on TG synthesis, we performed the radioactive flux assay to 
assess the uptake and esterification of FA (radiolabelled) for TG synthesis in low B12 
hepatocyte cell line. Similarly, in basal condition, the exposure of hepatocyte cell line to radio-
labelled FA (14C-Oleate) resulted in significantly high levels of TG in low B12 compared with 
control. However, adiponectin (positive control - AICAR) treatment resulted in significantly 
lower level of TG synthesized in low B12 (41.9%) compared with control (23.6%-decrease). 
This therefore shows that adiponectin treatment alleviates the effect of low B12 on the uptake 
and esterification of FA for TG synthesis in low B12 hepatocyte cell line (Fig 63).  
 
Figure 63: Adiponectin decreased synthesis of TGs:  Radioactive flux assay was performed after seeding 75.000 
Hep G2 cells under different conditions of B12 [500nM (control), and 25pM] until reaching 100% confluence at 
10th day of the cell culture. The cells were then treated with 25ng adiponectin (or 1mM AICAR) in a serum-free 
media for 24 hours. After this hepatocytes were incubated with 14C-Oleate (0.75mM concentration at 2000 
dpm/nmol) and L-carnitine (1mM) to facilitate incorporation of 14C-Oleate into the hepatocyte cell line for two (2) 
hours in EMEM, against five (5) minutes incubation for background normalizing control at 37oC and 5% CO2 
saturation. The cells were harvested in 2ml methanol and the synthesized radiolabelled. TG was extracted, 
following an initial total lipid isolation with the liquid-liquid (chloroform-methanol, 2:1 v/v) extraction method, 
using a mobile phase such as hexane/diethtyl ether/formic acid (v/v/v, 70/30/1) on thin layer chromatography 
(TLC) plate with 10 nmol glyceryltripalmitate (tripalmitin) as a standard. TG bands on TLC plates were transferred 
into vials of 5ml scintillation fluid for scintillation counter assessment of radioactivity (for 5 minutes) of the 
synthesized TG fraction, normalized per milligram (mg) protein concentration by Bradford method. The data is 
representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and 
$ represents significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 
0.01, $$$< 0.001. 
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7.3.4.4 Total intracellular TG level 
Since adiponectin was effective in the reduction of gene expression of lipid (FA, TG and 
cholesterol) synthesis, we further assessed its effect on the total intracellular TG levels in low 
B12 hepatocyte cell line. Similarly, we observed that total intracellular TG level in basal 
condition was initially higher in low B12 compared with control. Following treatment with 
adiponectin (positive control – AICAR), the total TG level in low B12 was significantly reduced 
by 33.2% compared with hepatocyte cell line in control B12 (20.5%). This suggests that 
adiponectin reduces intracellular TG levels significantly in hepatocyte cell line in low B12 (Fig 
64).  
 
 
Figure 64: Adiponectin decreased total intracellular TGs. Total intracellular level of TG was quantified in Hep 
G2 cells under different B12 conditions: 25pM and 500nM (control), using the TG kit (ab65336, Abcam 
plc, UK) and normalized per milligram protein of hepatocyte cell line in each B12 condition: 500nM (control) 
and 25pM (low B12). The data is representative of mean ± SEM (n=6), whereby * represents significance 
compared with 500nM-basal control; and $ represents significance compared with 25pM-basal control; * p< 0.05, 
** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
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7.3.4.5 Fatty acid oxidation (FAO) 
Since adiponectin decreased lipogenesis significantly in low B12 hepatocyte cell line, we 
further assessed how the FAO pathway may be affected by adiponectin treatment. In basal 
condition, the gene expression of CPT1α and ACADM regulating the FAO pathway was 
decreased in low B12 hepatocyte cell line compared with control B12. However, adiponectin 
(positive control- AICAR) treatment resulted in significant upregulation of the FAO genes in 
low B12 accounting for 60.8% increase in CPT1α and 56.6% in ACADM compared with 
control (CPT1 - 37.2% and ACADM - 47.6% - increase) (Fig 65).  
 
 
Figure 65: Adiponectin increased FAO genes in low B12 hepatocyte cell line. Expression of genes involved in 
oxidation of fatty acids such as CPT1a (A) and ACADM (B) were increased after adiponectin (or AICAR) 
treatment. The mRNA expressions in the hepatocyte cell line were normalized to 18S rRNA endogenous control 
(Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby * represents significance 
compared with 500nM-basal control; and $ represents significance compared with 25pM-basal control; * p< 0.05, 
** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
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7.3.4.6 Mitochondrial functional assessment 
a. Effect of adiponectin on the oxygen consumption rate (OCR) and spare respiratory 
capacity (SRC) in hepatocyte cell line 
Next, we assessed the independent effect of adiponectin on the mitochondrial functional 
efficiency in the utilization of substrate supply for respiration. We observed that in basal 
condition, the functional efficiency (OCR and SRC) was decreased in low B12 compared with 
control. However, treatment with adiponectin (positive control - AICAR) resulted in significant 
increase in mitochondrial functional efficiency (OCR and SRC) in low B12 (89%-increase) 
compared with basal control (42%).  This evidence indicates that there was significant 
improvement in the functional efficiency induced by adiponectin in hepatocyte cell line in low 
B12 (Fig 66).  
 
Figure 66: Adiponectin improves mitochondrial functional capacity in low B12 hepatocytes. The oxygen 
consumption rates and spare respiratory capacities were measured from hepatocytes in a substrate-rich media 
injected with respiratory inhibitors such as oligomycin, FCCP and rotenone /antimycin, The data is representative 
of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and $ represents 
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significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 
0.001. 
 
b. Effect of adiponectin on the uptake of palmitate for mitochondrial respiration  
Furthermore, we assessed the effect of adiponectin on the uptake of long chain FA palmitate 
from the substrate medium for mitochondrial respiration in Hep G2 cells. The functional 
efficiency (OCR and SRC), following adiponectin (positive control - AICAR) treatment, was 
significantly increased in the hepatocyte cell line exposed to only palmitate in low B12 (122%) 
compared to control (68%) (Fig 54). Likewise, exposure to palmitate in the presence of 
respiratory inhibitors (oligomycin, FCCP and rotenone/antimycin) accounted for 108% 
increase in low B12 compared with control (120%) (Fig 67). This evidence signifies that 
adiponectin enhanced the uptake and utilization of palmitate in low B12 hepatocyte cell line for 
mitochondrial respiration, therefore, preventing the accumulation of lipids in the hepatocyte 
cell line.  
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Figure 67: Adiponectin improves mitochondrial utilization of palmitate in low B12 hepatocyte cell line. The 
maximal respiratory capacity, assessed by the OCR, and the SRC were measured from Hep G2 cells (A) in 
substrate-limited media injected with palmitate and (B) in substrate-limited media injected with palmitate followed 
by respiratory inhibitors such as oligomycin, FCCP and rotenone / antimycin. The data is representative of mean 
± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and $ represents 
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significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 
0.001. 
 
7.3.5 Combined adiponectin-metformin treatment effect on lipid metabolism 
7.3.5.1 Effect of adiponectin and metformin co-treatment on adiponectin receptors  
Since adiponectin treatment independently reduced lipid accumulation in low B12 hepatocyte 
cell line, we further assessed the effect of combined adiponectin and metformin treatment on 
lipid metabolism of the hepatocyte cell line in low B12. We observed in our previous chapters 
that metformin alone had no effect on expression of AdipoR1 and R2 receptors in Hep G2. 
However, the gene expression of adipoR1 and R2 receptors was significantly upregulated in 
low B12 (56.6% and 56.9%) compared with control (28.3% and 26.8%- respectively) following 
the combined adiponectin-metformin treatment in hepatocyte cell line (Fig 68).  
 
Figure 68: Adiponectin and metformin co-treatment increased AdipoR1 and R2 receptors in low B12 
hepatocyte cell line. Expression of AdipoR1 (A) and R2 (B) receptors were unaffected by metformin but increased 
after adiponectin-metformin co-treatment. The mRNA expressions in hepatocytes were normalized to 18S rRNA 
endogenous control (Applied Biosystems, UK). The data is representative of mean ± SEM (n=6), whereby * 
represents significance compared with 500nM-basal control; and $ represents significance compared with 25pM-
basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
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7.3.5.2 Effect of adiponectin and metformin co-treatment on the activation of AMPKα in 
low B12 hepatocyte cell line: 
Further to the upregulation in adipoR1 and R2 by the combined adiponectin-metformin 
treatment in low B12 hepatocyte cell line, we subsequently assessed how this affects the 
phosphorylation of AMPK and ACC. We observed that the combined adiponectin-metformin 
treatment resulted in significant upregulation in pAMPKα and pACC levels (257.0% and 
229.0%) in low B12 compared with control (75.0% and 69.4%) (Fig 69). This evidence suggests 
that the combined adiponectin-metformin treatment resulted in a significant activation of 
AMPKα and subsequent inactivation of ACC in low B12 hepatocyte cell line.  
 
 
Figure 69: Adiponectin and metformin co-treatment increased pAMPKα and pACC levels in hepatocyte 
cell line: Level of pAMPKα (A) and pACC (B) proteins in hepatocytes significantly increased in combined 
adiponectin-metformin treated hepatocytes in different conditions of B12: 500nM (control) and 25pM. The data 
is representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; 
and $ represents significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, 
$$< 0.01, $$$< 0.001. 
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7.3.6 Effect of adiponectin and metformin co-treatment on lipogenesis  
7.3.6.1 De novo FA synthesis 
Following the increased levels of activated AMPK (pAMPKα) in hepatocyte cell line after the 
combined treatment with adiponectin and metformin, we further assessed the subsequent effect 
on lipogenesis. The expression genes regulating de novo FA synthesis was significantly 
downregulated in low B12, accounting for the respective decrease of - SREBF1 (47.7%), ACC 
(40.0%), FASN (46.7%) and ELOVL6 (42.5%), compared with control [SREBF1 (41.8%), 
ACC (32.4%), FASN (45.6%) and ELOVL6 (40.2%)-decrease] in the combined adiponectin-
metformin treated hepatocyte cell line (Fig 70).  
 
 
Figure 70: Adiponectin and metformin co-treatment decreased FA synthesis. The nuclear transcription factor 
SREBF1 (A) and downstream genes ACC (B), FASN (C) and ELOVL6 (D) involved in de novo FA synthesis 
were decreased after adiponectin-metformin co-treatment. The mRNA expressions in hepatocyte cell line were 
normalized to 18S rRNA endogenous control (Applied Biosystems, UK. The data is representative of mean ± SEM 
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(n=6), whereby * represents significance compared with 500nM-basal control; and $ represents significance 
compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
 
7.3.6.2 TG and cholesterol biosynthesis 
Similarly, assessment of the TG and cholesterol synthesis showed that combined adiponectin-
metformin treatment significantly downregulated the expression of genes regulating the 
synthesis of TG [SCD1 (49.7%), DGAT1 (45.6%) and DGAT2 (40.6%)-decrease] and the 
master regulator of cholesterol LDLR (44.2%) biosynthesis in low B12, than control [SCD1 
(36.6%), DGAT1 (38.2%), DGAT2 (30.5%) and LDLR (31.1%)-decrease] in the combined 
adiponectin-metformin treated hepatocytes (Fig 71).  
 
 
Figure 71: Adiponectin and metformin co-treatment decreased genes regulating TG and cholesterol 
synthesis: Expression of genes involved in triglyceride [SCD (A), DGAT2 (B) and DGAT1 (C)] and cholesterol 
[LDLR (D)] biosynthesis was decreased by adiponectin-metformin treatment. The mRNA expressions in 
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hepatocyte cell line were normalized to 18S rRNA endogenous control (Applied Biosystems, UK). The data is 
representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and 
$ represents significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 
0.01, $$$< 0.001. 
 
7.3.6.3 FA (radiolabelled) uptake for TG Synthesis  
To further validate the evidence of decreased expression of TG biosynthesis genes in low B12 
hepatocyte cell line resulting from the combined adiponectin-metformin treatment, we further 
assessed the level of radiolabelled TGs synthesized following exposure of the hepatocyte cell 
line to radiolabelled long chain fatty acid (14C-oleate) and L-carnitine. We observed that the 
level of radiolabelled TG synthesized in the hepatocyte cell line was significantly decreased 
(49.1%) in low B12 compared with control (38.5%) in the combined adiponectin-metformin 
treated hepatocyte cell line (Fig 72). This therefore suggests that combined adiponectin-
metformin treatment decreased the utilization of free long chain FA (oleate) for TG synthesis 
in low B12 hepatocyte cell line.  
 
 
Figure 72: Adiponectin-metformin co-treatment decreased synthesis of TGs:   Radio-active flux assay was 
performed after seeding 75.000 Hep G2 cells under different conditions of B12 [500nM (control), and 25pM] until 
reaching 100% confluence at 10th day of the cell culture. The cells were then treated with combined 25ng 
adiponectin and 1mM metformin in a serum-free media for 24-hours. After this, the cells were incubated with 14C-
Oleate (0.75mM concentration at 2000 dpm/nmol) and L-carnitine (1mM) to facilitate incorporation of 14C-Oleate 
into hepatocytes for two (2) hours in EMEM, against five (5) minutes incubation for background normalizing 
control at 37oC and 5% CO2 saturation. Hep G2 cells were harvested in 2ml methanol and the synthesized 
radiolabelled. TG was extracted, following an initial total lipid isolation with the liquid-liquid (chloroform-
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methanol, 2:1 v/v) extraction method, using a mobile phase such as hexane/diethtyl ether/formic acid (v/v/v, 
70/30/1) on thin layer chromatography (TLC) plate with 10 nmol glyceryltripalmitate (tripalmitin) as a standard. 
TG bands on TLC plates were transferred into vials of 5ml scintillation fluid for scintillation counter assessment 
of radioactivity (for 5 minutes) of the synthesized TG fraction, normalized per milligram (mg) protein 
concentration by Bradford method. The data is representative of mean ± SEM (n=6), whereby * represents 
significance compared with 500nM-basal control; and $ represents significance compared with 25pM-basal 
control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
 
7.3.6.4 Total intracellular triglyceride level 
To verify the impact of decreased lipogenesis resulting from the combined adiponectin-
metformin treatment in low B12 hepatocyte cell line, the total intracellular TG levels in Hep 
G2 cells were subsequently quantified and assessed. We observed that the total intracellular TG 
level was significantly decreased (36.1%) in low B12 compared to control (24.9 %) in the 
combined adiponectin-metformin treated hepatocyte cell line (Fig 73). This evidence therefore 
suggests that the combined therapy reduced the total TG levels significantly in low B12 
hepatocyte cell line.  
 
 
Figure 73: Adiponectin-metformin co-treatment decreased total intracellular TGs. Total intracellular levels 
of triglycerides following combined adiponectin and metformin treatment were quantified in hepatocyte cell line 
under different B12 conditions such as 25pM and 500nM (control) using the TG kit (ab65336, Abcam plc, 
UK) and normalized per milligram protein of hepatocytes under each B12 condition. The data is representative 
of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal control; and $ represents 
significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 
0.001. 
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7.3.7 Effect of combined adiponectin-metformin treatment on FAO in low B12 hepatocyte 
cell line 
Following the observation of significantly decreased lipogenesis by adiponectin-metformin co-
treatment in low B12 hepatocyte cell line, we further assessed the effect on the FAO. We 
observed that, the rate limiting enzyme CPT1a as well as ACADM were significantly 
upregulated, accounting for 68.8% (CPT1a) and 112.8% (ACADM) -increase in low B12 
compared with control [45.1% (CPT1a) and 53.7% (ACADM)] in the combined adiponectin-
metformin treated hepatocyte cell line (Fig 74). This suggests that FAO in the hepatocyte cell 
line was significantly improved by adiponectin-metformin combined treatment in low B12 
hepatocytes.  
 
 
Figure 74: Adiponectin-metformin co-treatment increases CPT1a and ACADM regulating FAO: The 
mRNA expression of enzymes involved in the regulation of FAO such as CPT1a (A), and ACADM (B)  normalized 
to 18S rRNA endogenous control (Applied Biosystems, UK) in hepatocytes with a combined adiponectin-
metformin treatment. The data is representative of mean ± SEM (n=6), whereby * represents significance 
compared with 500nM-basal control; and $ represents significance compared with 25pM-basal control; * p< 0.05, 
** p< 0.01, *** p< 0.001; $< 0.05, $$< 0.01, $$$< 0.001. 
 
7.3.8 Effect of combined adiponectin-metformin treatment on mitochondrial functional 
potency 
To obtain further evidence in support of the FAO, the mitochondrial functional integrity was 
assessed using the extracellular seahorse XF24 flux assay. Following the combined 
adiponectin-metformin treatment, we observed that the mitochondrial functional efficiency 
(OCR and SRC) of hepatocyte cell line in the presence of respiratory inhibitors (Oligomycin, 
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FCCP and rotenone/ antimycin) was significantly increased in low B12 (125%) compared with 
control (77%) (Fig 75A). The basal uptake of long chain FA (palmitate) by the hepatocyte cell 
line after adiponectin-metformin co-treatment resulted in significantly increased functional 
efficiency (OCR and SRC) in low B12 (186%) compared with control (109%) (Fig 75B). 
Lastly, the functional efficiency of adiponectin-metformin treated hepatocyte cell line exposed 
to palmitate in the presence of the respiratory inhibitors, was significantly higher in low B12 
(75%) compared to control (66%) (Fig 75C). This evidence shows that the efficiency of 
mitochondrial respiration utilizing palmitate in the substrate was significantly improved 
following combined adiponectin-metformin treatment, therefore, suggesting that accumulation 
of long chain FA (palmitate) in low B12 can be prevented by adding adiponectin treatment to 
metformin treated hepatocyte cell line.. 
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Figure 75: Adiponectin-metformin co-treatment improves mitochondrial functional capacity in low B12 
hepatocyte cell line. The oxygen consumption rates and spare respiratory capacities were measured from 
hepatocyte cell line; (A) in a substrate-rich media injected with respiratory inhibitors such as oligomycin, FCCP 
and rotenone /antimycin, (B) in substrate-limited media injected with palmitate and (C) in substrate-limited media 
injected with palmitate followed by respiratory inhibitors such as oligomycin, FCCP and rotenone / antimycin. 
The data is representative of mean ± SEM (n=6), whereby * represents significance compared with 500nM-basal 
control; and $ represents significance compared with 25pM-basal control; * p< 0.05, ** p< 0.01, *** p< 0.001; 
$< 0.05, $$< 0.01, $$$< 0.001. 
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7.4 Discussion  
In the current study we observed that; (1) adiponectin was not expressed in Hep G2 cell 
line, however, the expression of adiponectin receptors (AdipoR1 and AdipoR2) in the 
hepatocyte cell line was detected but decreased in low B12 compared with control. (2) 
Adiponectin treatment however increased adipo-R1 and R2 receptors in low B12 hepatocyte 
cell line and increased pAMPKα and pACC levels. (3) This resulted in downregulation of genes 
involved in FA, TG and cholesterol synthesis. (4) Similarly, adiponectin increased expression 
of key genes involved in FAO in low B12 hepatocyte cell line and improved mitochondrial 
functional efficiency. Observing the independent lipid lowering effect of adiponectin in low 
B12 hepatocyte cell line, we therefore combined adiponectin with metformin treatment in low 
B12 condition and (5) observed significant elevation in AdipoR1 and R2 receptors leading to 
increased pAMPKα and pACC levels. (6) This resulted in decreased FA, TG and cholesterol 
synthesis with increased FAO. (7) Finally, the mitochondrial functional integrity was also 
improved in low B12 hepatocyte cell line and therefore accounting for decreased accumulation 
of lipids in the cells.  
Recent studies in bovine hepatocytes [470] and pancreatic beta cells [473] have 
demonstrated that adiponectin activates AMPK signalling pathway, mediates suppression of 
lipid synthesis and promotes lipid oxidation.  Studies also showed that adiponectin decreased  
TG and FA levels in muscle and liver [474]. In this study, though adiponectin was not expressed 
in Hep G2 cells, the expression of adipoR1 and R2 receptors was detected but found reduced 
in low B12 condition. Following treatment with adiponectin, we observed an increase in the 
expression of adipoR1 and R2 receptors leading to higher activation of AMPK and pACC levels 
in low B12. A similar study confirmed that mRNA expression of adiponectin was undetectable 
in liver tissues of rat, humans and primary hepatocytes [475]. Some studies have also confirmed 
the detection of adipoR1 and R2 in the liver [476-479] and others report a reduction of both 
receptors in obesity [480] which is also clinically associated with low B12. In addition to 
increased phosphorylation of AMPK, we also observed that adiponectin treatment resulted in 
elevation of pACC levels in low B12 hepatocyte cell line. AMPK is reported to induce 
inhibition of lipid biosynthesis through phosphorylation of acetyl-CoA carboxylation (ACC) 
[479, 481]. Assessing the effect of the upregulation in AdipoR1 and R2, pAMPKα and pACC 
levels by adiponectin in low B12 state, we observed that the master regulator of lipogenesis 
SREBF1 and downstream genes involved in de novo FA (ACC, FASN and ELOVL6), TG 
(SCD, DGAT1 and DGAT2) and cholesterol (LDLR) synthesis were significantly decreased. 
Suppression of SREBP1c by adiponectin via AdipoR1 and AMPK dependent pathway has been 
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shown in a mice study [482, 483]. Similar studies have shown that AMPK activation accounts 
for inhibition of FA synthesis in the liver due to downregulation of genes such as ACC [484, 
485], FASN [485, 486] and ELOVL6 [485]. Similarly, activation of AMPK has been reported 
to downregulate enzymes involved in TG (SCD [485] and DGAT [487]) and cholesterol (LDLR 
[488, 489]) synthesis. In this study, we also observed that adiponectin promoted FAO via 
increasing the expression of CPT1a and ACADM in low B12 hepatocyte cell line. Adiponectin 
also improved the mitochondrial functional integrity in the utilization of substrates such as 
palmitate for energy metabolism in this study. This is consistent with findings in skeletal 
muscles demonstrating that adiponectin upregulated FAO by increasing the expression of  
CPT1 [490] as well as elevated mitochondrial number and function, leading to increased 
oxidation of palmitate [491]. A mice model has also shown that activation of AMPK with 
subsequent facilitation of FAO was achieved via binding of adiponectin to AdipoR1 and R2 
[492], therefore, confirming our observation that adiponectin in circulation might bind to these 
adipoR1/R2 in low B12 state and might activate AMPK and FAO.   
 
Observing the independent lipid lowering effect of adiponectin in low B12 hepatocyte 
cell line, we further assessed the combined effect of adiponectin and metformin on hepatic lipid 
metabolism in low B12 state. Combined adiponectin and metformin treatment resulted in a 
significant increase in adipoR1 and R2, pAMPKα, pACC, lipid synthesis and reduced FAO. 
An earlier study has shown that combination of adiponectin and metformin demonstrate a 
higher effect on blood glucose in animals [493]. Similarly, combination of metformin with 
another potent activator of AMPK, lactoferrin, resulted in significant alleviation in the 
accumulation of lipids in the liver by increasing pAMPK/AMPK ratio [494]. The authors also 
observed a significant reduction in the protein levels of enzymes involved in the synthesis of 
FA and cholesterol, therefore suggesting for obesity prevention and improvement in 
metabolism of lipids [494]. Adiponectin within circulation interacts with AdipoRs expressed in 
the liver leading to the regulation of hepatic metabolism of lipids through AMPK and SREBP-
1 signalling [495]. Activation of AMPK by adiponectin involves direct phosphorylation of 
threonine 172 (Thr172) located on the alpha subunit [495]. It has been reported that AMPK can 
also be indirectly activated by preservation of the alpha subunit from Thr172 phosphatase 
through allosteric modulation induced via high AMP/ATP ratio by metformin [414, 496]. In 
this study, it implies that metformin alone had no up-regulatory effect on adipoR1/R2 receptors. 
Therefore, activation of AMPK by metformin was achieved through a different axis resulting 
from high AMP/ATP levels. Moreover, AMPK activation via the latter mechanism has been 
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shown to be less than 5-fold [496, 497], whereas combination of both phosphorylation and 
allosteric mechanisms accounts for >1000-fold activation of AMPK [496, 498]. Therefore, the 
inclusion of adiponectin, rather than metformin only, accounted for the significant upregulation 
of adipoR1/R2 receptors, with subsequent activation of AMPK. It, therefore, suggests that the 
significant lipid lowering effect observed in low B12 condition was principally due to the 
presence of adiponectin in the combined treatment, rather than an equal additive effect of both 
adiponectin and metformin. This may therefore explain our observation that, co-treatment of 
adiponectin-metformin in low B12 state activates AMPK and pACC, which subsequently 
accounted for reduced hepatic lipid synthesis, upregulated oxidation of FA and improved 
mitochondrial functional integrity.  
 
7.5 Conclusion 
B12 deficiency is associated with dysregulated metabolism of lipids resulting from increased 
lipogenesis and impaired oxidation of fatty acids in the liver. Risk of developing B12 deficiency 
is associated with metformin treatment in type 2 diabetes patients. In this study, metformin 
treatment in low B12 hepatocyte cell line improved hepatic fatty acid biosynthesis but showed 
higher total TG levels and impaired FAO, Metformin playing a crucial role in the activation of 
AMPK, failed to restore pAMPK levels in low B12 hepatocyte cell line. The ultimate effect 
was an impairment of both the downregulation of lipogenesis and upregulation of mitochondrial 
oxidation of fatty acids in by metformin in low B12 condition. Therefore, indicating the desired 
lipid-lowering effect of metformin in hepatocyte cell liine was compromised by low B12 
condition. However, we showed that the lipid lowering effect of metformin in low B12 was 
mediated through adiponectin dependant AMPK signalling pathway. Treatment with 
adiponectin in Hep G2 cells resulted in significant upregulation of both receptors which 
accounted for increased pAMPKα and pACC protein levels in low B12 condition. The 
subsequent effect was a reduction in the expression of the master regulator of lipogenesis, 
SREBF1, and downstream genes regulating fatty acids (ACC, FASN and ELOVL6), 
triglyceride (SCD, DGAT1 and DGAT2) and cholesterol (LDLR) synthesis. Adiponectin also 
increased FAO enzymes CPT1a and ACADM as well as improved mitochondrial functional 
integrity by utilizing long chain FA (palmitate) for energy metabolism. Similarly, the combined 
adiponectin-metformin treatment restored the desired lipid lowering effect of metformin in 
hepatocyte cell line in low B12 condition. These findings may therefore suggest a key role for 
adiponectin-AMPK axis in hepatic accumulation of lipids in low B12 state. It also highlights 
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that in non-responsive patients to metformin treatment, the desired lipid lowering effect as 
suggested by this study may be achieved by adiponectin therapy. This study also suggests 
developing potential therapeutic agents targeting adiponectin-AMPK in low B12 state. 
However, validation of this evidence in vivo using animal and human models is recommended 
for future studies.  
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Chapter four – General discussion 
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8.1 Discussion 
The global epidemic of obesity is constantly increasing and currently estimated, by the 
World Health Organisation, that over 650 million (13% of adult population) adults have obesity 
[499]. Likewise, about 1.9 billion (39% of adult population) adults are overweight [499]. 
Equivalently, the incidence of complications associated with obesity, including non-alcoholic 
fatty liver disease (NAFLD), is also increasing. Moreover, NAFLD has become one of the 
principal causes of hepatic diseases globally. Growing evidence have also shown the 
association of vitamin B12 (B12) deficiency with obesity [172], GDM [500] and T2DM [501]. 
We earlier showed that in experimental studies, B12 deficiency was associated with altered 
lipid handling by adipocytes. This essentially resulted from increased TG accumulation as well 
as hypomethylation of the master regulators of lipid biosynthesis. We also showed in clinical 
studies that B12 deficiency was associated with high TG levels in both Whites and South 
Asians. As adipocytes contribute only small amount to the circulating levels of TGs, we 
designed the current study to assess whether similar observations occur in hepatocytes. If true, 
this will explain the clinical observations and may add further evidence that these associations 
may be clinically linked. In the current study, we assessed the role of B12 on hepatic 
metabolism of lipids with the elucidation of probable molecular mechanisms underlying B12 
deficiency.  
First, we assessed the hepatic regulation of B12 uptake and storage in varying 
circulating B12 levels. Hep G2 cells treated with low B12 resulted in 2-3-fold increase in 
intracellular levels of B12 in Hep G2 cells. We also observed increased gene and protein 
expression of B12 receptor (CD320) and transporter (TCN2) in hepatocyte cell line in low 
concentrations of B12. However, progressively increasing concentrations of extracellular B12 
resulted in decreased uptake of B12 and lower expressions of CD320 and TCN2. Similar results 
were observed in the liver tissue with low B12 levels compared with high circulatory B12 
levels. This indicated that compensatory upregulation of transporter activities is happening in 
low B12 condition to maintain intracellular B12 levels. This may compromise other 
intracellular activities in such conditions.  
Next, we investigated the effect of B12 deficiency on hepatic lipid metabolism, targeting de 
novo lipid (FA, TG and cholesterol) synthesis and the fatty acid oxidation (FAO). Low B12 
resulted in increased lipid droplets and higher intracellular TG levels in hepatocyte cell line, 
confirmed by increased synthesis of radio-labelled TGs. The gene expression of the master 
regulator of lipogenesis (SREBF1) and cholesterol (LDLR) synthesis was significantly higher 
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in low B12 with subsequent increase in the expression of key genes regulating FA, TG and 
cholesterol synthesis. Low B12 hepatocyte cell line had higher levels of total fatty acids (TFAs), 
saturated fatty acids (SFAs), monounsaturated fatty acids (MUFA) and trans-fatty acids 
compared with control. PUFAn-6, LC-PUFAn-6 and PUFA n-6/n-3 ratio were significantly 
higher in low B12 hepatocyte cell line compared with control. Fatty acids were significantly 
higher predominated by even chains (C16, C18 and C18:1) and to a lesser extent by odd chains 
(C17, C21, C23) in low B12 hepatocyte cell line compared with control.  
In the FAO pathway, low B12 resulted in significant reduction in expression of the rate limiting 
enzyme CPT1α as well as downstream genes crucial in the FAO pathway. The mitochondrial 
functional integrity was compromised in low B12 accounting for impaired utilization of long 
chain FA (palmitate) for energy metabolism, suggesting the likelihood of accumulation in the 
hepatocyte cell line.  
Prolonged oral therapy with metformin can cause B12 deficiency in significant proportion of 
T2DM patients. This has been shown to exacerbate the existing diabetic neuropathy and may 
indeed cause neuropathy [502]. Whether such B12 deficiency in metformin treated patients is 
causally related to the coexisting hypertriglyceridemia [503], is not known. Therefore, we 
assessed the probable effect of low B12 on the lipid lowering effect of metformin in hepatocyte 
cell line. We observed that B12 independently affected the activation of the master regulator of 
energy homeostasis AMPK, with decreased pAMPKα and pACC levels observed in low B12 
hepatocyte cell line. Treatment with metformin failed to restore pAMPKα and pACC levels 
significantly in low B12 hepatocyte cell line. We also observed higher levels of the total 
intracellular TG although de novo synthesis of lipids (FA, TG and cholesterol) was significantly 
decreased in metformin treated hepatocyte cell line in low B12 compared with basal control. In 
addition, low B12 impaired FAO significantly in metformin treated hepatocyte cell line by 
limiting CPT1α and other key genes crucial in the FAO pathway. Likewise, the mitochondrial 
functional integrity in metformin treated hepatocyte cell line was significantly impaired in low 
B12 compared with control, suggesting that the desired lipid lowering effect of metformin may 
be compromised by low B12.  
Finally, adiponectin is a well-known adipocytokine and potential therapeutic agent in several 
metabolic disorders including obesity and T2DM. Likewise, adiponectin demonstrates an 
independent lipid lowering effect in the liver via the AMPKα signalling axis. We therefore 
hypothesized that adiponectin might improve the compromised lipid lowering effect of 
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metformin in low B12 hepatocyte cell line. We observed that adiponectin was not expressed in 
the hepatocyte cell line, however, adiponectin receptors adipoR1 and R2 were expressed but 
significantly reduced in low B12. Adiponectin treatment resulted in the significant upregulation 
of adipoR1 and R2 receptors with subsequent activation of AMPKα in low B12 hepatocyte cell 
line. In effect, there was significant decrease in the key genes regulating FA, TG and cholesterol 
synthesis in low B12 hepatocyte cell line. The FAO and mitochondrial functional efficiency 
were also significantly upregulated in low B12 hepatocytes treated with adiponectin. In 
conclusion, we observed a significant lipid lowering effect via decreased lipogenesis and 
upregulated FAO and mitochondrial functional efficiency following a combined adiponectin-
metformin treatment in low B12 hepatocyte cell line, suggesting that adiponectin improves the 
lipid lowering effect of metformin in low B12 hepatocyte cell line. 
 
 Our findings may suggest that the liver plays a significant role in the maintenance of 
intrahepatic B12 levels. B12 is mandatory for normal DNA synthesis, improvement of 
cognitive function and red blood cells development. In the liver, B12 presenting as methyl-
cobalamin and adenosyl-cobalamin serve as coenzymes in two significant pathways 
[(methionine synthase (MS) and methyl malonyl-CoA mutase (MCM) pathways] regulating 
energy metabolism. The liver and kidneys are the main organs that store higher levels of B12 
due to possession of additional receptors (apart from CD320) such as asialoglycoprotein and 
megalin respectively, accounting for higher B12 uptake. The regulation of B12 uptake and 
storage in the liver is however less explored, therefore, our study is the first to characterize the 
regulation of intrahepatic storage in varying circulating B12 levels. Some studies have proposed 
that at higher concentrations of B12, some tissues adopt an efflux system that pushes excess of 
B12 out of cells whereas others modulate the expression of B12 receptors on cellular surfaces 
[296].  In the current study, when the circulatory level in low B12 medium was 25pM, the 
intracellular level was 178pM (2.8-fold) but when circulatory level in high B12 medium was 
500nM (20,000-fold higher than 25pM), the intracellular level was only 8nM (increased 0.02-
fold). Similarly in the animal model, we observed that when the circulatory level in LB was 
0.82nM, the intracellular level was 27nM (i.e. 33.8 fold higher) but when the circulatory level 
in HB was 5.36nM (6.5 fold higher than 0.82nM), the intracellular level was only 46nM (8.6 
fold). In addition to studies involving animal (rat) models, similar evidence has also been shown 
in placental tissues of pregnant subjects presenting with low plasma B12 [504]. It has been 
reported that excessive supply of B12 may not be internalized by cells, resulting in B12 
secretion in the bile [505]. We also observed a significant increase in the hepatic expression of 
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B12 receptors (CD320) and transporters (TCN2) in low extracellular levels of B12 and vice 
versa. Our findings confirm the evidence from earlier studies suggesting that B12 receptors 
(CD320) and transporters (TCN2) are de novo synthesized in the liver [296], therefore, hepatic 
modulations may account for the alterations in B12 uptake. Similarly, due to high foetal demand 
of B12 in pregnancy, higher serum levels of soluble CD320 were observed in mothers which 
was suggested to have originated from the placenta [301]. Similar observation was reported for 
TCN2 in the circulation of pregnant mothers with low B12, accounting for high cord blood and 
foetal B12 concentrations [278]. The limitation of the present study was its non-validation of 
the current evidence with further assessment on hepatic uptake of B12 in real-time, probably 
by monitoring the uptake of radiolabelled-B12. Also, metabolomics, targeting the levels of 
soluble B12 transporters and receptors released into circulation at different extracellular B12 
concentrations, are recommended. Altogether, evidence from this current study shows that 
hepatocytes modulate the intracellular levels and storage of B12 by regulating the expression 
of B12 transporters and receptors leading to the maintenance of intracellular B12 balance. A 
recent study has recommended a physiological dose of 2µg/day B12 for oral supplementation 
in Indian adolescents [506]. The recommendation was based on evidence from earlier clinical 
trials, by the same group, which showed that there was adequate absorption in majority of the 
population as well as improvement in B12 levels after one year of oral supplementation [506]. 
It is however recommendable to conduct similar trials to establish an optimal physiological 
dose for different ethnic and age-specific groups of individuals. Oral supplementation with 
2µg/day of B12 for eleven months yielded similar clinical results compared with 
supplementation with a greater dose of 500µg/day B12 for the first six weeks followed by 
15µg/day for successive twenty weeks [506, 507]. Apart from being more expensive and not 
likely to be utilized in a large-scale public health intervention in most developing countries, 
higher doses of B12, according to evidence from the current study, may not provide any 
additional benefit to the liver. Our data supports that the optimal physiological levels of B12 
may be required rather than overloading with supplements when subjects are B12 deficient, 
therefore, supporting a public health strategy to tackle the widely predominant status of low 
B12 in many developing countries. This provides us evidence and stimulates to further study 
whether dysregulation in hepatic metabolism in pathological conditions could be related to 
tissue-specific effect of low B12 in liver.  
 
Next, we assessed the effect of B12 deficiency on hepatic metabolism of lipids. Low 
B12 accounted for higher lipid droplets in hepatocyte cell line with increased level of total 
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intracellular TG and FA uptake for TG synthesis compared with control. Several studies have 
also reported the association of B12 with obesity [508] and dyslipidaemia [509] including high 
TG and cholesterol levels [510]. These evidence have been shown in pre-clinical (cell lines and 
animal models) and clinical studies. To buttress this observation, we further assessed the 
expression of the master regulator of lipogenesis (SREBF1) and cholesterol (LDLR) 
biosynthesis in low B12. We observed that both SREBF1 and LDLR as well as key downstream 
genes crucial in the FA, TG and cholesterol biosynthesis were significantly increased in low 
B12 compared with control. It has also been shown recently that epigenetic modification such 
as hypo-methylation near the promoter regions of SREBF1 and LDLR genes in low B12 
adipocytes accounted for their upregulation leading to increased lipid synthesis [510]. De novo 
lipogenesis (DNL) accounts for about 26% of intra hepatic TG levels which increases the risk 
of NAFLD development [511]. Therefore, low B12 upregulation of DNL could hasten the 
development of NAFLD, especially in susceptible individuals. Likewise, the contribution of 
hepatic lipogenesis, compared with adipose tissues, to the total TG stores of the body is much 
higher [512]. This suggests that low B12-augmented hepatic lipogenesis may exert a greater 
dysregulation to the total body fat.  We also observed that FA profile in hepatocyte cell line 
presented with higher total fatty acids (TFAs), Saturated FAs (SFAs), monounsaturated fatty 
acids (MUFAs) and trans-fatty acids in low B12 compared with control. Similarly, PUFAn-6, 
LC-PUFAn-6 and PUFA n-6/n-3 ratio were all higher in low B12 hepatocytes. In addition, FAs 
including palmitate (C16), stearate (C18) and oleate (C18:1) predominated in the hepatocyte 
cell line and were significantly higher in low B12 compared with control. These FA groups 
have been shown to be associated with non-alcoholic steatohepatitis (NASH) and higher risk 
of cardiovascular diseases [513-518], therefore, suggesting that low B12 increases hepatic 
synthesis of ‘unsafe’ FAs. However, quantifying the level of circulating lipids contributed via 
hepatic secretion in different conditions of B12 may be recommended to appreciate the impact 
on metabolic risk.  
We observed that low B12 impaired FAO by decreasing the expression of the rate limiting 
enzyme CPT1α and downstream genes crucial in the FAO pathway. Similar studies have shown 
that methyl donor (B12 and folate) deficiency accounted for impaired FAO in the myocardial 
cells [398] and adipocytes tissues [393] by decreasing the level of enzymes crucial in FAO the 
pathway. B12 is known to be involved in the regulation of methyl malonyl-CoA levels. 
Therefore, low B12 results in methyl malonic academia (MMA) which is known to be a potent 
inhibitor of CPT1. However, the precise mechanism of B12 regulation of downstream FAO 
enzymes requires further investigation. We also observed that low B12 impaired the 
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mitochondrial functional integrity resulting in impaired utilization of long chain FA (palmitate) 
for energy metabolism. Our findings may confirm a recent study which showed that 
supplementation with B12 improves mitochondrial health, whereas B12 deficiency is 
associated with dysfunction [519]. Basically, beta oxidation (FAO) and mitochondrial 
respiration (oxidative phosphorylation) are not entirely independent processes. FAO results in 
the generation of electron-rich donors (NADH and FADH2) which are required by the electron 
transport chain (ETC) of the mitochondria for ATP synthesis. Therefore, low B12 impairment 
of CPT1α and key enzymes in the FAO pathway may affect the supply of electrons to the ETC 
which compromises the efficiency of mitochondrial respiration. Altogether, the increased 
lipogenesis with altered FA profile, as well as impaired FAO and mitochondrial dysfunction in 
low B12, may trigger lipid accumulation in the liver. This may therefore explain the observation 
in several clinical studies indicating that B12 deficiency is associated with obesity and 
dyslipidaemia, predisposing subjects to a higher risk of GDM, T2DM and CVD.  
Several clinical studies have shown that prolonged treatment with metformin results in 
the development of B12 deficiency in patients [503], we therefore assessed whether B12 
deficiency affects the lipid lowering effect of metformin in human hepatocyte cell line. We 
observed that the total intracellular TG level was not significantly reduced in metformin treated 
hepatocytes in low B12 compared with control. Likewise, although the synthesis of lipids (FA, 
TG and cholesterol) was decreased, the FAO and mitochondrial functional efficiency were 
impaired in metformin treated hepatocytes in low B12 accounting for hepatic accumulation of 
lipids. Clinically, several studies (about 50%) have shown evidence that metformin treatment 
had no lowering effect on intrahepatic lipid levels [415]. The development of B12 deficiency 
after metformin administration, is associated with both dosage and duration (years) of treatment 
[428, 445]. Evidence shows that hepatic deficiency of B12 may also occur after prolonged 
deprivation since the liver is able to maintain physiological B12 reserves for 3-5 years [520]. 
This suggests the non-responsiveness of metformin to hepatic lipid levels may dominate in low 
B12 state. However, further in vivo studies in humans to validate the current evidence is 
required. To understand the mechanism underlying this observation, we assessed the AMPK 
signalling axis by which metformin achieves a lipid lowering effect. We observed that 
pAMPKα and pACC levels were significantly reduced in low B12, which could be due to 
epigenetic effect and needs exploration in future. However, treatment with metformin could not 
restore pAMPKα and pACC levels significantly in low B12 compared with control. This data 
therefore confirms that efficacy of metformin drug is less efficient in low B12 state and could 
be mediated through AMPK pathway. Recently, a study showed that the liver of mice when 
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supplemented with methyl donors including B12 resulted in a significant activation of AMPK 
[521] leading to NAFLD regression.  
Metformin activation of AMPK is achieved by higher levels of AMP: ATP or ADP: ATP ratio. 
However, the process leading to the generation of AMP, ADP and ATP such as TCA cycle, 
beta oxidation and oxidative phosphorylation [522] may not be entirely independent of methyl 
donors (such as B12).  This may be due to their epigenetic effect as well as cofactor roles in 
these pathways [523]. Derivatives of the benzimidazole ligand of cobalamin (B12) [524], have 
been shown to be potent activators of AMPK by binding to its beta subunit [525, 526]. It 
therefore suggests that unlike metformin, B12 may independently activate AMPK. However, 
elucidation of the precise mechanism of B12 activation of AMPK was not shown in the current 
study, therefore, requires further investigations.  
Adiponectin action through AMPK axis has the potential to regulate lipid metabolism. Finally, 
we proposed that adiponectin-AMPK axis might improve the lipid lowering effect of metformin 
in low B12 hepatocyte cell line. We observed that although adiponectin was not expressed in 
hepatocyte cell line, the expression of adiponectin receptors adipoR1 and R2 was detected but 
significantly reduced in low B12 compared with control. Some studies have also shown similar 
evidence [475] and others have reported reduced expression of adipoR1 and R2 in obese [480] 
and methyl donor deficient [477] subjects. However, evidence from an animal study showed 
that reduction in the expression of adipoR1 and R2 was not as a result of methylation in methyl 
donor deficient subjects [477], suggesting the need for further investigations. Adiponectin is 
synthesized chiefly by the adipose tissues and therefore, might account for its non-detection in 
the liver. We also, observed that adiponectin treatment resulted in increased expression of 
adipoR1 and R2 receptors and subsequent increase in pAMPKα and pACC levels in low B12 
hepatocyte cell line. In effect, there was significant reduction in the total intracellular TG levels 
in low B12 hepatocyte cell line. The expression of the master regulator of lipogenesis SREBF1 
and cholesterol (LDLR) as well as genes involved in lipogenesis was also decreased in low 
B12. Adiponectin also increased the FAO and mitochondrial functional efficiency, preventing 
the accumulation of long chain FA (palmitate) in low B12 hepatocyte cell line. This evidence 
confirms the potent role of adiponectin in activating AMPK and subsequent target genes in lipid 
regulation in low B12 hepatocyte cell line. Studies have also shown evidence of improvement 
in mitochondrial function [527] and reduction in hepatic lipid synthesis [484] resulting from 
adiponectin treatment. In addition, we observed that a combined adiponectin-metformin 
treatment resulted in a significant increase in pAMPKα and pACC levels in low B12 hepatocyte 
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cell line due to adiponectin. This accounted for a significant reduction in the total intracellular 
TG levels as well as radiolabelled-FA uptake fore TG synthesis in low B12 hepatocyte cell line. 
We also observed significant reduction in lipogenesis via decreased expression of genes 
involved in the FA, TG and cholesterol biosynthesis. Likewise, there was significant increase 
in FAO and mitochondrial functional efficiency in low B12. This evidence shows that 
adiponectin significantly alleviates the accumulation of lipids in metformin-treated hepatocyte 
cell line in low B12 condition. Clinical evidence showed that adiponectin synthesis from 
adipose tissues was inhibited in patients on metformin treatment [528] and low levels of 
adiponectin was associated with obesity and high serum lipids [529]. However, a combination 
of metformin and adiponectin was also shown to improve serum glucose levels in animal 
models [493], whereas combination with other potent activators of AMPK (such as lactoferrin) 
regressed hepatic accumulation of  lipid [494]. Adiponectin activation of AMPK results from 
direct phosphorylation of 172 (Thr172) in the alpha subunit. However, metformin achieves 
activation via allosteric modification leading to preservation of the phosphorylated alpha 
subunit resulting from AMP binding to the gamma subunit of AMPK. Evidence shows that 
utilisation of AMP (by metformin) accounts for 5-fold less activation of AMPK, whereas a 
combination of both mechanisms (direct phosphorylation and allosteric modulation) results in 
>1000-fold higher activation of AMPK [496, 498]. This may therefore explain our observation 
that, inclusion of adiponectin to metformin treatment may offer a greater additive action via 
direct phosphorylation of AMPK by adiponectin, to the allosteric modulation induced by 
metformin. This effect could significantly increase the activation of pAMPK/pACC leading to 
reduction of lipid levels in low B12 hepatocyte cell line.  
 
8.2 Conclusion and future direction 
The current thesis provides novel evidence of the potential role of B12 deficiency in the hepatic 
metabolism of lipids which could contribute to the development of metabolic disorders such as 
simple steatosis of the liver, NAFLD, obesity, T2DM and metabolic syndrome. The association 
of B12 deficiency and the manifestation of metabolic risk have been shown in clinical and pre-
clinical studies. In recent studies involving human adipocyte models, the probable underlying 
epigenetic mechanisms, such as DNA methylation and microRNAs, leading to dysregulated 
metabolism of lipids by low B12 has been shown. The current study provides novel evidence 
of hepatic regulation of B12 uptake and storage via modulation of B12 transporters and 
receptors in various circulatory levels including low and high B12. Low B12 accounted for 
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increased hepatic lipogenesis with evidence of higher lipid droplets, total intracellular TG level 
and utilization of radiolabelled-FA for TG synthesis. Hepatocyte cell line profile of FA in low 
B12 showed significantly higher levels of total FAs and predominant groups such as SFAs, 
MUFAs, trans-FAs and PUFAn-6/n-3 ratio, as well as individual FAs such as palmitate (C16), 
stearate (C18) and oleate (C18:1). This observation was buttressed by elevation in the master 
regulator of lipogenesis SREBF1 and cholesterol LDLR accounting for increased expression of 
genes regulating FAs, TGs and cholesterol biosynthesis under low B12. Concurrently, 
oxidation of FAs (FAO) and mitochondrial functional efficiency were decreased in low B12 
accounting for lipid accumulation in hepatocytes (Fig 76). Prolonged treatment with metformin 
induces B12 deficiency in T2DM patients and several clinical studies have reported that 
metformin does not improve intrahepatic TG levels in patients. The current study also provides 
novel evidence that low B12 impairs the activation (phosphorylation) of the master regulator 
of energy homeostasis, AMPKα, by metformin treatment. This accounted for decreased pACC 
levels which significantly impaired the reduction of total intracellular TG levels, FAO and 
mitochondrial functional efficiency leading to hepatic accumulation of lipids. However, we 
observed that adiponectin treatment via the upregulation of adipoR1 and R2 receptors 
intensified the activation (phosphorylation) of AMPKα in low B12 hepatocytes, therefore, 
improving hepatic lipid metabolism by decreasing lipogenesis and increasing FAO and 
mitochondrial respiration. Likewise, the combined adiponectin-metformin treatment also 
significantly alleviated hepatic accumulation of lipids by increasing AMPK activation as well 
as elevating the FAO and functional efficiency of the mitochondria in low B12 condition. 
Validation of the current evidence in primary hepatocytes in different pathologies and animal 
models with respect to B12 deficiency is recommended. 
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Figure 76: Modulations observed in hepatocytes in low B12 condition: Low B12 condition accounted for (1) 
active transport of B12 intracellularly in hepatocytes resulting from modulations in B12 transporters and receptors. 
(2) Hepatic lipogenesis is also increased in low B12 accounting for increased accumulation of intrahepatic TG 
levels. (3) Beta oxidation (FAO) in low B12 hepatocytes is significantly decreased resulting from decreased levels 
of key enzymes involved in the FAO pathway. (4) Likewise, the mitochondrial functional efficiency is impaired 
in low B12 and finally, (5) the expression of adiponectin receptors (adipoR1 and R2) are decreased in low B12 
hepatocytes.   
 
In conclusion, since the contribution of hepatic lipogenesis to the total body metabolism of 
lipids is significantly higher compared with adipose tissue, the current evidence explains the 
observation of increased lipogenesis accounting for higher adiposity and T2DM risk in low B12 
subjects. Hepatic deficiency of B12 resulting from prolonged metformin treatment in humans 
may account for the clinical observation of unimproved intrahepatic lipid levels. Therefore, 
combined metformin treatment with adiponectin is suggested to improve the lipid lowering 
effect of metformin in low B12 hepatocytes. This study therefore provides a novel model for 
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developing potential therapeutic agents to target B12-adiponectin-AMPK axis in subjects 
developing IR, obesity and CVD.  
Nevertheless, the current study was conducted principally using an immortal cell line of the 
liver, Hep G2. The use of cell lines, instead of primary cells, have some advantages including 
the provision of a wholesome cell population accounting for reliable samples that generates 
reproducible results. Other advantages include cost effectiveness, simplicity to use and higher 
likelihood to bypass ethical concerns governing the tissue usage. However, the behaviour of 
cell lines may not exactly mimic primary cells. The former, as result of series of passages over 
a lengthy period of time, could be genetically manipulated leading to generation of variations 
in both genotypic and phenotypic properties, therefore, making it difficult to adequately replace 
primary cells. However, similar evidence on the effect of B12 on the metabolism of lipids in 
adipocyte cell line (Chub-S7) has been investigated and endorsed in human adipose tissues 
collected at delivery from pregnant women by our group. Therefore we recommend future 
studies to validate our current findings in primary human liver cells and subsequently in animal 
and human liver tissues. Successful replication of the current evidence in the different models 
would be useful for clinical trials that could provide the strongest evidence in support of the 
cause-effect relationship. The latter could further serve as basis for clinical and public health 
policy. 
Regardless of the novel evidence shown by the current study, few questions remain unanswered 
therefore requiring further investigation. It is therefore suggested that future studies should be 
designed in similar models (Hep G2) and also in primary cells, animal and human liver tissues 
to examine; 
1. The in vivo modulation of liver B12 transporters and receptors regulating B12 uptake and 
storage. Further exploration of tissue-specific regulation of B12 uptake in other metabolic 
tissues should also be investigated.   
2. The probable epigenetic mechanism underlying dysregulation of hepatic lipid metabolism by 
low B12.  
3. The effect of hepatic lipid dysregulation by low B12 on circulating levels of lipid fractions 
4. The epigenetic mechanism underlying B12 regulation of AMPKα activation in the liver. 
5. The mechanism accounting for reduction in the hepatic expression of adipoR1 and R2 
receptors in low B12. 
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Abstract 
Obesity is currently a worldwide epidemic responsible for 5% of mortality globally. Obesity 
increases the risk of developing metabolic disorders like diabetes, hypertension and 
cardiovascular diseases (CVDs) which causes great public health concern. A series of studies 
involving many animal models and epidemiological investigations have demonstrated a 
relationship between importance of vitamin B12 (B12) and various components of metabolic 
syndrome. High prevalence of vitamin B12 deficiency has been shown in Europeans (27%) and 
South Indians (32%) with type 2 diabetes (T2D) patients. A longitudinal prospective study in 
pregnant women has shown that B12 deficiency could independently predict development of 
T2D after a period of five years post-delivery. Children born to B12 deficient mothers have 
augmented fat accumulation that may consequently lead to elevated resistance to insulin and 
risk of developing T2D and/or CVD in adulthood. However, the role of B12 in metabolism of 
lipids is not explored.  In this review, we provide evidences on the role of B12 deficiency in 
lipid metabolism and insights on the possible epigenetic markers such as DNA methylation, 
miRNAs and histone modifications. This will provide probable strategies for therapeutic targets 
in dyslipidaemia related to a micronutrient deficiency, such as vitamin B12. 
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Abstract 
Background: The liver is the principal storage organ for cobalamin (B12). Hepatocytes make 
up the bulk of the liver mass expressing specific receptors for B12-bound transporters in 
circulation that may regulate cellular uptake and storage of B12 in the liver. We assessed the 
regulation of cellular uptake and storage of B12 in hepatocytes in various concentrations of 
circulating B12.  
Methods: Hep G2 cell line was cultured using custom made B12 deficient Eagles’ Minimal 
Essential Medium (EMEM) and seeded in ten different concentrations of B12 media. Liver 
tissues from two different mice groups: (1) high and (2) low levels of B12 in plasma were used. 
Intracellular and circulating B12, gene and protein expression of B12 receptors and transporters 
were determined.  
Results: HepG2 cells treated with low B12 resulted in 2-3fold increase in intracellular levels 
of B12 in Hep G2 cells. We also observed increased gene and protein expression of B12 
receptor (CD320) and transporter (TCN2) in hepatocytes under low concentrations of B12. 
However, progressively increasing concentrations of extracellular B12 resulted in decreased 
uptake of B12 and lower expressions of CD320 and TCN2. Similar, results were observed in 
the liver tissue with low B12 levels compared to high circulatory B12 levels. 
Conclusion: This study shows that the active transport of B12 in both HepG2 cell line and liver 
tissues are higher at low concentration, which might be due to the higher expression of B12 
receptors/transporters in the membrane of hepatocytes but not the same when high B12 levels 
are present in circulation. Our data suggests that the optimal physiological levels of B12 is 
required rather than overloading with supplements, when subjects are B12 deficient.  
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Abstract  
Introduction: The impact of higher adiposity on metabolic health is greatly explored in recent 
times due to elevation in the global incidence of obesity. Evidence of association between low 
vitamin B12 (B12) in pregnancy and elevated BMI of mothers has been established. 
Dysregulation of lipogenesis by low B12 via hypomethylation of the master regulator of 
cholesterol biosynthesis was observed in human adipocytes. However, the contribution of the 
liver to the lipogenesis of the entire body is higher than adipose tissue. If similar effects happen 
in hepatocytes, this may explain the observation of dyslipidaemia in humans. Therefore, we 
investigated whether B12 deficiency affect hepatic metabolism of lipids. 
Methods: Hep G2 cell line was cultured using custom-made B12 deficient Eagle’s Minimal 
Essential Medium (EMEM) and seeded in four different concentrations of B12 media such as 
500nM (control), 1000pM (1nM), 100pM and 25pM (low) B12. Oil Red O (ORO) staining, 
RT-qPCR, total intracellular triglyceride (TG), radioactive flux assay, fatty acid profiling using 
gas chromatography and extracellular seahorse XF24 flux assay were employed to examine the 
effect of B12 on lipid metabolism. 
Results: Hep G2 cells in low B12 had more lipid droplets that were intensely stained with ORO 
compared to control. Total intracellular TG and incorporation of radio-labelled-FA for TG 
biosynthesis were also increased. Gene expression of the master regulator and key downstream 
enzymes regulating FA, TG and cholesterol biosynthesis were upregulated. Levels of total, 
saturated (SFAs), monounsaturated fatty acids (MUFAs) and trans-fatty acids as well as 
individual even-chain and odd-chain FAs were significantly increased. Lastly, low B12 
impaired FA oxidation and mitochondrial functional integrity in hepatocytes compared to 
control. In conclusion, our data provide novel evidence that B12 deficiency dysregulates lipid 
metabolism leading accumulation in hepatocytes. 
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Abstract 
Introduction: The global epidemic of obesity is constantly increasing. Likewise, the incidence 
of obesity-related complications such as non-alcoholic fatty liver disease (NAFLD) which is 
also associated with T2DM are increasing proportionately. Metformin is the first-line drug 
widely used for the treatment of T2DM and is known to decrease liver glucose production, body 
weight and lipid levels in plasma. However, prolonged treatment with metformin was shown to 
decrease vitamin B12 (B12) levels in T2DM patients, and evidence shows that low B12 is 
associated with obesity and dyslipidaemia. Several clinical studies (50%) have shown that 
metformin had no effect on intrahepatic triglyceride levels, whereas adiponectin was shown to 
regress NAFLD. Therefore, we proposed that low B12 may impair the lipid lowering effect of 
metformin in human hepatocytes which may however be improved by adiponectin.  
Methods: Hep G2 cell line was cultured using custom-made B12 deficient Eagle’s Minimal 
Essential Medium (EMEM) and seeded in different concentrations of B12 medium: 500nM 
(control) and 25pM (low) B12. Western blotting, RT-qPCR, total intracellular triglyceride (TG) 
estimation, radioactive flux assay and extracellular seahorse XF24 flux assay were undertaken 
in the current study. 
Results: Low B12 hepatocytes had higher total intracellular TG which was not significantly 
reduced by metformin treatment. FA uptake for TG synthesis and genes involved in de novo 
lipid [FA (SREBF1, ACLY, ACC FASN and ELOVL6), TG (SCD1, DGAT1 and DGAT2) and 
cholesterol (LDLR, HMGCS1 and HMGCR) synthesis were decreased by metformin in low 
B12, however, FAO and mitochondrial functional efficiency were significantly impaired by 
low B12 in metformin treated hepatocytes. The mechanism underlying this effect resulted from 
decreased levels of activated AMPK (pAMPKα) and pACC in low B12 hepatocytes which was 
not significantly restored in metformin treated hepatocytes. However, adiponectin 
independently improved intrahepatic lipid levels under low B12 via the activation of AMPK 
leading to improved intrahepatic lipid levels. Likewise, combined treatment of adiponectin and 
metformin treatment increased AMPK activation under low B12 with subsequent reduction in 
lipogenesis as well as improvement in FAO and mitochondrial respiration. In conclusion, low 
B12 impaired the lipid lowering effect of metformin, however, intrahepatic lipid levels were 
significantly decreased via combined adiponectin-metformin treatment. 
 
187 
 
List of conference presentations 
Poster presentations:  
1. Title(s): i). Metformin Treatment fails to restore fatty acid oxidation in low vitamin B12  
hepatocytes 
              ii). Hepatocytes regulate the uptake and storage of vitamin B12 by modulating B12 
transporters and receptors 
- Society for Endocrinology BES conference, Glasgow, UK, 2018 – Poster presentation 
 
2. Title: Effect of B12 deficiency on the lipid lowering effect of metformin in the liver  
- Society for Endocrinology BES conference, Harrogate, UK, 2017 - Poster presentation 
Nominated for early career Researcher’s award 
 
3. Title(s): i). Low vitamin B12 induces de novo lipogenesis in human hepatocytes 
              ii). B12 deficiency inhibits the lipid lowering effect of metformin in the liver 
              iii). Hepatocytes regulate the uptake and storage of vitamin B12 by modulating    
receptors in various circulatory B12 concentrations 
- DOHAD 10th World Congress, Rotterdam, Netherlands, 2017 - Oral (poster) 
presentation  
 
4. Title: Low vitamin B12 induces de novo lipogenesis in human hepatocytes 
- Annual symposium, University of Warwick, UK, 2017 - Poster presentation 
 
 
Oral presentations:  
1. Title: Vitamin B12 deficiency limits metformin-facilitated lowering of lipids in the liver 
- European Physiological society conference, London, UK, 2018 – Oral presentation 
 
2. Title: Low vitamin B12 triggers lipid accumulation in human hepatocytes 
- Annual symposium, University of Warwick, UK, 2018 - Oral presentation 
Awarded the Best Oral Presentation  
 
 
188 
 
Comment from chairperson:  
‘’Dear Joseph 
Well done on such a clear and interesting presentation. It was a pleasure to chair your session. 
Good Luck with the rest of your PhD. 
Best wishes 
Kate’’  
    
Kate Seers 
Professor of Health Research 
Warwick Research in Nursing 
Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL UK 
kate.seers@warwick.ac.uk External: +44(0)24 7615 0614   Internal: 50614 
 
3. Title: Effect of vitamin B12 deficiency on hepatic metabolism of lipids 
- PRiDE annual conference, University of Warwick, UK, 2017 - Oral presentation 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
 
 
 
 
 
 
List of references 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
1. Grundy, S.M., et al., Diagnosis and management of the metabolic syndrome: an American 
Heart Association/National Heart, Lung, and Blood Institute scientific statement. 2005. 
112(17): p. 2735-2752. 
2. Kaur, J.J.C.r. and practice, A comprehensive review on metabolic syndrome. 2014. 2014. 
3. Alberti, K., et al., Harmonizing the metabolic syndrome: a joint interim statement of the 
international diabetes federation task force on epidemiology and prevention; national heart, 
lung, and blood institute; American heart association; world heart federation; international 
atherosclerosis society; and international association for the study of obesity. 2009. 120(16): 
p. 1640-1645. 
4. Alberti, K.G.M., P. Zimmet, and J.J.T.L. Shaw, The metabolic syndrome—a new worldwide 
definition. 2005. 366(9491): p. 1059-1062. 
5. McCracken, E., M. Monaghan, and S.J.C.i.d. Sreenivasan, Pathophysiology of the metabolic 
syndrome. 2018. 36(1): p. 14-20. 
6. Desroches, S., B.J.A.P. Lamarche, Nutrition,, and Metabolism, The evolving definitions and 
increasing prevalence of the metabolic syndrome. 2007. 32(1): p. 23-32. 
7. Zimmet, P., K. Alberti, and J.J.D.v. Shaw, International Diabetes Federation: the IDF consensus 
worldwide definition of the metabolic syndrome. 2005. 50: p. 31-33. 
8. Beltrán-Sánchez, H., et al., Prevalence and trends of metabolic syndrome in the adult US 
population, 1999–2010. 2013. 62(8): p. 697-703. 
9. Aguilar, M., et al., Prevalence of the metabolic syndrome in the United States, 2003-2012. 
2015. 313(19): p. 1973-1974. 
10. Gao, W.J.I.j.o.o., Does the constellation of risk factors with and without abdominal adiposity 
associate with different cardiovascular mortality risk? 2008. 32(5): p. 757-762. 
11. Liu, M., et al., Increasing prevalence of metabolic syndrome in a Chinese elderly population: 
2001–2010. 2013. 8(6): p. e66233. 
12. Mabry, R., et al., Gender differences in prevalence of the metabolic syndrome in Gulf 
Cooperation Council Countries: a systematic review. 2010. 27(5): p. 593-597. 
13. Park, Y.-W., et al., The metabolic syndrome: prevalence and associated risk factor findings in 
the US population from the Third National Health and Nutrition Examination Survey, 1988-
1994. 2003. 163(4): p. 427-436. 
14. Gennuso, K.P., et al., Dose–response relationships between sedentary behaviour and the 
metabolic syndrome and its components. 2015. 58(3): p. 485-492. 
15. Lutsey, P.L., L.M. Steffen, and J.J.C. Stevens, Dietary intake and the development of the 
metabolic syndrome: the Atherosclerosis Risk in Communities study. 2008. 117(6): p. 754-761. 
16. Sun, K., J. Liu, and G.J.P.o. Ning, Active smoking and risk of metabolic syndrome: a meta-
analysis of prospective studies. 2012. 7(10): p. e47791. 
17. Lipińska, A., et al., Does family history of metabolic syndrome affect the metabolic profile 
phenotype in young healthy individuals? 2014. 6(1): p. 75. 
18. Fan, A.Z., et al., Patterns of alcohol consumption and the metabolic syndrome. 2008. 93(10): 
p. 3833-3838. 
19. Eckel, R.H., S.M. Grundy, and P.Z.J.T.l. Zimmet, The metabolic syndrome. 2005. 365(9468): p. 
1415-1428. 
20. Roberts, C.K., A.L. Hevener, and R.J.J.C.P. Barnard, Metabolic syndrome and insulin 
resistance: underlying causes and modification by exercise training. 2013. 3(1): p. 1-58. 
21. Reaven, G.M.J.N., Banting lecture 1988: role of insulin resistance in human disease. 1997. 
13(1): p. 64. 
22. Aganovic, I. and T. Dusek, Pathophysiology of Metabolic Syndrome. Ejifcc, 2007. 18(1): p. 3-6. 
23. Lebovitz, H.J.E., c. endocrinology, and diabetes, Insulin resistance: definition and 
consequences. 2001. 109(Suppl 2): p. S135-S148. 
24. Hardy, O.T., et al., What causes the insulin resistance underlying obesity? 2012. 19(2): p. 81. 
25. Reaven, G.M.J.D., Role of insulin resistance in human disease. 1988. 37(12): p. 1595-1607. 
191 
 
26. Boden, G. and G.J.E.j.o.c.i. Shulman, Free fatty acids in obesity and type 2 diabetes: defining 
their role in the development of insulin resistance and β‐cell dysfunction. 2002. 32: p. 14-23. 
27. Maria, P. and S.J.w. Evagelia, Obesity disease. 2009. 14: p. 16. 
28. Polikandrioti, M. and E.J.H.s.j. Stefanou, Obesity disease. 2009. 3(3). 
29. Bruce, K. and C.J.P.m.j. Byrne, The metabolic syndrome: common origins of a multifactorial 
disorder. 2009. 85(1009): p. 614-621. 
30. Lewis, G.F. and G.J.D.c. Steiner, Acute effects of insulin in the control of VLDL production in 
humans. Implications for the insulin-resistant state. 1996. 19(4): p. 390-393. 
31. McCracken, E., M. Monaghan, and S. Sreenivasan, Pathophysiology of the metabolic 
syndrome. Clin Dermatol, 2018. 36(1): p. 14-20. 
32. Carey, V.J., et al., Body fat distribution and risk of non-insulin-dependent diabetes mellitus in 
women: the Nurses' Health Study. 1997. 145(7): p. 614-619. 
33. Alberti, K.G.M.M. and P.f.J.D.m. Zimmet, Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. 
Provisional report of a WHO consultation. 1998. 15(7): p. 539-553. 
34. Expert Panel on Detection, E.J.J., Executive summary of the third report of the National 
Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment 
of high blood cholesterol in adults (Adult Treatment Panel III). 2001. 285(19): p. 2486. 
35. Standl, E.J.E.H.J.S., Aetiology and consequences of the metabolic syndrome. 2005. 7(suppl_D): 
p. D10-D13. 
36. Grundy, S.M.J.T.A.j.o.c., Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic 
syndrome. 1998. 81(4): p. 18B-25B. 
37. Howard, B.V., et al., Obesity and dyslipidemia. 2003. 32(4): p. 855-867. 
38. Ruotolo, G. and B.V. Howard, Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep, 
2002. 4(6): p. 494-500. 
39. Foëx, P., J.J.C.E.i.A.C.C. Sear, and Pain, Hypertension: pathophysiology and treatment. 2004. 
4(3): p. 71-75. 
40. Morse, S.A., et al., Hypertension and the metabolic syndrome. 2005. 330(6): p. 303-310. 
41. Malhotra, A., et al., Angiotensin II promotes glucose-induced activation of cardiac protein 
kinase C isozymes and phosphorylation of troponin I. 2001. 50(8): p. 1918-1926. 
42. Lee, L. and R.A.J.P.i.r. Sanders, Metabolic syndrome. 2012. 33(10): p. 459. 
43. Sookoian, S. and C.J.J.C.h.r. Pirola, Metabolic syndrome: from the genetics to the 
pathophysiology. 2011. 13(2): p. 149-157. 
44. O'neill, S. and L.J.O.r. O'driscoll, Metabolic syndrome: a closer look at the growing epidemic 
and its associated pathologies. 2015. 16(1): p. 1-12. 
45. Bjørge, T., et al., Metabolic syndrome and breast cancer in the me-can (metabolic syndrome 
and cancer) project. 2010. 19(7): p. 1737-1745. 
46. Handelsman, Y.J.T.P., Metabolic syndrome pathophysiology and clinical presentation. 2009. 
37(1): p. 18-20. 
47. Pais, R., et al., Metabolic syndrome and risk of subsequent colorectal cancer. 2009. 15(41): p. 
5141. 
48. Lam, J.C. and M.S.J.I.J.o.M.R. Ip, Sleep & the metabolic syndrome. 2010. 131(2): p. 206. 
49. Camacho, J.D.H. and M.H.J.R.e.d.n.h.y.d. Camacho, Clinical update on metabolic syndrome. 
2017. 21(4): p. 384-392. 
50. Locatelli, F., P. Pozzoni, and L.J.J.o.t.a.s.o.n. Del Vecchio, Renal manifestations in the 
metabolic syndrome. 2006. 17(4 suppl 2): p. S81-S85. 
51. care, A.D.A.J.D., Diagnosis and classification of diabetes mellitus. 2014. 37(Supplement 1): p. 
S81-S90. 
52. Piero, M., et al., Diabetes mellitus? a devastating metabolic disorder. 2015. 4(40). 
192 
 
53. Okur, M.E., I.D. Karantas, and P.I.J.A.P.S. Siafaka, Diabetes Mellitus: a review on 
pathophysiology, current status of oral pathophysiology, current status of oral medications 
and future perspectives. 2017. 55(1). 
54. Sobngwi, E., et al., Diabetes in africans. 2001. 6: p. 34. 
55. Barceló, A., et al., The cost of diabetes in Latin America and the Caribbean. 2003. 81: p. 19-
27. 
56. Hex, N., et al., Estimating the current and future costs of Type 1 and Type 2 diabetes in the 
UK, including direct health costs and indirect societal and productivity costs. Diabet Med, 
2012. 29(7): p. 855-62. 
57. Care, A.D.A.J.D., 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in 
Diabetes—2019. 2019. 42(Supplement 1): p. S13-S28. 
58. Das, A.K., Type 1 diabetes in India: Overall insights. Indian journal of endocrinology and 
metabolism, 2015. 19(Suppl 1): p. S31-S33. 
59. 2. Classification and Diagnosis of Diabetes. Diabetes Care, 2016. 39 Suppl 1: p. S13-22. 
60. Plows, J.F., et al., The Pathophysiology of Gestational Diabetes Mellitus. 2018. 19(11): p. 
3342. 
61. Winer, N. and J.R.J.T.J.o.C.P. Sowers, Epidemiology of diabetes. 2004. 44(4): p. 397-405. 
62. Olokoba, A.B., O.A. Obateru, and L.B.J.O.m.j. Olokoba, Type 2 diabetes mellitus: a review of 
current trends. 2012. 27(4): p. 269. 
63. Zheng, Y., S.H. Ley, and F.B. Hu, Global aetiology and epidemiology of type 2 diabetes mellitus 
and its complications. Nature Reviews Endocrinology, 2017. 14: p. 88. 
64. Harris, M.I., et al., Prevalence of diabetes, impaired fasting glucose, and impaired glucose 
tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–
1994. 1998. 21(4): p. 518-524. 
65. Knowler, W.C., et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention 
or metformin. 2002. 346(6): p. 393-403. 
66. Haffner, S.M., et al., Cardiovascular risk factors in confirmed prediabetic individuals: does the 
clock for coronary heart disease start ticking before the onset of clinical diabetes? 1990. 
263(21): p. 2893-2898. 
67. Harris, M. and D.J.D.C. Robbins, Prevalence of adult-onset diabetes in the US population. 
1995. 18: p. 885-886. 
68. Fagot-Campagna, A., K.M. Narayan, and G. Imperatore, Type 2 diabetes in children. BMJ 
(Clinical research ed.), 2001. 322(7283): p. 377-378. 
69. Dabelea, D., et al., Increasing prevalence of type II diabetes in American Indian children. 1998. 
41(8): p. 904-910. 
70. Scott, C.R., et al., Characteristics of youth-onset noninsulin-dependent diabetes mellitus and 
insulin-dependent diabetes mellitus at diagnosis. 1997. 100(1): p. 84-91. 
71. Neufeld, N.D., et al., Early presentation of type 2 diabetes in Mexican-American youth. 1998. 
21(1): p. 80-86. 
72. Kahn, S.E., M.E. Cooper, and S.J.T.L. Del Prato, Pathophysiology and treatment of type 2 
diabetes: perspectives on the past, present, and future. 2014. 383(9922): p. 1068-1083. 
73. Hackett, E.J.d., Type 2 diabetes. 4: p. 6. 
74. Homko, C., et al., Insulin secretion during and after pregnancy in patients with gestational 
diabetes mellitus. 2001. 86(2): p. 568-573. 
75. Defronzo, R.A., Banting Lecture. From the triumvirate to the ominous octet: a new paradigm 
for the treatment of type 2 diabetes mellitus. Diabetes, 2009. 58(4): p. 773-95. 
76. Zraika, S., et al., Toxic oligomers and islet beta cell death: guilty by association or convicted by 
circumstantial evidence? Diabetologia, 2010. 53(6): p. 1046-56. 
77. Weir, G.C., et al., Beta-cell adaptation and decompensation during the progression of 
diabetes. Diabetes, 2001. 50 Suppl 1: p. S154-9. 
193 
 
78. Prentki, M. and C.J. Nolan, Islet beta cell failure in type 2 diabetes. J Clin Invest, 2006. 116(7): 
p. 1802-12. 
79. Ashcroft, F.M., et al., Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic beta Cells? 
Cell Metab, 2017. 26(1): p. 17-23. 
80. Al Homsi, M., et al., An Update on the pathogenesis of Diabetes Mellitus. 1992. 
81. Baynes, H.W.J.J.d.m., Classification, pathophysiology, diagnosis and management of diabetes 
mellitus. 2015. 6(5): p. 1-9. 
82. Holt, R.I., Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for 
psychiatrists. Br J Psychiatry Suppl, 2004. 47: p. S55-63. 
83. Tripathi, B.K. and A.K. Srivastava, Diabetes mellitus: complications and therapeutics. Med Sci 
Monit, 2006. 12(7): p. Ra130-47. 
84. Nelson, R.G., et al., Kidney diseases in diabetes. 1995. 2(1). 
85. Mogensen, C., C. Christensen, and E.J.D. Vittinghus, The stages in diabetic renal disease: with 
emphasis on the stage of incipient diabetic nephropathy. 1983. 32(Supplement 2): p. 64-78. 
86. Grundy, S.M., et al., Diabetes and cardiovascular disease: a statement for healthcare 
professionals from the American Heart Association. 1999. 100(10): p. 1134-1146. 
87. Sanchis-Gomar, F., et al., Epidemiology of coronary heart disease and acute coronary 
syndrome. 2016. 4(13). 
88. Celermajer, D.S., et al., Cardiovascular disease in the developing world: prevalences, patterns, 
and the potential of early disease detection. 2012. 60(14): p. 1207-1216. 
89. Cannon, C.P.J.C.c., Cardiovascular disease and modifiable cardiometabolic risk factors. 2007. 
8(3): p. 11-28. 
90. Bhatnagar, P., et al., Trends in the epidemiology of cardiovascular disease in the UK. 2016. 
102(24): p. 1945-1952. 
91. Newton, J.N., et al., Changes in health in England, with analysis by English regions and areas 
of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 
2013. 2015. 386(10010): p. 2257-2274. 
92. Murray, C.J., A.D. Lopez, and W.H. Organization, The global burden of disease: a 
comprehensive assessment of mortality and disability from diseases, injuries, and risk factors 
in 1990 and projected to 2020: summary. 1996. 
93. Foley, R.N., P.S. Parfrey, and M.J. Sarnak, Epidemiology of cardiovascular disease in chronic 
renal disease. J Am Soc Nephrol, 1998. 9(12 Suppl): p. S16-23. 
94. Reddy, K.S., et al., Responding to the threat of chronic diseases in India. 2005. 366(9498): p. 
1744-1749. 
95. Joshi, P., et al., Risk factors for early myocardial infarction in South Asians compared with 
individuals in other countries. 2007. 297(3): p. 286-294. 
96. Harikrishnan, S., et al., A race against time: the challenge of cardiovascular disease in 
developing economies. 2014. 
97. Organization, W.H. and W.H.O.J.A.a.h.w.w.i.m.f.f.e.B.t.c. text, The top 10 causes of death. 
2012. 2015(2). 
98. Stewart, J., G. Manmathan, and P.J.J.c.d. Wilkinson, Primary prevention of cardiovascular 
disease: A review of contemporary guidance and literature. 2017. 6: p. 2048004016687211. 
99. Nason, E., An overview of cardiovascular disease and research. 2008. 
100. Brezina, V. and I.J.E.h.j. Padmos, Coronary heart disease risk factors in women. 1994. 15(11): 
p. 1571-1584. 
101. Thrainsdottir, I.S., et al., The association between glucose abnormalities and heart failure in 
the population-based Reykjavik study. 2005. 28(3): p. 612-616. 
102. Nielson, C. and T.J.D.C. Lange, Blood glucose and heart failure in nondiabetic patients. 2005. 
28(3): p. 607-611. 
194 
 
103. Muhlestein, J.B., et al., Effect of fasting glucose levels on mortality rate in patients with and 
without diabetes mellitus and coronary artery disease undergoing percutaneous coronary 
intervention. 2003. 146(2): p. 351-358. 
104. Dokken, B.B.J.D.S., The pathophysiology of cardiovascular disease and diabetes: beyond 
blood pressure and lipids. 2008. 21(3): p. 160-165. 
105. Singer, D.E., A.W. Moulton, and D.M.J.D. Nathan, Diabetic myocardial infarction: interaction 
of diabetes with other preinfarction risk factors. 1989. 38(3): p. 350-357. 
106. Fagot-campagna, A., et al., Prevalence of lipid abnormalities, awareness, and treatment in US 
adults with diabetes. 2000. 49(5): p. A78-A78. 
107. Merz, C.N.B., et al., Physician attitudes and practices and patient awareness of the 
cardiovascular complications of diabetes. 2002. 40(10): p. 1877-1881. 
108. Patil, R. and G.K. Sood, Non-alcoholic fatty liver disease and cardiovascular risk. World 
journal of gastrointestinal pathophysiology, 2017. 8(2): p. 51. 
109. Francque, S.M., D. van der Graaff, and W.J. Kwanten, Non-alcoholic fatty liver disease and 
cardiovascular risk: Pathophysiological mechanisms and implications. Journal of hepatology, 
2016. 65(2): p. 425-443. 
110. Wong, C.R. and J.K. Lim, The Association Between Nonalcoholic Fatty Liver Disease and 
Cardiovascular Disease Outcomes. Clinical liver disease, 2018. 12(2): p. 39. 
111. Brouwers, M., et al., Non-alcoholic fatty liver disease and cardiovascular disease: assessing 
the evidence for causality. Diabetologia, 2019. 
112. Wingard, D.L., et al., Prevalence of cardiovascular and renal complications in older adults with 
normal or impaired glucose tolerance or NIDDM: a population-based study. 1993. 16(7): p. 
1022-1025. 
113. Rubler, S., et al., New type of cardiomyopathy associated with diabetic glomerulosclerosis. 
1972. 30(6): p. 595-602. 
114. Regan, T.J.J.A.r.o.m., Congestive heart failure in the diabetic. 1983. 34(1): p. 161-168. 
115. Van Hoeven, K. and S.M.J.C. Factor, A comparison of the pathological spectrum of 
hypertensive, diabetic, and hypertensive-diabetic heart disease. 1990. 82(3): p. 848-855. 
116. Stamler, J., et al., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men 
screened in the Multiple Risk Factor Intervention Trial. 1993. 16(2): p. 434-444. 
117. Yajnik, C.S.J.A.o.N. and Metabolism, Transmission of obesity-adiposity and related disorders 
from the mother to the baby. 2014. 64(Suppl. 1): p. 8-17. 
118. Waddington, C.H.J.N., Embryology, epigenetics and biogenetics. 1956. 177(4522): p. 1241. 
119. Palinski, W. and C.J.T.F.J. Napoli, The fetal origins of atherosclerosis: maternal 
hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy 
influence in utero programming and postnatal susceptibility to atherogenesis. 2002. 16(11): 
p. 1348-1360. 
120. Palinski, W. and C. Napoli, Impaired fetal growth, cardiovascular disease, and the need to 
move on. 2008, Am Heart Assoc. 
121. Ng, S.P., et al., Prenatal exposure to cigarette smoke induces diet-and sex-dependent 
dyslipidemia and weight gain in adult murine offspring. 2009. 117(7): p. 1042. 
122. Daniels, S.R., et al., American Heart Association childhood obesity research summit: Executive 
summary. 2009. 119(15): p. 2114-2123. 
123. Sukumar, N., et al., Vitamin B12 Status among Pregnant Women in the UK and Its Association 
with Obesity and Gestational Diabetes. Nutrients, 2016. 8(12): p. 768. 
124. Knight, B.A., et al., Lower Circulating B12 Is Associated with Higher Obesity and Insulin 
Resistance during Pregnancy in a Non-Diabetic White British Population. PloS one, 2015. 
10(8): p. e0135268-e0135268. 
125. Sun, C., M.A. Velazquez, and T.P. Fleming, DOHaD and the periconceptional period, a critical 
window in time, in The epigenome and developmental origins of health and disease. 2016, 
Elsevier. p. 33-47. 
195 
 
126. O’Leary, F. and S.J.n. Samman, Vitamin B12 in health and disease. 2010. 2(3): p. 299-316. 
127. Stabler, S.P. and R.H.J.A.R.N. Allen, Vitamin B12 deficiency as a worldwide problem. 2004. 24: 
p. 299-326. 
128. Healton, E.B., et al., Neurologic aspects of cobalamin deficiency. 1991. 70(4): p. 229-245. 
129. Michaud, J., et al., Nutritional vitamin B 12 deficiency: two cases detected by routine newborn 
urinary screening. 1992. 151(3): p. 218-220. 
130. de Benoist, B., Conclusions of a WHO Technical Consultation on folate and vitamin B12 
deficiencies. Food Nutr Bull, 2008. 29(2 Suppl): p. S238-44. 
131. Green, R., Metabolite assays in cobalamin and folate deficiency. Baillieres Clin Haematol, 
1995. 8(3): p. 533-66. 
132. Waldmann, A., et al., German vegan study: diet, life-style factors, and cardiovascular risk 
profile. Ann Nutr Metab, 2005. 49(6): p. 366-72. 
133. Khan, K.M. and I. Jialal, Folic Acid (Folate) Deficiency, in StatPearls. 2019, StatPearls 
Publishing 
StatPearls Publishing LLC.: Treasure Island (FL). 
134. Green, R., et al., Vitamin B12 deficiency. Nat Rev Dis Primers, 2017. 3: p. 17040. 
135. McLean, E., et al., Review of the magnitude of folate and vitamin B12 deficiencies worldwide. 
2008. 29(2_suppl1): p. S38-S51. 
136. Saravanan, P., C.S.J.T.B.J.o.D. Yajnik, and V. Disease, Role of maternal vitamin B12 on the 
metabolic health of the offspring: a contributor to the diabetes epidemic? 2010. 10(3): p. 109-
114. 
137. Hunt, A., D. Harrington, and S.J.b. Robinson, Vitamin B12 deficiency. 2014. 349: p. g5226. 
138. Allen, L.H.J.T.A.j.o.c.n., How common is vitamin B-12 deficiency?–. 2008. 89(2): p. 693S-696S. 
139. Pawlak, R., et al., How prevalent is vitamin B12 deficiency among vegetarians? 2013. 71(2): p. 
110-117. 
140. Stabler, S.P.J.N.E.J.o.M., Vitamin B12 deficiency. 2013. 368(2): p. 149-160. 
141. Dali-Youcef, N. and E.J.Q.A.I.J.o.M. Andrès, An update on cobalamin deficiency in adults. 
2009. 102(1): p. 17-28. 
142. Langan, R.C. and A.J.J.A.f.p. Goodbred, Vitamin B 12 Deficiency: Recognition and 
Management. 2017. 96(6). 
143. Carmel, R., et al., Update on cobalamin, folate, and homocysteine. 2003. 2003(1): p. 62-81. 
144. Sukumar, N., et al., Vitamin B12 status in women of childbearing age in the UK and its 
relationship with national nutrient intake guidelines: results from two National Diet and 
Nutrition Surveys. 2016. 6(8): p. e011247. 
145. McLean, E., B. de Benoist, and L.H. Allen, Review of the magnitude of folate and vitamin B12 
deficiencies worldwide. Food Nutr Bull, 2008. 29(2 Suppl): p. S38-51. 
146. Saravanan, P. and C.S. Yajnik, Role of maternal vitamin B12 on the metabolic health of the 
offspring: a contributor to the diabetes epidemic? The British Journal of Diabetes & Vascular 
Disease, 2010. 10(3): p. 109-114. 
147. Smith, A.D., M.J. Warren, and H. Refsum, Vitamin B12. Adv Food Nutr Res, 2018. 83: p. 215-
279. 
148. Smith, E.L., Purification of anti-pernicious anaemia factors from liver. Nature, 1948. 
161(4095): p. 638. 
149. Rickes, E.L., et al., Crystalline Vitamin B12. Science, 1948. 107(2781): p. 396-7. 
150. Hodgkin, D.C., et al., Structure of vitamin B12. Nature, 1956. 178(4524): p. 64-6. 
151. Froese, D.S. and R.A. Gravel, Genetic disorders of vitamin B(1)(2) metabolism: eight 
complementation groups--eight genes. Expert Rev Mol Med, 2010. 12: p. e37. 
152. Heyssel, R.M., et al., Vitamin B12 turnover in man. The assimilation of vitamin B12 from 
natural foodstuff by man and estimates of minimal daily dietary requirements. Am J Clin 
Nutr, 1966. 18(3): p. 176-84. 
196 
 
153. Sato, K., X. Wang, and K. Mizoguchi, A modified form of a vitamin B12 compound extracted 
from whey fermented by Lactobacillus helveticus. J Dairy Sci, 1997. 80(11): p. 2701-5. 
154. O'Leary, F. and S. Samman, Vitamin B12 in health and disease. Nutrients, 2010. 2(3): p. 299-
316. 
155. Linden, D., et al., Liver-directed overexpression of mitochondrial glycerol-3-phosphate 
acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced 
fatty acid oxidation. FASEB J, 2006. 20(3): p. 434-43. 
156. Joske, R.A., THE VITAMIN B12 CONTENT OF HUMAN LIVER TISSUE OBTAINED BY ASPIRATION 
BIOPSY. Gut, 1963. 4: p. 231-5. 
157. Joske, R.J.G., The vitamin B12 content of human liver tissue obtained by aspiration biopsy. 
1963. 4(3): p. 231-235. 
158. Shinton, N.K., Vitamin B 12 and folate metabolism. Br Med J, 1972. 1(5799): p. 556-9. 
159. Nakashima, K.J.N.j.o.m.s., Glycolytic and gluconeogenic metabolites and enzymes in the liver 
of obese hyperglycemic mice (KK) and alloxan diabetic mice. 1969. 32(1): p. 143-158. 
160. Vidal-Alabró, A., et al., Liver Glucokinase and Lipid Metabolism, in Dyslipidemia-From 
Prevention to Treatment. 2012, InTech. 
161. Denechaud, P.-D., et al., ChREBP, but not LXRs, is required for the induction of glucose-
regulated genes in mouse liver. 2008. 118(3): p. 956-964. 
162. Lee, A.-H., et al., Regulation of hepatic lipogenesis by the transcription factor XBP1. 2008. 
320(5882): p. 1492-1496. 
163. Lakshmanan, M., C.M. Nepokroeff, and J.W.J.P.o.t.N.A.o.S. Porter, Control of the synthesis of 
fatty-acid synthetase in rat liver by insulin, glucagon, and adenosine 3′: 5′ cyclic 
monophosphate. 1972. 69(12): p. 3516-3519. 
164. Mao, J., et al., Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride 
accumulation without affecting glucose homeostasis. 2006. 103(22): p. 8552-8557. 
165. Schultz, J.R., et al., Role of LXRs in control of lipogenesis. 2000. 14(22): p. 2831-2838. 
166. Ferre, P., F.J.D. Foufelle, Obesity, and Metabolism, Hepatic steatosis: a role for de novo 
lipogenesis and the transcription factor SREBP‐1c. 2010. 12: p. 83-92. 
167. Marchesini, G., et al., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. 
2003. 37(4): p. 917-923. 
168. Kumar, K.A., et al., Maternal dietary folate and/or vitamin B12 restrictions alter body 
composition (adiposity) and lipid metabolism in Wistar rat offspring. J Nutr Biochem, 2013. 
24(1): p. 25-31. 
169. Ghosh, S., et al., Severe but Not Moderate Vitamin B12 Deficiency Impairs Lipid Profile, 
Induces Adiposity, and Leads to Adverse Gestational Outcome in Female C57BL/6 Mice. Front 
Nutr, 2016. 3: p. 1. 
170. Shampa, G., et al., Chronic transgenerational vitamin B12 deficiency of severe and moderate 
magnitudes modulates adiposity—probable underlying mechanisms. BioFactors, 2017. 43(3): 
p. 400-414. 
171. Sun, Y., et al., Inverse Association Between Serum Vitamin B12 Concentration and Obesity 
Among Adults in the United States. Front Endocrinol (Lausanne), 2019. 10: p. 414. 
172. Baltaci, D., et al., Association of vitamin B12 with obesity, overweight, insulin resistance and 
metabolic syndrome, and body fat composition; primary care-based study. Med Glas (Zenica), 
2013. 10(2): p. 203-10. 
173. Pinhas-Hamiel, O., et al., Obese children and adolescents: a risk group for low vitamin B12 
concentration. Arch Pediatr Adolesc Med, 2006. 160(9): p. 933-6. 
174. Özer, S., E. Sönmezgöz, and O.J.J.T.J.o.t.P.M.A. Demir, Negative correlation among vitamin 
B12 levels, obesity severity and metabolic syndrome in obese children: A case control study. 
2017. 67(11): p. 1648-1653. 
197 
 
175. Ozer, S., E. Sonmezgoz, and O. Demir, Negative correlation among vitamin B12 levels, obesity 
severity and metabolic syndrome in obese children: A case control study. J Pak Med Assoc, 
2017. 67(11): p. 1648-1653. 
176. O'Malley, E.G., et al., Folate and vitamin B12 levels in early pregnancy and maternal obesity. 
Eur J Obstet Gynecol Reprod Biol, 2018. 231: p. 80-84. 
177. Wiebe, N., C.J. Field, and M. Tonelli, A systematic review of the vitamin B12, folate and 
homocysteine triad across body mass index. Obes Rev, 2018. 19(11): p. 1608-1618. 
178. Sukumar, N., et al., Vitamin B12 Status among Pregnant Women in the UK and Its Association 
with Obesity and Gestational Diabetes. Nutrients, 2016. 8(12). 
179. Yajnik, C.S., et al., Vitamin B12 and folate concentrations during pregnancy and insulin 
resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia, 2008. 51(1): p. 
29-38. 
180. Sinclair, K.D., et al., DNA methylation, insulin resistance, and blood pressure in offspring 
determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci 
U S A, 2007. 104(49): p. 19351-6. 
181. Cooney, C.A., A.A. Dave, and G.L. Wolff, Maternal methyl supplements in mice affect 
epigenetic variation and DNA methylation of offspring. J Nutr, 2002. 132(8 Suppl): p. 2393S-
2400S. 
182. Dursun, F. and N. Gerenli, Relationship Between Insulin Resistance and Vitamin B12 
Deficiency in Obese Children. The Medical Journal Of Haydarpaşa Numune Training and 
Research Hospital, 2019. 59(1): p. 84-87. 
183. Sukumar, N., et al., Vitamin B12 status in women of childbearing age in the UK and its 
relationship with national nutrient intake guidelines: results from two National Diet and 
Nutrition Surveys. BMJ Open, 2016. 6(8): p. e011247. 
184. Ho, M., et al., Vitamin B12 in obese adolescents with clinical features of insulin resistance. 
Nutrients, 2014. 6(12): p. 5611-8. 
185. Kaya, C., S.D. Cengiz, and H. Satiroglu, Obesity and insulin resistance associated with lower 
plasma vitamin B12 in PCOS. Reprod Biomed Online, 2009. 19(5): p. 721-6. 
186. Ho, M., et al., Vitamin B12 in obese adolescents with clinical features of insulin resistance. 
Nutrients, 2014. 6(12): p. 5611-5618. 
187. Stewart, C.P., et al., Low Maternal Vitamin B-12 Status Is Associated with Offspring Insulin 
Resistance Regardless of Antenatal Micronutrient Supplementation in Rural Nepal. The 
Journal of Nutrition, 2011. 141(10): p. 1912-1917. 
188. Mamabolo, R.L., M. Alberts, and N.S. Levitt, The effect of maternal glucose metabolism, iron, 
vitamin B12 and folate status on pregnancy outcomes. South African Journal of Clinical 
Nutrition, 2006. 19(3). 
189. Adaikalakoteswari, A., et al., Low Vitamin B12 in Pregnancy Is Associated With Adipose-
Derived Circulating miRs Targeting PPARgamma and Insulin Resistance. J Clin Endocrinol 
Metab, 2017. 102(11): p. 4200-4209. 
190. Antoine, D. and B. Sherazade, Coenzyme B12 synthesis as a baseline to study metabolite 
contribution of animal microbiota. Microbial Biotechnology, 2017. 10(4): p. 688-701. 
191. Ahmad, S., et al., PPAR signaling pathway is a key modulator of liver proteome in pups born 
to vitamin B(12) deficient rats. J Proteomics, 2013. 91: p. 297-308. 
192. Pooya, S., et al., Methyl donor deficiency impairs fatty acid oxidation through PGC-1alpha 
hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver. J 
Hepatol, 2012. 57(2): p. 344-51. 
193. Adaikalakoteswari, A., et al., Vitamin B12 insufficiency induces cholesterol biosynthesis by 
limiting s-adenosylmethionine and modulating the methylation of SREBF1 and LDLR genes. 
Clin Epigenetics, 2015. 7(1): p. 14. 
198 
 
194. Saraswathy, K.N., et al., Metabolic distress in lipid & one carbon metabolic pathway through 
low vitamin B-12: a population based study from North India. Lipids Health Dis, 2018. 17(1): 
p. 96. 
195. Guarnizo-Poma, M., et al., Association between serum vitamin B12 levels and metabolic 
syndrome in a euthyroid population. Diabetes Metab Syndr, 2018. 12(6): p. 943-948. 
196. Adaikalakoteswari, A., et al., Vitamin B12 insufficiency induces cholesterol biosynthesis by 
limiting s-adenosylmethionine and modulating the methylation of SREBF1 and LDLR genes. 
Clin Epigenetics, 2015. 7: p. 14. 
197. Bhargava, S.K., et al., Relation of serial changes in childhood body-mass index to impaired 
glucose tolerance in young adulthood. N Engl J Med, 2004. 350(9): p. 865-75. 
198. Abdullah N., M.S., Abdulrahman R, Relation between vitamin B12 and Non-alcoholic fatty 
Liver Disease: A Hospital Based Study. 2015. 3 (6): p. 1335-134  
199. Setola, E., et al., Insulin resistance and endothelial function are improved after folate and 
vitamin B12 therapy in patients with metabolic syndrome: relationship between 
homocysteine levels and hyperinsulinemia. Eur J Endocrinol, 2004. 151(4): p. 483-9. 
200. Lodhi, R. and A. Panchal, Interrelationship of Vitamin B12, Androgens and Cortisol in Chronic 
Stress and Associated Vascular Dysfunction. 
201. Hagar, H.H.J.P.r., Folic acid and vitamin B12 supplementation attenuates isoprenaline-
induced myocardial infarction in experimental hyperhomocysteinemic rats. 2002. 46(3): p. 
213-219. 
202. Sachdev, P.J.B.J.o.P., Homocysteine and neuropsychiatric disorders. 2004. 26(1): p. 50-56. 
203. Mager, A., et al., Impact of homocysteine-lowering vitamin therapy on long-term outcome of 
patients with coronary artery disease. 2009. 104(6): p. 745-749. 
204. Mao, X., et al., Folic acid and vitamins D and B12 correlate with homocysteine in Chinese 
patients with type-2 diabetes mellitus, hypertension, or cardiovascular disease. 2016. 95(6). 
205. Cui, R., et al., Dietary folate and vitamin b6 and B12 intake in relation to mortality from 
cardiovascular diseases: Japan collaborative cohort study. 2010. 41(6): p. 1285-1289. 
206. Albert, C.M., et al., Effect of folic acid and B vitamins on risk of cardiovascular events and 
total mortality among women at high risk for cardiovascular disease: a randomized trial. 
2008. 299(17): p. 2027-2036. 
207. Lee, B., et al., Folic acid and vitamin B 12 are more effective than vitamin B 6 in lowering 
fasting plasma homocysteine concentration in patients with coronary artery disease. 2004. 
58(3): p. 481. 
208. Mendonça, N., et al., Elevated total homocysteine in all participants and plasma vitamin B12 
concentrations in women are associated with all-cause and cardiovascular mortality in the 
very old: the Newcastle 85+ Study. 2018. 73(9): p. 1258-1264. 
209. Chakraverty, R. and P.J.A.S.P.S. Chakraborty, Recent Insights into the Role of Vitamin B12 and 
Vitamin D upon Cardiovascular Mortality: A Systematic Review. 2018. 2: p. 61-65. 
210. Ryan-Harshman, M. and W.J.C.F.P. Aldoori, Vitamin B12 and health. 2008. 54(4): p. 536-541. 
211. Robinson, K.J.C., Renal disease, homocysteine, and cardiovascular complications. 2004. 
109(3): p. 294-295. 
212. Langan, R.C. and A.J.J.A.f.p. Goodbred, Vitamin B12 deficiency: recognition and management. 
2017. 96(6). 
213. McMahon, G.M., et al., The association between vitamin B12, albuminuria and reduced 
kidney function: an observational cohort study. 2015. 16(1): p. 7. 
214. Capelli, I., et al., Folic Acid and Vitamin B12 Administration in CKD, Why Not? 2019. 11(2): p. 
383. 
215. Lee, J.H., S. Friso, and S.W. Choi, Epigenetic mechanisms underlying the link between non-
alcoholic fatty liver diseases and nutrition. Nutrients, 2014. 6(8): p. 3303-25. 
216. Zhao, M., et al., Vitamin B-6 restriction impairs fatty acid synthesis in cultured human 
hepatoma (HepG2) cells. Am J Physiol Endocrinol Metab, 2013. 304(4): p. E342-51. 
199 
 
217. Mooney, S., et al., Vitamin B6: a long known compound of surprising complexity. Molecules, 
2009. 14(1): p. 329-51. 
218. Sun, C., J.G. Fan, and L. Qiao, Potential epigenetic mechanism in non-alcoholic Fatty liver 
disease. Int J Mol Sci, 2015. 16(3): p. 5161-79. 
219. Gallego-Duran, R. and M. Romero-Gomez, Epigenetic mechanisms in non-alcoholic fatty liver 
disease: An emerging field. World J Hepatol, 2015. 7(24): p. 2497-502. 
220. Takahashi-Iniguez, T., et al., Role of vitamin B12 on methylmalonyl-CoA mutase activity. J 
Zhejiang Univ Sci B, 2012. 13(6): p. 423-37. 
221. Finer, S., et al., The role of the one-carbon cycle in the developmental origins of Type 2 
diabetes and obesity. Diabet Med, 2014. 31(3): p. 263-72. 
222. Rush, E.C., P. Katre, and C.S. Yajnik, Vitamin B12: one carbon metabolism, fetal growth and 
programming for chronic disease. Eur J Clin Nutr, 2014. 68(1): p. 2-7. 
223. Yajnik, C.S., Fetal programming of diabetes: still so much to learn! Diabetes Care, 2010. 33(5): 
p. 1146-8. 
224. VARMA, B.A., et al., FOLIC ACID, VITAMIN B12, AND DNA METHYLATION: AN UPDATE. 2018. 
11(1): p. 17-20. 
225. Yu, D., et al., Mitochondrial DNA hypomethylation is a biomarker associated with induced 
senescence in human fetal heart mesenchymal stem cells. Stem cells international, 2017. 
2017. 
226. Iacobazzi, V., et al., Mitochondrial DNA methylation as a next-generation biomarker and 
diagnostic tool. Mol Genet Metab, 2013. 110(1-2): p. 25-34. 
227. Yi, P., et al., Increase in plasma homocysteine associated with parallel increases in plasma S-
adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem, 2000. 275(38): p. 
29318-23. 
228. Dominguez-Salas, P., et al., Maternal nutritional status, C(1) metabolism and offspring DNA 
methylation: a review of current evidence in human subjects. Proc Nutr Soc, 2012. 71(1): p. 
154-65. 
229. Skjaerven, K.H., et al., Parental micronutrient deficiency distorts liver DNA methylation and 
expression of lipid genes associated with a fatty-liver-like phenotype in offspring. Sci Rep, 
2018. 8(1): p. 3055. 
230. Pogribny, I.P., et al., Molecular alterations in hepatocarcinogenesis induced by dietary methyl 
deficiency. 2012. 56(1): p. 116-125. 
231. Byrne, C.D., et al., Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond), 
2009. 116(7): p. 539-64. 
232. Choi, S.W., et al., Vitamin B-12 deficiency induces anomalies of base substitution and 
methylation in the DNA of rat colonic epithelium. J Nutr, 2004. 134(4): p. 750-5. 
233. Kulkarni, A., et al., Effects of altered maternal folic acid, vitamin B12 and docosahexaenoic 
acid on placental global DNA methylation patterns in Wistar rats. PLoS One, 2011. 6(3): p. 
e17706. 
234. Nilsson, E., et al., Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes 
in Parallel With Reduced Folate Levels. The Journal of clinical endocrinology and metabolism, 
2015. 100(11): p. E1491-E1501. 
235. Cordero, P., et al., Dietary supplementation with methyl donors reduces fatty liver and 
modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. 
Genes & nutrition, 2013. 8(1): p. 105. 
236. da Silva, R.P., et al., Novel insights on interactions between folate and lipid metabolism. 
Biofactors, 2014. 40(3): p. 277-83. 
237. Cordero, P., et al., Transcriptomic and epigenetic changes in early liver steatosis associated to 
obesity: effect of dietary methyl donor supplementation. Mol Genet Metab, 2013. 110(3): p. 
388-95. 
200 
 
238. He, L. and G.J. Hannon, MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev 
Genet, 2004. 5(7): p. 522-31. 
239. Finch, M.L., et al., Regulation of microRNAs and their role in liver development, regeneration 
and disease. Int J Biochem Cell Biol, 2014. 54: p. 288-303. 
240. Ferreira, D.M., et al., Revisiting the metabolic syndrome and paving the way for microRNAs in 
non-alcoholic fatty liver disease. FEBS J, 2014. 281(11): p. 2503-24. 
241. Hamam, D., et al., microRNAs as regulators of adipogenic differentiation of mesenchymal 
stem cells. Stem cells and development, 2014. 24(4): p. 417-425. 
242. Xie, H., B. Lim, and H.F. Lodish, MicroRNAs induced during adipogenesis that accelerate fat 
cell development are downregulated in obesity. Diabetes, 2009. 58(5): p. 1050-7. 
243. Davalos, A., et al., miR-33a/b contribute to the regulation of fatty acid metabolism and insulin 
signaling. Proc Natl Acad Sci U S A, 2011. 108(22): p. 9232-7. 
244. Severson, T.J., S. Besur, and H.L. Bonkovsky, Genetic factors that affect nonalcoholic fatty 
liver disease: A systematic clinical review. World journal of gastroenterology, 2016. 22(29): p. 
6742. 
245. Cheung, O., et al., Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA 
expression. Hepatology, 2008. 48(6): p. 1810-20. 
246. Elmen, J., et al., LNA-mediated microRNA silencing in non-human primates. Nature, 2008. 
452(7189): p. 896-9. 
247. Sacco, J. and K. Adeli, MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr 
Opin Lipidol, 2012. 23(3): p. 220-5. 
248. Sun, C., J.-G. Fan, and L.J.I.j.o.m.s. Qiao, Potential epigenetic mechanism in non-alcoholic 
fatty liver disease. 2015. 16(3): p. 5161-5179. 
249. Ghosh, S., et al., Increased stress and altered expression of histone modifying enzymes in 
brain are associated with aberrant behaviour in vitamin B12 deficient female mice. Nutr 
Neurosci, 2018: p. 1-10. 
250. Garcia, B.A., et al., Folate deficiency affects histone methylation. 2016. 88: p. 63-67. 
251. Li, J., et al., Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through 
generational effects of high fat diets. 2012. 56(4): p. 900-907. 
252. Choi, S.-W. and S.J.A.i.n. Friso, Epigenetics: a new bridge between nutrition and health. 2010. 
1(1): p. 8-16. 
253. Mehedint, M.G., et al., Choline deficiency alters global histone methylation and epigenetic 
marking at the Re1 site of the calbindin 1 gene. 2010. 24(1): p. 184-195. 
254. Lee, J., S. Friso, and S.-W.J.N. Choi, Epigenetic mechanisms underlying the link between non-
alcoholic fatty liver diseases and nutrition. 2014. 6(8): p. 3303-3325. 
255. Okamura, M., et al., Role of histone methylation and demethylation in adipogenesis and 
obesity. 2010. 6(1): p. 24-32. 
256. Tateishi, K., et al., Role of Jhdm2a in regulating metabolic gene expression and obesity 
resistance. 2009. 458(7239): p. 757. 
257. Postic, C. and J. Girard, Contribution of de novo fatty acid synthesis to hepatic steatosis and 
insulin resistance: lessons from genetically engineered mice. The Journal of clinical 
investigation, 2008. 118(3): p. 829-838. 
258. Jones, K.M., et al., Prevalent vitamin B-12 deficiency in twelve-month-old Guatemalan infants 
is predicted by maternal B-12 deficiency and infant diet. J Nutr, 2007. 137(5): p. 1307-13. 
259. Sun, C., J.-G. Fan, and L. Qiao, Potential epigenetic mechanism in non-alcoholic fatty liver 
disease. International journal of molecular sciences, 2015. 16(3): p. 5161-5179. 
260. Wang, L.J., et al., Betaine attenuates hepatic steatosis by reducing methylation of the MTTP 
promoter and elevating genomic methylation in mice fed a high-fat diet. J Nutr Biochem, 
2014. 25(3): p. 329-36. 
261. Yadav, D.K., et al., Vitamin B12 supplementation influences methylation of genes associated 
with Type 2 diabetes and its intermediate traits. Epigenomics, 2018. 10(1): p. 71-90. 
201 
 
262. Devi, S., et al., Combined Vitamin B-12 and Balanced Protein-Energy Supplementation Affect 
Homocysteine Remethylation in the Methionine Cycle in Pregnant South Indian Women of 
Low Vitamin B-12 Status–4. 2017. 147(6): p. 1094-1103. 
263. Kuniskii, D.G., [Effect of methionine and vitamins B12 and B15 on the content and distribution 
of proteins, glycogen and lipids in the hepatic lobules of chickens]. Arkh Anat Gistol Embriol, 
1980. 79(10): p. 97-101. 
264. Duggan, C., et al., Vitamin B-12 supplementation during pregnancy and early lactation 
increases maternal, breast milk, and infant measures of vitamin B-12 status. J Nutr, 2014. 
144(5): p. 758-64. 
265. Aden, D.P., et al., Controlled synthesis of HBsAg in a differentiated human liver carcinoma-
derived cell line. 1979. 282(5739): p. 615. 
266. López-Terrada, D., et al., Hep G2 is a hepatoblastoma-derived cell line. 2009. 40(10): p. 1512. 
267. Eroğlu, C., et al., Investigation of Apoptotic Effect of Sinapic Acid in Hep3B and HepG2 Human 
Hepatocellular Carcinoma Cells. 2017. 1(10): p. 1000. 
268. Shalaby, N.A., et al., Prognostic value of renin gene expression in acute myeloid leukemia. 
2018. 43(2): p. 69. 
269. Folch, J., M. Lees, and G.J.J.b.C. Sloane Stanley, A simple method for the isolation and 
purification of total lipides from animal tissues. 1957. 226(1): p. 497-509. 
270. Bass, J.J., et al., An overview of technical considerations for Western blotting applications to 
physiological research. 2017. 27(1): p. 4-25. 
271. Prieto-Sánchez, M.T., et al., Placental MFSD2a transporter is related to decreased DHA in 
cord blood of women with treated gestational diabetes. 2017. 36(2): p. 513-521. 
272. Larque, E., et al., Dietary trans fatty acids alter the compositions of microsomes and 
mitochondria and the activities of microsome Δ6-fatty acid desaturase and glucose-6-
phosphatase in livers of pregnant rats. 2003. 133(8): p. 2526-2531. 
273. van der Windt, G.J., C.H. Chang, and E.L.J.C.p.i.i. Pearce, Measuring bioenergetics in T cells 
using a Seahorse Extracellular Flux Analyzer. 2016. 113(1): p. 3.16 B. 1-3.16 B. 14. 
274. Hariri, N. and L.J.N.r.r. Thibault, High-fat diet-induced obesity in animal models. 2010. 23(2): 
p. 270-299. 
275. Thomas, H., Maternal metformin treatment in obese pregnancy alters priming of offspring 
metabolic dysfunction and non-alcoholic fatty liver disease in mice. 2017, University of 
Southampton. 
276. Andrès, E., H. Fothergill, and M.J.E.O.o.P. Mecili, Efficacy of oral cobalamin (vitamin B12) 
therapy. 2010. 11(2): p. 249-256. 
277. Nielsen, M.J., et al., Vitamin B 12 transport from food to the body's cells—a sophisticated, 
multistep pathway. 2012. 9(6): p. 345. 
278. Layden, A.J., et al., Vitamin B12 and placental expression of transcobalamin in pregnant 
adolescents. 2016. 45: p. 1-7. 
279. Bernard, D.J., et al., Mice lacking the transcobalamin-vitamin B12 receptor, CD320, suffer 
from anemia and reproductive deficits when fed vitamin B12-deficient diet. Hum Mol Genet, 
2018. 27(20): p. 3627-3640. 
280. Greibe, E., et al., Differences in Tissue Distribution of Cyano–B12 and Hydroxo–B12 One Week 
after Oral Intake: An Experimental Study in Male Wistar Rats. 2018. 10(10): p. 1487. 
281. Greibe, E., et al., The tissue profile of metabolically active coenzyme forms of vitamin B 12 
differs in vitamin B 12-depleted rats treated with hydroxo-B 12 or cyano-B 12. 2018. 120(1): 
p. 49-56. 
282. Greibe, E., et al., Dietary intake of vitamin B12 is better for restoring a low B12 status than a 
daily high-dose vitamin pill: An experimental study in rats. 2018. 10(8): p. 1096. 
283. Greibe, E., et al., Absorption of Vitamin B12 Administered in Buffalo Milk: An Experimental 
Study in Rats. 2017. 2(1): p. 1006. 
202 
 
284. Kornerup, L.S., et al., Tissue distribution of oral vitamin B12 is influenced by B12 status and 
B12 form: an experimental study in rats. Eur J Nutr, 2018. 57(4): p. 1459-1469. 
285. Kornerup, L.S., et al., Absorption and retention of free and milk protein-bound cyano- and 
hydroxocobalamins. An experimental study in rats. Biochimie, 2016. 126: p. 57-62. 
286. Thagaard MS, N.E., Greibe E Vitamin B12 Levels in Rat Organs - No Change Following 
Prolonged Treatment with Metformin  Int J Diabetes Clin Res, 2015. 2( 5): p. p1-4. 
287. Nymark, O., E. Nexo, and E.J.N. Greibe, Nutritional 1C imbalance, B12 tissue accumulation, 
and pregnancy outcomes: An experimental study in rats. 2018. 10(11): p. 1579. 
288. Golding, P.H., Holotranscobalamin (HoloTC, Active-B12) and Herbert’s model for the 
development of vitamin B12 deficiency: a review and alternative hypothesis. SpringerPlus, 
2016. 5(1): p. 668. 
289. Wurie, H.R., L. Buckett, and V.A. Zammit, Diacylglycerol acyltransferase 2 acts upstream of 
diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized 
fatty acids in HepG2 cells. FEBS J, 2012. 279(17): p. 3033-47. 
290. Alhusaini, S., et al., Lipopolysaccharide, high glucose and saturated fatty acids induce 
endoplasmic reticulum stress in cultured primary human adipocytes: Salicylate alleviates this 
stress. Biochem Biophys Res Commun, 2010. 397(3): p. 472-8. 
291. Langan, R.C. and A.J. Goodbred, Vitamin B12 Deficiency: Recognition and Management. Am 
Fam Physician, 2017. 96(6): p. 384-389. 
292. Rogne, T., et al., Associations of Maternal Vitamin B12 Concentration in Pregnancy With the 
Risks of Preterm Birth and Low Birth Weight: A Systematic Review and Meta-Analysis of 
Individual Participant Data. American journal of epidemiology, 2017. 185(3): p. 212-223. 
293. Hannibal, L., et al., Transcellular transport of cobalamin in aortic endothelial cells. 2018: p. fj. 
201701141RR. 
294. Scott, J., et al., The regulatory roles of liver and kidney in cobalamin (vitamin B12) 
metabolism in the rat: the uptake and intracellular binding of cobalamin and the activity of 
the cobalamin-dependent enzymes in response to varying cobalamin supply. Clinical Science, 
1984. 67(3): p. 299-306. 
295. Wani, N.A., A. Hamid, and J. Kaur, Folate status in various pathophysiological conditions. 
IUBMB Life, 2008. 60(12): p. 834-42. 
296. Quadros, E.V. and J.M. Sequeira, Cellular uptake of cobalamin: transcobalamin and the 
TCblR/CD320 receptor. Biochimie, 2013. 95(5): p. 1008-1018. 
297. Pannérec, A., et al., Vitamin B12 deficiency and impaired expression of amnionless during 
aging. Journal of cachexia, sarcopenia and muscle, 2018. 9(1): p. 41-52. 
298. Hall, C.A., P.D. Colligan, and J.A.J.J.o.c.p. Begley, Cyclic activity of the receptors of cobalamin 
bound to transcobalamin II. 1987. 133(1): p. 187-191. 
299. Molloy, A.M., et al., Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, 
infant, and child development. 2008. 29(2_suppl1): p. S101-S111. 
300. Abuyaman, O., et al., The soluble receptor for vitamin B12 uptake (sCD320) increases during 
pregnancy and occurs in higher concentration in urine than in serum. PloS one, 2013. 8(8): p. 
e73110-e73110. 
301. Quadros, E.V., Y. Nakayama, and J.M.J.B. Sequeira, The protein and the gene encoding the 
receptor for the cellular uptake of transcobalamin-bound cobalamin. 2009. 113(1): p. 186-
192. 
302. Moestrup, S.K., et al., Megalin-mediated endocytosis of transcobalamin-vitamin-B12 
complexes suggests a role of the receptor in vitamin-B12 homeostasis. Proc Natl Acad Sci U S 
A, 1996. 93(16): p. 8612-7. 
303. Birn, H., et al., Diversity in rat tissue accumulation of vitamin B12 supports a distinct role for 
the kidney in vitamin B12 homeostasis. Nephrology Dialysis Transplantation, 2003. 18(6): p. 
1095-1100. 
203 
 
304. Arora, K., et al., Behavioral alterations are associated with vitamin B12 deficiency in the 
transcobalamin receptor/CD320 KO mouse. PloS one, 2017. 12(5): p. e0177156. 
305. Lai, S.-C., et al., The transcobalamin receptor knockout mouse: a model for vitamin B12 
deficiency in the central nervous system. The FASEB Journal, 2013. 27(6): p. 2468-2475. 
306. Herbert, V.J.A.i.T.A.s.D., Etiology of vitamin B12 (cobalamin) deficiency and staging of B12 
status. 1994. 1: p. 139-148. 
307. Zittoun, J.J.H., Cobalamins: an update of fundamental and clinical data. 1996. 2(2): p. 119-29. 
308. Ermens, A., L. Vlasveld, and J.J.C.b. Lindemans, Significance of elevated cobalamin (vitamin 
B12) levels in blood. 2003. 36(8): p. 585-590. 
309. Cooksley, W., et al., Hepatic vitamin B12 release and transcobalamin II synthesis in the rat. 
Clinical Science, 1974. 47(6): p. 531-545. 
310. England, J., et al., Studies on the transcobalamins. British journal of haematology, 1973. 
25(6): p. 737-749. 
311. Refsum, H., et al., The Hordaland Homocysteine Study: a community-based study of 
homocysteine, its determinants, and associations with disease. 2006. 136(6): p. 1731S-1740S. 
312. Baik, H. and R.J.A.r.o.n. Russell, Vitamin B12 deficiency in the elderly. 1999. 19(1): p. 357-377. 
313. Arendt, J.F.B. and E. Nexo, Cobalamin related parameters and disease patterns in patients 
with increased serum cobalamin levels. PloS one, 2012. 7(9): p. e45979-e45979. 
314. Knight, B.A., et al., Lower circulating B12 is associated with higher obesity and insulin 
resistance during pregnancy in a non-diabetic white British population. 2015. 10(8): p. 
e0135268. 
315. Mittendorfer, B., Origins of metabolic complications in obesity: adipose tissue and free fatty 
acid trafficking. Current opinion in clinical nutrition and metabolic care, 2011. 14(6): p. 535-
541. 
316. Caballero, B.J.E.r., The global epidemic of obesity: an overview. 2007. 29(1): p. 1-5. 
317. Gómez-Hernández, A., et al., Differential role of adipose tissues in obesity and related 
metabolic and vascular complications. 2016. 2016. 
318. Pasanta, D., et al., Body mass index and its effects on liver fat content in overweight and 
obese young adults by proton magnetic resonance spectroscopy technique. World J Hepatol, 
2018. 10(12): p. 924-933. 
319. McDevitt, R.M., et al., De novo lipogenesis during controlled overfeeding with sucrose or 
glucose in lean and obese women. Am J Clin Nutr, 2001. 74(6): p. 737-46. 
320. Torchon, E., et al., Fasting rapidly increases fatty acid oxidation in white adipose tissue 
(269.2). 2014. 28(1_supplement): p. 269.2. 
321. Lee, J., et al., Hepatic Fatty Acid Oxidation Restrains Systemic Catabolism during Starvation. 
Cell reports, 2016. 16(1): p. 201-212. 
322. Stirm, L., et al., BMI-Independent Effects of Gestational Diabetes on Human Placenta. J Clin 
Endocrinol Metab, 2018. 103(9): p. 3299-3309. 
323. Chen, X., et al., Individual free fatty acids have unique associations with inflammatory 
biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic 
pregnant women. BMJ Open Diabetes Res Care, 2019. 7(1): p. e000632. 
324. Lomba, A., et al., Weight gain induced by an isocaloric pair-fed high fat diet: a nutriepigenetic 
study on FASN and NDUFB6 gene promoters. 2010. 101(2-3): p. 273-278. 
325. Saraswathy, K.N., et al., Metabolic distress in lipid & one carbon metabolic pathway through 
low vitamin B-12: a population based study from North India. 2018. 17(1): p. 96. 
326. Cordero, P., et al., Dietary supplementation with methyl donors reduces fatty liver and 
modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. 2013. 
8(1): p. 105. 
327. Pooya, S., et al., Methyl donor deficiency impairs fatty acid oxidation through PGC-1α 
hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver. 2012. 57(2): p. 344-
351. 
204 
 
328. Yajnik, C.S., et al., Vitamin B12 and folate concentrations during pregnancy and insulin 
resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia, 2008. 51(1): p. 
29-38. 
329. Stewart, C.P., et al., Low maternal vitamin B-12 status is associated with offspring insulin 
resistance regardless of antenatal micronutrient supplementation in rural Nepal. J Nutr, 
2011. 141(10): p. 1912-7. 
330. Krishnaveni, G.V., et al., Low plasma vitamin B12 in pregnancy is associated with gestational 
'diabesity' and later diabetes. Diabetologia, 2009. 52(11): p. 2350-8. 
331. Li, J., et al., The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. 2016. 
11: p. IMI. S31451. 
332. Koplay, M., E. Gulcan, and F.J.J.o.I.M. Ozkan, Association between serum vitamin B12 levels 
and the degree of steatosis in patients with nonalcoholic fatty liver disease. 2011. 59(7): p. 
1137-1140. 
333. Adaikalakoteswari, A., et al., Low maternal vitamin B12 status is associated with lower cord 
blood HDL cholesterol in white Caucasians living in the UK. 2015. 7(4): p. 2401-2414. 
334. Adaikalakoteswari, A., et al., Low Vitamin B12 in Pregnancy Is Associated With Adipose-
Derived Circulating miRs Targeting PPAR γ and Insulin Resistance. 2017. 102(11): p. 4200-
4209. 
335. Ghosh, S., et al., Severe but not moderate vitamin B12 deficiency impairs lipid profile, induces 
adiposity, and leads to adverse gestational outcome in female C57BL/6 mice. 2016. 3: p. 1. 
336. Kumar, K.A., et al., Maternal dietary folate and/or vitamin B12 restrictions alter body 
composition (adiposity) and lipid metabolism in Wistar rat offspring. 2013. 24(1): p. 25-31. 
337. Gueant, J.L., et al., Nutritional models of foetal programming and nutrigenomic and 
epigenomic dysregulations of fatty acid metabolism in the liver and heart. Pflugers Arch, 
2014. 466(5): p. 833-50. 
338. Garcia, M.M., et al., Methyl donor deficiency induces cardiomyopathy through altered 
methylation/acetylation of PGC-1alpha by PRMT1 and SIRT1. J Pathol, 2011. 225(3): p. 324-
35. 
339. Letexier, D., et al., Comparison of the expression and activity of the lipogenic pathway in 
human and rat adipose tissue. 2003. 44(11): p. 2127-2134. 
340. Marin, P., et al., Uptake of glucose carbon in muscle glycogen and adipose tissue triglycerides 
in vivo in humans. 1992. 263(3): p. E473-E480. 
341. Ortega, F.J., et al., The gene expression of the main lipogenic enzymes is downregulated in 
visceral adipose tissue of obese subjects. 2010. 18(1): p. 13-20. 
342. Jensen-Urstad, A.P., C.F.J.B.e.B.A.-M. Semenkovich, and C.B.o. Lipids, Fatty acid synthase and 
liver triglyceride metabolism: housekeeper or messenger? 2012. 1821(5): p. 747-753. 
343. Schwarz, J.-M., et al., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic 
subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic 
diets. 2003. 77(1): p. 43-50. 
344. Ebbert, J. and M.J.N. Jensen, Fat depots, free fatty acids, and dyslipidemia. 2013. 5(2): p. 498-
508. 
345. Khaire, A., et al., Vitamin B12 Deficiency Across Three Generations Adversely Influences Long-
chain Polyunsaturated Fatty Acid Status and Cardiometabolic Markers in Rats. Vol. 47. 2016. 
427-435. 
346. Sousa, S., et al., The relationship of plasma fatty acid profile and metabolic biomarkers 
among postmenopausal obese and overweight women. Vol. 10. 2018. 
347. Mayneris-Perxachs, J., et al., Plasma fatty acid composition, estimated desaturase activities, 
and their relation with the metabolic syndrome in a population at high risk of cardiovascular 
disease. Clinical Nutrition, 2014. 33(1): p. 90-97. 
205 
 
348. Morioka, T., et al., Plasma polyunsaturated fatty acid profile is associated with vascular 
endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res, 2018. 15(4): p. 352-
355. 
349. Irshad, Z., et al., Diacylglycerol acyltransferase 2 links glucose utilization to fatty acid 
oxidation in the brown adipocytes. 2017. 58(1): p. 15-30. 
350. Chitraju, C., et al., Lipidomic analysis of lipid droplets from murine hepatocytes reveals 
distinct signatures for nutritional stress. 2012. 53(10): p. 2141-2152. 
351. Güemes, M., S.A. Rahman, and K. Hussain, What is a normal blood glucose? Archives of 
disease in childhood, 2016. 101(6): p. 569-574. 
352. Mashek, D.G., et al., Hepatic lipid droplet biology: getting to the root of fatty liver. 2015. 
62(3): p. 964-967. 
353. Adaikalakoteswari, A., et al., Low maternal vitamin B12 status is associated with lower cord 
blood HDL cholesterol in white Caucasians living in the UK. Nutrients, 2015. 7(4): p. 2401-14. 
354. Mahalle, N., et al., Vitamin B12 deficiency and hyperhomocysteinemia as correlates of 
cardiovascular risk factors in Indian subjects with coronary artery disease. 2013. 61(4): p. 
289-294. 
355. Narang, M., M. Singh, and S.J.J.A.P.I. Dange, Serum homocysteine, vitamin B12 and folic acid 
levels in patients with metabolic syndrome. 2016. 64: p. 22-26. 
356. Ghosh, S., et al., Severe but Not Moderate Vitamin B12 Deficiency Impairs Lipid Profile, 
Induces Adiposity, and Leads to Adverse Gestational Outcome in Female C57BL/6 Mice. 
Frontiers in nutrition, 2016. 3: p. 1-1. 
357. Meher, A., A. Joshi, and S.J.P.o. Joshi, Differential regulation of hepatic transcription factors 
in the Wistar rat offspring born to dams fed folic acid, vitamin B12 deficient diets and 
supplemented with omega-3 fatty acids. 2014. 9(2): p. e90209. 
358. Shimomura, I., et al., Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance 
and sensitivity in livers of lipodystrophic and ob/ob mice. 2000. 6(1): p. 77-86. 
359. Shimomura, I., Y. Bashmakov, and J.D.J.J.o.B.C. Horton, Increased levels of nuclear SREBP-1c 
associated with fatty livers in two mouse models of diabetes mellitus. 1999. 274(42): p. 
30028-30032. 
360. Adaikalakoteswari, A., et al., Vitamin B12 insufficiency induces cholesterol biosynthesis by 
limiting s-adenosylmethionine and modulating the methylation of SREBF1 and LDLR genes. 
Clinical Epigenetics, 2015. 7(1): p. 14. 
361. Donnelly, K.L., et al., Sources of fatty acids stored in liver and secreted via lipoproteins in 
patients with nonalcoholic fatty liver disease. 2005. 115(5): p. 1343-1351. 
362. Zhu, Y., et al., A prospective and longitudinal study of plasma phospholipid saturated fatty 
acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes. Am 
J Clin Nutr, 2018. 107(6): p. 1017-1026. 
363. Chen, X., et al., Differences in maternal circulating fatty acid composition and dietary fat 
intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. 
Diabetes Care, 2010. 33(9): p. 2049-54. 
364. Chen, X., et al., Individual free fatty acids have unique associations with inflammatory 
biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic 
pregnant women. 2019. 7(1): p. e000632. 
365. Briggs, M., K. Petersen, and P. Kris-Etherton. Saturated fatty acids and cardiovascular 
disease: replacements for saturated fat to reduce cardiovascular risk. in Healthcare. 2017. 
Multidisciplinary Digital Publishing Institute. 
366. Schwingshackl, L. and G. Hoffmann, Monounsaturated fatty acids and risk of cardiovascular 
disease: synopsis of the evidence available from systematic reviews and meta-analyses. 
Nutrients, 2012. 4(12): p. 1989-2007. 
206 
 
367. Iglesia, I., et al., Folate and Vitamin B12 concentrations are associated with plasma DHA and 
EPA fatty acids in European adolescents: The Healthy Lifestyle in Europe by Nutrition in 
Adolescence (HELENA) study. Vol. 117. 2017. 1-10. 
368. Martin-Saborido, C., et al., Public health economic evaluation of different European Union–
level policy options aimed at reducing population dietary trans fat intake. 2016. 104(5): p. 
1218-1226. 
369. Juárez-Hernández, E., et al., Role of bioactive fatty acids in nonalcoholic fatty liver disease. 
2015. 15(1): p. 72. 
370. Da Silva, H.E., et al., A cross-sectional study assessing dietary intake and physical activity in 
Canadian patients with nonalcoholic fatty liver disease vs healthy controls. 2014. 114(8): p. 
1181-1194. 
371. Khaire, A., et al., Vitamin B12 and omega-3 fatty acids together regulate lipid metabolism in 
Wistar rats. 2015. 99: p. 7-17. 
372. Stirm, L., et al., BMI-independent effects of gestational diabetes on human placenta. 2018. 
103(9): p. 3299-3309. 
373. Cansanção, K., et al., Advanced liver fibrosis is independently associated with palmitic acid 
and insulin levels in patients with non-alcoholic fatty liver disease. 2018. 10(11): p. 1586. 
374. Guerendiain, M., et al., Changes in plasma fatty acid composition are associated with 
improvements in obesity and related metabolic disorders: A therapeutic approach to 
overweight adolescents. Clin Nutr, 2018. 37(1): p. 149-156. 
375. Serra, D., et al., Mitochondrial fatty acid oxidation in obesity. 2013. 19(3): p. 269-284. 
376. Begriche, K., et al., Mitochondrial dysfunction in NASH: causes, consequences and possible 
means to prevent it. 2006. 6(1): p. 1-28. 
377. McGarry, J.D. and N.F.J.E.j.o.b. Brown, The mitochondrial carnitine palmitoyltransferase 
system—from concept to molecular analysis. 1997. 244(1): p. 1-14. 
378. Herrero Rodríguez, L., et al., New strategies in the modulation of fatty acid oxidation as a 
treatment for obesity. 2013. 
379. Takahashi-Iñiguez, T., et al., Role of vitamin B12 on methylmalonyl-CoA mutase activity. 
Journal of Zhejiang University. Science. B, 2012. 13(6): p. 423-437. 
380. Taubes, G., Prosperity's plague. 2009, American Association for the Advancement of Science. 
381. Marcelin, G. and S.J.C.o.i.p. Chua Jr, Contributions of adipocyte lipid metabolism to body fat 
content and implications for the treatment of obesity. 2010. 10(5): p. 588-593. 
382. Kusminski, C.M., P.E.J.T.i.e. Scherer, and metabolism, Mitochondrial dysfunction in white 
adipose tissue. 2012. 23(9): p. 435-443. 
383. Lee, Y.-H., E.P. Mottillo, and J.G.J.B.e.B.A.-M.B.o.D. Granneman, Adipose tissue plasticity from 
WAT to BAT and in between. 2014. 1842(3): p. 358-369. 
384. Harper, R.D. and E.D.J.B.J. Saggerson, Some aspects of fatty acid oxidation in isolated fat-cell 
mitochondria from rat. 1975. 152(3): p. 485-494. 
385. Böttcher, H. and P.J.I.j.o.o. Fürst, Decreased white fat cell thermogenesis in obese individuals. 
1997. 21(6): p. 439. 
386. Yajnik, C., et al., Vitamin B 12 and folate concentrations during pregnancy and insulin 
resistance in the offspring: the Pune Maternal Nutrition Study. 2008. 51(1): p. 29-38. 
387. Saravanan, P. and C. Yajnik, Role of maternal vitamin B12 on the metabolic health of the 
offspring: A contributor to the diabetes epidemic? Vol. 10. 2010. 109-114. 
388. Magoulas, P.L. and A.W.J.O.J.o.R.D. El-Hattab, Systemic primary carnitine deficiency: an 
overview of clinical manifestations, diagnosis, and management. 2012. 7(1): p. 68. 
389. Wei, Y., et al., Nonalcoholic fatty liver disease and mitochondrial dysfunction. Vol. 14. 2008. 
193-9. 
390. Ramaswamy, M., et al., A Rare Case of Malonic Aciduria Diagnosed by Newborn Screening in 
Qatar. 2017. 3(1): p. 5. 
207 
 
391. Rosca, M.G., et al., Oxidation of fatty acids is the source of increased mitochondrial reactive 
oxygen species production in kidney cortical tubules in early diabetes. 2012. 61(8): p. 2074-
2083. 
392. Dahlhoff, C., et al., Methyl-donor supplementation in obese mice prevents the progression of 
NAFLD, activates AMPK and decreases acyl-carnitine levels. 2014. 3(5): p. 565-580. 
393. Samavat, J., et al. Vitamin B12 deficiency leads to adipocyte dysfunction by enhancing 
triglyceride biosynthesis and impairing fatty-acid oxidation: a new protagonist in metabolic 
disease? in Society for Endocrinology BES 2018. 2018. BioScientifica. 
394. Browning, J.D. and J.D.J.T.J.o.c.i. Horton, Molecular mediators of hepatic steatosis and liver 
injury. 2004. 114(2): p. 147-152. 
395. Schönfeld, P. and L.J.J.o.l.r. Wojtczak, Short-and medium-chain fatty acids in energy 
metabolism: the cellular perspective. 2016. 57(6): p. 943-954. 
396. Morris, M.C. and C.C.J.N.o.a. Tangney, Dietary fat composition and dementia risk. 2014. 35: 
p. S59-S64. 
397. Kaneko, J.J., J.W. Harvey, and M.L. Bruss, Clinical biochemistry of domestic animals. 2008: 
Academic press. 
398. Garcia, M.M., et al., Methyl donor deficiency induces cardiomyopathy through altered 
methylation/acetylation of PGC‐1α by PRMT1 and SIRT1. 2011. 225(3): p. 324-335. 
399. Wang, M.-E., et al., Increasing dietary medium-chain fatty acid ratio mitigates high-fat diet-
induced non-alcoholic steatohepatitis by regulating autophagy. 2017. 7(1): p. 13999. 
400. Wong, B.W., et al., The role of fatty acid β-oxidation in lymphangiogenesis. Nature, 2016. 
542: p. 49. 
401. Hosios, A.M. and M.G.J.D.c. Vander Heiden, Endothelial Cells Get β-ox-ed In to Support 
Lymphangiogenesis. 2017. 40(2): p. 118-119. 
402. Hannibal, L., et al., Hampered Vitamin B12 Metabolism in Gaucher Disease? Journal of Inborn 
Errors of Metabolism and Screening, 2017. 5: p. 2326409817692359. 
403. Gegg, M.E. and A.H.J.N.o.d. Schapira, Mitochondrial dysfunction associated with 
glucocerebrosidase deficiency. 2016. 90: p. 43-50. 
404. Natarajan, S.K., et al., Liver injury in acute fatty liver of pregnancy: possible link to placental 
mitochondrial dysfunction and oxidative stress. 2010. 51(1): p. 191-200. 
405. Wilcox, G., Impact of pregnancy on inborn errors of metabolism. Reviews in Endocrine and 
Metabolic Disorders, 2018. 19(1): p. 13-33. 
406. Wang, Y., et al., Evidence for physical association of mitochondrial fatty acid oxidation and 
oxidative phosphorylation complexes. 2010. 285(39): p. 29834-29841. 
407. Fan, J.G., S.U. Kim, and V.W. Wong, New trends on obesity and NAFLD in Asia. J Hepatol, 
2017. 67(4): p. 862-873. 
408. Younossi, Z.M., et al., Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic 
assessment of prevalence, incidence, and outcomes. 2016. 64(1): p. 73-84. 
409. Smits, M.M., et al., Non‐alcoholic fatty liver disease as an independent manifestation of the 
metabolic syndrome: results of a US national survey in three ethnic groups. 2013. 28(4): p. 
664-670. 
410. Szczepaniak, L.S., et al., Magnetic resonance spectroscopy to measure hepatic triglyceride 
content: prevalence of hepatic steatosis in the general population. 2005. 288(2): p. E462-
E468. 
411. Townsend, S. and P.N.J.B.m.b. Newsome, Non-alcoholic fatty liver disease in 2016. 2016. 
119(1): p. 143. 
412. Haas, J.T., S. Francque, and B. Staels, Pathophysiology and Mechanisms of Nonalcoholic Fatty 
Liver Disease. Annu Rev Physiol, 2016. 78: p. 181-205. 
413. Lutz, T.A. and E.J.C.o.i.l. Osto, Glucagon-like peptide-1, glucagon-like peptide-2, and lipid 
metabolism. 2016. 27(3): p. 257-263. 
208 
 
414. Duca, F.A., et al., Metformin activates duodenal AMPK and a neuronal network to lower 
glucose production. 2015. 21(5): p. 506. 
415. Green, C.J., et al., Of mice and men: Is there a future for metformin in the treatment of 
hepatic steatosis? 2019. 21(4): p. 749-760. 
416. Lin, H.Z., et al., Metformin reverses fatty liver disease in obese, leptin-deficient mice. 2000. 
6(9): p. 998. 
417. Lin, M.-J., et al., Metformin improves nonalcoholic fatty liver disease in obese mice via down-
regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. 2017. 8(65): p. 
108802. 
418. Woo, S.L., et al., Metformin ameliorates hepatic steatosis and inflammation without altering 
adipose phenotype in diet-induced obesity. PLoS One, 2014. 9(3): p. e91111. 
419. Zhu, X., et al., Metformin attenuates triglyceride accumulation in HepG2 cells through 
decreasing stearyl-coenzyme A desaturase 1 expression. Lipids Health Dis, 2018. 17(1): p. 
114. 
420. Priya, G. and S.J.D.i.c. Kalra, Metformin in the management of diabetes during pregnancy and 
lactation. 2018. 7. 
421. Ford, R.J., et al., Metformin and salicylate synergistically activate liver AMPK, inhibit 
lipogenesis and improve insulin sensitivity. 2015. 468(1): p. 125-132. 
422. Said, A. and A. Akhter, Meta-Analysis of Randomized Controlled Trials of Pharmacologic 
Agents in Non-alcoholic Steatohepatitis. Annals of hepatology, 2017. 16(4): p. 538-547. 
423. Liu, Q., et al., Vitamin B12 status in metformin treated patients: systematic review. PLoS One, 
2014. 9(6): p. e100379. 
424. Reinstatler, L., et al., Association of biochemical B(1)(2) deficiency with metformin therapy 
and vitamin B(1)(2) supplements: the National Health and Nutrition Examination Survey, 
1999-2006. Diabetes Care, 2012. 35(2): p. 327-33. 
425. Singh, A.K., et al., Association of B12 deficiency and clinical neuropathy with metformin use in 
type 2 diabetes patients. J Postgrad Med, 2013. 59(4): p. 253-7. 
426. Beulens, J.W., et al., Influence of duration and dose of metformin on cobalamin deficiency in 
type 2 diabetes patients using metformin. Acta Diabetol, 2015. 52(1): p. 47-53. 
427. de Jager, J., et al., Long term treatment with metformin in patients with type 2 diabetes and 
risk of vitamin B-12 deficiency: randomised placebo controlled trial. Bmj, 2010. 340: p. c2181. 
428. Aroda, V.R., et al., Long-term metformin use and vitamin B12 deficiency in the Diabetes 
Prevention Program Outcomes Study. 2016. 101(4): p. 1754-1761. 
429. Geerling, J.J., et al., Metformin lowers plasma triglycerides by promoting VLDL-triglyceride 
clearance by brown adipose tissue in mice. 2014. 63(3): p. 880-891. 
430. Swain, J.V., et al., Nef induces multiple genes involved in cholesterol synthesis and uptake in 
human immunodeficiency virus type 1-infected T cells. 2005. 79(15): p. 10053-10058. 
431. Mikalayeva, V., et al., Fatty Acid Synthesis and Degradation Interplay to Regulate the 
Oxidative Stress in Cancer Cells. 2019. 20(6): p. 1348. 
432. Wang, Y., et al., Mitochondrial fatty acid oxidation and the electron transport chain comprise 
a multifunctional mitochondrial protein complex. 2019: p. jbc. RA119. 008680. 
433. Foretz, M., P. Even, and B.J.I.j.o.m.s. Viollet, AMPK activation reduces hepatic lipid content by 
increasing fat oxidation in vivo. 2018. 19(9): p. 2826. 
434. Zang, M., et al., AMP-activated protein kinase is required for the lipid-lowering effect of 
metformin in insulin-resistant human HepG2 cells. J Biol Chem, 2004. 279(46): p. 47898-905. 
435. Adaikalakoteswari, A., et al., Vitamin B12 deficiency is associated with adverse lipid profile in 
Europeans and Indians with type 2 diabetes. Cardiovasc Diabetol, 2014. 13: p. 129. 
436. Li, Y., et al., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis 
and atherosclerosis in diet-induced insulin-resistant mice. 2011. 13(4): p. 376-388. 
437. Zhou, G., et al., Role of AMP-activated protein kinase in mechanism of metformin action. 
2001. 108(8): p. 1167-1174. 
209 
 
438. Madsen, A., et al., Metformin inhibits hepatocellular glucose, lipid and cholesterol 
biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2). 
Sci Rep, 2015. 5: p. 16430. 
439. Wilmanns, J.C., et al., Metformin intervention prevents cardiac dysfunction in a murine model 
of adult congenital heart disease. 2019. 20: p. 102-114. 
440. Allen, L., et al., Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, 
inflammation and hepatic steatosis in high-fat-fed mice. 2017. 48: p. 128-137. 
441. Zabielski, P., et al., The effect of high fat diet and metformin treatment on liver lipids 
accumulation and their impact on insulin action. Sci Rep, 2018. 8(1): p. 7249. 
442. Gormsen, L.C., et al., Metformin does not affect postabsorptive hepatic free fatty acid uptake, 
oxidation or resecretion in humans: A 3-month placebo-controlled clinical trial in patients 
with type 2 diabetes and healthy controls. Diabetes Obes Metab, 2018. 20(6): p. 1435-1444. 
443. Fullerton, M.D., et al., Single phosphorylation sites in Acc1 and Acc2 regulate lipid 
homeostasis and the insulin-sensitizing effects of metformin. Nat Med, 2013. 19(12): p. 1649-
54. 
444. Fulgencio, J.P., et al., Effect of metformin on fatty acid and glucose metabolism in freshly 
isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem 
Pharmacol, 2001. 62(4): p. 439-46. 
445. Niafar, M., et al., The role of metformin on vitamin B12 deficiency: a meta-analysis review. 
2015. 10(1): p. 93-102. 
446. Han, Y.-Y., et al., Diet and asthma: vitamins and methyl donors. 2013. 1(10): p. 813-822. 
447. Dahlhoff, C., et al., Methyl-donor supplementation in obese mice prevents the progression of 
NAFLD, activates AMPK and decreases acyl-carnitine levels. Mol Metab, 2014. 3(5): p. 565-80. 
448. Shaharyar, M. and A.J.A.J.o.C. Mazumder, Benzimidazoles: A biologically active compounds. 
2017. 10: p. S157-S173. 
449. Xiao, B., et al., Structural basis of AMPK regulation by small molecule activators. 2013. 4: p. 
3017. 
450. Kim, J., et al., AMPK activators: mechanisms of action and physiological activities. 2016. 
48(4): p. e224. 
451. King-Himmelreich, T.S., et al., The impact of endurance exercise on global and AMPK gene-
specific DNA methylation. 2016. 474(2): p. 284-290. 
452. Boudaba, N., et al., AMPK re-activation suppresses hepatic steatosis but its downregulation 
does not promote fatty liver development. 2018. 28: p. 194-209. 
453. Greibe, E., et al., Metformin increases liver accumulation of vitamin B12 - an experimental 
study in rats. Biochimie, 2013. 95(5): p. 1062-5. 
454. Aroda, V.R., et al., Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes 
Prevention Program Outcomes Study. J Clin Endocrinol Metab, 2016. 101(4): p. 1754-61. 
455. Musi, N. and L.J.A.P.S. Goodyear, AMP‐activated protein kinase and muscle glucose uptake. 
2003. 178(4): p. 337-345. 
456. Zhou, G., et al., Role of AMP-activated protein kinase in mechanism of metformin action. J 
Clin Invest, 2001. 108(8): p. 1167-74. 
457. Rena, G., E.R. Pearson, and K. Sakamoto, Molecular mechanism of action of metformin: old or 
new insights? Diabetologia, 2013. 56(9): p. 1898-906. 
458. Esfandiari, F., et al., S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed 
ethanol with a folate-deficient diet. Alcohol Clin Exp Res, 2007. 31(7): p. 1231-9. 
459. Henry, C.J., et al., Folate dietary insufficiency and folic acid supplementation similarly impair 
metabolism and compromise hematopoiesis. Haematologica, 2017. 102(12): p. 1985-1994. 
460. Friedman, S.L., et al., Mechanisms of NAFLD development and therapeutic strategies. 2018. 
24(7): p. 908. 
461. Tiwari-Heckler, S., et al., Circulating phospholipid patterns in nafld patients associated with a 
combination of metabolic risk factors. 2018. 10(5): p. 649. 
210 
 
462. Lindenmeyer, C.C. and A.J.J.C.i.l.d. McCullough, The natural history of nonalcoholic fatty liver 
disease—an evolving view. 2018. 22(1): p. 11-21. 
463. Mahaling, D.U., M.M. Basavaraj, and A.J.J.A.P.j.o.t.b. Bika, Comparison of lipid profile in 
different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. 2013. 3(11): p. 
907-912. 
464. Musso, G., et al., Impact of current treatments on liver disease, glucose metabolism and 
cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-
analysis of randomised trials. 2012. 55(4): p. 885-904. 
465. Fontana, L., et al., Long-term calorie restriction is highly effective in reducing the risk for 
atherosclerosis in humans. 2004. 101(17): p. 6659-6663. 
466. Kistler, K.D., et al., Physical activity recommendations, exercise intensity, and histological 
severity of nonalcoholic fatty liver disease. 2011. 106(3): p. 460. 
467. Chalasani, N., et al., The diagnosis and management of nonalcoholic fatty liver disease: 
practice guidance from the American Association for the Study of Liver Diseases. 2018. 67(1): 
p. 328-357. 
468. Tao, C., et al., Regulation of glucose and lipid homeostasis by adiponectin: effects on 
hepatocytes, pancreatic β cells and adipocytes. 2014. 28(1): p. 43-58. 
469. Buechler, C., J. Wanninger, and M.J.W.j.o.g.W. Neumeier, Adiponectin, a key adipokine in 
obesity related liver diseases. 2011. 17(23): p. 2801. 
470. Chen, H., et al., Adiponectin activates the AMPK signaling pathway to regulate lipid 
metabolism in bovine hepatocytes. J Steroid Biochem Mol Biol, 2013. 138: p. 445-54. 
471. Wang, Y., et al., Protective roles of adiponectin in obesity-related fatty liver diseases: 
Mechanisms and therapeutic implications. Vol. 53. 2009. 201-12. 
472. Udomsinprasert, W., S. Honsawek, and Y. Poovorawan, Adiponectin as a novel biomarker for 
liver fibrosis. World J Hepatol, 2018. 10(10): p. 708-718. 
473. Huypens, P., et al., Adiponectin-mediated stimulation of AMP-activated protein kinase 
(AMPK) in pancreatic beta cells. Life Sci, 2005. 77(11): p. 1273-82. 
474. Diez, J.J. and P.J.E.J.o.e. Iglesias, The role of the novel adipocyte-derived hormone adiponectin 
in human disease. 2003. 148(3): p. 293-300. 
475. Neumeier, M., et al., Adiponectin and its receptors in rodent models of fatty liver disease and 
liver cirrhosis. World journal of gastroenterology, 2006. 12(34): p. 5490-5494. 
476. Alzahrani, B., et al., The role of AdipoR1 and AdipoR2 in liver fibrosis. 2018. 1864(3): p. 700-
708. 
477. Asada, K., et al., Crosstalk between high-molecular-weight adiponectin and T-cadherin during 
liver fibrosis development in rats. Int J Mol Med, 2007. 20(5): p. 725-9. 
478. Esfandiari, F., et al., S‐adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed 
ethanol with a folate‐deficient diet. 2007. 31(7): p. 1231-1239. 
479. Yamauchi, T., et al., Cloning of adiponectin receptors that mediate antidiabetic metabolic 
effects. Nature, 2003. 423(6941): p. 762-9. 
480. Yamauchi, T., et al., Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of 
adiponectin binding and metabolic actions. Nat Med, 2007. 13(3): p. 332-9. 
481. Gamberi, T., et al., Adiponectin signaling pathways in liver diseases. 2018. 6(2): p. 52. 
482. Awazawa, M., et al., Adiponectin suppresses hepatic SREBP1c expression in an 
AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun, 2009. 382(1): p. 
51-6. 
483. Shklyaev, S., et al., Sustained peripheral expression of transgene adiponectin offsets the 
development of diet-induced obesity in rats. Proc Natl Acad Sci U S A, 2003. 100(24): p. 
14217-22. 
484. Stern, J.H., J.M. Rutkowski, and P.E. Scherer, Adiponectin, Leptin, and Fatty Acids in the 
Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell metabolism, 
2016. 23(5): p. 770-784. 
211 
 
485. Liu, Q., et al., Adiponectin regulates expression of hepatic genes critical for glucose and lipid 
metabolism. 2012. 109(36): p. 14568-14573. 
486. Finelli, C. and G.J.W.j.o.g.W. Tarantino, What is the role of adiponectin in obesity related non-
alcoholic fatty liver disease? 2013. 19(6): p. 802. 
487. Ruderman, N.B., A.K. Saha, and E.W.J.E. Kraegen, Minireview: malonyl CoA, AMP-activated 
protein kinase, and adiposity. 2003. 144(12): p. 5166-5171. 
488. Brusq, J.-M., et al., Inhibition of lipid synthesis through activation of AMP kinase: an 
additional mechanism for the hypolipidemic effects of berberine. 2006. 47(6): p. 1281-1288. 
489. Wang, Y. and J.A.J.C. Zidichouski, Update on the benefits and mechanisms of action of the 
bioactive vegetal alkaloid berberine on lipid metabolism and homeostasis. 2018. 2018. 
490. Yoon, M.J., et al., Adiponectin increases fatty acid oxidation in skeletal muscle cells by 
sequential activation of AMPK, p38 MAPK, and PPARalpha. 2006. 2006: p. 262-262. 
491. Civitarese, A.E., et al., Role of adiponectin in human skeletal muscle bioenergetics. Cell 
metabolism, 2006. 4(1): p. 75-87. 
492. Kadowaki, T. and T.J.E.r. Yamauchi, Adiponectin and adiponectin receptors. 2005. 26(3): p. 
439-451. 
493. Fard, A.A., et al., The effects of combined Adiponectin-Metformin on glucose and lipids levels 
in mice and acute toxicity and anti-ulcerogenic activity of Adiponectin against ethanol-
induced gastric mucosal injuries in rat. 2011. 16(11): p. 9534-9552. 
494. Min, Q.Q., et al., Effects of Metformin Combined with Lactoferrin on Lipid Accumulation and 
Metabolism in Mice Fed with High-Fat Diet. Nutrients, 2018. 10(11). 
495. Rogers, C.Q., J.M. Ajmo, and M. You, Adiponectin and alcoholic fatty liver disease. IUBMB 
Life, 2008. 60(12): p. 790-7. 
496. Cantó, C. and J. Auwerx, AMP-activated protein kinase and its downstream transcriptional 
pathways. Cellular and molecular life sciences : CMLS, 2010. 67(20): p. 3407-3423. 
497. Hawley, S.A., et al., Characterization of the AMP-activated protein kinase kinase from rat liver 
and identification of threonine 172 as the major site at which it phosphorylates AMP-
activated protein kinase. J Biol Chem, 1996. 271(44): p. 27879-87. 
498. Suter, M., et al., Dissecting the role of 5'-AMP for allosteric stimulation, activation, and 
deactivation of AMP-activated protein kinase. J Biol Chem, 2006. 281(43): p. 32207-16. 
499. Younossi, Z.M.J.C.l.d., The epidemiology of nonalcoholic steatohepatitis. 2018. 11(4): p. 92. 
500. Lai, J.S., et al., High folate and low vitamin B12 status during pregnancy is associated with 
gestational diabetes mellitus. Clin Nutr, 2018. 37(3): p. 940-947. 
501. Khan, A., I. Shafiq, and M. Hassan Shah, Prevalence of Vitamin B12 Deficiency in Patients with 
Type II Diabetes Mellitus on Metformin: A Study from Khyber Pakhtunkhwa. Cureus, 2017. 
9(8): p. e1577-e1577. 
502. Bell, D.S., Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. 
Southern medical journal, 2010. 103(3): p. 265-267. 
503. Aroda, V.R., et al., Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes 
Prevention Program Outcomes Study. The Journal of clinical endocrinology and metabolism, 
2016. 101(4): p. 1754-1761. 
504. Arora, K., J.M. Sequeira, and E.V. Quadros, Maternofetal transport of vitamin B(12): role of 
TCblR/CD320 and megalin. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology, 2017. 31(7): p. 3098-3106. 
505. Herbert, V., Staging vitamin B-12 (cobalamin) status in vegetarians. Am J Clin Nutr, 1994. 
59(5 Suppl): p. 1213s-1222s. 
506. Yajnik, C.S., et al., A physiological dose of oral vitamin B-12 improves hematological, 
biochemical-metabolic indices and peripheral nerve function in B-12 deficient Indian 
adolescent women. PLoS One, 2019. 14(10): p. e0223000. 
212 
 
507. Bansal, P.G., et al., Impact of weekly iron folic acid supplementation with and without vitamin 
B12 on anaemic adolescent girls: a randomised clinical trial. European journal of clinical 
nutrition, 2016. 70(6): p. 730. 
508. Baltaci, D., et al., Association of vitamin B12 with obesity, overweight, insulin resistance and 
metabolic syndrome, and body fat composition; primary care-based study. Vol. 10. 2013. 203-
10. 
509. Khoharo, H.K., et al., Serum cobalamin and dyslipidemia in type 2 diabetics. 2015. 14: p. 21-5. 
510. Adaikalakoteswari, A., et al., Vitamin B12 deficiency is associated with adverse lipid profile in 
Europeans and Indians with type 2 diabetes. Cardiovascular diabetology, 2014. 13: p. 129-
129. 
511. Kawano, Y. and D.E. Cohen, Mechanisms of hepatic triglyceride accumulation in non-alcoholic 
fatty liver disease. Journal of gastroenterology, 2013. 48(4): p. 434-441. 
512. Diraison, F., et al., Differences in the regulation of adipose tissue and liver lipogenesis by 
carbohydrates in humans. 2003. 44(4): p. 846-853. 
513. Briggs, M.A., K.S. Petersen, and P.M. Kris-Etherton, Saturated Fatty Acids and Cardiovascular 
Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk. Healthcare (Basel, 
Switzerland), 2017. 5(2): p. 29. 
514. Willett, W.C.J.J.o.i.m., Dietary fats and coronary heart disease. 2012. 272(1): p. 13-24. 
515. Zhu, Y., Y. Bo, and Y. Liu, Dietary total fat, fatty acids intake, and risk of cardiovascular 
disease: a dose-response meta-analysis of cohort studies. Lipids in Health and Disease, 2019. 
18(1): p. 91. 
516. Harris, W.S., et al., Omega-6 fatty acids and risk for cardiovascular disease: a science advisory 
from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, 
Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on 
Epidemiology and Prevention. 2009. 119(6): p. 902-907. 
517. Araya, J., et al., Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to 
hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond), 2004. 
106(6): p. 635-43. 
518. Patterson, E., et al., Health implications of high dietary omega-6 polyunsaturated fatty acids. 
2012. 2012. 
519. Revtovich, A.V., R. Lee, and N.V. Kirienko, Interplay between mitochondria and diet mediates 
pathogen and stress resistance in Caenorhabditis elegans. PLOS Genetics, 2019. 15(3): p. 
e1008011. 
520. Andres, E., et al., The pathophysiology of elevated vitamin B12 in clinical practice. Qjm, 2013. 
106(6): p. 505-15. 
521. Dahlhoff, C., et al., Methyl-donor supplementation in obese mice prevents the progression of 
NAFLD, activates AMPK and decreases acyl-carnitine levels. Molecular metabolism, 2014. 
3(5): p. 565-580. 
522. Bonora, M., et al., ATP synthesis and storage. Purinergic signalling, 2012. 8(3): p. 343-357. 
523. Donohoe, D.R. and S.J. Bultman, Metaboloepigenetics: interrelationships between energy 
metabolism and epigenetic control of gene expression. Journal of cellular physiology, 2012. 
227(9): p. 3169-3177. 
524. Crofts, T., et al., A bioassay for the detection of benzimidazoles reveals their presence in a 
range of environmental samples. Vol. 5. 2014. 592. 
525. Bultot, L., et al., Benzimidazole derivative small-molecule 991 enhances AMPK activity and 
glucose uptake induced by AICAR or contraction in skeletal muscle. 2016. 311(4): p. E706-
E719. 
526. Kim, J., et al., AMPK activators: mechanisms of action and physiological activities. 
Experimental & molecular medicine, 2016. 48(4): p. e224-e224. 
527. Koh, E.H., et al., Essential role of mitochondrial function in adiponectin synthesis in 
adipocytes. 2007. 56(12): p. 2973-2981. 
213 
 
528. Huypens, P., et al., Metformin reduces adiponectin protein expression and release in 3T3-L1 
adipocytes involving activation of AMP activated protein kinase. 2005. 518(2-3): p. 90-95. 
529. Meilleur, K.G., et al., Circulating adiponectin is associated with obesity and serum lipids in 
West Africans. 2010. 95(7): p. 3517-3521. 
 
 
 
